title,type,agency_names,abstract,citation,document_number,html_url,pdf_url,publication_date,Title Product,Title Note,Assignment,Product Name,Patent No.,Company,Reg Rev Period,Testing Phase,Approval Phase,IND/IDE Filing Date,NDA/PMA Filing Date,Approval Date,Application No.,Pat Term Ext
Determination of Regulatory Review Period for Purposes of Patent Extension; BetaseronRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Betaseron<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biologic product.",59 FR 305,94-36,https://www.federalregister.gov/documents/1994/01/04/94-36/determination-of-regulatory-review-period-for-purposes-of-patent-extension-betaseronregister,,1994-01-04, BetaseronRegister,,,Betaseron<Register>,4588585,the Cetus Oncology Corp.,3720.0,3319.0,401.0,"May 19, 1983",1983-05-19,1993-07-23,PLA 92-0495,1500
Determination of Regulatory Review Period for Purposes of Patent Extension; ImagentRegister GI,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Imagent<Register> GI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-4802,https://www.federalregister.gov/documents/1994/03/03/94-4802/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imagentregister-gi,,1994-03-03, ImagentRegister GI,,,Imagent<Register> GI,3975512,the Board of Trustees of the University of Illinois,7493.0,6469.0,1024.0,"February 8, 1973",1973-02-08,1993-08-13,NDA 20-091,730
Determination of Regulatory Review Period for Purposes of Patent Extension; PirsueSUPTM Aqueous Gel,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Pirsue<SUP>TM Aqueous Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",,94-4801,https://www.federalregister.gov/documents/1994/03/03/94-4801/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pirsuesuptm-aqueous-gel,,1994-03-03, PirsueSUPTM Aqueous Gel,,,Pirsue<SUP>TM Aqueous Gel,4278789,The Upjohn Co.,3860.0,3778.0,82.0,"February 17, 1983",1993-09-10,1993-09-10,NADA 141-036,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; SporanoxRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Sporanox<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-5635,https://www.federalregister.gov/documents/1994/03/11/94-5635/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sporanoxregister,,1994-03-11, SporanoxRegister,,,Sporanox<Register>,4267179,Janssen Pharmaceutica N.V.,2990.0,2155.0,835.0,"July 7, 1984",1984-07-07,1992-09-11,NDA 20-,1510
Determination of Regulatory Review Period for Purposes of Patent Extension; PRO OSTEONSUPTM Implant 500 Coralline Hydroxyapatite Bone Void Filler,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRO OSTEON<SUP>TM Implant 500 Coralline Hydroxyapatite Bone Void Filler and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",,94-5672,https://www.federalregister.gov/documents/1994/03/11/94-5672/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pro-osteonsuptm-implant,,1994-03-11, PRO OSTEONSUPTM Implant 500 Coralline Hydroxyapatite Bone Void Filler,,,the PRO OSTEON<SUP>TM Implant 500 Coralline Hydroxyapatite Bone Void Filler,3929971,Research Corp. Technologies,3774.0,2049.0,1725.0,"July 2, 1982",1982-07-02,1992-10-29,PMA P860005,730
Determination of Regulatory Review Period for Purposes of Patent Extension; SupprelinRegister; Correction,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 2, 1992 (57 FR 23237), that announced its determination of the regulatory review period for purposes of patent extension for Supprelin<Register> (histrelin acetate). The document was published with some mathematical errors. The document incorrectly stated, ``FDA has determined that the applicable regulatory review period for Supprelin<Register> is 2,876 days. Of this time, 1,930 days occurred during the testing phase of the regulatory review period, while 946 days occurred during the approval phase.'' It should have stated, ``FDA has determined that the applicable regulatory review period for Supprelin<Register> is 2,878 days. Of this time, 1,931 days occurred during the testing phase of the regulatory review period, while 947 days occurred during the approval phase.'' This document corrects those errors.",,94-9047,https://www.federalregister.gov/documents/1994/04/14/94-9047/determination-of-regulatory-review-period-for-purposes-of-patent-extension-supprelinregister,,1994-04-14, SupprelinRegister, Correction,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MycobutinSUPTM,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Mycobutin<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-9099,https://www.federalregister.gov/documents/1994/04/15/94-9099/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycobutinsuptm,,1994-04-15, MycobutinSUPTM,,,Mycobutin<SUP>TM,4219478,Adria Laboratories,2831.0,2124.0,707.0,"March 23, 1986",1986-03-23,1992-12-23,NDA 50-689,1392
Determination of Regulatory Review Period for Purposes of Patent Extension; MycobutinSUPTM; Correction,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 15, 1994 (59 FR 18133), that announced its determination of the regulatory review period for purposes of patent extension for Mycobutin<SUP>TM (rifabutin). The document was published with some mathematical errors. The document incorrectly stated, ``FDA has determined that the applicable regulatory review period for Mycobutin<SUP>TM is 2,831 days. Of this time, 2,124 days occurred during the testing phase of the regulatory review period, while 707 days occurred during the approval phase.'' It should have stated, ``FDA has determined that the applicable regulatory review period for Mycobutin<SUP>TM is 2,469 days. Of this time, 2,127 days occurred during the testing phase of the regulatory review period, while 342 days occurred during the approval phase.'' This document corrects those errors.",,94-14446,https://www.federalregister.gov/documents/1994/06/14/94-14446/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycobutinsuptm-correction,,1994-06-14, MycobutinSUPTM, Correction,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RealitySUPTM Female Condom,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Reality<SUP>TM Female Condom and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",,94-14445,https://www.federalregister.gov/documents/1994/06/14/94-14445/determination-of-regulatory-review-period-for-purposes-of-patent-extension-realitysuptm-female,,1994-06-14, RealitySUPTM Female Condom,,,the Reality<SUP>TM Female Condom,4735621,Chartex International Plc,2017.0,1460.0,557.0,"October 31, 1987",1991-10-29,1993-05-07,PMA P910064,762
Determination of Regulatory Review Period for Purposes of Patent Extension; AceonSUPTM,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aceon<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-17737,https://www.federalregister.gov/documents/1994/07/21/94-17737/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aceonsuptm,,1994-07-21, AceonSUPTM,,,Aceon<SUP>TM,4508729,Adir,2284.0,1367.0,917.0,"October 1, 1987",1987-10-01,1993-12-30,NDA 20-184,1588
Determination of Regulatory Review Period for Purposes of Patent Extension; DemadexSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Demadex<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-17738,https://www.federalregister.gov/documents/1994/07/21/94-17738/determination-of-regulatory-review-period-for-purposes-of-patent-extension-demadexsuptm,,1994-07-21, DemadexSUPTM,,,Demadex<SUP>TM,Re. 30633,A. Christians Societe Anonyme,2790.0,1882.0,908.0,"January 4, 1986",1986-01-10,1993-08-23,NDA 20-136,5
Determination of Regulatory Review Period for Purposes of Patent Extension; CattlystRegister 50 Type A Medicated Article,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Cattlyst<Register> 50 Type A Medicated Article and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",,94-17814,https://www.federalregister.gov/documents/1994/07/22/94-17814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cattlystregister-50-type,,1994-07-22, CattlystRegister 50 Type A Medicated Article,,,Cattlyst<Register> 50 Type A Medicated Article,4431665,"Syntex (U.S.A), Inc.",4253.0,3762.0,491.0,"July 14, 1982",1982-07-14,1994-03-04,NADA 141-025,3
Determination of Regulatory Review Period for Purposes of Patent Extension; DovonexRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Dovonex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21156,https://www.federalregister.gov/documents/1994/08/29/94-21156/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dovonexregister,,1994-08-29, DovonexRegister,,,Dovonex<Register>,4866048,"Leo Pharmaceutical Products, Ltd.",1149.0,510.0,639.0,"November 8, 1990",1990-11-08,1993-12-29,NDA 20-273,473
Determination of Regulatory Review Period for Purposes of Patent Extension; EffexorRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Effexor<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21287,https://www.federalregister.gov/documents/1994/08/30/94-21287/determination-of-regulatory-review-period-for-purposes-of-patent-extension-effexorregister,,1994-08-30, EffexorRegister,,,Effexor<Register>,4535186,American Home Products Corp.,2959.0,1981.0,978.0,"November 23, 1985",1991-04-26,1993-12-28,NDA 20-151,5
Determination of Regulatory Review Period for Purposes of Patent Extension; KytrilSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Kytril<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21282,https://www.federalregister.gov/documents/1994/08/30/94-21282/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kytrilsuptm,,1994-08-30, KytrilSUPTM,,,Kytril<SUP>TM,4886808,Beecham Group p.l.c.,1996.0,1371.0,625.0,"July 14, 1988",1988-07-14,1993-12-29,NDA 20-,382
Determination of Regulatory Review Period for Purposes of Patent Extension; LipidilRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lipidil<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21285,https://www.federalregister.gov/documents/1994/08/30/94-21285/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lipidilregister,,1994-08-30, LipidilRegister,,,Lipidil<Register>,4739101,Fournier Innovation et Synergie,4501.0,1003.0,3498.0,"September 6, 1981",1981-09-06,1993-12-31,NDA 19-304,256
Determination of Regulatory Review Period for Purposes of Patent Extension; LivostinRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Livostin<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21283,https://www.federalregister.gov/documents/1994/08/30/94-21283/determination-of-regulatory-review-period-for-purposes-of-patent-extension-livostinregister,,1994-08-30, LivostinRegister,,,Livostin<Register>,4369184,Janssen Pharmaceutica N.V.,2779.0,2000.0,779.0,"April 4, 1986",1986-04-04,1993-11-10,NDA 20-219,1779
Determination of Regulatory Review Period for Purposes of Patent Extension; NeurontinRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neurontin<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21288,https://www.federalregister.gov/documents/1994/08/30/94-21288/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neurontinregister,,1994-08-30, NeurontinRegister,,,Neurontin<Register>,4087544,Warner-Lambert Co.,2740.0,2040.0,700.0,"July 2, 1986",1992-01-31,1993-12-30,NDA 20-235,1726
Determination of Regulatory Review Period for Purposes of Patent Extension; NeutrexinSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neutrexin<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21280,https://www.federalregister.gov/documents/1994/08/30/94-21280/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neutrexinsuptm,,1994-08-30, NeutrexinSUPTM,,,Neutrexin<SUP>TM,4376858,Warner-Lambert Co.,2251.0,1934.0,317.0,"October 21, 1987",1987-03-30,1993-12-17,IND 29,1310
Determination of Regulatory Review Period for Purposes of Patent Extension; RisperdalRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Risperdal<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21284,https://www.federalregister.gov/documents/1994/08/30/94-21284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-risperdalregister,,1994-08-30, RisperdalRegister,,,Risperdal<Register>,4804663,Janssen Pharmaceutica N.V.,1940.0,1316.0,624.0,"September 8, 1988",1988-09-08,1993-12-29,NDA 20-272,683
Determination of Regulatory Review Period for Purposes of Patent Extension; ZosynRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zosyn<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21286,https://www.federalregister.gov/documents/1994/08/30/94-21286/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zosynregister,,1994-08-30, ZosynRegister,,,Zosyn<Register>,4562073,"Taiho Pharmaceutical Co., Ltd.",1819.0,1038.0,781.0,"October 31, 1988",1988-06-14,1993-10-22,IND 31,1358
Determination of Regulatory Review Period for Purposes of Patent Extension; AviaxRegister,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aviax<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",,94-21789,https://www.federalregister.gov/documents/1994/09/06/94-21789/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aviaxregister,,1994-09-06, AviaxRegister,,,Aviax<Register>,4804680,Pfizer Inc.,2438.0,736.0,1702.0,"July 9, 1987",1994-03-10,1994-03-10,NADA 140-940,755
Determination of Regulatory Review Period for Purposes of Patent Extension; PrografSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Prograf<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-22036,https://www.federalregister.gov/documents/1994/09/07/94-22036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prografsuptm,,1994-09-07, PrografSUPTM,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZemuronSUPTM Injection,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zemuron<SUP>TM Injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-22760,https://www.federalregister.gov/documents/1994/09/15/94-22760/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemuronsuptm-injection,,1994-09-15, ZemuronSUPTM Injection,,,Zemuron<SUP>TM Injection,4894369,"Akzo Nobel, N.V.",1889.0,1627.0,262.0,"January 15, 1994",1994-01-15,1994-03-17,NDA 20-214,427
Determination of Regulatory Review Period for Purposes of Patent Extension; SemprexSUPTM-D Capsules,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Semprex<SUP>TM-D Capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-23276,https://www.federalregister.gov/documents/1994/09/21/94-23276/determination-of-regulatory-review-period-for-purposes-of-patent-extension-semprexsuptm-d-capsules,,1994-09-21, SemprexSUPTM-D Capsules,,,Semprex<SUP>TM-D Capsules,4650807,Burroughs Wellcome Co.,3489.0,1210.0,2279.0,"September 6, 1984",1984-09-06,1994-03-25,NDA 19-806,1469
Determination of Regulatory Review Period for Purposes of Patent Extension; Netrexingreek-Tgreek-M,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,,,X94-41005,https://www.federalregister.gov/documents/1994/10/05/X94-41005/determination-of-regulatory-review-period-for-purposes-of-patent-extension-netrexingreek-tgreek-m,,1994-10-05, Netrexingreek-Tgreek-M,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NeurontinRegister,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,,,X94-51005,https://www.federalregister.gov/documents/1994/10/05/X94-51005/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neurontinregister,,1994-10-05, NeurontinRegister,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CPIRegister VentakRegister PRxRegister AICD System,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CPI<Register> Ventak<Register> PRx<Register> AICD System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",,94-28064,https://www.federalregister.gov/documents/1994/11/15/94-28064/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cpiregister,,1994-11-15, CPIRegister VentakRegister PRxRegister AICD System,,,CPI<Register> Ventak<Register> PRx<Register> AICD System,4407288,"Cardiac Pacemakers, Inc.",1306.0,398.0,908.0,"November 21, 1990",1990-11-21,1994-06-17,PMA P910077,394
Determination of Regulatory Review Period for Purposes of Patent Extension; ZeritRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zerit<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-28194,https://www.federalregister.gov/documents/1994/11/16/94-28194/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zeritregister,,1994-11-16, ZeritRegister,,,Zerit<Register>,4978655,Yale University,1984.0,1805.0,179.0,"January 19, 1989",1988-12-16,1994-06-24,IND 32,188
Determination of Regulatory Review Period For Purposes of Patent Extension; CognexRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Cognex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-30235,https://www.federalregister.gov/documents/1994/12/08/94-30235/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cognexregister,,1994-12-08, CognexRegister,,,Cognex<Register>,4 816456,William K. Summers,2289.0,1095.0,1194.0,"June 6, 1987",1990-06-04,1993-09-09,NDA 20-,531
Determination of Regulatory Review Period for Purposes of Patent Extension; ZemuronSUPTM Injection; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of September 15, 1994. The document announced FDA's determination of the regulatory review period for purposes of patent extension for Zeuron<SUP>TM Injection (rocuronium bromide). The document was published with some errors. The document incorrectly stated: ``1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: January 15, 1994. The applicant claims January 14, 1989, as [[Page 130]] the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 15, 1994, which was 30 days after FDA receipt of the IND.'' The document should have stated: ``1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: January 15, 1989. The applicant claims January 14, 1989, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 15, 1989, which was 30 days after FDA receipt of the IND.'' This document corrects those errors.",60 FR 129,94-32242,https://www.federalregister.gov/documents/1995/01/03/94-32242/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemuronsuptm-injection,https://www.govinfo.gov/content/pkg/FR-1995-01-03/pdf/94-32242.pdf,1995-01-03, ZemuronSUPTM Injection, Correction,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NetrexinSUPTM,Correction,Health and Human Services Department; Food and Drug Administration,,60 FR 5252,X95-50126,https://www.federalregister.gov/documents/1995/01/26/X95-50126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-netrexinsuptm,https://www.govinfo.gov/content/pkg/FR-1995-01-26/pdf/X95-50126.pdf,1995-01-26, NetrexinSUPTM,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AlbunexRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Albunex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 11671,95-5183,https://www.federalregister.gov/documents/1995/03/02/95-5183/determination-of-regulatory-review-period-for-purposes-of-patent-extension-albunexregister,https://www.govinfo.gov/content/pkg/FR-1995-03-02/pdf/95-5183.pdf,1995-03-02, AlbunexRegister,,,Albunex<Register>,4844882,"Molecular Biosystems, Inc.",2397.0,975.0,1422.0,"January 14, 1988",1988-01-14,1994-08-05,PMA P900059,763
Determination of Regulatory Review Period for Purposes of Patent Extension; SemprexSUPTM-D Capsules,Correction,Health and Human Services Department; Food and Drug Administration,,60 FR 15822,X95-30327,https://www.federalregister.gov/documents/1995/03/27/X95-30327/determination-of-regulatory-review-period-for-purposes-of-patent-extension-semprexsuptm-d-capsules,https://www.govinfo.gov/content/pkg/FR-1995-03-27/pdf/X95-30327.pdf,1995-03-27, SemprexSUPTM-D Capsules,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LUVOXSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUVOX<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 20105,95-10073,https://www.federalregister.gov/documents/1995/04/24/95-10073/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luvoxsuptm,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10073.pdf,1995-04-24, LUVOXSUPTM,,,LUVOX<SUP>TM,4085225,Duphar International,6958.0,5886.0,1072.0,"November 19, 1975",1975-11-19,1994-12-05,NDA 20-243,730
Determination of Regulatory Review Period for Purposes of Patent Extension; SERZONERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for SERZONE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 20106,95-10077,https://www.federalregister.gov/documents/1995/04/24/95-10077/determination-of-regulatory-review-period-for-purposes-of-patent-extension-serzoneregister,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10077.pdf,1995-04-24, SERZONERegister,,,SERZONE<Register>,4338317,Bristol-Myers Squibb,4420.0,3216.0,1204.0,"November 17, 1982",1982-11-17,1994-12-22,NDA 20-152,730
Determination of Regulatory Review Period for Purposes of Patent Extension; ZosynRegister; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of August 30, 1994. The document announced FDA's determination of the regulatory review period for purposes of patent extension for Zosyn<Register> (tazobactam sodium and piperacillin sodium). The document was published with some errors. The document incorrectly stated: FDA has determined that the applicable regulatory review period for Zosyn<Register> is 1,819 days. Of this time, 1,038 days occurred during the testing phase of the regulatory review period, while 781 days occurred during the approval phase. 1. The date an exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: October 31, 1988. The applicant claims July 10, 1988, as the date the investigational new drug application (IND) for Zosyn<Register> (IND 31,705) became effective. However, IND 31,705 was received on June 14, 1988, and it was placed on clinical hold on July 1, 1988. It was removed from clinical hold on October 31, 1988, making the IND effective date October 31, 1988. It should have stated: FDA has determined that the applicable regulatory review period for Zosyn<Register> is 1,906 days. Of this time, 1,125 days occurred during the testing phase of the regulatory review period, while 781 days occurred during the approval phase. 1. The date an exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: August 5, 1988. The applicant claims July 10, 1988, as the date the investigational new drug application (IND) for Zosyn<Register> (IND 31,705) became effective. However, IND 31,705 was received on June 14, 1988, and it was placed on clinical hold on July 1, 1988. It was removed from clinical hold on August 5, 1988, making the IND effective date August 5, 1988. This document corrects those errors. FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1382.",60 FR 20107,95-10074,https://www.federalregister.gov/documents/1995/04/24/95-10074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zosynregister-correction,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10074.pdf,1995-04-24, ZosynRegister, Correction,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Sonic Accelerated Fracture Healing System (SAFHSRegister),Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAFHS<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 20107,95-10076,https://www.federalregister.gov/documents/1995/04/24/95-10076/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sonic-accelerated,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10076.pdf,1995-04-24, Sonic Accelerated Fracture Healing System (SAFHSRegister),,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FRAGMINRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for FRAGMIN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 27981,95-13032,https://www.federalregister.gov/documents/1995/05/26/95-13032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fragminregister,https://www.govinfo.gov/content/pkg/FR-1995-05-26/pdf/95-13032.pdf,1995-05-26, FRAGMINRegister,,,FRAGMIN<Register>,4303651,Pharmacia Aktiebolag,3555.0,2832.0,723.0,"March 31, 1985",1985-03-31,1994-12-22,IND 25,661
Determination of Regulatory Review Period for Purposes of Patent Extension; NeuroliteRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neurolite<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 27982,95-13033,https://www.federalregister.gov/documents/1995/05/26/95-13033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuroliteregister,https://www.govinfo.gov/content/pkg/FR-1995-05-26/pdf/95-13033.pdf,1995-05-26, NeuroliteRegister,,,Neurolite<Register>,5279811,Dupont Merck Pharmaceutical Co.,2595.0,1602.0,993.0,"October 18, 1987",1987-10-18,1994-11-23,NDA 20-256,156
Determination of Regulatory Review Period for Purposes of Patent Extension; RENORMAXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for RENORMAX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 36291,95-17345,https://www.federalregister.gov/documents/1995/07/14/95-17345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-renormaxregister,https://www.govinfo.gov/content/pkg/FR-1995-07-14/pdf/95-17345.pdf,1995-07-14, RENORMAXRegister,,,RENORMAX<Register>,4470972,Schering Corp.,3996.0,2901.0,1095.0,"January 22, 1984",1984-01-22,1994-12-29,NDA 20-240,730
Determination of Regulatory Review Period for Purposes of Patent Extension; NAVELBINERegister Injection,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for NAVELBINE<Register> Injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 36812,95-17503,https://www.federalregister.gov/documents/1995/07/18/95-17503/determination-of-regulatory-review-period-for-purposes-of-patent-extension-navelbineregister,https://www.govinfo.gov/content/pkg/FR-1995-07-18/pdf/95-17503.pdf,1995-07-18, NAVELBINERegister Injection,,,NAVELBINE<Register> Injection,4307100,Burroughs Wellcome Co.,1621.0,1137.0,484.0,"July 18, 1990",1990-07-18,1994-12-23,NDA 20-388,1067
Determination of Regulatory Review Period for Purposes of Patent Extension; LAMICTALRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for LAMICTAL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 36813,95-17504,https://www.federalregister.gov/documents/1995/07/18/95-17504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lamictalregister,https://www.govinfo.gov/content/pkg/FR-1995-07-18/pdf/95-17504.pdf,1995-07-18, LAMICTALRegister,,,LAMICTAL<Register>,4602017,Burroughs Wellcome Co.,3703.0,2693.0,1010.0,"November 8, 1984",1984-04-12,1994-12-27,IND 23,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; NISOCOR,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for NISOCOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 39000,95-18687,https://www.federalregister.gov/documents/1995/07/31/95-18687/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nisocor,https://www.govinfo.gov/content/pkg/FR-1995-07-31/pdf/95-18687.pdf,1995-07-31, NISOCOR,,,NISOCOR,4154839,Bayer AG,4965.0,4292.0,673.0,"July 2, 1981",1981-07-02,1995-02-02,IND 33,1377
Determination of Regulatory Review Period for Purposes of Patent Extension; Allergen Patch Test (Thin-layer Rapid Use Epicutaneous (T.R.U.E.) TestSUPTM),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Allergen Patch Test (Thin-layer Rapid Use Epicutaneous (T.R.U.E.) Test<SUP>TM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biologic product.",60 FR 39752,95-19060,https://www.federalregister.gov/documents/1995/08/03/95-19060/determination-of-regulatory-review-period-for-purposes-of-patent-extension-allergen-patch-test,https://www.govinfo.gov/content/pkg/FR-1995-08-03/pdf/95-19060.pdf,1995-08-03, Allergen Patch Test (Thin-layer Rapid Use Epicutaneous (T.R.U.E.) TestSUPTM),,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ExcimedSUPTM UV200LA/SVS APEX Excimer Laser Systems,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Excimed<SUP>TM UV200LA/SVS APEX Excimer Laser Systems and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 40183,95-19425,https://www.federalregister.gov/documents/1995/08/07/95-19425/determination-of-regulatory-review-period-for-purposes-of-patent-extension-excimedsuptm-uv200lasvs,https://www.govinfo.gov/content/pkg/FR-1995-08-07/pdf/95-19425.pdf,1995-08-07, ExcimedSUPTM UV200LA/SVS APEX Excimer Laser Systems,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ULTRAVISTRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULTRAVIST<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 54694,95-26501,https://www.federalregister.gov/documents/1995/10/25/95-26501/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ultravistregister,https://www.govinfo.gov/content/pkg/FR-1995-10-25/pdf/95-26501.pdf,1995-10-25, ULTRAVISTRegister,,,ULTRAVIST<Register>,4364921,Schering Aktiengesellschaft,2518.0,1353.0,1165.0,"June 19, 1988",1988-06-19,1995-05-10,NDA 20-220,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; CELLCEPTRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CELLCEPT<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62865,95-29768,https://www.federalregister.gov/documents/1995/12/07/95-29768/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cellceptregister,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29768.pdf,1995-12-07, CELLCEPTRegister,,,CELLCEPT<Register>,4753935,"Syntex, Inc.",2479.0,2304.0,175.0,"July 21, 1988",1988-07-21,1995-05-03,IND 31,824
Determination of Regulatory Review Period for Purposes of Patent Extension; ZINECARDSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZINECARD<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62866,95-29769,https://www.federalregister.gov/documents/1995/12/07/95-29769/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zinecardsuptm,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29769.pdf,1995-12-07, ZINECARDSUPTM,,,ZINECARD<SUP>TM,4275063,British Technology Group Ltd.,2748.0,1546.0,1202.0,"November 18, 1987",1987-09-22,1995-05-26,IND 30,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; CPIRegister VentakRegister P2 AICD System,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CPI<Register> Ventak<Register> P2 AICD System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 62867,95-29766,https://www.federalregister.gov/documents/1995/12/07/95-29766/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cpiregister,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29766.pdf,1995-12-07, CPIRegister VentakRegister P2 AICD System,,,CPI<Register> Ventak<Register> P2 AICD System,Re. 34879,"Cardiac Pacemakers, Inc.",1178.0,620.0,558.0,"December 20, 1991",1991-12-20,1995-03-10,PMA P930035,363
Determination of Regulatory Review Period for Purposes of Patent - Extension; VALTREXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for VALTREX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62868,95-29809,https://www.federalregister.gov/documents/1995/12/07/95-29809/determination-of-regulatory-review-period-for-purposes-of-patent---extension-valtrexregister,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29809.pdf,1995-12-07, VALTREXRegister,,,VALTREX<Register>,4957924,Burroughs Wellcome Co.,1907.0,1541.0,366.0,"April 5, 1990",1990-03-06,1995-06-23,IND 34,1052
Determination of Regulatory Review Period for Purposes of Patent Extension; ULTANESUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULTANE<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62869,95-29808,https://www.federalregister.gov/documents/1995/12/07/95-29808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ultanesuptm,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29808.pdf,1995-12-07, ULTANESUPTM,,,ULTANE<SUP>TM,4250334,"Baxter International, Inc.",3418.0,3086.0,332.0,"January 29, 1986",1994-07-08,1995-06-07,IND 27,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVACIDRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVACID<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 72,95-31557,https://www.federalregister.gov/documents/1996/01/02/95-31557/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevacidregister,https://www.govinfo.gov/content/pkg/FR-1996-01-02/pdf/95-31557.pdf,1996-01-02, PREVACIDRegister,,,PREVACID<Register>,4628098,Hiroshi Akimoto,2870.0,2328.0,542.0,"July 3, 1987",1987-07-03,1995-05-10,NDA 20-406,1706
Determination of Regulatory Review Period for Purposes of Patent Extension; ADENOSCANRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADENOSCAN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 73,95-31555,https://www.federalregister.gov/documents/1996/01/02/95-31555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adenoscanregister,https://www.govinfo.gov/content/pkg/FR-1996-01-02/pdf/95-31555.pdf,1996-01-02, ADENOSCANRegister,,,ADENOSCAN<Register>,5070877,"Medco Research, Inc.",2688.0,768.0,1920.0,"January 9, 1988",1988-01-09,1995-05-18,NDA 20-059,159
Determination of Regulatory Review Period for Purposes of Patent Extension; IMMITICIDERegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMMITICIDE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 11054,96-6454,https://www.federalregister.gov/documents/1996/03/18/96-6454/determination-of-regulatory-review-period-for-purposes-of-patent-extension-immiticideregister,https://www.govinfo.gov/content/pkg/FR-1996-03-18/pdf/96-6454.pdf,1996-03-18, IMMITICIDERegister,,,IMMITICIDE<Register>,4514390,Rockefeller University,2650.0,2037.0,613.0,"April 20, 1988",1988-04-20,1995-07-21,NADA 141-042,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; OPTIMMUNERegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPTIMMUNE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 15264,96-8474,https://www.federalregister.gov/documents/1996/04/05/96-8474/determination-of-regulatory-review-period-for-purposes-of-patent-extension-optimmuneregister,https://www.govinfo.gov/content/pkg/FR-1996-04-05/pdf/96-8474.pdf,1996-04-05, OPTIMMUNERegister,,,OPTIMMUNE<Register>,4839342,Schering Corp.,1898.0,1668.0,230.0,"May 24, 1990",1995-08-02,1995-08-02,NADA 141-052,698
Determination of Regulatory Review Period for Purposes of Patent Extension; FLOLANRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLOLAN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 15265,96-8363,https://www.federalregister.gov/documents/1996/04/05/96-8363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flolanregister,https://www.govinfo.gov/content/pkg/FR-1996-04-05/pdf/96-8363.pdf,1996-04-05, FLOLANRegister,,,FLOLAN<Register>,4338325 and 4883812,Glaxo Wellcome Inc.,5927.0,5357.0,570.0,"July 1, 1979",1979-07-01,1995-09-20,IND 16,730
Determination of Regulatory Review Period for Purposes of Patent Extension; CASODEXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CASODEX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 17308,96-9671,https://www.federalregister.gov/documents/1996/04/19/96-9671/determination-of-regulatory-review-period-for-purposes-of-patent-extension-casodexregister,https://www.govinfo.gov/content/pkg/FR-1996-04-19/pdf/96-9671.pdf,1996-04-19, CASODEXRegister,,,CASODEX<Register>,4636505,Zeneca Ltd.,3059.0,2673.0,386.0,"May 22, 1987",1987-05-22,1995-10-14,NDA 20-498,1721
Determination of Regulatory Review Period for Purposes of Patent Extension; EPIVIRSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for EPIVIR<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application of the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.",61 FR 24316,96-12092,https://www.federalregister.gov/documents/1996/05/14/96-12092/determination-of-regulatory-review-period-for-purposes-of-patent-extension-epivirsuptm,https://www.govinfo.gov/content/pkg/FR-1996-05-14/pdf/96-12092.pdf,1996-05-14, EPIVIRSUPTM,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRUSOPTRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRUSOPT<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 24317,96-12093,https://www.federalregister.gov/documents/1996/05/14/96-12093/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trusoptregister,https://www.govinfo.gov/content/pkg/FR-1996-05-14/pdf/96-12093.pdf,1996-05-14, TRUSOPTRegister,,,TRUSOPT<Register>,4797413,"Merck & Co., Inc.",2101.0,1736.0,365.0,"March 11, 1989",1989-03-11,1994-12-09,NDA 20-408,1232
Determination of Regulatory Review Period for Purposes of Patent Extension; COREGRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for COREG<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 26911,96-13307,https://www.federalregister.gov/documents/1996/05/29/96-13307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-coregregister,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13307.pdf,1996-05-29, COREGRegister,,,COREG<Register>,4503067,Boehringer Mannheim GmbH,3625.0,2727.0,898.0,"October 13, 1985",1985-10-13,1995-09-14,NDA 20-,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; FOSAMAXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for FOSAMAX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 26912,96-13308,https://www.federalregister.gov/documents/1996/05/29/96-13308/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fosamaxregister,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13308.pdf,1996-05-29, FOSAMAXRegister,,,FOSAMAX<Register>,4621077,Instituto Gentili S.p.A.,2558.0,2375.0,183.0,"September 29, 1988",1988-09-29,1995-09-29,NDA 20-560,1369
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYRTECSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZYRTEC<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.",61 FR 26913,96-13310,https://www.federalregister.gov/documents/1996/05/29/96-13310/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zyrtecsuptm,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13310.pdf,1996-05-29, ZYRTECSUPTM,,,ZYRTEC<SUP>TM,4525358,"UCB PHARMA, INC.",4210.0,1493.0,2717.0,"May 31, 1984",1984-05-31,1995-12-08,NDA 19-835,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; AMARYLRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMARYL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims human drug product.",61 FR 26913,96-13311,https://www.federalregister.gov/documents/1996/05/29/96-13311/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amarylregister,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13311.pdf,1996-05-29, AMARYLRegister,,,AMARYL<Register>,4379785,Hoechst Atiengesellschaft,2683.0,2225.0,458.0,"July 28, 1988",1988-07-28,1995-11-30,NDA 20-,1569
Determination of Regulatory Review Period for Purposes of Patent Extension; PRECOSESUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRECOSE<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 27085,96-13535,https://www.federalregister.gov/documents/1996/05/30/96-13535/determination-of-regulatory-review-period-for-purposes-of-patent-extension-precosesuptm,https://www.govinfo.gov/content/pkg/FR-1996-05-30/pdf/96-13535.pdf,1996-05-30, PRECOSESUPTM,,,PRECOSE<SUP>TM,4904769,Bayer AG,5647.0,3789.0,1858.0,"March 23, 1980",1980-03-23,1995-09-06,NDA 20-,922
Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41635,96-20339,https://www.federalregister.gov/documents/1996/08/09/96-20339/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cedaxregister,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20339.pdf,1996-08-09, CEDAXRegister,,,CEDAX<Register>,4812561,Schering-Plough Corp.,2641.0,1179.0,1462.0,"September 28, 1988",1988-09-28,1995-12-20,NDA 50-686,902
Determination of Regulatory Review Period for Purposes of Patent Extension; DYNABACRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DYNABAC<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41636,96-20340,https://www.federalregister.gov/documents/1996/08/09/96-20340/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dynabacregister,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20340.pdf,1996-08-09, DYNABACRegister,,,DYNABAC<Register>,4048306,Boehringer Ingelheim GmbH,2469.0,1687.0,782.0,"September 16, 1988",1988-09-16,1995-06-19,NDA 50-678,1726
Determination of Regulatory Review Period for Purposes of Patent Extension; CORVERT,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CORVERT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41637,96-20342,https://www.federalregister.gov/documents/1996/08/09/96-20342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corvert,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20342.pdf,1996-08-09, CORVERT,,,CORVERT,5155268,the Upjohn Co.,2292.0,1865.0,427.0,"September 20, 1989",1989-09-20,1995-12-28,NDA 20-491,73
Determination of Regulatory Review Period for Purposes of Patent Extension; MAXIPIMERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for MAXIPIME<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41638,96-20343,https://www.federalregister.gov/documents/1996/08/09/96-20343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maxipimeregister,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20343.pdf,1996-08-09, MAXIPIMERegister,,,MAXIPIME<Register>[[Page 41639]],4406899,Bristol-Myers Squibb Co.,3741.0,2444.0,1297.0,"October 23, 1985",1985-10-23,1996-01-18,NDA 50-,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; ARIMIDEXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARIMIDEX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 44069,96-21849,https://www.federalregister.gov/documents/1996/08/27/96-21849/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arimidexregister,https://www.govinfo.gov/content/pkg/FR-1996-08-27/pdf/96-21849.pdf,1996-08-27, ARIMIDEXRegister,,,ARIMIDEX<Register>,4935437,Zeneca Ltd.,1336.0,1062.0,274.0,"May 2, 1992",1992-05-02,1995-12-27,NDA 20-541,565
Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAXRegister Oral Suspension,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> Oral Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 44068,96-21844,https://www.federalregister.gov/documents/1996/08/27/96-21844/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cedaxregister-oral,https://www.govinfo.gov/content/pkg/FR-1996-08-27/pdf/96-21844.pdf,1996-08-27, CEDAXRegister Oral Suspension,,,CEDAX<Register> Oral Suspension,4634697,Schering-Plough Corp.,2641.0,1179.0,1462.0,"September 28, 1988",1988-09-28,1995-12-20,NDA 50-686,1826
Determination of Regulatory Review Period for Purposed of Patent Extension; CEDAXRegister Capsules,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> Capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 44070,96-21851,https://www.federalregister.gov/documents/1996/08/27/96-21851/determination-of-regulatory-review-period-for-purposed-of-patent-extension-cedaxregister-capsules,https://www.govinfo.gov/content/pkg/FR-1996-08-27/pdf/96-21851.pdf,1996-08-27, CEDAXRegister Capsules,,,CEDAX<Register> Capsules,4812561,Schering-Plough Corp.,3065.0,1603.0,1462.0,"August 1, 1987",1987-08-01,1995-12-20,NDA 50-685,902
Determination of Regulatory Review Period for Purposes of Patent Extension; VEXOLSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for VEXOL<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 45433,96-22123,https://www.federalregister.gov/documents/1996/08/29/96-22123/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vexolsuptm,https://www.govinfo.gov/content/pkg/FR-1996-08-29/pdf/96-22123.pdf,1996-08-29, VEXOLSUPTM,,,VEXOL<SUP>TM,4686214,"Alcon Laboratories, Inc.",1779.0,1566.0,213.0,"February 17, 1990",1990-02-17,1994-12-30,NDA 20-474,995
Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAXRegister Capsules,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 46465,96-22285,https://www.federalregister.gov/documents/1996/09/03/96-22285/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cedaxregister-capsules,https://www.govinfo.gov/content/pkg/FR-1996-09-03/pdf/96-22285.pdf,1996-09-03, CEDAXRegister Capsules,,,CEDAX<Register> capsules,4 634697,Schering-Plough Corp.,3065.0,1603.0,1462.0,"August 1, 1987",1987-08-01,1995-12-20,NDA 20-685,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; NeutrexinSUPTM; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of August 30, 1994 (59 FR 44737). The document announced FDA's determination of the regulatory review period for purposes of patent extension for Neutrexin<SUP>TM (trimetrexate glucuronate). The document was published with an error in one of the dates stated as part of the regulatory review period and requires additional clarification between the patent extension applicant's records and FDA's records.",61 FR 53748,96-26301,https://www.federalregister.gov/documents/1996/10/15/96-26301/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neutrexinsuptm-correction,https://www.govinfo.gov/content/pkg/FR-1996-10-15/pdf/96-26301.pdf,1996-10-15, NeutrexinSUPTM, Correction,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NuflorRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Nuflor<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 60106,96-30196,https://www.federalregister.gov/documents/1996/11/26/96-30196/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuflorregister,https://www.govinfo.gov/content/pkg/FR-1996-11-26/pdf/96-30196.pdf,1996-11-26, NuflorRegister,,,Nuflor<Register>,4235892,Schering Corp.,4209.0,4205.0,4.0,"November 23, 1984",1984-11-23,1996-05-31,NADA 141-063,1096
Determination of Regulatory Review Period for Purposes of Patent Extension; Buphenyl Powder,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Buphenyl Powder and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 60107,96-30195,https://www.federalregister.gov/documents/1996/11/26/96-30195/determination-of-regulatory-review-period-for-purposes-of-patent-extension-buphenyl-powder,https://www.govinfo.gov/content/pkg/FR-1996-11-26/pdf/96-30195.pdf,1996-11-26, Buphenyl Powder,,,[[Page 60108]]Buphenyl Powder,4457942,"Ucyclyd Pharma, Inc.",4528.0,4089.0,439.0,"December 9, 1983",1983-12-09,1996-04-30,NDA 20-573,730
Determination of Regulatory Review Period for Purposes of Patent Extension; DOMITORRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DOMITOR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 60708,96-30388,https://www.federalregister.gov/documents/1996/11/29/96-30388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-domitorregister,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30388.pdf,1996-11-29, DOMITORRegister,,,DOMITOR<Register>,4544664,ORION-YHTYMA OY,4000.0,2294.0,1706.0,"April 8, 1985",1985-04-08,1996-03-19,NADA 140-999,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; DOMITORRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DOMITOR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 60709,96-30389,https://www.federalregister.gov/documents/1996/11/29/96-30389/determination-of-regulatory-review-period-for-purposes-of-patent-extension-domitorregister,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30389.pdf,1996-11-29, DOMITORRegister,,,DOMITOR<Register>,4670455,ORION-YHTYMA OY,4000.0,2294.0,1706.0,"April 8, 1985",1985-04-08,1996-03-19,NADA 140-999,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; TAXOTERERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for TAXOTERE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 60710,96-30386,https://www.federalregister.gov/documents/1996/11/29/96-30386/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taxotereregister,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30386.pdf,1996-11-29, TAXOTERERegister,,,TAXOTERE<Register>,4814470,Rhone-Poulenc Rorer S.A.,2016.0,1358.0,658.0,"November 8, 1990",1990-11-08,1996-05-14,NDA 20-449,1035
Determination of Regulatory Review Period for Purposes of Patent Extension; MYOVIEWSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYOVIEW<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 60711,96-30387,https://www.federalregister.gov/documents/1996/11/29/96-30387/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myoviewsuptm,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30387.pdf,1996-11-29, MYOVIEWSUPTM,,,MYOVIEW<SUP>TM,5045302,Amersham International PLC,2062.0,1084.0,978.0,"June 20, 1990",1990-06-20,1996-02-09,NDA 20-372,491
Determination of Regulatory Review Period for Purposes of Patent Extension; VISTIDESUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for VISTIDE<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 66675,96-32033,https://www.federalregister.gov/documents/1996/12/18/96-32033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vistidesuptm,https://www.govinfo.gov/content/pkg/FR-1996-12-18/pdf/96-32033.pdf,1996-12-18, VISTIDESUPTM,,,VISTIDE<SUP>TM,5142051,the Institute of Organic Chemistry & Biochemistry of the Academy of Science of the Czech Republic,1533.0,1266.0,267.0,"April 17, 1992",1992-04-17,1996-06-26,NDA 20-638,305
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 101,96-33381,https://www.federalregister.gov/documents/1997/01/02/96-33381/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-02/pdf/96-33381.pdf,1997-01-02, DIFFERIN Solution,,,DIFFERIN Solution,5212303,Centre International de Recherches Dermatologiques (CIRD),2814.0,1651.0,1163.0,"September 18, 1988",1988-09-18,1996-05-31,NDA 20-338,13
Determination of Regulatory Review Period for Purposes of Patent Extension; Olean,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Olean and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive product.",62 FR 763,97-138,https://www.federalregister.gov/documents/1997/01/06/97-138/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olean,https://www.govinfo.gov/content/pkg/FR-1997-01-06/pdf/97-138.pdf,1997-01-06, Olean,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMPTOSARRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CAMPTOSAR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4066,97-2067,https://www.federalregister.gov/documents/1997/01/28/97-2067/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camptosarregister,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2067.pdf,1997-01-28, CAMPTOSARRegister,,,CAMPTOSAR<Register>,4604463,Kabushiki Kaisha Yakult Honsha,2111.0,1941.0,170.0,"September 5, 1990",1990-09-05,1996-06-14,NDA 20-571,1139
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4065,97-2066,https://www.federalregister.gov/documents/1997/01/28/97-2066/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2066.pdf,1997-01-28, DIFFERIN Solution,,,DIFFERIN Solution,4717720,Centre International de Recherches Dermatologiques (CIRD),2814.0,1651.0,1163.0,"September 18, 1988",1988-09-18,1996-05-31,NDA 20-338,1512
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4067,97-2068,https://www.federalregister.gov/documents/1997/01/28/97-2068/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2068.pdf,1997-01-28, DIFFERIN Solution,,,DIFFERIN Solution,5015758,Centre International de Recherches Dermatologiques (CIRD),2814.0,1651.0,1163.0,"September 18, 1988",1988-09-18,1996-05-31,NDA 20-338,257
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4064,97-2064,https://www.federalregister.gov/documents/1997/01/28/97-2064/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2064.pdf,1997-01-28, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,5212303,Centre International de Recherches Dermatologiques (CIRD),2447.0,1401.0,1046.0,"September 20, 1989",1989-09-20,1996-05-31,NDA 20-380,13
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4065,97-2065,https://www.federalregister.gov/documents/1997/01/28/97-2065/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2065.pdf,1997-01-28, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,5015758,Centre International de Recherches Dermatologiques (``CIRD''),2447.0,1401.0,1046.0,"September 20, 1989","September 20, 1989","May 31, 1996",NDA 20-380,257
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4300,97-2141,https://www.federalregister.gov/documents/1997/01/29/97-2141/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-29/pdf/97-2141.pdf,1997-01-29, DIFFERIN Solution,,,DIFFERIN Solution,Re. 34440,Centre International de Recherches Dermatologiques (CIRD),2814.0,1651.0,1163.0,"September 18, 1988","September 18, 1988","May 31, 1996",NDA 20-338,433
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 5432,97-2871,https://www.federalregister.gov/documents/1997/02/05/97-2871/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-02-05/pdf/97-2871.pdf,1997-02-05, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,Re. 34440,Centre International de Recherches Dermatologiques (CIRD),2447.0,1401.0,1046.0,"September 20, 1989","September 20, 1989","May 31, 1996",NDA 20-,433
Determination of Regulatory Review Period for Purposes of Patent Extension; DECTOMAX,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DECTOMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 6263,97-3315,https://www.federalregister.gov/documents/1997/02/11/97-3315/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dectomax,https://www.govinfo.gov/content/pkg/FR-1997-02-11/pdf/97-3315.pdf,1997-02-11, DECTOMAX,,,DECTOMAX,5089480,"Pfizer, Inc.",21.0,2836.0,2695.0,"October 26, 1988","July 30, 1996","July 30, 1996",NADA 141-061,527
Determination of Regulatory Review Period for Purposes of Patent Extension; MERREMRegister I.V.,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MERREM<Register> I.V. and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 6261,97-3313,https://www.federalregister.gov/documents/1997/02/11/97-3313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-merremregister-iv,https://www.govinfo.gov/content/pkg/FR-1997-02-11/pdf/97-3313.pdf,1997-02-11, MERREMRegister I.V.,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 6262,97-3314,https://www.federalregister.gov/documents/1997/02/11/97-3314/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-02-11/pdf/97-3314.pdf,1997-02-11, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,4717720,Centre International de Recherches Dermatologiques (CIRD),2447.0,1401.0,1046.0,"September 20, 1989","September 20, 1989","May 31, 1996",NDA 20-380,1512
Determination of Regulatory Review Period for Purposes of Patent Extension; ULTIVASUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULTIVA<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 6549,97-3417,https://www.federalregister.gov/documents/1997/02/12/97-3417/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ultivasuptm,https://www.govinfo.gov/content/pkg/FR-1997-02-12/pdf/97-3417.pdf,1997-02-12, ULTIVASUPTM,,,ULTIVA<SUP>TM,5019583,"Glaxo Wellcome, Inc.",2222.0,1920.0,302.0,"June 14, 1990","June 14, 1990","July 12, 1996",NDA 20-,1088
Determination of Regulatory Review Period for Purposes of Patent Extension; REDUXSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for REDUX<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 9198,97-4961,https://www.federalregister.gov/documents/1997/02/28/97-4961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reduxsuptm,https://www.govinfo.gov/content/pkg/FR-1997-02-28/pdf/97-4961.pdf,1997-02-28, REDUXSUPTM,,,REDUX<SUP>TM,4309445,"Interneuron Pharmaceuticals, Inc.",1613.0,541.0,1072.0,"December 1, 1991","December 1, 1991","April 29, 1996",IND 38,1322
Determination of Regulatory Review Period for Purposes of Patent Extension; Olean; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of January 6, 1997 (62 FR 763). The document announced FDA's determination of the regulatory review period for purposes of patent extension for Olean (olestra). The document was published with an error. This document corrects that error.",62 FR 9197,97-4960,https://www.federalregister.gov/documents/1997/02/28/97-4960/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olean-correction,https://www.govinfo.gov/content/pkg/FR-1997-02-28/pdf/97-4960.pdf,1997-02-28, Olean, Correction,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EXCENELRegister Sterile Suspension,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXCENEL<Register> Sterile Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 9195,97-4954,https://www.federalregister.gov/documents/1997/02/28/97-4954/determination-of-regulatory-review-period-for-purposes-of-patent-extension-excenelregister-sterile,https://www.govinfo.gov/content/pkg/FR-1997-02-28/pdf/97-4954.pdf,1997-02-28, EXCENELRegister Sterile Suspension,,,EXCENEL<Register> Sterile Suspension,4902683,Pharmacia & Upjohn Co.,900.0,881.0,19.0,"November 10, 1993","November 10, 1993","April 26, 1996",NADA 140-890,1151
Determination of Regulatory Review Period for Purposes of Patent Extension; IVY BLOCKSUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IVY BLOCK<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 12652,97-6590,https://www.federalregister.gov/documents/1997/03/17/97-6590/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ivy-blocksuptm,https://www.govinfo.gov/content/pkg/FR-1997-03-17/pdf/97-6590.pdf,1997-03-17, IVY BLOCKSUPTM,,,IVY BLOCK<SUP>TM,4861584,"United Catalysts, Inc.",2644.0,1946.0,698.0,"June 2, 1989","June 2, 1989","August 26, 1996",IND 33,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; BAYTRILRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BAYTRIL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 12831,97-6719,https://www.federalregister.gov/documents/1997/03/18/97-6719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baytrilregister,https://www.govinfo.gov/content/pkg/FR-1997-03-18/pdf/97-6719.pdf,1997-03-18, BAYTRILRegister,,,BAYTRIL<Register>,4670444,Bayer Aktiengesellschaft,4334.0,648.0,3686.0,"November 24, 1984","October 4, 1996","October 4, 1996",NADA 140-828,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; CEREBYXRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEREBYX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 13387,97-6976,https://www.federalregister.gov/documents/1997/03/20/97-6976/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerebyxregister,https://www.govinfo.gov/content/pkg/FR-1997-03-20/pdf/97-6976.pdf,1997-03-20, CEREBYXRegister,,,CEREBYX<Register>,4260769,Warner-Lambert Co.,3748.0,3218.0,530.0,"May 4, 1986","May 4, 1986","August 5, 1996",NDA 20-450,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; HYCAMTINSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYCAMTIN<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 13388,97-6977,https://www.federalregister.gov/documents/1997/03/20/97-6977/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hycamtinsuptm,https://www.govinfo.gov/content/pkg/FR-1997-03-20/pdf/97-6977.pdf,1997-03-20, HYCAMTINSUPTM,,,HYCAMTIN<SUP>TM,5004758,SmithKline Beecham Corp.,2644.0,2485.0,159.0,"March 4, 1989","February 2, 1989","May 28, 1996",IND 32,572
Determination of Regulatory Review Period for Purposes of Patent Extension; DAUNOXOMERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DAUNOXOME<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 13651,97-7135,https://www.federalregister.gov/documents/1997/03/21/97-7135/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daunoxomeregister,https://www.govinfo.gov/content/pkg/FR-1997-03-21/pdf/97-7135.pdf,1997-03-21, DAUNOXOMERegister,,,DAUNOXOME<Register>,5435989; 5441745; and 5019369,"NeXstar Pharmaceuticals, Inc.",2771.0,1629.0,1142.0,"September 8, 1988","September 8, 1988","April 8, 1996",IND 31,258
Determination of Regulatory Review Period for Purposes of Patent Extension; ACCOLATERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACCOLATE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16164,97-8622,https://www.federalregister.gov/documents/1997/04/04/97-8622/determination-of-regulatory-review-period-for-purposes-of-patent-extension-accolateregister,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8622.pdf,1997-04-04, ACCOLATERegister,,,ACCOLATE<Register>,4859692,"Zeneca, Inc.",3110.0,2651.0,459.0,"March 24, 1988","March 24, 1988","September 26, 1996",NDA 20-547,1496
Determination of Regulatory Review Period for Purposes of Patent Extension; TRITECRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRITEC<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16166,97-8624,https://www.federalregister.gov/documents/1997/04/04/97-8624/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tritecregister,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8624.pdf,1997-04-04, TRITECRegister,,,TRITEC<Register>,5008256,"Glaxo Wellcome, Inc.",1074.0,485.0,589.0,"September 1, 1993","September 1, 1993","August 8, 1996",NDA 20-,831
Determination of Regulatory Review Period for Purposes of Patent Extension; PHOTOFRINRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for PHOTOFRIN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16163,97-8621,https://www.federalregister.gov/documents/1997/04/04/97-8621/determination-of-regulatory-review-period-for-purposes-of-patent-extension-photofrinregister,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8621.pdf,1997-04-04, PHOTOFRINRegister,,,PHOTOFRIN<Register>,5145863,"Health Research, Inc.",4065.0,3441.0,624.0,"November 11, 1984","November 11, 1984","December 27, 1995",NDA 20-,915
Determination of Regulatory Review Period for Purposes of Patent Extension; XALATANSUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALATAN<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16162,97-8619,https://www.federalregister.gov/documents/1997/04/04/97-8619/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalatansuptm,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8619.pdf,1997-04-04, XALATANSUPTM,,,XALATAN<SUP>TM,4599353,the Trustees of Columbia University in the City of New York,1875.0,1519.0,356.0,"April 20, 1991","April 20, 1991","June 5, 1996",NDA 20-597,1116
Determination of Regulatory Review Period for Purposes of Patent Extension; REMERONSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for REMERON<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16165,97-8623,https://www.federalregister.gov/documents/1997/04/04/97-8623/determination-of-regulatory-review-period-for-purposes-of-patent-extension-remeronsuptm,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8623.pdf,1997-04-04, REMERONSUPTM,,,REMERON<SUP>TM,4062848,Akzona Inc.,5003.0,4501.0,502.0,"October 5, 1982","October 5, 1982","June 14, 1996",NDA 20-415,730
Determination of Regulatory Review Period for Purposes of Patent Extension; AstelinRegister Nasal Spray,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Astelin<Register> Nasal Spray and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16167,97-8626,https://www.federalregister.gov/documents/1997/04/04/97-8626/determination-of-regulatory-review-period-for-purposes-of-patent-extension-astelinregister-nasal,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8626.pdf,1997-04-04, AstelinRegister Nasal Spray,,,Astelin<Register> Nasal Spray,5164194,Astra Medica AG,2797.0,749.0,2048.0,"March 8, 1989","March 8, 1989","November 1, 1996",NDA 20-114,349
Determination of Regulatory Review Period for Purposes of Patent Extension; MERETEK UBTSUPTM Breath Test,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for MERETEK UBT<SUP>TM Breath Test and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16166,97-8625,https://www.federalregister.gov/documents/1997/04/04/97-8625/determination-of-regulatory-review-period-for-purposes-of-patent-extension-meretek-ubtsuptm-breath,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8625.pdf,1997-04-04, MERETEK UBTSUPTM Breath Test,,,MERETEK UBT<SUP>TM Breath Test,4830010,"Meretekdiagnostics, Inc.",2023.0,1527.0,496.0,"March 7, 1991","August 7, 1985","September 17, 1996",IND 26,780
Determination of Regulatory Review Period for Purposes of Patent Extension; OXILANSUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OXILAN<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 18775,97-9917,https://www.federalregister.gov/documents/1997/04/17/97-9917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxilansuptm,https://www.govinfo.gov/content/pkg/FR-1997-04-17/pdf/97-9917.pdf,1997-04-17, OXILANSUPTM,,,OXILAN<SUP>TM,4954348,Cook Imaging Corp.,2757.0,1644.0,1113.0,"June 5, 1988","June 5, 1988","December 21, 1995",NDA 20-,737
Determination of Regulatory Review Period for Purposes of Patent Extension; MENTAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MENTAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 19324,97-10133,https://www.federalregister.gov/documents/1997/04/21/97-10133/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mentax,https://www.govinfo.gov/content/pkg/FR-1997-04-21/pdf/97-10133.pdf,1997-04-21, MENTAX,,,MENTAX,5021458,"Penederm, Inc.",1201.0,638.0,563.0,"July 7, 1993","July 7, 1993","October 18, 1996",NDA 20-524,866
Determination of Regulatory Review Period for Purposes of Patent Extension; PATANOLSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PATANOL<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 29143,97-14108,https://www.federalregister.gov/documents/1997/05/29/97-14108/determination-of-regulatory-review-period-for-purposes-of-patent-extension-patanolsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-05-29/pdf/97-14108.pdf,1997-05-29, PATANOLSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ALLEGRASUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALLEGRA<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 37267,97-18125,https://www.federalregister.gov/documents/1997/07/11/97-18125/determination-of-regulatory-review-period-for-purposes-of-patent-extension-allegrasuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-11/pdf/97-18125.pdf,1997-07-11, ALLEGRASUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ANTISEDANRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANTISEDAN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 38563,97-18911,https://www.federalregister.gov/documents/1997/07/18/97-18911/determination-of-regulatory-review-period-for-purposes-of-patent-extension-antisedanregister,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18911.pdf,1997-07-18, ANTISEDANRegister,,,ANTISEDAN<Register>,4689339,ANTISEDAN<Register>,2663.0,1429.0,1234.0,"April 24, 1989","April 24, 1989","August 6, 1996",NADA 141-033,1718
Determination of Regulatory Review Period for Purposes of Patent Extension; GLYSETSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLYSET<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38561,97-18909,https://www.federalregister.gov/documents/1997/07/18/97-18909/determination-of-regulatory-review-period-for-purposes-of-patent-extension-glysetsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18909.pdf,1997-07-18, GLYSETSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYFLOSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZYFLO<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38562,97-18910,https://www.federalregister.gov/documents/1997/07/18/97-18910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zyflosuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18910.pdf,1997-07-18, ZYFLOSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LipitorSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lipitor<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38564,97-18915,https://www.federalregister.gov/documents/1997/07/18/97-18915/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lipitorsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18915.pdf,1997-07-18, LipitorSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ARICEPTSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARICEPT<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38564,97-18916,https://www.federalregister.gov/documents/1997/07/18/97-18916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ariceptsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18916.pdf,1997-07-18, ARICEPTSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NAROPINSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NAROPIN<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38565,97-18917,https://www.federalregister.gov/documents/1997/07/18/97-18917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-naropinsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18917.pdf,1997-07-18, NAROPINSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MONUROLSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MONUROL<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38566,97-18919,https://www.federalregister.gov/documents/1997/07/18/97-18919/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monurolsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18919.pdf,1997-07-18, MONUROLSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ProstaScintSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ProstaScint<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biologic product.",62 FR 39002,97-19011,https://www.federalregister.gov/documents/1997/07/21/97-19011/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prostascintsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-21/pdf/97-19011.pdf,1997-07-21, ProstaScintSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BAKSUPTM/SUP Interbody Fusion System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BAK<SUP>TM</SUP> Interbody Fusion System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",62 FR 40829,97-19984,https://www.federalregister.gov/documents/1997/07/30/97-19984/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baksuptmsup-interbody,https://www.govinfo.gov/content/pkg/FR-1997-07-30/pdf/97-19984.pdf,1997-07-30, BAKSUPTM/SUP Interbody Fusion System,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; INTEGRARegister Artificial Skin,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INTEGRA<Register> Artificial Skin and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",62 FR 44477,97-22266,https://www.federalregister.gov/documents/1997/08/21/97-22266/determination-of-regulatory-review-period-for-purposes-of-patent-extension-integraregister,https://www.govinfo.gov/content/pkg/FR-1997-08-21/pdf/97-22266.pdf,1997-08-21, INTEGRARegister Artificial Skin,,,INTEGRA<Register> Artificial Skin,4947840,the Massachusetts Institute of Technology,4477.0,3173.0,1304.0,"November 30, 1983","November 30, 1983","March 1, 1996",PMA P900033,923
Determination of Regulatory Review Period for Purposes of Patent Extension; PRELAYSUPTM/SUP and REZULINSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRELAY<SUP>TM</SUP> and REZULIN<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 46501,97-23244,https://www.federalregister.gov/documents/1997/09/03/97-23244/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prelaysuptmsup-and,https://www.govinfo.gov/content/pkg/FR-1997-09-03/pdf/97-23244.pdf,1997-09-03, PRELAYSUPTM/SUP and REZULINSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LEVAQUINSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEVAQUIN<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 18204,98-9703,https://www.federalregister.gov/documents/1998/04/14/98-9703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-levaquinsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-04-14/pdf/98-9703.pdf,1998-04-14, LEVAQUINSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZAGAMRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZAGAM<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 18431,98-9864,https://www.federalregister.gov/documents/1998/04/15/98-9864/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zagamregister,https://www.govinfo.gov/content/pkg/FR-1998-04-15/pdf/98-9864.pdf,1998-04-15, ZAGAMRegister,,,ZAGAM<Register>,4795751,"Dainippon Pharmaceutical Co., Ltd.",2030.0,1671.0,359.0,"June 1, 1991","June 1, 1991","December 19, 1996",NDA 20-677,1194
Determination of Regulatory Review Period for Purposes of Patent Extension; LIPOSORBERRegister LA-15 System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LIPOSORBER<Register> LA-15 System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 24557,98-11682,https://www.federalregister.gov/documents/1998/05/04/98-11682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-liposorberregister-la-15,https://www.govinfo.gov/content/pkg/FR-1998-05-04/pdf/98-11682.pdf,1998-05-04, LIPOSORBERRegister LA-15 System,,,LIPOSORBER<Register> LA-15 System,4637994,Kanegafuchi Kagaku Kogyo Kabushiki Kaisha,3598.0,1995.0,1603.0,"April 18, 1986","April 18, 1996","February 21, 1996",PMA 880019,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; IVOMECRegister EPRINEXSUPTM/SUP Pour-On for Beef and Dairy Cattle,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IVOMEC<Register> EPRINEX<SUP>TM</SUP> Pour-On for Beef and Dairy Cattle and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",63 FR 36922,98-18141,https://www.federalregister.gov/documents/1998/07/08/98-18141/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ivomecregister,https://www.govinfo.gov/content/pkg/FR-1998-07-08/pdf/98-18141.pdf,1998-07-08, IVOMECRegister EPRINEXSUPTM/SUP Pour-On for Beef and Dairy Cattle,,,Beef and Dairy Cattle,4427663,"Merck & Co., Inc.",2492.0,2475.0,17.0,"June 22, 1990","June 22, 1990","April 16, 1997",NADA 141-079,1255
Determination of Regulatory Review Period for Purposes of Patent Extension; STROMECTOLRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STROMECTOL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 37398,98-18400,https://www.federalregister.gov/documents/1998/07/10/98-18400/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stromectolregister,https://www.govinfo.gov/content/pkg/FR-1998-07-10/pdf/98-18400.pdf,1998-07-10, STROMECTOLRegister,,,STROMECTOL<Register>,4199569,"Merck & Co., Inc.",2291.0,2055.0,236.0,"August 17, 1990","August 17, 1990","November 22, 1996",NDA 50-742,1026
Determination of Regulatory Review Period for Purposes of Patent Extension; VERLUMASUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VERLUMA<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",63 FR 37397,98-18408,https://www.federalregister.gov/documents/1998/07/10/98-18408/determination-of-regulatory-review-period-for-purposes-of-patent-extension-verlumasuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-07-10/pdf/98-18408.pdf,1998-07-10, VERLUMASUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FlowmaxSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Flowmax<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 37399,98-18407,https://www.federalregister.gov/documents/1998/07/10/98-18407/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flowmaxsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-07-10/pdf/98-18407.pdf,1998-07-10, FlowmaxSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PANDEL Cream,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PANDEL Cream and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 38410,98-18878,https://www.federalregister.gov/documents/1998/07/16/98-18878/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pandel-cream,https://www.govinfo.gov/content/pkg/FR-1998-07-16/pdf/98-18878.pdf,1998-07-16, PANDEL Cream,,,PANDEL Cream,4290962,Taisho Pharmaceutical Co. Ltd.,4165.0,3078.0,1087.0,"October 6, 1985","October 6, 1985","February 28, 1997",NDA 20-453,1096
Determination of Regulatory Review Period for Purposes of Patent Extension; QUADRAMETRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for QUADRAMET<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 38656,98-19027,https://www.federalregister.gov/documents/1998/07/17/98-19027/determination-of-regulatory-review-period-for-purposes-of-patent-extension-quadrametregister,https://www.govinfo.gov/content/pkg/FR-1998-07-17/pdf/98-19027.pdf,1998-07-17, QUADRAMETRegister,,,QUADRAMET<Register>,4898724,The Dow Chemical Co.,2844.0,2189.0,655.0,"June 16, 1989","May 16, 1989","March 28, 1997",IND 33,1412
Determination of Regulatory Review Period for Purposes of Patent Extension; FlowmaxSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Flowmax<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 39097,98-19379,https://www.federalregister.gov/documents/1998/07/21/98-19379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flowmaxsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-07-21/pdf/98-19379.pdf,1998-07-21, FlowmaxSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GEMZARRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GEMZAR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41263,98-20593,https://www.federalregister.gov/documents/1998/08/03/98-20593/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gemzarregister,https://www.govinfo.gov/content/pkg/FR-1998-08-03/pdf/98-20593.pdf,1998-08-03, GEMZARRegister,,,GEMZAR<Register>,4808614,Eli Lilly & Co.,3293.0,2824.0,469.0,"May 12, 1987","May 12, 1987","May 15, 1996",NDA 20-509,1537
Determination of Regulatory Review Period for Purposes of Patent Extension; PosicorRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Posicor<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41582,98-20743,https://www.federalregister.gov/documents/1998/08/04/98-20743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-posicorregister,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20743.pdf,1998-08-04, PosicorRegister,,,Posicor<Register>,4808605,"Hoffman-La Roche, Inc.",1793.0,1326.0,467.0,"July 25, 1992","July 25, 1992","June 20, 1997",NDA 20-689,1130
Determination of Regulatory Review Period for Purposes of Patent Extension; AniprylRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Anipryl<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",63 FR 41578,98-20708,https://www.federalregister.gov/documents/1998/08/04/98-20708/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aniprylregister,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20708.pdf,1998-08-04, AniprylRegister,,,Anipryl<Register>,5192808,"Deprenyl Animal Health, Inc.",2329.0,2275.0,54.0,"January 15, 1991","May 30, 1997","May 30, 1997",NADA 141-080,448
Determination of Regulatory Review Period for Purposes of Patent Extension; DostinexRegister Tablets,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Dostinex<Register> Tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41581,98-20739,https://www.federalregister.gov/documents/1998/08/04/98-20739/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dostinexregister-tablets,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20739.pdf,1998-08-04, DostinexRegister Tablets,,,Dostinex<Register> Tablets,4526892,Upjohn & Pharmacia,2188.0,1825.0,363.0,"December 29, 1990","December 29, 1990","December 23, 1996",NDA 20-664,1273
Determination of Regulatory Review Period for Purposes of Patent Extension; BeneFIXSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BeneFIX<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",63 FR 41579,98-20742,https://www.federalregister.gov/documents/1998/08/04/98-20742/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benefixsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20742.pdf,1998-08-04, BeneFIXSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 41580,98-20707,https://www.federalregister.gov/documents/1998/08/04/98-20707/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aqueous-aryl,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20707.pdf,1998-08-04, AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ETOPOPHOSRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ETOPOPHOS<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41859,98-20826,https://www.federalregister.gov/documents/1998/08/05/98-20826/determination-of-regulatory-review-period-for-purposes-of-patent-extension-etopophosregister,https://www.govinfo.gov/content/pkg/FR-1998-08-05/pdf/98-20826.pdf,1998-08-05, ETOPOPHOSRegister,,,ETOPOPHOS<Register>,4904768,Bristol-Myers Squibb Co.,1719.0,1029.0,690.0,"September 4, 1991","September 4, 1991","May 17, 1996",NDA 20-457,1017
Determination of Regulatory Review Period for Purposes of Patent Extension; MirapexRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Mirapex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 42407,98-21090,https://www.federalregister.gov/documents/1998/08/07/98-21090/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mirapexregister,https://www.govinfo.gov/content/pkg/FR-1998-08-07/pdf/98-21090.pdf,1998-08-07, MirapexRegister,,,Mirapex<Register>,4886812,Boehringer Ingelheim International GmbH,2576.0,2024.0,552.0,"June 14, 1990","June 14, 1990","July 1, 1997",NDA 20-667,1440
Determination of Regulatory Review Period for Purposes of Patent Extension; Aqueous Aryl Fluorophosphite Suspension,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aqueous Aryl Fluorophosphite Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 42405,98-21130,https://www.federalregister.gov/documents/1998/08/07/98-21130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aqueous-aryl,https://www.govinfo.gov/content/pkg/FR-1998-08-07/pdf/98-21130.pdf,1998-08-07, Aqueous Aryl Fluorophosphite Suspension,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Cook GRIISUPTM/SUP Coronary Stent,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Cook GRII<SUP>TM</SUP> Coronary Stent and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 42408,98-21089,https://www.federalregister.gov/documents/1998/08/07/98-21089/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cook-griisuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-08-07/pdf/98-21089.pdf,1998-08-07, Cook GRIISUPTM/SUP Coronary Stent,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FarestonRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Fareston<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.",63 FR 42857,98-21407,https://www.federalregister.gov/documents/1998/08/11/98-21407/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farestonregister,https://www.govinfo.gov/content/pkg/FR-1998-08-11/pdf/98-21407.pdf,1998-08-11, FarestonRegister,,,Fareston<Register>,4696949,ORION-YHTYMA OY,3706.0,2828.0,878.0,"April 8, 1987","April 8, 1987","May 29, 1997",NDA 20-497,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; Silvacote K,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Silvacote K and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 51939,98-25908,https://www.federalregister.gov/documents/1998/09/29/98-25908/determination-of-regulatory-review-period-for-purposes-of-patent-extension-silvacote-k,https://www.govinfo.gov/content/pkg/FR-1998-09-29/pdf/98-25908.pdf,1998-09-29, Silvacote K,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SkelidRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Skelid<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 54481,98-27078,https://www.federalregister.gov/documents/1998/10/09/98-27078/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skelidregister,https://www.govinfo.gov/content/pkg/FR-1998-10-09/pdf/98-27078.pdf,1998-10-09, SkelidRegister,,,Skelid<Register>,4876248,"Sanofi Pharmaceuticals, Inc.",2013.0,1639,374.0,"September 4, 1991","September 4, 1991","March 7, 1997",NDA 20-707,1192
Determination of Regulatory Review Period for Purposes of Patent Extension; Rimadyl,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rimadyl and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",63 FR 54716,98-27285,https://www.federalregister.gov/documents/1998/10/13/98-27285/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rimadyl,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27285.pdf,1998-10-13, Rimadyl,,,Rimadyl,4264500,Pfizer Inc.,6572.0,5910,662.0,"October 30, 1978","October 25, 1996","October 25, 1996",NADA 141-053,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; NormifloRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Normiflo<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 54717,98-27286,https://www.federalregister.gov/documents/1998/10/13/98-27286/determination-of-regulatory-review-period-for-purposes-of-patent-extension-normifloregister,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27286.pdf,1998-10-13, NormifloRegister,,,Normiflo<Register>,4757057,Pharmacia & Upjohn Aktiebolag,3503.0,1883,1620.0,"October 22, 1987","October 22, 1987","May 23, 1997",NDA 20-227,1820
Determination of Regulatory Review Period for Purposes of Patent Extension; CorlopamRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Corlopam<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 54718,98-27357,https://www.federalregister.gov/documents/1998/10/13/98-27357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corlopamregister,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27357.pdf,1998-10-13, CorlopamRegister,,,Corlopam<Register>,4197297,Neurex Corp.,5081.0,1873,3208.0,"October 28, 1983","October 28, 1983","September 23, 1997",NDA 19-922,730
Determination of Regulatory Review Period for Purposes of Patent Extension; WiktorRegister Prime Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Wiktor<Register> Prime Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 54720,98-27392,https://www.federalregister.gov/documents/1998/10/13/98-27392/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wiktorregister-prime,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27392.pdf,1998-10-13, WiktorRegister Prime Coronary Stent System,,,Wiktor<Register> Prime Coronary Stent System,4886062,"Medtronic, Inc.",2489.0,2066,423.0,"September 5, 1990","September 5, 1990","June 27, 1997",PMA P960010,1347
Determination of Regulatory Review Period for Purposes of Patent Extension; Ray Threaded Fusion CageSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Ray Threaded Fusion Cage<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 54719,98-27284,https://www.federalregister.gov/documents/1998/10/13/98-27284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ray-threaded-fusion,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27284.pdf,1998-10-13, Ray Threaded Fusion CageSUPTM/SUP,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; AldaraSUPTM/SUP (4,689,338)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aldara<SUP>TM</SUP> (4,689,338) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 55398,98-27584,https://www.federalregister.gov/documents/1998/10/15/98-27584/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aldarasuptmsup-4689338,https://www.govinfo.gov/content/pkg/FR-1998-10-15/pdf/98-27584.pdf,1998-10-15," AldaraSUPTM/SUP (4,689,338)",,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; AldaraSUPTM/SUP (5,238,944)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aldara<SUP>TM</SUP> (5,238,944) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 56035,98-27995,https://www.federalregister.gov/documents/1998/10/20/98-27995/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aldarasuptmsup-5238944,https://www.govinfo.gov/content/pkg/FR-1998-10-20/pdf/98-27995.pdf,1998-10-20," AldaraSUPTM/SUP (5,238,944)",,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Neuro Cybernetic Prosthesis (NCPRegister) System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neuro Cybernetic Prosthesis (NCP<Register>) System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 63066,98-30005,https://www.federalregister.gov/documents/1998/11/10/98-30005/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuro-cybernetic,https://www.govinfo.gov/content/pkg/FR-1998-11-10/pdf/98-30005.pdf,1998-11-10, Neuro Cybernetic Prosthesis (NCPRegister) System,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AvaproRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Avapro<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 64268,98-30990,https://www.federalregister.gov/documents/1998/11/19/98-30990/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avaproregister,https://www.govinfo.gov/content/pkg/FR-1998-11-19/pdf/98-30990.pdf,1998-11-19, AvaproRegister,,,Avapro<Register>,5270317,Sanofi,1616.0,1246,370.0,"April 30, 1993","April 30, 1993","September 30, 1997",NDA 20-757,194
Determination of Regulatory Review Period for Purposes of Patent Extension; SeroquelRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Seroquel<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 64721,98-31101,https://www.federalregister.gov/documents/1998/11/23/98-31101/determination-of-regulatory-review-period-for-purposes-of-patent-extension-seroquelregister,https://www.govinfo.gov/content/pkg/FR-1998-11-23/pdf/98-31101.pdf,1998-11-23, SeroquelRegister,,,Seroquel<Register>,4879288,Zeneca Inc.,3264.0,2839,425.0,"October 21, 1988","October 21, 1988","September 26, 1997",NDA 20-639,1651
Determination of Regulatory Review Period for Purposes of Patent Extension; Tisseel VH Kit,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Tisseel VH Kit and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",63 FR 65211,98-31413,https://www.federalregister.gov/documents/1998/11/25/98-31413/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tisseel-vh-kit,https://www.govinfo.gov/content/pkg/FR-1998-11-25/pdf/98-31413.pdf,1998-11-25, Tisseel VH Kit,,,Tisseel VH Kit,4362567,Immuno Aktiengesellschaft fur chemsih-medizinshe Produkte,5065.0,1203,3862.0,"June 20, 1984","June 20, 1984","May 1, 1998",PLA 87-,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; Tasmar,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Tasmar and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 65599,98-31576,https://www.federalregister.gov/documents/1998/11/27/98-31576/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tasmar,https://www.govinfo.gov/content/pkg/FR-1998-11-27/pdf/98-31576.pdf,1998-11-27, Tasmar,,,Tasmar<Register>,5236952,"Hoffman-La Roche, Inc.",2618.0,2014,604.0,"December 1, 1990","December 1, 1990","January 29, 1998",NDA 20-697,530
Determination of Regulatory Review Period for Purposes of Patent Extension; VitreonRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Vitreon<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 69633,98-33457,https://www.federalregister.gov/documents/1998/12/17/98-33457/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vitreonregister,https://www.govinfo.gov/content/pkg/FR-1998-12-17/pdf/98-33457.pdf,1998-12-17, VitreonRegister,,,Vitreon<Register>,4490351,"Vitrophage, Inc.",2729.0,603,2126.0,"April 13, 1990","April 13, 1990","September 30, 1997",PMA P910068,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; Silicone AMORegister ARRAYRegister Multifocal IOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Silicone AMO<Register> ARRAY<Register> multifocal IOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 69632,98-33453,https://www.federalregister.gov/documents/1998/12/17/98-33453/determination-of-regulatory-review-period-for-purposes-of-patent-extension-silicone-amoregister,https://www.govinfo.gov/content/pkg/FR-1998-12-17/pdf/98-33453.pdf,1998-12-17, Silicone AMORegister ARRAYRegister Multifocal IOL,,,Silicone AMO<Register> ARRAY<Register> multifocal IOL,4898461,"Vision Pharmaceuticals, L.P.",2846.0,2478,368.0,"November 22, 1989","November 22, 1989","September 5, 1997",PMA P960028,1533
Determination of Regulatory Review Period for Purposes of Patent Extension; Sucralose,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Sucralose and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 70411,98-33638,https://www.federalregister.gov/documents/1998/12/21/98-33638/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sucralose,https://www.govinfo.gov/content/pkg/FR-1998-12-21/pdf/98-33638.pdf,1998-12-21, Sucralose,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Requip,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Requip and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 70411,98-33639,https://www.federalregister.gov/documents/1998/12/21/98-33639/determination-of-regulatory-review-period-for-purposes-of-patent-extension-requip,https://www.govinfo.gov/content/pkg/FR-1998-12-21/pdf/98-33639.pdf,1998-12-21, Requip,,,Requip,4452808,SmithKline Beecham Corp.,3356.0,2729,627.0,"July 14, 1988","July 14, 1988","September 19, 1997",NDA 20-658,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; MeridiaRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Meridia<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 71493,98-34171,https://www.federalregister.gov/documents/1998/12/28/98-34171/determination-of-regulatory-review-period-for-purposes-of-patent-extension-meridiaregister,https://www.govinfo.gov/content/pkg/FR-1998-12-28/pdf/98-34171.pdf,1998-12-28, MeridiaRegister,,,Meridia<Register>,4746680,Knoll Aktiengesellschaft,4323.0,3486,837.0,"January 23, 1986","January 23, 1986","November 22, 1997",NDA 20-632,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; AnzemetRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Anzemet<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 3953,99-1710,https://www.federalregister.gov/documents/1999/01/26/99-1710/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anzemetregister,https://www.govinfo.gov/content/pkg/FR-1999-01-26/pdf/99-1710.pdf,1999-01-26, AnzemetRegister,,,Anzemet<Register>,4906755,"Hoechst Marion Roussel, Inc.",2443.0,1729,714.0,"January 5, 1991","January 5, 1991","September 11, 1997",NDA 20-623,1578
Determination of Regulatory Review Period for Purposes of Patent Extension; ViagraSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Viagra<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4115,99-1796,https://www.federalregister.gov/documents/1999/01/27/99-1796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viagrasuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-01-27/pdf/99-1796.pdf,1999-01-27, ViagraSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XelodaSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xeloda<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4115,99-1851,https://www.federalregister.gov/documents/1999/01/27/99-1851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xelodasuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-01-27/pdf/99-1851.pdf,1999-01-27, XelodaSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EmadineSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Emadine<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4116,99-1792,https://www.federalregister.gov/documents/1999/01/27/99-1792/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emadinesuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-01-27/pdf/99-1792.pdf,1999-01-27, EmadineSUPTM/SUP,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Prandin (5,312,924)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Prandin and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4426,99-1937,https://www.federalregister.gov/documents/1999/01/28/99-1937/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prandin-5312924,https://www.govinfo.gov/content/pkg/FR-1999-01-28/pdf/99-1937.pdf,1999-01-28," Prandin (5,312,924)",,,Prandin,5312924,Dr. Karl Thomae GmbH,2091.0,1916,175.0,"April 3, 1992","April 3, 1992","December 22, 1997",NDA 20-741,747
"Determination of Regulatory Review Period for Purposes of Patent Extension; PrandinSUPTM/SUP (5,216,167)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Prandin<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4425,99-1936,https://www.federalregister.gov/documents/1999/01/28/99-1936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prandinsuptmsup-5216167,https://www.govinfo.gov/content/pkg/FR-1999-01-28/pdf/99-1936.pdf,1999-01-28," PrandinSUPTM/SUP (5,216,167)",,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Zemplar,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zemplar and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10003,99-4877,https://www.federalregister.gov/documents/1999/03/01/99-4877/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemplar,https://www.govinfo.gov/content/pkg/FR-1999-03-01/pdf/99-4877.pdf,1999-03-01, Zemplar,,,Zemplar,5246925,Wisconsin Alumni Research Foundation,1079.0,623,456.0,"May 6, 1995","May 6, 1995","April 17, 1998",NDA 20-819,574
Determination of Regulatory Review Period for Purposes of Patent Extension; Atacand,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Atacand and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10156,99-5032,https://www.federalregister.gov/documents/1999/03/02/99-5032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-atacand,https://www.govinfo.gov/content/pkg/FR-1999-03-02/pdf/99-5032.pdf,1999-03-02, Atacand,,,Atacand,5196444,Takeda Chemical Industries Ltd.,1087.0,686,401.0,"June 15, 1995","June 15, 1995","June 4, 1998",NDA 20,413
Determination of Regulatory Review Period for Purposes of Patent Extension; SingulairRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Singulair<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10304,99-5132,https://www.federalregister.gov/documents/1999/03/03/99-5132/determination-of-regulatory-review-period-for-purposes-of-patent-extension-singulairregister,https://www.govinfo.gov/content/pkg/FR-1999-03-03/pdf/99-5132.pdf,1999-03-03, SingulairRegister,,,Singulair<Register>,5565473,Merck & Co.,2090.0,1725,365.0,"June 3, 1992","June 3, 1992","February 20, 1998",NDA 20-,428
Determination of Regulatory Review Period for Purposes of Patent Extension; LumenHanceRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LumenHance<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10303,99-5130,https://www.federalregister.gov/documents/1999/03/03/99-5130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumenhanceregister,https://www.govinfo.gov/content/pkg/FR-1999-03-03/pdf/99-5130.pdf,1999-03-03, LumenHanceRegister,,,LumenHance<Register>,5368840,Bracco Diagnostics Inc.,1796.0,1067,729.0,"January 18, 1993","January 20, 1993","December 19, 1997",NDA 20-686,20
Determination of Regulatory Review Period for Purposes of Patent Extension; RegranexRegister and Becaplermin Concentrate,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Regranex<Register> and Becaplermin Concentrate and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims those human biological products.",64 FR 10474,99-5388,https://www.federalregister.gov/documents/1999/03/04/99-5388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-regranexregister-and,https://www.govinfo.gov/content/pkg/FR-1999-03-04/pdf/99-5388.pdf,1999-03-04, RegranexRegister and Becaplermin Concentrate,,,Regranex<Register> and Becaplermin Concentrate,4845075,"ZymoGenetics, Inc.",2790.0,2424,366.0,"April 29, 1990","April 29, 1990","December 16, 1997",PLA 96-1408,1593
Determination of Regulatory Review Period for Purposes of Patent Extension; AmergeSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Amerge<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 23086,99-10698,https://www.federalregister.gov/documents/1999/04/29/99-10698/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amergesuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-04-29/pdf/99-10698.pdf,1999-04-29, AmergeSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Gonal-FRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Gonal-F<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 23338,99-10846,https://www.federalregister.gov/documents/1999/04/30/99-10846/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gonal-fregister,https://www.govinfo.gov/content/pkg/FR-1999-04-30/pdf/99-10846.pdf,1999-04-30, Gonal-FRegister,,,Gonal-F<Register>,5156957,Genzyme Corp.,2044.0,569,1475.0,"February 26, 1992","February 26, 1992","September 29, 1997",NDA 20-378,1605
Determination of Regulatory Review Period for Purposes of Patent Extension; ApligrafSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Apligraf<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",64 FR 23339,99-10795,https://www.federalregister.gov/documents/1999/04/30/99-10795/determination-of-regulatory-review-period-for-purposes-of-patent-extension-apligrafsuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-04-30/pdf/99-10795.pdf,1999-04-30, ApligrafSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FemaraRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Femara<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25046,99-11584,https://www.federalregister.gov/documents/1999/05/10/99-11584/determination-of-regulatory-review-period-for-purposes-of-patent-extension-femararegister,https://www.govinfo.gov/content/pkg/FR-1999-05-10/pdf/99-11584.pdf,1999-05-10, FemaraRegister,,,Femara<Register>,4978672,Novartis Corp.,2160.0,1794,366.0,"August 28, 1991","August 28, 1991","July 25, 1997",NDA 20-726,1232
Determination of Regulatory Review Period for Purposes of Patent Extension; DenavirSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Denavir<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25047,99-11585,https://www.federalregister.gov/documents/1999/05/10/99-11585/determination-of-regulatory-review-period-for-purposes-of-patent-extension-denavirsuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-05-10/pdf/99-11585.pdf,1999-05-10, DenavirSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GenESARegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GenESA<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25350,99-11822,https://www.federalregister.gov/documents/1999/05/11/99-11822/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genesaregister,https://www.govinfo.gov/content/pkg/FR-1999-05-11/pdf/99-11822.pdf,1999-05-11, GenESARegister,,,GenESA<Register>,5234404,"Gensia Sicor, Inc.",2641.0,1295,1346.0,"June 22, 1990","June 22, 1990","September 12, 1997",NDA 20-420,399
Determination of Regulatory Review Period for Purposes of Patent Extension; AggrastatRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aggrastat<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25350,99-11821,https://www.federalregister.gov/documents/1999/05/11/99-11821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aggrastatregister,https://www.govinfo.gov/content/pkg/FR-1999-05-11/pdf/99-11821.pdf,1999-05-11, AggrastatRegister,,,Aggrastat<Register>,5292756,Merck & Co.,2247.0,2051,196.0,"March 21, 1992","March 21, 1992","May 14, 1998",NDA 20-912,433
Determination of Regulatory Review Period for Purposes of Patent Extension; LotemaxSUPTM/SUP and AlrexSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lotemax<SUP>TM</SUP> and Alrex<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 26986,99-12392,https://www.federalregister.gov/documents/1999/05/18/99-12392/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lotemaxsuptmsup-and,https://www.govinfo.gov/content/pkg/FR-1999-05-18/pdf/99-12392.pdf,1999-05-18, LotemaxSUPTM/SUP and AlrexSUPTM/SUP,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Trovan,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Trovan and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27272,99-12526,https://www.federalregister.gov/documents/1999/05/19/99-12526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trovan,https://www.govinfo.gov/content/pkg/FR-1999-05-19/pdf/99-12526.pdf,1999-05-19, Trovan,,,Trovan,5164402,"Pfizer, Inc.",1967.0,1613,354.0,"August 1, 1992","August 1, 1992","December 18, 1997",NDA 20-759,761
Determination of Regulatory Review Period for Purposes of Patent Extension; NeumegaRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neumega<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",64 FR 27271,99-12527,https://www.federalregister.gov/documents/1999/05/19/99-12527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neumegaregister,https://www.govinfo.gov/content/pkg/FR-1999-05-19/pdf/99-12527.pdf,1999-05-19, NeumegaRegister,,,Neumega<Register>,5215895,"Genetics Institute, Inc.",1854.0,1513,341.0,"October 30, 1992","October 30, 1992","November 25, 1997",PLA 96-1433,542
Determination of Regulatory Review Period for Purposes of Patent Extension; MonostrutSUPTM/SUP Cardiac Valve Prosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Monostrut<SUP>TM</SUP> Cardiac Valve Prosthesis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",64 FR 27273,99-12528,https://www.federalregister.gov/documents/1999/05/19/99-12528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monostrutsuptmsup-cardiac,https://www.govinfo.gov/content/pkg/FR-1999-05-19/pdf/99-12528.pdf,1999-05-19, MonostrutSUPTM/SUP Cardiac Valve Prosthesis,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TazoracRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Tazorac<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27578,99-12652,https://www.federalregister.gov/documents/1999/05/20/99-12652/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tazoracregister,https://www.govinfo.gov/content/pkg/FR-1999-05-20/pdf/99-12652.pdf,1999-05-20, TazoracRegister,,,Tazorac<Register>,5089509,"Allergan, Inc.",2684.0,1958,726.0,"February 8, 1990","February 8, 1990","June 13, 1997",NDA 20-600,845
Determination of Regulatory Review Period for Purposes of Patent Extension; OmnicefRegister Tablets,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Omnicef<Register> Tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27578,99-12651,https://www.federalregister.gov/documents/1999/05/20/99-12651/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omnicefregister-tablets,https://www.govinfo.gov/content/pkg/FR-1999-05-20/pdf/99-12651.pdf,1999-05-20, OmnicefRegister Tablets,,,Omnicef<Register> Tablets,4559334,Warner-Lambert Co.,2745.0,2288,457.0,"June 1, 1990","June 1, 1990","December 4, 1997",NDA 50-739,1601
Determination of Regulatory Review Period for Purposes of Patent Extension; OmnicefRegister Oral Suspension,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Omnicef<Register> Oral Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27579,99-12654,https://www.federalregister.gov/documents/1999/05/20/99-12654/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omnicefregister-oral,https://www.govinfo.gov/content/pkg/FR-1999-05-20/pdf/99-12654.pdf,1999-05-20, OmnicefRegister Oral Suspension,,,Omnicef<Register> Oral Suspension,4935507,Warner-Lambert Co.,2745.0,2406,339.0,"June 1, 1990","June 1, 1990","December 4, 1997",NDA 50-749,1213
Determination of Regulatory Review Period for Purposes of Patent Extension; Therma ChoiceSUPTM/SUP Uterine Ballon Therapy System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Therma Choice<SUP>TM</SUP> Uterine Ballon Therapy System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",64 FR 29046,99-13671,https://www.federalregister.gov/documents/1999/05/28/99-13671/determination-of-regulatory-review-period-for-purposes-of-patent-extension-therma-choicesuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-05-28/pdf/99-13671.pdf,1999-05-28, Therma ChoiceSUPTM/SUP Uterine Ballon Therapy System,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZiagenTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Ziagen<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4431,00-1871,https://www.federalregister.gov/documents/2000/01/27/00-1871/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ziagentm,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1871.pdf,2000-01-27, ZiagenTM,,Benson,Ziagen (abacavir),5034394,Glaxo Wellcome,1632.0,1455.0,177.0,1994-07-01 00:00:00,1998-06-24,1998-12-17,NDA 20-977,906
Determination of Regulatory Review Period for Purposes of Patent Extension; VitraveneTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Vitravene<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4434,00-1874,https://www.federalregister.gov/documents/2000/01/27/00-1874/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vitravenetm,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1874.pdf,2000-01-27, VitraveneTM,,Benson,Vitravene (fomivirsen sodium),4689320,Isis Pharmaceuticals,1738.0,1598.0,140.0,1993-11-24 00:00:00,1998-04-09,1998-08-26,NDA 30-961,954
Determination of Regulatory Review Period for Purposes of Patent Extension; AzoptTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Azopt<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4435,00-1875,https://www.federalregister.gov/documents/2000/01/27/00-1875/determination-of-regulatory-review-period-for-purposes-of-patent-extension-azopttm,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1875.pdf,2000-01-27, AzoptTM,,Benson,Azopt^TM (brinzolamide),5378703,Alcon Laboratories,2049.0,1620.0,429.0,1992-08-23 00:00:00,1997-01-28,1998-04-01,NDA 20-816,579
Determination of Regulatory Review Period for Purposes of Patent Extension; MaxaltÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Maxalt<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4428,00-1865,https://www.federalregister.gov/documents/2000/01/27/00-1865/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maxalt,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1865.pdf,2000-01-27, MaxaltÂ®,,Anthony,Maxalt ® (rizatriptan benzoate),5298520,Merck & Co.,2099.0,1734.0,365.0,1992-10-01 00:00:00,1997-06-30,1998-06-29,NDA 20-864,153
Determination of Regulatory Review Period for Purposes of Patent Extension; PlavixÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Plavix<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4430,00-1868,https://www.federalregister.gov/documents/2000/01/27/00-1868/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plavix,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1868.pdf,2000-01-27, PlavixÂ®,,Anthony,Plavix ® (clopidogrel bisulfate),4847265,Sanofi Pharmaceuticals,2755.0,2551.0,204.0,1990-05-05 00:00:00,1997-04-28,1997-11-17,NDA 20-839,1374
Determination of Regulatory Review Period for Purposes of Patent Extension; RefludanÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Refludan<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4431,00-1870,https://www.federalregister.gov/documents/2000/01/27/00-1870/determination-of-regulatory-review-period-for-purposes-of-patent-extension-refludan,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1870.pdf,2000-01-27, RefludanÂ®,,Anthony,Refludan ® (lepirudin),5180668,Hoechst AG,1149.0,718.0,431.0,1995-01-14 00:00:00,1996-12-31,1998-03-06,NDA 20-807,777
Determination of Regulatory Review Period for Purposes of Patent Extension; AravaÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Arava<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4429,00-1867,https://www.federalregister.gov/documents/2000/01/27/00-1867/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arava,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1867.pdf,2000-01-27, AravaÂ®,,Anthony,Arava® (leflunomide),4284786,Hoechst Aktiengesellschaft,2032.0,1908.0,124.0,1993-02-18 00:00:00,1998-05-10,1998-09-10,NDA 20-905,1110
Determination of Regulatory Review Period for Purposes of Patent Extension; GlucaGenÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GlucaGen<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4432,00-1872,https://www.federalregister.gov/documents/2000/01/27/00-1872/determination-of-regulatory-review-period-for-purposes-of-patent-extension-glucagen,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1872.pdf,2000-01-27, GlucaGenÂ®,,Anthony,GlucaGen ® (glucagon (rDNA origin)),4826763,Novo Nordisk A/S,2569.0,2296.0,273.0,1991-06-12 00:00:00,1997-09-23,1998-06-22,NDA 20-918,1423
Determination of Regulatory Review Period for Purposes of Patent Extension; Sentinel Model 2000/2010Â®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Sentinel Model 2000/2010<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",65 FR 4433,00-1873,https://www.federalregister.gov/documents/2000/01/27/00-1873/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sentinel-model-20002010,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1873.pdf,2000-01-27, Sentinel Model 2000/2010Â®,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Teslascan,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Teslascan and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4615,00-2030,https://www.federalregister.gov/documents/2000/01/31/00-2030/determination-of-regulatory-review-period-for-purposes-of-patent-extension-teslascan,https://www.govinfo.gov/content/pkg/FR-2000-01-31/pdf/00-2030.pdf,2000-01-31, Teslascan,,Anthony,Teslascan,4933456,"Nycomed Salutar, Inc.",3129.0,2325,804.0,"May 5, 1989","May 5, 1989","November 26, 1997",NDA 20-652,1628
Determination of Regulatory Review Period for Purposes of Patent Extension; CertivaTM,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Certiva<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",65 FR 4614,00-2031,https://www.federalregister.gov/documents/2000/01/31/00-2031/determination-of-regulatory-review-period-for-purposes-of-patent-extension-certivatm,https://www.govinfo.gov/content/pkg/FR-2000-01-31/pdf/00-2031.pdf,2000-01-31, CertivaTM,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Lumbar I/F CageÂ®,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lumbar I/F Cage<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",65 FR 4616,00-2032,https://www.federalregister.gov/documents/2000/01/31/00-2032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumbar-if-cage,https://www.govinfo.gov/content/pkg/FR-2000-01-31/pdf/00-2032.pdf,2000-01-31, Lumbar I/F CageÂ®,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RotashieldÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rotashield<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",65 FR 4983,00-2243,https://www.federalregister.gov/documents/2000/02/02/00-2243/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rotashield,https://www.govinfo.gov/content/pkg/FR-2000-02-02/pdf/00-2243.pdf,2000-02-02, RotashieldÂ®,,Anthony,Rotashield<Register>,4704275,American Home Products Corp.,3804.0,3226,578.0,"April 3, 1988","April 3, 1988","August 31, 1998",PLA 97-0111,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; BaptenÂ®,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Bapten<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",65 FR 4982,00-2149,https://www.federalregister.gov/documents/2000/02/02/00-2149/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bapten,https://www.govinfo.gov/content/pkg/FR-2000-02-02/pdf/00-2149.pdf,2000-02-02, BaptenÂ®,,Anthony,Bapten<Register>,4485088,"Alaco, Inc.",5845.0,5734,111.0,"June 11, 1982","June 10, 1998","June 10, 1998",NADA 141-107,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; Wallstent Coronary Endoprosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Wallstent Coronary Endoprosthesis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",65 FR 7023,00-3172,https://www.federalregister.gov/documents/2000/02/11/00-3172/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wallstent-coronary,https://www.govinfo.gov/content/pkg/FR-2000-02-11/pdf/00-3172.pdf,2000-02-11, Wallstent Coronary Endoprosthesis,,Anthony,Wallstent Coronary Endoprosthesis,4954126,Boston Scientific Corp.,1533.0,1351,182.0,"July 21, 1994","July 21, 1994","September 29, 1998",PMA P980009,857
Determination of Regulatory Review Period for Purposes of Patent Extension; Neuro Cybernetic Prosthesis (NCPÂ®) System; Amendment,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is amending a previous determination regarding the regulatory review period for the Neuro Cybernetic Prosthesis (NCP<Register>) System that appeared in the Federal Register of November 10, 1998 (63 FR 63066). FDA is amending the notice because the agency agrees with the information provided in a request from the applicant for revision of the regulatory review period (Request) (Docket No. 98E-022 8/PRC 1, dated and received on January 8, 1999).",65 FR 31010,00-12117,https://www.federalregister.gov/documents/2000/05/15/00-12117/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuro-cybernetic,https://www.govinfo.gov/content/pkg/FR-2000-05-15/pdf/00-12117.pdf,2000-05-15, Neuro Cybernetic Prosthesis (NCPÂ®) System, Amendment,Anthony,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Synvisc Hylan G-F 20 (4,713,448)Â®",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synvisc Hylan G-F 20 (4,713,448)<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",66 FR 1992,01-681,https://www.federalregister.gov/documents/2001/01/10/01-681/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synvisc-hylan-g-f-20,https://www.govinfo.gov/content/pkg/FR-2001-01-10/pdf/01-681.pdf,2001-01-10," Synvisc Hylan G-F 20 (4,713,448)Â®",,Anthony,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Synvisc Hylan G-F 20 (5,143,724)Â®",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synvisc Hylan G-F 20 (5,143,724)<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",66 FR 1993,01-683,https://www.federalregister.gov/documents/2001/01/10/01-683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synvisc-hylan-g-f-20,https://www.govinfo.gov/content/pkg/FR-2001-01-10/pdf/01-683.pdf,2001-01-10," Synvisc Hylan G-F 20 (5,143,724)Â®",,Anthony,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Synvisc Hylan G-F 20 (5,099,013)Â®",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synvisc Hylan G-F 20 (5,099,013)<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",66 FR 2910,01-974,https://www.federalregister.gov/documents/2001/01/12/01-974/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synvisc-hylan-g-f-20,https://www.govinfo.gov/content/pkg/FR-2001-01-12/pdf/01-974.pdf,2001-01-12," Synvisc Hylan G-F 20 (5,099,013)Â®",,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AciphexTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aciphex\<SUP>TM</SUP>\ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",66 FR 13770,01-5513,https://www.federalregister.gov/documents/2001/03/07/01-5513/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aciphextm,https://www.govinfo.gov/content/pkg/FR-2001-03-07/pdf/01-5513.pdf,2001-03-07, AciphexTM,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Provigil,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Provigil and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",66 FR 14153,01-5812,https://www.federalregister.gov/documents/2001/03/09/01-5812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-provigil,https://www.govinfo.gov/content/pkg/FR-2001-03-09/pdf/01-5812.pdf,2001-03-09, Provigil,,Anthony,Provigil,4177290,Cephalon,1975.0,1250,725.0,"May 10, 1999","July 30, 1993","December 24, 1998",NDA 20-717,985
Determination of Regulatory Review Period for Purposes of Patent Extension; Baycol,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Baycol and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 24144,01-11961,https://www.federalregister.gov/documents/2001/05/11/01-11961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baycol,https://www.govinfo.gov/content/pkg/FR-2001-05-11/pdf/01-11961.pdf,2001-05-11, Baycol,,Anthony,Baycol,5006530,Bayer Corp.,2262.0,1896,366.0,"April 19, 1991","April 19, 1991","June 26, 1997",NDA 20-740,890
Determination of Regulatory Review Period for Purposes of Patent Extension; Infergen,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Infergen and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",66 FR 24389,01-12025,https://www.federalregister.gov/documents/2001/05/14/01-12025/determination-of-regulatory-review-period-for-purposes-of-patent-extension-infergen,https://www.govinfo.gov/content/pkg/FR-2001-05-14/pdf/01-12025.pdf,2001-05-14, Infergen,,Anthony,Infergen,4695623,"Amgen, Inc.",4394.0,3849,545.0,"September 27, 1985","September 27, 1985","October 6, 1997",PLA 96-0486,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; Xenical,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xenical and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 26866,01-12093,https://www.federalregister.gov/documents/2001/05/15/01-12093/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenical,https://www.govinfo.gov/content/pkg/FR-2001-05-15/pdf/01-12093.pdf,2001-05-15, Xenical,,Anthony,Xenical,4598089,HLR Technology Corporation,3969.0,3091,878.0,"June 12, 1988","June 12, 1988","April 23, 1999",NDA 20-766,1824
Determination of Regulatory Review Period for Purposes of Patent Extension; Uvasorb HA88,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Uvasorb HA88 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that food additive.",66 FR 27149,01-12228,https://www.federalregister.gov/documents/2001/05/16/01-12228/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uvasorb-ha88,https://www.govinfo.gov/content/pkg/FR-2001-05-16/pdf/01-12228.pdf,2001-05-16, Uvasorb HA88,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Detrol,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Detrol and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 35989,01-17105,https://www.federalregister.gov/documents/2001/07/10/01-17105/determination-of-regulatory-review-period-for-purposes-of-patent-extension-detrol,https://www.govinfo.gov/content/pkg/FR-2001-07-10/pdf/01-17105.pdf,2001-07-10, Detrol,,Anthony,Detrol,5382600,Pharmacia & Upjohn Atiebolag,1267.0,901,366.0,"October 7, 1994","October 7, 1994","March 25, 1998",NDA 20-771,64
Determination of Regulatory Review Period for Purposes of Patent Extension; Gabitril,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Gabitril and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 35988,01-17103,https://www.federalregister.gov/documents/2001/07/10/01-17103/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gabitril,https://www.govinfo.gov/content/pkg/FR-2001-07-10/pdf/01-17103.pdf,2001-07-10, Gabitril,,Anthony,Gabitril,5010090,Novo Nordisk A/S,2346.0,1651,695.0,"May 1, 1991","May 1, 1991","September 30, 1997",NDA 20-646,1255
Determination of Regulatory Review Period for Purposes of Patent Extension; Synercid,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synercid and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48690,01-23703,https://www.federalregister.gov/documents/2001/09/21/01-23703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synercid,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23703.pdf,2001-09-21, Synercid,,Anthony,Synercid,4798827,Rhone Poulenc Rorer S.A.,2793.0,2046,747.0,"January 30, 1992","January 30, 1992","September 21, 1999",NDA 50-748,1770
Determination of Regulatory Review Period for Purposes of Patent Extension; Kaletra,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Kaletra and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48687,01-23700,https://www.federalregister.gov/documents/2001/09/21/01-23700/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kaletra,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23700.pdf,2001-09-21, Kaletra,,Anthony,Kaletra,5886036,"Abbott Laboratories, Inc.",1397.0,1290,107.0,"November 20, 1996","November 20, 1996","September 15, 2000",NDA 21-226,324
Determination of Regulatory Review Period for Purposes of Patent Extension; Synercid,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synercid and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48688,01-23701,https://www.federalregister.gov/documents/2001/09/21/01-23701/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synercid,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23701.pdf,2001-09-21, Synercid,,Anthony,Synercid,4668669,Rhone Poulenc Rorer S.A.,1919.0,1172,747.0,"June 22, 1994","June 22, 1994","September 21, 1999",NDA 50-747,1333
Determination of Regulatory Review Period for Purposes of Patent Extension; Rescula,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rescula and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48689,01-23702,https://www.federalregister.gov/documents/2001/09/21/01-23702/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rescula,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23702.pdf,2001-09-21, Rescula,,Anthony,Rescula,5221763,"R-Tech Veno, Ltd./ Novartis",1347.0,1186,161.0,"November 27, 1996","November 27, 1996","August 3, 2000",NDA 21-214,774
Determination of Regulatory Review Period for Purposes of Patent Extension; Trileptal,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Trileptal and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48882,01-23750,https://www.federalregister.gov/documents/2001/09/24/01-23750/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trileptal,https://www.govinfo.gov/content/pkg/FR-2001-09-24/pdf/01-23750.pdf,2001-09-24, Trileptal,,Anthony,Trileptal,4559174,Novartis,2523.0,2046,477.0,"February 18, 1993","February 18, 1993","January 14, 2000",NDA 21-014,1690
Determination of Regulatory Review Period for Purposes of Patent Extension; TNKase,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TNKase and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human biological product.",66 FR 49392,01-24126,https://www.federalregister.gov/documents/2001/09/27/01-24126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tnkase,https://www.govinfo.gov/content/pkg/FR-2001-09-27/pdf/01-24126.pdf,2001-09-27, TNKase,,Anthony,TNKase,5385732,"Genetech, Inc.",1990.0,1741,249.0,"December 23, 1994","December 23, 1994","June 2, 2000",BLA 99-0903,853
Determination of Regulatory Review Period for Purposes of Patent Extension; Synercid; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of September 21, 2001 (66 FR 486920). The document determined the regulatory review period for Synercid and published the notice of that determination as required by law. The document published with an inadvertent error. This document corrects that error.",66 FR 52774,01-25998,https://www.federalregister.gov/documents/2001/10/17/01-25998/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synercid-correction,https://www.govinfo.gov/content/pkg/FR-2001-10-17/pdf/01-25998.pdf,2001-10-17, Synercid, Correction,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Heart Laser System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for the Heart Laser System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 2663,02-1320,https://www.federalregister.gov/documents/2002/01/18/02-1320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-heart-laser-system,https://www.govinfo.gov/content/pkg/FR-2002-01-18/pdf/02-1320.pdf,2002-01-18, Heart Laser System,,Anthony,the Heart Laser System,5125926,"PLC Medical Systems, Inc.",3135.0,2586,549.0,"January 21, 1990","January 21, 1990","August 20, 1998",PMA P950015,695
Determination of Regulatory Review Period for Purposes of Patent Extension; T-Scan 2000,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for T-Scan 2000 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 3501,02-1723,https://www.federalregister.gov/documents/2002/01/24/02-1723/determination-of-regulatory-review-period-for-purposes-of-patent-extension-t-scan-2000,https://www.govinfo.gov/content/pkg/FR-2002-01-24/pdf/02-1723.pdf,2002-01-24, T-Scan 2000,,Anthony,T-Scan 2000,4291708,Transcan Research,1595.0,964,631.0,"September 13, 2000","December 5, 1994","April 16, 1999",PMA P970033,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; SONATA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SONATA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 3723,02-1925,https://www.federalregister.gov/documents/2002/01/25/02-1925/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sonata,https://www.govinfo.gov/content/pkg/FR-2002-01-25/pdf/02-1925.pdf,2002-01-25, SONATA,,Anthony,SONATA,4626538,American Cyanamid Co.,3027.0,2435,592.0,"May 2, 1991","May 2, 1991","August 13, 1999",NDA 20-859,1835
Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MIFEPREX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 3724,02-1926,https://www.federalregister.gov/documents/2002/01/25/02-1926/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mifeprex,https://www.govinfo.gov/content/pkg/FR-2002-01-25/pdf/02-1926.pdf,2002-01-25, MIFEPREX,,Anthony,MIFEPREX,4386085,the Population Council,49.0,2249,593.0,"August 3, 1994","August 4, 1994","September 28, 2000",NDA 20-687,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; KEPPRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KEPPRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 3725,02-1927,https://www.federalregister.gov/documents/2002/01/25/02-1927/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keppra,https://www.govinfo.gov/content/pkg/FR-2002-01-25/pdf/02-1927.pdf,2002-01-25, KEPPRA,,Anthony,KEPPRA,4943639,UCB Societe Anonyme,2010.0,1707,303.0,"June 1, 1994","June 1, 1994","November 30, 1999",NDA 21-035,1155
Determination of Regulatory Review Period for Purposes of Patent Extension; REFACTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REFACTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",67 FR 5289,02-2671,https://www.federalregister.gov/documents/2002/02/05/02-2671/determination-of-regulatory-review-period-for-purposes-of-patent-extension-refacto,https://www.govinfo.gov/content/pkg/FR-2002-02-05/pdf/02-2671.pdf,2002-02-05, REFACTO,,Anthony,REFACTO,4868112,"the Genetics Institute, Inc.",1751.0,987,764.0,"May 23, 1995","May 23, 1995","March 6, 2000",PLA 98-0137,1475
Determination of Regulatory Review Period for Purposes of Patent Extension; Celexa,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Celexa and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 8546,02-4382,https://www.federalregister.gov/documents/2002/02/25/02-4382/determination-of-regulatory-review-period-for-purposes-of-patent-extension-celexa,https://www.govinfo.gov/content/pkg/FR-2002-02-25/pdf/02-4382.pdf,2002-02-25, Celexa,,Anthony,Celexa,4650884,H. Lundbeck A/S,5498.0,5061,437.0,"July 30, 1983","July 30, 1983","July 17, 1998",NDA 20-822,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; Menicon Z Rigid Gas Permeable Contact Lens,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Menicon Z Rigid Gas Permeable Contact Lens and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 8547,02-4383,https://www.federalregister.gov/documents/2002/02/25/02-4383/determination-of-regulatory-review-period-for-purposes-of-patent-extension-menicon-z-rigid-gas,https://www.govinfo.gov/content/pkg/FR-2002-02-25/pdf/02-4383.pdf,2002-02-25, Menicon Z Rigid Gas Permeable Contact Lens,,Anthony,Menicon Z Rigid Gas Permeable Contact Lens,4594401,Menicon Co.,7.0,1917,1435.0,"September 6, 2001","September 6, 2001","July 11, 2000",PMA P990018,1205
Determination of Regulatory Review Period for Purposes of Patent Extension; RELENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RELENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 8988,02-4596,https://www.federalregister.gov/documents/2002/02/27/02-4596/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relenza,https://www.govinfo.gov/content/pkg/FR-2002-02-27/pdf/02-4596.pdf,2002-02-27, RELENZA,,Anthony,RELENZA,5360817,"Glaxo Wellcome, Inc.",1800.0,1527,273.0,"August 23, 1994","August 23, 1994","July 26, 1999",NDA 21-036,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; NEXIUM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEXIUM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 9299,02-4681,https://www.federalregister.gov/documents/2002/02/28/02-4681/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nexium,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4681.pdf,2002-02-28, NEXIUM,,Anthony,NEXIUM,4738974,Astrazenica,1284.0,838,446.0,"August 18, 1997","August 18, 1997","February 20, 2001",NDA 21-153,865
Determination of Regulatory Review Period for Purposes of Patent Extension; REMINYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REMINYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 9301,02-4683,https://www.federalregister.gov/documents/2002/02/28/02-4683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reminyl,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4683.pdf,2002-02-28, REMINYL,,Anthony,REMINYL,4663318,Janssen Research Foundation,1608.0,1089,519.0,"October 6, 1996","October 6, 1996","February 28, 2001",NDA 21-169,1063
Determination of Regulatory Review Period for Purposes of Patent Extension; EVISTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EVISTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9300,02-4682,https://www.federalregister.gov/documents/2002/02/28/02-4682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evista,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4682.pdf,2002-02-28, EVISTA,,Anthony,EVISTA,4418068,Eli Lilly,5412.0,5228,184.0,"February 16, 1983","February 16, 1983","December 9, 1997",NDA 20-815,1103
Determination of Regulatory Review Period for Purposes of Patent Extension; ABREVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ABREVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9303,02-4685,https://www.federalregister.gov/documents/2002/02/28/02-4685/determination-of-regulatory-review-period-for-purposes-of-patent-extension-abreva,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4685.pdf,2002-02-28, ABREVA,,Anthony,ABREVA,4874794,Avanir Pharmaceuticals,3270.0,2323,947.0,"August 14, 1991","August 14, 1991","July 25, 2000",NDA 20-941,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; AVELOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVELOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9304,02-4748,https://www.federalregister.gov/documents/2002/02/28/02-4748/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avelox,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4748.pdf,2002-02-28, AVELOX,,Anthony,AVELOX,4490517,Bayer Corp.,1435.0,1069,366.0,"January 7, 1996","January 7, 1996","December 10, 1999",NDA 21-085,889
Determination of Regulatory Review Period for Purposes of Patent Extension; PAYLEAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PAYLEAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",67 FR 9298,02-4747,https://www.federalregister.gov/documents/2002/02/28/02-4747/determination-of-regulatory-review-period-for-purposes-of-patent-extension-paylean,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4747.pdf,2002-02-28, PAYLEAN,,Anthony,PAYLEAN,4690951,Eli Lilly & Co.,5707.0,1211,4496.0,"May 9, 1984","May 9, 1984","December 22, 1999",NADA 140-863,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; TRAVATAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRAVATAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9302,02-4684,https://www.federalregister.gov/documents/2002/02/28/02-4684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-travatan,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4684.pdf,2002-02-28, TRAVATAN,,Anthony,TRAVATAN,5889052,"Alcon Laboratories, Inc.",1694.0,1441,253.0,"July 28, 1996","July 28, 1996","March 16, 2001",NDA 21-257,484
Determination of Regulatory Review Period for Purposes of Patent Extension; HECTOROL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HECTOROL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 9455,02-4889,https://www.federalregister.gov/documents/2002/03/01/02-4889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hectorol,https://www.govinfo.gov/content/pkg/FR-2002-03-01/pdf/02-4889.pdf,2002-03-01, HECTOROL,,Anthony,HECTOROL,4555364,The Wisconsin Alumni Research Foundation,4072.0,3614,458.0,"April 17, 1988","April 17, 1988","June 9, 1999",NDA 20-862,1824
Determination of Regulatory Review Period for Purposes of Patent Extension; Diphenylmethane Diisocyanate,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for diphenylmethane diisocyanate and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",67 FR 9756,02-4965,https://www.federalregister.gov/documents/2002/03/04/02-4965/determination-of-regulatory-review-period-for-purposes-of-patent-extension-diphenylmethane,https://www.govinfo.gov/content/pkg/FR-2002-03-04/pdf/02-4965.pdf,2002-03-04, Diphenylmethane Diisocyanate,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Extension of Comment Period,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is extending to April 26, 2002, the comment period for the regulatory review period determination for MIFEPREX, published in the Federal Register of January 25, 2002 (67 FR 3724). The agency is taking this action in response to a request for an extension.",67 FR 18921,02-9364,https://www.federalregister.gov/documents/2002/04/17/02-9364/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mifeprex-extension-of,https://www.govinfo.gov/content/pkg/FR-2002-04-17/pdf/02-9364.pdf,2002-04-17, MIFEPREX, Extension of Comment Period,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 34721,02-12092,https://www.federalregister.gov/documents/2002/05/15/02-12092/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actos,https://www.govinfo.gov/content/pkg/FR-2002-05-15/pdf/02-12092.pdf,2002-05-15, ACTOS,,Anthony,ACTOS,4687777,"Takeda Chemical Industries, Ltd.",3556.0,3374,182.0,"October 21, 1989","October 21, 1989","July 15, 1999",NDA 21-073,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; COMTAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COMTAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 36008,02-12784,https://www.federalregister.gov/documents/2002/05/22/02-12784/determination-of-regulatory-review-period-for-purposes-of-patent-extension-comtan,https://www.govinfo.gov/content/pkg/FR-2002-05-22/pdf/02-12784.pdf,2002-05-22, COMTAN,,Anthony,COMTAN,5446194,Orion Corp.,2937.0,2281,656.0,"October 6, 1991","October 6, 1991","October 19, 1999",NDA 20-796,416
Determination of Regulatory Review Period for Purposes of Patent Extension; ENBREL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENBREL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",67 FR 36897,02-13227,https://www.federalregister.gov/documents/2002/05/28/02-13227/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enbrel,https://www.govinfo.gov/content/pkg/FR-2002-05-28/pdf/02-13227.pdf,2002-05-28, ENBREL,,Anthony,ENBREL,5712155,Immunex Corp.,2322.0,2143,179.0,"June 26, 1992","June 26, 1992","November 2, 1998",BLA 98-0286,240
Determination of Regulatory Review Period for Purposes of Patent Extension; BETAXON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BETAXON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 43128,02-16052,https://www.federalregister.gov/documents/2002/06/26/02-16052/determination-of-regulatory-review-period-for-purposes-of-patent-extension-betaxon,https://www.govinfo.gov/content/pkg/FR-2002-06-26/pdf/02-16052.pdf,2002-06-26, BETAXON,,Anthony,BETAXON,4911920,Alcon Laboratories,947.0,765,182.0,"July 23, 1997","July 23, 1997","February 23, 2000",NDA 21-114,579
Determination of Regulatory Review Period for Purposes of Patent Extension; Protonix,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Protonix and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 46681,02-17781,https://www.federalregister.gov/documents/2002/07/16/02-17781/determination-of-regulatory-review-period-for-purposes-of-patent-extension-protonix,https://www.govinfo.gov/content/pkg/FR-2002-07-16/pdf/02-17781.pdf,2002-07-16, Protonix,,Anthony,Protonix,4758579,BYK Gulden Lomerg Chemische Fabrik GmbH,10.0,3401,2818.0,"October 13, 1990","October 13, 1990","February 2, 2000",NDA 20-987,5
Determination of Regulatory Review Period for Purposes of Patent Extension; Axert,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Axert and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 46682,02-17782,https://www.federalregister.gov/documents/2002/07/16/02-17782/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axert,https://www.govinfo.gov/content/pkg/FR-2002-07-16/pdf/02-17782.pdf,2002-07-16, Axert,,Anthony,Axert,5565447,Almirall Prodesfarma S.A.,1348.0,843,505.0,"August 30, 1997","August 30, 1997","May 7, 2001",NDA 20-001,569
Determination of Regulatory Review Period for Purposes of Patent Extension; PEG-Intron,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PEG-Intron and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",67 FR 46680,02-17783,https://www.federalregister.gov/documents/2002/07/16/02-17783/determination-of-regulatory-review-period-for-purposes-of-patent-extension-peg-intron,https://www.govinfo.gov/content/pkg/FR-2002-07-16/pdf/02-17783.pdf,2002-07-16, PEG-Intron,,Anthony,PEG-Intron,5951974,Schering Corp.,1271.0,877,394.0,"July 30, 1997","July 30, 1997","January 19, 2001",BLA 99-1488,435
Determination of Regulatory Review Period for Purposes of Patent Extension; CeeOn Model 911A,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CeeOn Model 911A and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 46989,02-17904,https://www.federalregister.gov/documents/2002/07/17/02-17904/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ceeon-model-911a,https://www.govinfo.gov/content/pkg/FR-2002-07-17/pdf/02-17904.pdf,2002-07-17, CeeOn Model 911A,,Anthony,CeeOn Model 911A,5444106,Pharmacia AB,1594.0,1101,493.0,"November 25, 1996","November 25, 1996","April 5, 2001",PMA P990080,956
Determination of Regulatory Review Period for Purposes of Patent Extension; Definity,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Definity and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 48919,02-18975,https://www.federalregister.gov/documents/2002/07/26/02-18975/determination-of-regulatory-review-period-for-purposes-of-patent-extension-definity,https://www.govinfo.gov/content/pkg/FR-2002-07-26/pdf/02-18975.pdf,2002-07-26, Definity,,Anthony,Definity,5527521,"Dupont Contrast Imaging, Inc.",2160.0,1193,967.0,"September 3, 1995","September 3, 1995","July 31, 2001",NDA 21-064,1418
Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Amendment,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is amending a previous determination of the regulatory review period for MIFEPREX that appeared in the Federal Register of January 25, 2002 (67 FR 3724). The agency is taking this action in response to received comments. FDA is publishing notice of that amendment as required by law.",67 FR 65358,02-27096,https://www.federalregister.gov/documents/2002/10/24/02-27096/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mifeprex-amendment,https://www.govinfo.gov/content/pkg/FR-2002-10-24/pdf/02-27096.pdf,2002-10-24, MIFEPREX, Amendment,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LOTRONEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LOTRONEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69014,02-28883,https://www.federalregister.gov/documents/2002/11/14/02-28883/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lotronex,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28883.pdf,2002-11-14, LOTRONEX,,Anthony,LOTRONEX,5360800,"Glaxo Wellcome, Inc.",3564.0,3339,225.0,"May 10, 1990","May 10, 1990","February 9, 2000",NDA 21-107,1076
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLAGE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLAGE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69016,02-28885,https://www.federalregister.gov/documents/2002/11/14/02-28885/determination-of-regulatory-review-period-for-purposes-of-patent-extension-solage,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28885.pdf,2002-11-14, SOLAGE,,Anthony,SOLAGE,5194247,Bristol-Myers Squibb Co.,2689.0,1978,711.0,"August 1, 1992","August 1, 1992","December 10, 1999",NDA 20-922,1365
Determination of Regulatory Review Period for Purposes of Patent Extension; COLAZAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COLAZAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69014,02-28882,https://www.federalregister.gov/documents/2002/11/14/02-28882/determination-of-regulatory-review-period-for-purposes-of-patent-extension-colazal,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28882.pdf,2002-11-14, COLAZAL,,Anthony,COLAZAL,4412992,Biorex Laboratories Unlimited,2950.0,1828,1122.0,"June 22, 1992","June 22, 1992","July 18, 2000",NDA 20-610,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; ACOVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACOVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69015,02-28884,https://www.federalregister.gov/documents/2002/11/14/02-28884/determination-of-regulatory-review-period-for-purposes-of-patent-extension-acova,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28884.pdf,2002-11-14, ACOVA,,Anthony,ACOVA,5214052,Texas Biotechnology Corp.,4022.0,2971,1051.0,"June 28, 1989","June 28, 1989","June 30, 2000",NDA 20-883,839
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,2002-11-18, GLEEVEC,,Anthony,GLEEVEC,5521184,Novartis Corp.,1098.0,1025,73.0,"May 10, 1998","May 10, 1998","May 10, 2001",NDA 21-335,599
Determination of Regulatory Review Period for Purposes of Patent Extension; EVOXAC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EVOXAC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29188,https://www.federalregister.gov/documents/2002/11/18/02-29188/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evoxac,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29188.pdf,2002-11-18, EVOXAC,,Anthony,EVOXAC,4855290,"the State of Israel, Israel Institute for Biological Research",1733.0,1230,503.0,"April 16, 1995","April 16, 1995","January 11, 2000",NDA 20-989,1133
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,2003-01-24, NOVOSEVEN,,Anthony,NOVOSEVEN,4784950,"ZymoGenetics, Inc.",3954.0,2904,1050.0,"May 29, 1988","May 29, 1988","March 25, 1999",PLA 96-0597,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; TEMODAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEMODAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 6176,03-2970,https://www.federalregister.gov/documents/2003/02/06/03-2970/determination-of-regulatory-review-period-for-purposes-of-patent-extension-temodar,https://www.govinfo.gov/content/pkg/FR-2003-02-06/pdf/03-2970.pdf,2003-02-06, TEMODAR,,Anthony,TEMODAR,5260291,Schering Corp.,2032.0,1668,364.0,"January 19, 1994","January 19, 1994","August 11, 1999",NDA 21-029,1136
Determination of Regulatory Review Period for Purposes of Patent Extension; Rapamune,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rapamune and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 7382,03-3556,https://www.federalregister.gov/documents/2003/02/13/03-3556/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapamune,https://www.govinfo.gov/content/pkg/FR-2003-02-13/pdf/03-3556.pdf,2003-02-13, Rapamune,,Anthony,Rapamune,5100899,Sir Roy Caine,2709.0,2434,275.0,"April 17, 1992","April 17, 1992","September 15, 1999",NDA 21-083,1492
Determination of Regulatory Review Period for Purposes of Patent Extension; Avandia,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Avandia and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 7381,03-3555,https://www.federalregister.gov/documents/2003/02/13/03-3555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avandia,https://www.govinfo.gov/content/pkg/FR-2003-02-13/pdf/03-3555.pdf,2003-02-13, Avandia,,Anthony,Avandia,5002953,Smithkline Beecham Corp.,2042.0,1859,183.0,"October 23, 1993","October 23, 1993","May 25, 1999",NDA 21-071,1021
Determination of Regulatory Review Period for Purposes of Patent Extension; VALCYTE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VALCYTE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 8027,03-3872,https://www.federalregister.gov/documents/2003/02/19/03-3872/determination-of-regulatory-review-period-for-purposes-of-patent-extension-valcyte,https://www.govinfo.gov/content/pkg/FR-2003-02-19/pdf/03-3872.pdf,2003-02-19, VALCYTE,,Anthony,VALCYTE,6083953,Syntex,2101.0,1919,182.0,"June 30, 1995","June 30, 1995","March 29, 2001",NDA 21-304,226
Determination of Regulatory Review Period for Purposes of Patent Extension; CANCIDAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CANCIDAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 8028,03-3873,https://www.federalregister.gov/documents/2003/02/19/03-3873/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cancidas,https://www.govinfo.gov/content/pkg/FR-2003-02-19/pdf/03-3873.pdf,2003-02-19, CANCIDAS,,Anthony,CANCIDAS,5514650,"Merck & Co., Inc.",1974.0,1791,183.0,"September 3, 1995","September 3, 1995","January 26, 2001",NDA 21-227,682
Determination of Regulatory Review Period for Purposes of Patent Extension; Starlix,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Starlix and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 9091,03-4567,https://www.federalregister.gov/documents/2003/02/27/03-4567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-starlix,https://www.govinfo.gov/content/pkg/FR-2003-02-27/pdf/03-4567.pdf,2003-02-27, Starlix,,Anthony,Starlix,34878,Novartis,2147.0,1775,372.0,"March 9, 1995","March 9, 1995","December 22, 2000",NDA 21-204,1259
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOMETA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZOMETA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 9690,03-4691,https://www.federalregister.gov/documents/2003/02/28/03-4691/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zometa,https://www.govinfo.gov/content/pkg/FR-2003-02-28/pdf/03-4691.pdf,2003-02-28, ZOMETA,,Anthony,ZOMETA,4939130,Novartis Corp.,2810.0,2201,609.0,"December 12, 1993","December 12, 1993","August 20, 2001",NDA 21-223,1752
Determination of Regulatory Review Period for Purposes of Patent Extension; VITREON; Amendment,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is amending its determination regarding the regulatory review period for purposes of patent extension for VITREON that appeared in the Federal Register of December 17, 1998 (63 FR 69633). FDA is amending the document because the agency agrees with the information provided in a request from the applicant for revision of the regulatory review period.",68 FR 12707,03-6226,https://www.federalregister.gov/documents/2003/03/17/03-6226/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vitreon-amendment,https://www.govinfo.gov/content/pkg/FR-2003-03-17/pdf/03-6226.pdf,2003-03-17, VITREON, Amendment,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRECEDEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRECEDEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 13314,03-6490,https://www.federalregister.gov/documents/2003/03/19/03-6490/determination-of-regulatory-review-period-for-purposes-of-patent-extension-precedex,https://www.govinfo.gov/content/pkg/FR-2003-03-19/pdf/03-6490.pdf,2003-03-19, PRECEDEX,,Anthony,PRECEDEX,4910214,Orion Corp.,3894.0,3529,365.0,"April 21, 1989","April 21, 1989","December 17, 1999",NDA 21-038,3919
Determination of Regulatory Review Period for Purposes of Patent Extension; TOPAMAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TOPAMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 13315,03-6507,https://www.federalregister.gov/documents/2003/03/19/03-6507/determination-of-regulatory-review-period-for-purposes-of-patent-extension-topamax,https://www.govinfo.gov/content/pkg/FR-2003-03-19/pdf/03-6507.pdf,2003-03-19, TOPAMAX,,Anthony,TOPAMAX,4513006,"McNeilab, Inc.",3844.0,2984,860.0,"June 18, 1986","June 18, 1986","December 24, 1996",NDA 20-505,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; GENESIS NEUROSTIMULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GENESIS NEUROSTIMULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 14244,03-6892,https://www.federalregister.gov/documents/2003/03/24/03-6892/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genesis-neurostimulation,https://www.govinfo.gov/content/pkg/FR-2003-03-24/pdf/03-6892.pdf,2003-03-24, GENESIS NEUROSTIMULATION SYSTEM,,Anthony,GENESIS NEUROSTIMULATION SYSTEM,4793353,Advanced Neuromodulation Systems,469.0,292,177.0,"August 11, 2000","August 11, 2000","November 21, 2001",PMA P010032,840
Determination of Regulatory Review Period for Purposes of Patent Extension; TEQUIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEQUIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 14665,03-7280,https://www.federalregister.gov/documents/2003/03/26/03-7280/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tequin,https://www.govinfo.gov/content/pkg/FR-2003-03-26/pdf/03-7280.pdf,2003-03-26, TEQUIN,,Anthony,TEQUIN,4980470,Kyorin Pharmaceutical Co. through Bristol Myers Squibb,1087.0,732,355.0,"May 2, 2001","December 27, 1996","December 17, 1999",NDA 21-061,720
Determination of Regulatory Review Period for Purposes of Patent Extension; LEVULAN KERASTICK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEVULAN KERASTICK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 15730,03-7711,https://www.federalregister.gov/documents/2003/04/01/03-7711/determination-of-regulatory-review-period-for-purposes-of-patent-extension-levulan-kerastick,https://www.govinfo.gov/content/pkg/FR-2003-04-01/pdf/03-7711.pdf,2003-04-01, LEVULAN KERASTICK,,Anthony,LEVULAN KERASTICK,5079262,"DUSA Pharmaceuticals, Inc.",2528.0,2007,521.0,"January 2, 1993","January 2, 1993","December 3, 1999",NDA 20-965,1524
Determination of Regulatory Review Period for Purposes of Patent Extension; GYNECARE INTERGEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GYNECARE INTERGEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 16061,03-7819,https://www.federalregister.gov/documents/2003/04/02/03-7819/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gynecare-intergel,https://www.govinfo.gov/content/pkg/FR-2003-04-02/pdf/03-7819.pdf,2003-04-02, GYNECARE INTERGEL,,Anthony,GYNECARE INTERGEL,5532221,"Lifecore Medical, Inc.",2438.0,1453,985.0,"March 17, 1995","March 17, 1995","November 16, 2001",PMA P990015,867
Determination of Regulatory Review Period for Purposes of Patent Extension; OP-1 IMPLANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OP-1 IMPLANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 16062,03-7820,https://www.federalregister.gov/documents/2003/04/02/03-7820/determination-of-regulatory-review-period-for-purposes-of-patent-extension-op-1-implant,https://www.govinfo.gov/content/pkg/FR-2003-04-02/pdf/03-7820.pdf,2003-04-02, OP-1 IMPLANT,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FASLODEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FASLODEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 18992,03-9536,https://www.federalregister.gov/documents/2003/04/17/03-9536/determination-of-regulatory-review-period-for-purposes-of-patent-extension-faslodex,https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9536.pdf,2003-04-17, FASLODEX,,Anthony,FASLODEX,4659516,"AstraZeneca UK, Ltd.",1935.0,1541,394.0,"January 8, 1997","January 8, 1997","April 25, 2002",NDA 21-344,1165
Determination of Regulatory Review Period for Purposes of Patent Extension; ZETIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZETIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 18992,03-9534,https://www.federalregister.gov/documents/2003/04/17/03-9534/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zetia,https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9534.pdf,2003-04-17, ZETIA,,Anthony,ZETIA,37721,Schering Corp.,1983.0,1680,303.0,"May 23, 1997","May 23, 1997","October 25, 2002",NDA 21-445,497
Determination of Regulatory Review Period for Purposes of Patent Extension; HYPERION LTK SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYPERION LTK SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 18990,03-9535,https://www.federalregister.gov/documents/2003/04/17/03-9535/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hyperion-ltk-system,https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9535.pdf,2003-04-17, HYPERION LTK SYSTEM,,Anthony,HYPERION LTK SYSTEM,4976709,"Sunrise Technologies International, Inc.",3047.0,2806,241.0,"February 28, 1992","February 28, 1992","June 30, 2000",PMA P990078,1644
Determination of Regulatory Review Period for Purposes of Patent Extension; VFEND,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VFEND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 19212,03-9577,https://www.federalregister.gov/documents/2003/04/18/03-9577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vfend,https://www.govinfo.gov/content/pkg/FR-2003-04-18/pdf/03-9577.pdf,2003-04-18, VFEND,,Anthony,VFEND,5567817,"Pfizer, Inc.",2452.0,1898,554.0,"September 8, 1995","September 8, 1995","May 24, 2002",NDA 21-266,945
Determination of Regulatory Review Period for Purposes of Patent Extension; TIKOSYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TIKOSYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 19212,03-9578,https://www.federalregister.gov/documents/2003/04/18/03-9578/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tikosyn,https://www.govinfo.gov/content/pkg/FR-2003-04-18/pdf/03-9578.pdf,2003-04-18, TIKOSYN,,Anthony,TIKOSYN,4959366,Pfizer,3350.0,2778,572.0,"August 1, 1990","August 1, 1990","October 1, 1999",NDA 20-931,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; IMAGENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMAGENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 19546,03-9809,https://www.federalregister.gov/documents/2003/04/21/03-9809/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imagent,https://www.govinfo.gov/content/pkg/FR-2003-04-21/pdf/03-9809.pdf,2003-04-21, IMAGENT,,Anthony,IMAGENT,5639443,Alliance Pharmaceutical Corp.,2264.0,1303,961.0,"March 21, 1996","March 21, 1996","May 31, 2002",NDA 21-191,423
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEVALIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZEVALIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 19547,03-9694,https://www.federalregister.gov/documents/2003/04/21/03-9694/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zevalin,https://www.govinfo.gov/content/pkg/FR-2003-04-21/pdf/03-9694.pdf,2003-04-21, ZEVALIN,,Anthony,ZEVALIN,5776456,IDEC Pharmaceuticals Corp.,3363.0,2887,476.0,"December 7, 1992","December 7, 1992","February 19, 2002",BLA 1250190,227
Determination of Regulatory Review Period for Purposes of Patent Extension; EXELON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXELON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 19548,03-9663,https://www.federalregister.gov/documents/2003/04/21/03-9663/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exelon,https://www.govinfo.gov/content/pkg/FR-2003-04-21/pdf/03-9663.pdf,2003-04-21, EXELON,,Anthony,EXELON,4948807,Novartis,3424.0,2313,1111.0,"December 8, 1990","December 8, 1990","April 21, 2000",NDA 20-823,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; AROMASIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AROMASIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 22390,03-10298,https://www.federalregister.gov/documents/2003/04/28/03-10298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aromasin,https://www.govinfo.gov/content/pkg/FR-2003-04-28/pdf/03-10298.pdf,2003-04-28, AROMASIN,,Anthony,AROMASIN,4808616,Pharmacia,3153.0,2848,305.0,"March 6, 1991","March 6, 1991","October 21, 1999",NDA 20-753,1745
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVNAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVNAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 22389,03-10302,https://www.federalregister.gov/documents/2003/04/28/03-10302/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevnar,https://www.govinfo.gov/content/pkg/FR-2003-04-28/pdf/03-10302.pdf,2003-04-28, PREVNAR,,Anthony,PREVNAR,5360897,the University of Rochester through American Home Products,1910.0,1648,262.0,"November 27, 1994","November 27, 1994","February 17, 2000",PLA 99-0279,1086
Determination of Regulatory Review Period for Purposes of Patent Extension; TRACLEER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRACLEER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 24485,03-11215,https://www.federalregister.gov/documents/2003/05/07/03-11215/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tracleer,https://www.govinfo.gov/content/pkg/FR-2003-05-07/pdf/03-11215.pdf,2003-05-07, TRACLEER,,Anthony,TRACLEER,5292740,"Hoffman-La Roche, Inc.",2176.0,1807,369.0,"December 8, 1995","December 8, 1995","November 20, 2001",NDA 21-290,1259
Determination of Regulatory Review Period for Purposes of Patent Extension; BENICAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BENICAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 44954,03-19446,https://www.federalregister.gov/documents/2003/07/31/03-19446/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benicar,https://www.govinfo.gov/content/pkg/FR-2003-07-31/pdf/03-19446.pdf,2003-07-31, BENICAR,,Anthony,BENICAR,5616599,"Sankyo Company, Ltd.",2522.0,1882,640.0,"June 1, 1995","June 1, 1995","April 25, 2002",NDA 21-286,756
Determination of Regulatory Review Period for Purposes of Patent Extension; SPECTRACEF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SPECTRACEF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 45245,03-19621,https://www.federalregister.gov/documents/2003/08/01/03-19621/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spectracef,https://www.govinfo.gov/content/pkg/FR-2003-08-01/pdf/03-19621.pdf,2003-08-01, SPECTRACEF,,Anthony,SPECTRACEF,4839350,"Meiji Seika Kaisha, Ltd.",1461.0,851,610.0,"August 31, 1997","August 31, 1997","August 29, 2001",NDA 21-222,1032
Determination of Regulatory Review Period for Purposes of Patent Extension; XIGRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIGRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents which claim that human biological product.",68 FR 66112,03-29333,https://www.federalregister.gov/documents/2003/11/25/03-29333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xigris,https://www.govinfo.gov/content/pkg/FR-2003-11-25/pdf/03-29333.pdf,2003-11-25, XIGRIS,,Anthony,XIGRIS,4775624; 5681932; and 5270040,Eli Lilly & Co.,2493.0,2193,300.0,"January 26, 1995","January 26, 1995","November 21, 2001",BLA 125029,1397
Determination of Regulatory Review Period for Purposes of Patent Extension; ABILIFY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ABILIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 66449,03-29464,https://www.federalregister.gov/documents/2003/11/26/03-29464/determination-of-regulatory-review-period-for-purposes-of-patent-extension-abilify,https://www.govinfo.gov/content/pkg/FR-2003-11-26/pdf/03-29464.pdf,2003-11-26, ABILIFY,,Anthony,ABILIFY,5006528,"Otsuka Pharmaceutical Co., Ltd.",3416.0,3035,381.0,"July 11, 1993","July 11, 1993","November 15, 2002",NDA 21-436,5
Determination of Regulatory Review Period for Purposes of Patent Extension; DERAMAXX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DERAMAXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",68 FR 67194,03-29742,https://www.federalregister.gov/documents/2003/12/01/03-29742/determination-of-regulatory-review-period-for-purposes-of-patent-extension-deramaxx,https://www.govinfo.gov/content/pkg/FR-2003-12-01/pdf/03-29742.pdf,2003-12-01, DERAMAXX,,Anthony,DERAMAXX,5521207,G. D. Searle L.L.C.,1675.0,1578,97.0,"January 21, 1998","May 17, 2002","August 21, 2002",NADA 141-203,882
Determination of Regulatory Review Period for Purposes of Patent Extension; LEXAPRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEXAPRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67455,03-29927,https://www.federalregister.gov/documents/2003/12/02/03-29927/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lexapro,https://www.govinfo.gov/content/pkg/FR-2003-12-02/pdf/03-29927.pdf,2003-12-02, LEXAPRO,,Anthony,LEXAPRO,34712,H. Lundbeck A/S,1146.0,636,510.0,"June 27, 1999","June 27, 1999","August 14, 2002",NDA 21-323,827
Determination of Regulatory Review Period for Purposes of Patent Extension; INVANZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVANZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67457,03-29929,https://www.federalregister.gov/documents/2003/12/02/03-29929/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invanz,https://www.govinfo.gov/content/pkg/FR-2003-12-02/pdf/03-29929.pdf,2003-12-02, INVANZ,,Anthony,INVANZ,5478820,Syngenta Ltd.,2273.0,1916,357.0,"September 3, 1995","September 3, 1995","November 21, 2001",NDA 21-337,1023
Determination of Regulatory Review Period for Purposes of Patent Extension; ELOXATIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELOXATIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67456,03-29928,https://www.federalregister.gov/documents/2003/12/02/03-29928/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eloxatin,https://www.govinfo.gov/content/pkg/FR-2003-12-02/pdf/03-29928.pdf,2003-12-02, ELOXATIN,,Anthony,ELOXATIN,5420319,Sanofi-Synthelabo,3417.0,3370,47.0,"April 3, 1993","August 16, 1993","August 9, 2002",NDA 21-063,1138
Determination of Regulatory Review Period for Purposes of Patent Extension; STRATTERA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STRATTERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67678,03-30028,https://www.federalregister.gov/documents/2003/12/03/03-30028/determination-of-regulatory-review-period-for-purposes-of-patent-extension-strattera,https://www.govinfo.gov/content/pkg/FR-2003-12-03/pdf/03-30028.pdf,2003-12-03, STRATTERA,,Anthony,STRATTERA,5658590,Eli Lilly & Co.,7718.0,7307,411.0,"October 11, 1981","October 11, 1981","November 26, 2002",NDA 21-411,685
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMIGAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUMIGAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",69 FR 4170,E4-130,https://www.federalregister.gov/documents/2004/01/28/E4-130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumigan,https://www.govinfo.gov/content/pkg/FR-2004-01-28/pdf/E4-130.pdf,2004-01-28, LUMIGAN,,Anthony,LUMIGAN,5688819,Allergan,1967.0,1787,180.0,"October 29, 1995","October 29, 1995","March 16, 2001",NDA 21-275,907
Determination of Regulatory Review Period for Purposes of Patent Extension; REMODULIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REMODULIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 4306,04-1841,https://www.federalregister.gov/documents/2004/01/29/04-1841/determination-of-regulatory-review-period-for-purposes-of-patent-extension-remodulin,https://www.govinfo.gov/content/pkg/FR-2004-01-29/pdf/04-1841.pdf,2004-01-29, REMODULIN,,Anthony,REMODULIN,5153222,United Therapeutics,4026.0,3443,583.0,"May 15, 1991","May 15, 1991","May 21, 2002",NDA 21-272,337
Determination of Regulatory Review Period for Purposes of Patent Extension; FROVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FROVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of two patents that claims that human drug product.",69 FR 4305,04-1840,https://www.federalregister.gov/documents/2004/01/29/04-1840/determination-of-regulatory-review-period-for-purposes-of-patent-extension-frova,https://www.govinfo.gov/content/pkg/FR-2004-01-29/pdf/04-1840.pdf,2004-01-29, FROVA,,Anthony,FROVA,5464864 and 5616603,"Vernalis, Ltd.",2201.0,1186,1015.0,"November 1, 1995","November 1, 1995","November 8, 2001",NDA 21-006,1096
Determination of Regulatory Review Period for Purposes of Patent Extension; EXTRANAEAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXTRANAEAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 5858,04-2546,https://www.federalregister.gov/documents/2004/02/06/04-2546/determination-of-regulatory-review-period-for-purposes-of-patent-extension-extranaeal,https://www.govinfo.gov/content/pkg/FR-2004-02-06/pdf/04-2546.pdf,2004-02-06, EXTRANAEAL,,Anthony,EXTRANAEAL,4761237,"Baxter International, Inc.",2207.0,1478,729.0,"December 6, 1996","December 6, 1996","December 20, 2002",NDA 21-321,1467
Determination of Regulatory Review Period for Purposes of Patent Extension; ORTHO-EVRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ORTHO-EVRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 5859,04-2547,https://www.federalregister.gov/documents/2004/02/06/04-2547/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ortho-evra,https://www.govinfo.gov/content/pkg/FR-2004-02-06/pdf/04-2547.pdf,2004-02-06, ORTHO-EVRA,,Anthony,ORTHO-EVRA,5876746,Johnson,2001.0,1666,335.0,"May 31, 1996","May 31, 1996","November 20, 2001",NDA 21-180,664
Determination of Regulatory Review Period for Purposes of Patent Extension; ZELNORM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZELNORM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 12161,04-5758,https://www.federalregister.gov/documents/2004/03/15/04-5758/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zelnorm,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5758.pdf,2004-03-15, ZELNORM,,Anthony,ZELNORM,5510353,Novartis Pharmaceuticals,2826.0,1931,895.0,"October 30, 1994","October 30, 1994","July 24, 2002",NDA 21-200,1888
Determination of Regulatory Review Period for Purposes of Patent Extension; IPRIVASK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IPRIVASK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 12158,04-5703,https://www.federalregister.gov/documents/2004/03/15/04-5703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iprivask,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5703.pdf,2004-03-15, IPRIVASK,,Anthony,IPRIVASK,4745177,Novartis Corp.,4707.0,3696,1011.0,"May 17, 1990","May 17, 1990","April 4, 2003",NDA 21-271,5
Determination of Regulatory Review Period for Purposes of Patent Extension; FABRAZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FABRAZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 12159,04-5760,https://www.federalregister.gov/documents/2004/03/15/04-5760/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fabrazyme,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5760.pdf,2004-03-15, FABRAZYME,,Anthony,FABRAZYME,5356804,Genzyme,1843.0,807,1036.0,"April 9, 1998","April 9, 1998","April 24, 2003",PLA 103979,1438
Determination of Regulatory Review Period for Purposes of Patent Extension; FACTIVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FACTIVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents that claim that human drug product.",69 FR 12160,04-5759,https://www.federalregister.gov/documents/2004/03/15/04-5759/determination-of-regulatory-review-period-for-purposes-of-patent-extension-factive,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5759.pdf,2004-03-15, FACTIVE,,Anthony,FACTIVE,5962468 5776944 and 5633262,LG Life Sciences,2038.0,832,1206.0,"September 6, 1997","September 6, 1997","April 4, 2003",NDA 21-158,659
Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VELCADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 13055,04-6159,https://www.federalregister.gov/documents/2004/03/19/04-6159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-velcade,https://www.govinfo.gov/content/pkg/FR-2004-03-19/pdf/04-6159.pdf,2004-03-19, VELCADE,,Anthony,VELCADE,5780454,Millenium Pharmaceuticals,1723.0,1610,113.0,"August 26, 1998","August 26, 1998","May 13, 2003",NDA 21-602,920
Determination of Regulatory Review Period for Purposes of Patent Extension; Neotame,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for neotame and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",69 FR 40946,04-15275,https://www.federalregister.gov/documents/2004/07/07/04-15275/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neotame,https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15275.pdf,2004-07-07, Neotame,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DAPTACEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DAPTACEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 40945,04-15274,https://www.federalregister.gov/documents/2004/07/07/04-15274/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daptacel,https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15274.pdf,2004-07-07, DAPTACEL,,Anthony,DAPTACEL,5667787,Aventis Pasteur,3591.0,1415,2176.0,"July 16, 1992","July 16, 1992","May 14, 2002",BLA 103666,242
Determination of Regulatory Review Period for Purposes of Patent Extension; NEUTERSOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEUTERSOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of two patents which claim that animal drug product.",69 FR 40944,04-15301,https://www.federalregister.gov/documents/2004/07/07/04-15301/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neutersol,https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15301.pdf,2004-07-07, NEUTERSOL,,Anthony,NEUTERSOL,5070808 and 4937234,"Technology Transfer, Inc.",4222.0,4188,34.0,"August 27, 1991","March 17, 2003","March 17, 2003",NADA 141-217,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ELITEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELITEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 41509,04-15569,https://www.federalregister.gov/documents/2004/07/09/04-15569/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elitek,https://www.govinfo.gov/content/pkg/FR-2004-07-09/pdf/04-15569.pdf,2004-07-09, ELITEK,,Anthony,ELITEK,5382518,Sanofi-Synthelabo,2360.0,1420,940.0,"January 27, 1996","January 27, 1996","July 12, 2002",BLA 103946,1638
Determination of Regulatory Review Period for Purposes of Patent Extension; XOPENEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XOPENEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 41812,04-15712,https://www.federalregister.gov/documents/2004/07/12/04-15712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xopenex,https://www.govinfo.gov/content/pkg/FR-2004-07-12/pdf/04-15712.pdf,2004-07-12, XOPENEX,,Anthony,XOPENEX,5362755,"Sepracor, Inc.",1458.0,824,634.0,"March 30, 1995","March 30, 1995","March 25, 1999",NDA 20-837,502
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMPATH,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CAMPATH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 42059,04-15802,https://www.federalregister.gov/documents/2004/07/13/04-15802/determination-of-regulatory-review-period-for-purposes-of-patent-extension-campath,https://www.govinfo.gov/content/pkg/FR-2004-07-13/pdf/04-15802.pdf,2004-07-13, CAMPATH,,Anthony,CAMPATH,5545403,Millenium,3423.0,2921,502.0,"December 25, 1991","December 25, 1991","May 7, 2001",BLA 103948,632
Determination of Regulatory Review Period for Purposes of Patent Extension; LEA'S SHIELD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEA'S SHIELD and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",69 FR 45335,04-17209,https://www.federalregister.gov/documents/2004/07/29/04-17209/determination-of-regulatory-review-period-for-purposes-of-patent-extension-leas-shield,https://www.govinfo.gov/content/pkg/FR-2004-07-29/pdf/04-17209.pdf,2004-07-29, LEA'S SHIELD,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REYATAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REYATAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 57937,04-21625,https://www.federalregister.gov/documents/2004/09/28/04-21625/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reyataz,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21625.pdf,2004-09-28, REYATAZ,,Anthony,REYATAZ,5849911,Novartis Corp.,1723.0,1540,183.0,"October 3, 1998","October 3, 1998","June 20, 2003",NDA 21-567,72
Determination of Regulatory Review Period for Purposes of Patent Extension; VISUDYNE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VISUDYNE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 57939,04-21678,https://www.federalregister.gov/documents/2004/09/28/04-21678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-visudyne,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21678.pdf,2004-09-28, VISUDYNE,,Anthony,VISUDYNE,5095030,University of British Columbia,3194.0,2953,241.0,"July 17, 1991","July 17, 1991","April 12, 2000",NDA 21-119,5
Determination of Regulatory Review Period for Purposes of Patent Extension; KINERET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KINERET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 57938,04-21675,https://www.federalregister.gov/documents/2004/09/28/04-21675/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kineret,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21675.pdf,2004-09-28, KINERET,,Anthony,Kineret,5075222,"Amgen, Inc.",4101.0,3413,688.0,"August 25, 1990","August 25, 1990","November 14, 2001",BLA 103950,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; DERMAGRAFT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DERMAGRAFT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",69 FR 58176,04-21749,https://www.federalregister.gov/documents/2004/09/29/04-21749/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dermagraft,https://www.govinfo.gov/content/pkg/FR-2004-09-29/pdf/04-21749.pdf,2004-09-29, DERMAGRAFT,,Anthony,Dermagraft,4963489,"Advanced Tissue Sciences, Inc.",4050.0,3650,400.0,"August 29, 1990","August 29, 1990","September 28, 2001",PMA P00036,5
Determination of Regulatory Review Period for Purposes of Patent Extension; AMEVIVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMEVIVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 58445,04-21874,https://www.federalregister.gov/documents/2004/09/30/04-21874/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amevive,https://www.govinfo.gov/content/pkg/FR-2004-09-30/pdf/04-21874.pdf,2004-09-30, AMEVIVE,,Anthony,AMEVIVE,5547853,"Biogen, Inc.",2104.0,1618,486.0,"April 29, 1997","April 29, 1997","January 30, 2003",BLA 12536,1259
Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GANIRELIX ACETATE INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 63547,04-24378,https://www.federalregister.gov/documents/2004/11/02/04-24378/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ganirelix-acetate,https://www.govinfo.gov/content/pkg/FR-2004-11-02/pdf/04-24378.pdf,2004-11-02, GANIRELIX ACETATE INJECTION (Formerly ANTAGON),,Anthony,GANIRELIX ACETATE INJECTION,4801577,Syntex,3558.0,3376,182.0,"November 2, 1989","November 2, 1989","July 29, 1999",NDA 21-057,5
Determination of Regulatory Review Period for Purposes of Patent Extension; GEODON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GEODON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",70 FR 22341,05-8587,https://www.federalregister.gov/documents/2005/04/29/05-8587/determination-of-regulatory-review-period-for-purposes-of-patent-extension-geodon,https://www.govinfo.gov/content/pkg/FR-2005-04-29/pdf/05-8587.pdf,2005-04-29, GEODON,,Anthony,GEODON,4831031,"Pfizer, Inc.",3933.0,2511,1422.0,"May 3, 1990","March 17, 1997","February 5, 2001",NDA 20-825,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; ERTACZO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ERTACZO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",70 FR 25091,05-9462,https://www.federalregister.gov/documents/2005/05/12/05-9462/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ertaczo,https://www.govinfo.gov/content/pkg/FR-2005-05-12/pdf/05-9462.pdf,2005-05-12, ERTACZO,,Anthony,ERTACZO,5135943,"Ferrer Internacional, S.A.",2718.0,1914,804.0,"July 3, 1996","July 3, 1996","December 10, 2003",NDA 21-385,1776
Determination of Regulatory Review Period for Purposes of Patent Extension; CLARINEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLARINEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",70 FR 43159,05-14695,https://www.federalregister.gov/documents/2005/07/26/05-14695/determination-of-regulatory-review-period-for-purposes-of-patent-extension-clarinex,https://www.govinfo.gov/content/pkg/FR-2005-07-26/pdf/05-14695.pdf,2005-07-26, CLARINEX,,Anthony,CLARINEX,4659716,Schering Corp.,1354.0,561,793.0,"April 9, 1998","April 9, 1998","December 21, 2001",NDA 21-165,1074
Determination of Regulatory Review Period for Purposes of Patent Extension; ATS Open Pivot Bileaf Heart Valve,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ATS Open Pivot Bileaf Heart Valve and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",70 FR 43437,05-14748,https://www.federalregister.gov/documents/2005/07/27/05-14748/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ats-open-pivot-bileaf,https://www.govinfo.gov/content/pkg/FR-2005-07-27/pdf/05-14748.pdf,2005-07-27, ATS Open Pivot Bileaf Heart Valve,,Anthony,ATS Open Pivot Bileaf Heart Valve,5354330,"ATS Medical, Inc.",1418.0,980,438.0,"November 27, 1996","November 27, 1996","October 13, 2000",PMA P990046,505
Determination of Regulatory Review Period for Purposes of Patent Extension; ZUBRIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZUBRIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",70 FR 43701,05-14921,https://www.federalregister.gov/documents/2005/07/28/05-14921/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zubrin,https://www.govinfo.gov/content/pkg/FR-2005-07-28/pdf/05-14921.pdf,2005-07-28, ZUBRIN,,Anthony,ZUBRIN,4826868,Johnson & Johnson,2347.0,1887,460.0,"October 28, 1996","March 31, 2003","March 31, 2003",NADA 141-193,1405
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOMETA; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of February 28, 2003 (68 FR 9690). The document announced that FDA had determined the regulatory review period for ZOMETA. A Request for Revision of Regulatory Review Period was filed for the product on May 4, 2005. FDA reviewed its records and found that the effective date of the investigational new drug application (IND) was incorrect due to a clerical error. Therefore, FDA is revising the determination of the regulatory review period to reflect the correct effective date for the IND.",70 FR 67178,05-22012,https://www.federalregister.gov/documents/2005/11/04/05-22012/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zometa-correction,https://www.govinfo.gov/content/pkg/FR-2005-11-04/pdf/05-22012.pdf,2005-11-04, ZOMETA, Correction,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SPIRIVA HANDIHALER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SPIRIVA HANDIHALER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 4592,E6-1050,https://www.federalregister.gov/documents/2006/01/27/E6-1050/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spiriva-handihaler,https://www.govinfo.gov/content/pkg/FR-2006-01-27/pdf/E6-1050.pdf,2006-01-27, SPIRIVA HANDIHALER,,Anthony,SPIRIVA HANDIHALER,5610163,Boehringer Ingelheim Corporation,3318.0,2557,761.0,"August 31, 2004","January 1, 1995","January 30, 2004",NDA 21-395,1421
Determination of Regulatory Review Period for Purposes of Patent Extension; ENABLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENABLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 4919,E6-1072,https://www.federalregister.gov/documents/2006/01/30/E6-1072/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enablex,https://www.govinfo.gov/content/pkg/FR-2006-01-30/pdf/E6-1072.pdf,2006-01-30, ENABLEX,,Anthony,ENABLEX,5096890,Novartis International Phamaceutical Ltd.,3824.0,3073,751.0,"July 8, 2005","July 6, 1994","December 22, 2004",NDA 21-513,2298
Determination of Regulatory Review Period for Purposes of Patent Extension; XOLAIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XOLAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 4920,E6-1078,https://www.federalregister.gov/documents/2006/01/30/E6-1078/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xolair,https://www.govinfo.gov/content/pkg/FR-2006-01-30/pdf/E6-1078.pdf,2006-01-30, XOLAIR,,Anthony,XOLAIR,6267958,Genentech,3440.0,2329,1111.0,"April 8, 2005","January 20, 1994","June 20, 2003",BLA 103976,463
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2006-02-01, HUMIRA,,Anthony,HUMIRA,6090382,Abbott Biotechnology Ltd.,1722.0,1443,279.0,"April 8, 2005","April 16, 1998","December 31, 2002",BLA 125057,326
Determination of Regulatory Review Period for Purposes of Patent Extension; ALOXI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALOXI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 5668,06-903,https://www.federalregister.gov/documents/2006/02/02/06-903/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aloxi,https://www.govinfo.gov/content/pkg/FR-2006-02-02/pdf/06-903.pdf,2006-02-02, ALOXI,,Anthony,ALOXI,5202333,"Roche Palo Alto, LLC",3867.0,3565,302.0,"October 19, 2004","December 24, 1992","July 25, 2003",NDA 21-372,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; OMACOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OMACOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents that claim that human drug product.",71 FR 5669,E6-1365,https://www.federalregister.gov/documents/2006/02/02/E6-1365/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omacor,https://www.govinfo.gov/content/pkg/FR-2006-02-02/pdf/E6-1365.pdf,2006-02-02, OMACOR,,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CYPHER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYPHER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",71 FR 5860,E6-1436,https://www.federalregister.gov/documents/2006/02/03/E6-1436/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cypher,https://www.govinfo.gov/content/pkg/FR-2006-02-03/pdf/E6-1436.pdf,2006-02-03, CYPHER,,Anthony,CYPHER,5563146,Wyeth,814.0,513,301.0,"June 24, 2004","February 1, 2001","April 24, 2003",PMA P020023,557
Determination of Regulatory Review Period for Purposes of Patent Extension; SURPASS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SURPASS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 5859,E6-1434,https://www.federalregister.gov/documents/2006/02/03/E6-1434/determination-of-regulatory-review-period-for-purposes-of-patent-extension-surpass,https://www.govinfo.gov/content/pkg/FR-2006-02-03/pdf/E6-1434.pdf,2006-02-03, SURPASS,,Anthony,SURPASS,4937078,"Mezei Associates, Ltd.",2262.0,1028,1234.0,"April 8, 2005","May 13, 2004","May 13, 2004",NADA 141-186,1590
Determination of Regulatory Review Period for Purposes of Patent Extension; ALIMTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALIMTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 6504,E6-1642,https://www.federalregister.gov/documents/2006/02/08/E6-1642/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alimta,https://www.govinfo.gov/content/pkg/FR-2006-02-08/pdf/E6-1642.pdf,2006-02-08, ALIMTA,,Anthony,ALIMTA,5344932,Eli Lilly,4166.0,4038,128.0,"August 31, 2004","September 10, 1992","February 4, 2004",NDA 21-462,1784
Determination of Regulatory Review Period for Purposes of Patent Extension; ERBITUX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ERBITUX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 8595,E6-2354,https://www.federalregister.gov/documents/2006/02/17/E6-2354/determination-of-regulatory-review-period-for-purposes-of-patent-extension-erbitux,https://www.govinfo.gov/content/pkg/FR-2006-02-17/pdf/E6-2354.pdf,2006-02-17, ERBITUX,,Anthony,ERBITUX,6217866,Aventis Pharmaceuticals,3375.0,3192,183.0,"July 8, 2005","November 18, 1994","February 12, 2004",BLA 125084,391
Determination of Regulatory Review Period for Purposes of Patent Extension; RELPAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RELPAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13408,E6-3711,https://www.federalregister.gov/documents/2006/03/15/E6-3711/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relpax,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3711.pdf,2006-03-15, RELPAX,,Anthony,RELPAX,5545644,"Pfizer, Inc.",2829.0,1307,1522.0,"April 6, 2004","March 31, 1995","December 26, 2002",NDA 21-016,1230
Determination of Regulatory Review Period for Purposes of Patent Extension; OVIDREL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OVIDREL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13406,E6-3640,https://www.federalregister.gov/documents/2006/03/15/E6-3640/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ovidrel,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3640.pdf,2006-03-15, OVIDREL,,Anthony,OVIDREL,4840896,Genzyme Corp.,1787.0,1485,302.0,"July 8, 2005","November 1, 1995","September 20, 2000",NDA 21-149,1054
Determination of Regulatory Review Period for Purposes of Patent Extension; CRESTOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CRESTOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13407,E6-3641,https://www.federalregister.gov/documents/2006/03/15/E6-3641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crestor,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3641.pdf,2006-03-15, CRESTOR,,Anthony,CRESTOR,RE37314,Shionogi Seiyaku Kabushiki Kaisha,1831.0,1053,778.0,"April 6, 2004","June 26, 2001","August 12, 2003",NDA 21-366,1304
Determination of Regulatory Review Period for Purposes of Patent Extension; PRIALT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRIALT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of two patents which claims that human drug product.",71 FR 13409,E6-3712,https://www.federalregister.gov/documents/2006/03/15/E6-3712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prialt,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3712.pdf,2006-03-15, PRIALT,,Anthony,PRIALT,5795864 and 5364842,"Elan Pharmaceuticals, Inc.",3801.0,1973,1828.0,"July 8, 2005","August 4, 1994","December 28, 2004",NDA 21-060,1228
Determination of Regulatory Review Period for Purposes of Patent Extension; TYSABRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYSABRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 13604,E6-3781,https://www.federalregister.gov/documents/2006/03/16/E6-3781/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tysabri,https://www.govinfo.gov/content/pkg/FR-2006-03-16/pdf/E6-3781.pdf,2006-03-16, TYSABRI,,Anthony,TYSABRI,5840299,"Athena Neurosciences, Inc.",2924.0,2740,184.0,"July 8, 2005","November 23, 1996","November 23, 2004",BLA 125104,1189
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13979,E6-3956,https://www.federalregister.gov/documents/2006/03/20/E6-3956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine,https://www.govinfo.gov/content/pkg/FR-2006-03-20/pdf/E6-3956.pdf,2006-03-20, MYCAMINE,,Anthony,MYCAMINE,5376634,"Astellas Pharma, Inc.",2546.0,1493,1053.0,"July 8, 2005","March 29, 1998","March 16, 2005",NDA 21-506,1814
Determination of Regulatory Review Period for Purposes of Patent Extension; ALAMAST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALAMAST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 14707,E6-4163,https://www.federalregister.gov/documents/2006/03/23/E6-4163/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alamast,https://www.govinfo.gov/content/pkg/FR-2006-03-23/pdf/E6-4163.pdf,2006-03-23, ALAMAST,,Anthony,ALAMAST,5034230,"Santen Pharmaceutical Co., Ltd.",1298.0,1115,183.0,"April 26, 2000","March 7, 1996","September 24, 1999",NDA 21-079,755
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 14709,E6-4165,https://www.federalregister.gov/documents/2006/03/23/E6-4165/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine,https://www.govinfo.gov/content/pkg/FR-2006-03-23/pdf/E6-4165.pdf,2006-03-23, MYCAMINE,,Anthony,MYCAMINE,5376634,"Astellas Pharma, Inc.",2546.0,2221,325.0,"July 8, 2005","March 29, 1998","March 16, 2005",NDA 21-754,476
Determination of Regulatory Review Period for Purposes of Patent Extension; VESICARE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VESICARE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 14708,E6-4164,https://www.federalregister.gov/documents/2006/03/23/E6-4164/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vesicare,https://www.govinfo.gov/content/pkg/FR-2006-03-23/pdf/E6-4164.pdf,2006-03-23, VESICARE,,Anthony,VESICARE,6017927,"Yamanouchi Pharmaceutical Co., Ltd.",2027.0,1325,702.0,"July 8, 2005","December 19, 2002","November 19, 2004",NDA 21-518,329
Determination of Regulatory Review Period for Purposes of Patent Extension; FASLODEX; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 17, 2003 (68 FR 18992). The document announced that FDA had determined the regulatory review period for FASLODEX. A request for revision of regulatory review period was filed for the product on June 16, 2003. FDA reviewed its records and found that the effective date of the investigational new drug application (IND) was incorrect due to a clerical error. Therefore, FDA is revising the determination of the regulatory review period to reflect the correct effective date for the IND.",71 FR 21029,E6-6083,https://www.federalregister.gov/documents/2006/04/24/E6-6083/determination-of-regulatory-review-period-for-purposes-of-patent-extension-faslodex-correction,https://www.govinfo.gov/content/pkg/FR-2006-04-24/pdf/E6-6083.pdf,2006-04-24, FASLODEX, Correction,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CETROTIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 33465,E6-9031,https://www.federalregister.gov/documents/2006/06/09/E6-9031/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cetrotide,https://www.govinfo.gov/content/pkg/FR-2006-06-09/pdf/E6-9031.pdf,2006-06-09, CETROTIDE,,Anthony,CETROTIDE,5198533,Administrators of the Tulane Educational Fund,2103.0,1815,288.0,"April 6, 2004","November 10, 1994","August 11, 2000",NDA 21-197,1491
Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INCRELEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34135,E6-9138,https://www.federalregister.gov/documents/2006/06/13/E6-9138/determination-of-regulatory-review-period-for-purposes-of-patent-extension-increlex,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9138.pdf,2006-06-13, INCRELEX,,Anthony,INCRELEX,5681814,"Genentech, Inc.",4828.0,4644,184.0,"February 24, 2006","June 13, 1992","August 30, 2005",NDA 21-839,1058
Determination of Regulatory Review Period for Purposes of Patent Extension; RESTYLANE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RESTYLANE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",71 FR 34138,E6-9213,https://www.federalregister.gov/documents/2006/06/13/E6-9213/determination-of-regulatory-review-period-for-purposes-of-patent-extension-restylane,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9213.pdf,2006-06-13, RESTYLANE,,Anthony,RESTYLANE,5827937,Q-Med AB,1491.0,949,542.0,"November 14, 1999","November 14, 1999","December 12, 2003",PMA P020023,879
Determination of Regulatory Review Period for Purposes of Patent Extension; LUVERIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUVERIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34136,E6-9139,https://www.federalregister.gov/documents/2006/06/13/E6-9139/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luveris,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9139.pdf,2006-06-13, LUVERIS,,Anthony,LUVERIS,5639639,Genzyme Corp.,3927.0,2670,1257.0,"February 24, 2006","January 9, 1994","October 8, 2004",NDA 21-322,1780
Determination of Regulatory Review Period for Purposes of Patent Extension; UROXATRAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for UROXATRAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34137,E6-9201,https://www.federalregister.gov/documents/2006/06/13/E6-9201/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uroxatral,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9201.pdf,2006-06-13, UROXATRAL,,Anthony,UROXATRAL,4661491,Sanofi-Synthelabo,2477.0,1560,917.0,"October 19, 2004","September 1, 1996","June 12, 2003",NDA 21-287,1481
Determination of Regulatory Review Period for Purposes of Patent Extension; TYGACIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYGACIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34139,E6-9214,https://www.federalregister.gov/documents/2006/06/13/E6-9214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tygacil,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9214.pdf,2006-06-13, TYGACIL,,Anthony,TYGACIL,5529990,Wyeth Holdings Corp.,2487.0,2304,183.0,"February 24, 2006","August 26, 1998","June 15, 2005",NDA 21-821,1335
Determination of Regulatory Review Period for Purposes of Patent Extension; DUTASTERIDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DUTASTERIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34374,E6-9224,https://www.federalregister.gov/documents/2006/06/14/E6-9224/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dutasteride,https://www.govinfo.gov/content/pkg/FR-2006-06-14/pdf/E6-9224.pdf,2006-06-14, DUTASTERIDE,,Anthony,DUTASTERIDE,5565467,GlaxoSmithKline,2373.0,2038,335.0,"October 31, 2002","May 25, 1995","November 20, 2001",NDA 21-319,769
Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CUBICIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34375,E6-9225,https://www.federalregister.gov/documents/2006/06/14/E6-9225/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cubicin,https://www.govinfo.gov/content/pkg/FR-2006-06-14/pdf/E6-9225.pdf,2006-06-14, CUBICIN,,Anthony,CUBICIN,4885243,"Cubist Pharmaceuticals, Inc.",6444.0,6177,267.0,"February 24, 2006","January 22, 1986","September 12, 2003",NDA 21-572,1347
Determination of Regulatory Review Period for Purposes of Patent Extension; INSPRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INSPRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34944,E6-9412,https://www.federalregister.gov/documents/2006/06/16/E6-9412/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inspra,https://www.govinfo.gov/content/pkg/FR-2006-06-16/pdf/E6-9412.pdf,2006-06-16, INSPRA,,Anthony,INSPRA,4559332,Novartis Corp.,2135.0,1832,303.0,"June 16, 2003","November 24, 1996","September 27, 2002",NDA 21-437,1218
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMLIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYMLIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34945,E6-9414,https://www.federalregister.gov/documents/2006/06/16/E6-9414/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symlin,https://www.govinfo.gov/content/pkg/FR-2006-06-16/pdf/E6-9414.pdf,2006-06-16, SYMLIN,,Anthony,SYMLIN,5686411,Amylin Pharmaceuticals,4620.0,3060,1560.0,"February 24, 2006","July 24, 1992","March 16, 2005",NDA 21-332,1586
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZEREM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ROZEREM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 35274,E6-9509,https://www.federalregister.gov/documents/2006/06/19/E6-9509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozerem,https://www.govinfo.gov/content/pkg/FR-2006-06-19/pdf/E6-9509.pdf,2006-06-19, ROZEREM,,Anthony,ROZEREM,6034239,"Takeda Pharmaceutical Co., Ltd.",2224.0,1920,304.0,"February 24, 2006","June 22, 1999","July 22, 2005",NDA 21-782,808
Determination of Regulatory Review Period for Purposes of Patent Extension; BONIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BONIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 35918,E6-9817,https://www.federalregister.gov/documents/2006/06/22/E6-9817/determination-of-regulatory-review-period-for-purposes-of-patent-extension-boniva,https://www.govinfo.gov/content/pkg/FR-2006-06-22/pdf/E6-9817.pdf,2006-06-22, BONIVA,,Anthony,BONIVA,4927814,Hoffmann-La Roche Inc.,2559.0,2254,305.0,"October 19, 2004","May 15, 1996","May 16, 2003",NDA 21-455,337
Determination of Regulatory Review Period for Purposes of Patent Extension; CIALIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CIALIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 35919,E6-9899,https://www.federalregister.gov/documents/2006/06/22/E6-9899/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cialis,https://www.govinfo.gov/content/pkg/FR-2006-06-22/pdf/E6-9899.pdf,2006-06-22, CIALIS,,Anthony,CIALIS,5859006,ICOS Corporation,1943.0,1067,876.0,"October 19, 2004","July 29, 1998","November 21, 2003",NDA 21-368,679
Determination of Regulatory Review Period for Purposes of Patent Extension; TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",71 FR 38170,E6-10408,https://www.federalregister.gov/documents/2006/07/05/E6-10408/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taxus-express,https://www.govinfo.gov/content/pkg/FR-2006-07-05/pdf/E6-10408.pdf,2006-07-05, TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System,,Anthony,TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System,5716981,"Angiotech Phamaceuticals, Inc.",716.0,456,260.0,"February 24, 2006","February 24, 2006","March 4, 2004",PMA P030025,807
Determination of Regulatory Review Period for Purposes of Patent Extension; MULTIHANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MULTIHANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 39120,E6-10796,https://www.federalregister.gov/documents/2006/07/11/E6-10796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-multihance,https://www.govinfo.gov/content/pkg/FR-2006-07-11/pdf/E6-10796.pdf,2006-07-11, MULTIHANCE,,Anthony,MULTIHANCE,4916246,Bracco International B.V.,3789.0,2482,1307.0,"July 8, 2005","July 12, 1994","November 23, 2004",NDA 21-357,5
Determination of Regulatory Review Period for Purposes of Patent Extension; CYMBALTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYMBALTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 44034,E6-12574,https://www.federalregister.gov/documents/2006/08/03/E6-12574/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cymbalta,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12574.pdf,2006-08-03, CYMBALTA,,Anthony,CYMBALTA,5023269,Eli Lilly,4781.0,3786,995.0,"February 24, 2006","July 4, 1991","August 3, 2004",NDA 21-427,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IPLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 44031,E6-12571,https://www.federalregister.gov/documents/2006/08/03/E6-12571/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iplex,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12571.pdf,2006-08-03, IPLEX,,Anthony,IPLEX,5681818,Insmed Inc.,3527.0,3183,344.0,"May 19, 2006","April 18, 1996","December 12, 2005",NDA 21-884,1657
Determination of Regulatory Review Period for Purposes of Patent Extension; CLINACOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLINACOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 44032,E6-12572,https://www.federalregister.gov/documents/2006/08/03/E6-12572/determination-of-regulatory-review-period-for-purposes-of-patent-extension-clinacox,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12572.pdf,2006-08-03, CLINACOX,,Anthony,CLINACOX,4631278,Janssen Pharmaceutica N.V.,5111.0,1749,3362.0,"October 4, 2000","April 25, 1985","April 21, 1999",NADA 140-951,1096
Determination of Regulatory Review Period for Purposes of Patent Extension; EMEND,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMEND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 44033,E6-12573,https://www.federalregister.gov/documents/2006/08/03/E6-12573/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emend,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12573.pdf,2006-08-03, EMEND,,Anthony,EMEND,5719147,Merck & Co.,2513.0,2332,181.0,"November 18, 2003","May 10, 1996","March 26, 2003",NDA 21-549,1022
Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FUZEON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54996,E6-15554,https://www.federalregister.gov/documents/2006/09/20/E6-15554/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fuzeon,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15554.pdf,2006-09-20, FUZEON,,Anthony,FUZEON,6133418,Duke University,2312.0,2133,179.0,"April 6, 2004","November 14, 1996","March 13, 2003",NDA 21-481,569
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,2006-09-20, AVASTIN,,Anthony,AVASTIN,6054297,"Genentech, Inc.",2551.0,2401,150.0,"July 8, 2005","March 5, 1997","February 26, 2004",BLA 125085,307
Determination of Regulatory Review Period for Purposes of Patent Extension; MACUGEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MACUGEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54998,E6-15556,https://www.federalregister.gov/documents/2006/09/20/E6-15556/determination-of-regulatory-review-period-for-purposes-of-patent-extension-macugen,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15556.pdf,2006-09-20, MACUGEN,,Anthony,MACUGEN,6051698,"Gilead Sciences, Inc.",2312.0,2128,184.0,"June 28, 2005","August 21, 1998","December 17, 2004",NDA 21-756,990
Determination of Regulatory Review Period for Purposes of Patent Extension; APTIVUS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for APTIVUS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54995,E6-15553,https://www.federalregister.gov/documents/2006/09/20/E6-15553/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aptivus,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15553.pdf,2006-09-20, APTIVUS,,Anthony,APTIVUS,5852195,"Pharmacia & Upjohn Co., LLC",3114.0,2931,183.0,"February 24, 2006","December 14, 1996","June 22, 2005",NDA 21-814,1278
Determination of Regulatory Review Period for Purposes of Patent Extension; CYDECTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYDECTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 54993,06-7800,https://www.federalregister.gov/documents/2006/09/20/06-7800/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cydectin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/06-7800.pdf,2006-09-20, CYDECTIN,,Anthony,CYDECTIN,4916154,American Cyanamid Company,2857.0,2841,16.0,"April 6, 2004","January 28, 1998","January 28, 1998",NADA 141-099,1754
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE-New Drug Application 21-754,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54994,06-7985,https://www.federalregister.gov/documents/2006/09/20/06-7985/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/06-7985.pdf,2006-09-20, MYCAMINE-New Drug Application 21-754,,Anthony,MYCAMINE,6107458 and 6265536,"Astellas Pharma, Inc.",2546.0,2221,325.0,"February 24, 2006","March 29, 1998","March 16, 2005",NDA 21-754,476
Determination of Regulatory Review Period for Purposes of Patent Extension; CLOLAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLOLAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 55799,06-8115,https://www.federalregister.gov/documents/2006/09/25/06-8115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-clolar,https://www.govinfo.gov/content/pkg/FR-2006-09-25/pdf/06-8115.pdf,2006-09-25, CLOLAR,,Anthony,CLOLAR,5661136,Southern Research Institute,2200.0,1926,274.0,"February 24, 2006","December 22, 1998","December 28, 2004",NDA 21-673,1303
Determination of Regulatory Review Period for Purposes of Patent Extension; KETEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KETEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 56156,E6-15690,https://www.federalregister.gov/documents/2006/09/26/E6-15690/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ketek,https://www.govinfo.gov/content/pkg/FR-2006-09-26/pdf/E6-15690.pdf,2006-09-26, KETEK,,Anthony,KETEK,5635485,Aventis S. A.,2206.0,713,1493.0,"March 29, 2006","March 20, 1998","April 1, 2004",NDA 21-144,1076
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE-New Drug Application 21-506,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",71 FR 56157,E6-15767,https://www.federalregister.gov/documents/2006/09/26/E6-15767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-26/pdf/E6-15767.pdf,2006-09-26, MYCAMINE-New Drug Application 21-506,,Anthony,MYCAMINE,6107458 and 6265536,"Astellas Pharma, Inc.",2546.0,1493,1053.0,"February 24, 2006","March 29, 1998","March 16, 2005",NDA 21-506,1192
Determination of Regulatory Review Period for Purposes of Patent Extension; LYRICA (New Drug Application 21-446),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LYRICA (new drug application (NDA) 21-446) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 56540,E6-15908,https://www.federalregister.gov/documents/2006/09/27/E6-15908/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lyrica-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-27/pdf/E6-15908.pdf,2006-09-27, LYRICA (New Drug Application 21-446),,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PLENAXIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PLENAXIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 57545,E6-15969,https://www.federalregister.gov/documents/2006/09/29/E6-15969/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plenaxis,https://www.govinfo.gov/content/pkg/FR-2006-09-29/pdf/E6-15969.pdf,2006-09-29, PLENAXIS,,Anthony,PLENAXIS,5843901,"Praecis Pharmaceuticals, Inc.",2566.0,1487,1079.0,"October 19, 2004","November 17, 1996","November 25, 2003",NDA 21-320,725
Determination of Regulatory Review Period for Purposes of Patent Extension; TARCEVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TARCEVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 57546,E6-15987,https://www.federalregister.gov/documents/2006/09/29/E6-15987/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tarceva,https://www.govinfo.gov/content/pkg/FR-2006-09-29/pdf/E6-15987.pdf,2006-09-29, TARCEVA,,Anthony,TARCEVA,5747498,"Pfizer, Inc.",2653.0,2541,112.0,"July 8, 2005","August 16, 1997","November 18, 2004",NDA 21-743,1261
Determination of Regulatory Review Period for Purposes of Patent Extension; LYRICA (New Drug Application 21-723),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LYRICA (new drug application (NDA) 21-723) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 57545,E6-15962,https://www.federalregister.gov/documents/2006/09/29/E6-15962/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lyrica-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-29/pdf/E6-15962.pdf,2006-09-29, LYRICA (New Drug Application 21-723),,Anthony,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BYETTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 57977,E6-16086,https://www.federalregister.gov/documents/2006/10/02/E6-16086/determination-of-regulatory-review-period-for-purposes-of-patent-extension-byetta,https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16086.pdf,2006-10-02, BYETTA,,John,BYETTA (exenatide injection),5424286,"Amylin Pharmaceuticals, Inc",2271.0,1968.0,303.0,1999-02-10 00:00:00,2004-06-30,2005-04-28,NDA 21-773,1286
Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NATRECOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 57979,E6-16091,https://www.federalregister.gov/documents/2006/10/02/E6-16091/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natrecor,https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16091.pdf,2006-10-02, NATRECOR,,John,NATRECOR,5114923,"Scios, Inc.",2790.0,1588,1202.0,"May 19, 2006","December 22, 1993","August 10, 2001",NDA 20-920,5
Determination of Regulatory Review Period for Purposes of Patent Extension; DRAXXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DRAXXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 57978,E6-16087,https://www.federalregister.gov/documents/2006/10/02/E6-16087/determination-of-regulatory-review-period-for-purposes-of-patent-extension-draxxin,https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16087.pdf,2006-10-02, DRAXXIN,,John,DRAXXIN,6420536,"Pfizer, Inc.",2451.0,2414,37.0,"February 24, 2006","September 9, 1998","May 24, 2005",NADA 141-244,360
Redetermination of Regulatory Review Period for Purposes of Patent Extension; BONIVA; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 22, 2006 (71 FR 35918). The document announced that FDA had determined the regulatory review period for BONIVA. The notice provided that on or before August 21, 2006, anyone with knowledge that any of the dates as published are incorrect may submit a request for a redetermination of the regulatory review period. A request for revision of the regulatory review period was filed for the product on July 25, 2006. FDA reviewed its records and found that the effective date of the investigational new drug application (IND) was incorrect because of a clerical error. Therefore, FDA is republishing a determination of the regulatory review period to reflect the corrected effective date for the IND. FDA has made a determination of the regulatory review period because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 59797,E6-16816,https://www.federalregister.gov/documents/2006/10/11/E6-16816/redetermination-of-regulatory-review-period-for-purposes-of-patent-extension-boniva-correction,https://www.govinfo.gov/content/pkg/FR-2006-10-11/pdf/E6-16816.pdf,2006-10-11, BONIVA, Correction,John,BONIVA,4927814,"Hoffmann-La Roche, Inc.",3122.0,2817,305.0,"October 19, 2004","MD 20857, 301","May 16, 2003",NDA 21-455,1713
Determination of Regulatory Review Period for Purposes of Patent Extension; TYGACIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYGACIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 7664,E7-2805,https://www.federalregister.gov/documents/2007/02/16/E7-2805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tygacil,https://www.govinfo.gov/content/pkg/FR-2007-02-16/pdf/E7-2805.pdf,2007-02-16, TYGACIL,,John,TYGACIL,5494903,Wyeth Holdings Corp.,2487.0,2304,183.0,"June 14, 2006","August 26, 1998","June 15, 2005",NDA 21-821,1335
Determination of Regulatory Review Period for Purposes of Patent Extension; LEVEMIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEVEMIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 7999,E7-3001,https://www.federalregister.gov/documents/2007/02/22/E7-3001/determination-of-regulatory-review-period-for-purposes-of-patent-extension-levemir,https://www.govinfo.gov/content/pkg/FR-2007-02-22/pdf/E7-3001.pdf,2007-02-22, LEVEMIR,,John,LEVEMIR,5750497,Novo Nordisk A/S,2896.0,1971,925.0,"July 24, 2006","July 14, 1997","June 16, 2005",NDA 21-536,1496
Determination of Regulatory Review Period for Purposes of Patent Extension; EXJADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXJADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 8180,E7-3041,https://www.federalregister.gov/documents/2007/02/23/E7-3041/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exjade,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3041.pdf,2007-02-23, EXJADE,,John,EXJADE,6465504,Novartis AG,2288.0,2103,185.0,"July 24, 2006","July 31, 1999","November 2, 2005",NDA 21-882,648
Determination of Regulatory Review Period for Purposes of Patent Extension; BARACLUDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BARACLUDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 8181,E7-3042,https://www.federalregister.gov/documents/2007/02/23/E7-3042/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baraclude,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3042.pdf,2007-02-23, BARACLUDE,,John,BARACLUDE,5206244,Bristol-Myers Squibb Co.,2993.0,2811,182.0,"September 5, 2006","January 19, 1997","March 29, 2005",NDA 21-797,1587
Determination of Regulatory Review Period for Purposes of Patent Extension; AMITIZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMITIZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 8183,E7-3128,https://www.federalregister.gov/documents/2007/02/23/E7-3128/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amitiza,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3128.pdf,2007-02-23, AMITIZA,,John,AMITIZA,5284858,Sucampo AG,2197.0,1890,307.0,"September 5, 2006","January 28, 2000","January 31, 2006",NDA 21-908,1251
Determination of Regulatory Review Period for Purposes of Patent Extension; S8 OVER-THE-WIRE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for S8 OVER-THE-WIRE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 8182,E7-3127,https://www.federalregister.gov/documents/2007/02/23/E7-3127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-s8-over-the-wire-system,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3127.pdf,2007-02-23, S8 OVER-THE-WIRE SYSTEM,,John,S8 OVER-THE-WIRE SYSTEM,5292331; 5800509; 5836965; 5879382; 5891190; 6159229; 6309402; and 6344053,Medtronic Vascular,652.0,477,175.0,"February 24, 2006","December 20, 2001","October 1, 2003",PMA P030009,413
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,2007-03-26, REVLIMID,,John,REVLIMID,5635517,Celgene Corp.,2069.0,1804,265.0,"June 14, 2006","April 30, 2000","December 27, 2005",NDA 21-880,1166
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVICOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVICOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",72 FR 14119,E7-5443,https://www.federalregister.gov/documents/2007/03/26/E7-5443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-previcox,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5443.pdf,2007-03-26, PREVICOX,,John,PREVICOX,5981576,Merck Frosst Canada & Co.,2216.0,2118,98.0,"June 14, 2006","June 29, 1998","July 21, 2004",NADA 141-230,650
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOLOG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOLOG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14121,E7-5445,https://www.federalregister.gov/documents/2007/03/26/E7-5445/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novolog,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5445.pdf,2007-03-26, NOVOLOG,,John,NOVOLOG,5618913,Novo Nordisk A/S,1776.0,1145,631.0,"December 12, 2006","July 30, 1995","June 7, 2000",NDA 20-986,59
Determination of Regulatory Review Period for Purposes of Patent Extension; EMTRIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMTRIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14122,E7-5446,https://www.federalregister.gov/documents/2007/03/26/E7-5446/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emtriva,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5446.pdf,2007-03-26, EMTRIVA,,John,EMTRIVA,5914331,Emory University,2114.0,1811,303.0,"July 8, 2005","September 19, 1997","July 2, 2003",NDA 21-500,642
Determination of Regulatory Review Period for Purposes of Patent Extension; ONYX LES,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ONYX LES and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 14120,E7-5444,https://www.federalregister.gov/documents/2007/03/26/E7-5444/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onyx-les,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5444.pdf,2007-03-26, ONYX LES,,John,ONYX LES,5667767,"Micro Therapeutics, Inc.",1682.0,825,857.0,"June 14, 2006","December 14, 2000","July 21, 2005",PMA P030004,1271
Determination of Regulatory Review Period for Purposes of Patent Extension; A180,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for A180 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",72 FR 14280,E7-5504,https://www.federalregister.gov/documents/2007/03/27/E7-5504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-a180,https://www.govinfo.gov/content/pkg/FR-2007-03-27/pdf/E7-5504.pdf,2007-03-27, A180,,John,A180,4861779,"Pfizer, Inc.",5365.0,5314,51.0,"July 16, 2003","August 1, 2002","September 20, 2002",NADA 141-,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that medical device.",72 FR 14582,E7-5635,https://www.federalregister.gov/documents/2007/03/28/E7-5635/determination-of-regulatory-review-period-for-purposes-of-patent-extension-infuse-bone-graftlt-cage,https://www.govinfo.gov/content/pkg/FR-2007-03-28/pdf/E7-5635.pdf,2007-03-28, INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VAPRISOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VAPRISOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 14819,E7-5737,https://www.federalregister.gov/documents/2007/03/29/E7-5737/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vaprisol,https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/E7-5737.pdf,2007-03-29, VAPRISOL,,John,VAPRISOL,5723606,"Astellas Pharma, Inc.",2796.0,2096,700.0,"September 5, 2006","January 30, 2004","December 29, 2005",NDA 21-697,1745
Determination of Regulatory Review Period for Purposes of Patent Extension; RETEVASE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RETEVASE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 14818,E7-5736,https://www.federalregister.gov/documents/2007/03/29/E7-5736/determination-of-regulatory-review-period-for-purposes-of-patent-extension-retevase,https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/E7-5736.pdf,2007-03-29, RETEVASE,,John,RETEVASE,5223256,Boehringer Mannheim GmbH,1919.0,1430,489.0,"February 6, 1997","August 1, 1991","October 30, 1996",PLA 95-1167,123
Determination of Regulatory Review Period for Purposes of Patent Extension; KEPIVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KEPIVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 15699,E7-6053,https://www.federalregister.gov/documents/2007/04/02/E7-6053/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kepivance,https://www.govinfo.gov/content/pkg/FR-2007-04-02/pdf/E7-6053.pdf,2007-04-02, KEPIVANCE,,John,KEPIVANCE,5677278,Chiron Corp.,3303.0,3119,184.0,"June 14, 2006","December 2, 1995","December 15, 2004",BLA 125103,1417
Determination of Regulatory Review Period for Purposes of Patent Extension; RANEXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RANEXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 15700,E7-6061,https://www.federalregister.gov/documents/2007/04/02/E7-6061/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ranexa,https://www.govinfo.gov/content/pkg/FR-2007-04-02/pdf/E7-6061.pdf,2007-04-02, RANEXA,,John,RANEXA,4567264,"Roche Palo Alto, L.L.C.",6770.0,5645,1125.0,"September 5, 2006","July 18, 1987","January 27, 2006",NDA 21-526,5
Determination of Regulatory Review Period for Purposes of Patent Extension; NOXAFIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOXAFIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28496,E7-9730,https://www.federalregister.gov/documents/2007/05/21/E7-9730/determination-of-regulatory-review-period-for-purposes-of-patent-extension-noxafil,https://www.govinfo.gov/content/pkg/FR-2007-05-21/pdf/E7-9730.pdf,2007-05-21, NOXAFIL,,John,NOXAFIL,5661151,Schering Corp.,3650.0,3382,268.0,"March 12, 2007","September 19, 1996","September 15, 2006",NDA 22-003,1789
Determination of Regulatory Review Period for Purposes of Patent Extension; IRESSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IRESSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28497,E7-9733,https://www.federalregister.gov/documents/2007/05/21/E7-9733/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iressa,https://www.govinfo.gov/content/pkg/FR-2007-05-21/pdf/E7-9733.pdf,2007-05-21, IRESSA,,John,IRESSA,5770599,AstraZeneca UK Limited,1967.0,1693,274.0,"October 19, 2004","December 17, 1997","May 5, 2003",NDA 21-399,374
Determination of Regulatory Review Period for Purposes of Patent Extension; GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 28498,E7-9720,https://www.federalregister.gov/documents/2007/05/21/E7-9720/determination-of-regulatory-review-period-for-purposes-of-patent-extension-galileo-intravascular,https://www.govinfo.gov/content/pkg/FR-2007-05-21/pdf/E7-9720.pdf,2007-05-21, GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM,,John,GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM,5199939,Guidant Corp.,1523.0,1203,320.0,"October 31, 2002","September 3, 1997","November 2, 2001",PMA P000052,1062
Determination of Regulatory Review Period for Purposes of Patent Extension; FOSRENOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FOSRENOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28700,E7-9787,https://www.federalregister.gov/documents/2007/05/22/E7-9787/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fosrenol,https://www.govinfo.gov/content/pkg/FR-2007-05-22/pdf/E7-9787.pdf,2007-05-22, FOSRENOL,,John,FOSRENOL,5968976,"Shire International Licensing, B.V.",2449.0,1538,911.0,"July 8, 2005","February 13, 1998","October 26, 2004",NDA 21-468,951
Determination of Regulatory Review Period for Purposes of Patent Extension; ORENCIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ORENCIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 28978,E7-9945,https://www.federalregister.gov/documents/2007/05/23/E7-9945/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orencia,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9945.pdf,2007-05-23, ORENCIA,,John,ORENCIA,5851795,Bristol-Myers Squibb Company,3803.0,3536,267.0,"September 5, 2006","July 28, 1995","December 23, 2005",BLA 125118,1414
Determination of Regulatory Review Period for Purposes of Patent Extension; ELAPRASE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELAPRASE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 28980,E7-9951,https://www.federalregister.gov/documents/2007/05/23/E7-9951/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elaprase,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9951.pdf,2007-05-23, ELAPRASE,,John,ELAPRASE,5932211,Women's,2008.0,1764,244.0,"February 6, 2007","January 25, 2001","July 24, 2006",BLA 125151,1103
Determination of Regulatory Review Period for Purposes of Patent Extension; BEXTRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEXTRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28984,E7-9957,https://www.federalregister.gov/documents/2007/05/23/E7-9957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bextra,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9957.pdf,2007-05-23, BEXTRA,,John,BEXTRA,5633272,"G.D. Searle, LLC",1767.0,1462,305.0,"August 31, 2004","January 16, 1997","November 16, 2001",NDA 21-341,276
Determination of Regulatory Review Period for Purposes of Patent Extension; GARDASIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GARDASIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 28979,E7-9950,https://www.federalregister.gov/documents/2007/05/23/E7-9950/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gardasil,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9950.pdf,2007-05-23, GARDASIL,,John,GARDASIL,5820870,"Merck & Co., Inc.",2215.0,2031,184.0,"Types 6, 11","May 17, 2000","June 8, 2006",BLA 125126,1200
Determination of Regulatory Review Period for Purposes of Patent Extension; SOMAVERT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOMAVERT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 29172,E7-10052,https://www.federalregister.gov/documents/2007/05/24/E7-10052/determination-of-regulatory-review-period-for-purposes-of-patent-extension-somavert,https://www.govinfo.gov/content/pkg/FR-2007-05-24/pdf/E7-10052.pdf,2007-05-24, SOMAVERT,,John,SOMAVERT,5849535,"Genentech, Inc.",2169.0,1349,820.0,"April 6, 2004","April 18, 1997","March 25, 2003",NDA 21-106,466
Determination of Regulatory Review Period for Purposes of Patent Extension; MYOZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYOZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 29333,E7-10087,https://www.federalregister.gov/documents/2007/05/25/E7-10087/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myozyme,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10087.pdf,2007-05-25, MYOZYME,,John,MYOZYME,6118045,"Genzyme Corp., Erasmus MC, Erasmus Universiteit",1225.0,950,275.0,"February 6, 2007","December 22, 2002","April 28, 2006",BLA 125141,1251
Determination of Regulatory Review Period for Purposes of Patent Extension; PREZISTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREZISTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 29335,E7-10147,https://www.federalregister.gov/documents/2007/05/25/E7-10147/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prezista,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10147.pdf,2007-05-25, PREZISTA,,John,PREZISTA,6248775,G.D. Searle & Co.,1253.0,1070,183.0,"February 6, 2007","January 19, 2003","June 23, 2006",NDA 21-976,717
Determination of Regulatory Review Period for Purposes of Patent Extension; KDR 401 and 403 PACEMAKERS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KDR 401 and 403 PACEMAKERS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims those medical devices.",72 FR 29336,E7-10127,https://www.federalregister.gov/documents/2007/05/25/E7-10127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kdr-401-and-403,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10127.pdf,2007-05-25, KDR 401 and 403 PACEMAKERS,,John,KDR 401 and 403 PACEMAKERS,4958632,"Medtronic, Inc.",716.0,358,358.0,"February 22, 2007","February 22, 2007","January 30, 1998",PMA 970012,358
Determination of Regulatory Review Periods for Purposes of Patent Extension; SPRYCEL-New Drug Applications 21-986 and 22-072,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SPRYCEL--new drug applications (NDAs) 21- 986 and 22-072 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 29334,E7-10089,https://www.federalregister.gov/documents/2007/05/25/E7-10089/determination-of-regulatory-review-periods-for-purposes-of-patent-extension-sprycel-new-drug,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10089.pdf,2007-05-25, SPRYCEL-New Drug Applications 21-986 and 22-072,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZILMAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZILMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",72 FR 30594,E7-10602,https://www.federalregister.gov/documents/2007/06/01/E7-10602/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zilmax,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10602.pdf,2007-06-01, ZILMAX,,John,ZILMAX,4900735,Intervet International B.V.,40.0,4720,4674.0,"March 5, 2007","September 9, 1993","August 10, 2006",NADA 141-258,5
Determination of Regulatory Review Period for Purposes of Patent Extension; LANTUS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LANTUS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 30595,E7-10632,https://www.federalregister.gov/documents/2007/06/01/E7-10632/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lantus,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10632.pdf,2007-06-01, LANTUS,,John,LANTUS,5101013,Hoechst Aktiengesellschaft,1591.0,1227,364.0,"January 26, 2007","December 14, 1995","April 20, 2000",NDA 21-081,976
Determination of Regulatory Review Period for Purposes of Patent Extension; PHAKIC INTRAOCULAR LENSES,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PHAKIC INTRAOCULAR LENSES and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 30597,E7-10631,https://www.federalregister.gov/documents/2007/06/01/E7-10631/determination-of-regulatory-review-period-for-purposes-of-patent-extension-phakic-intraocular-lenses,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10631.pdf,2007-06-01, PHAKIC INTRAOCULAR LENSES,,John,PHAKIC INTRAOCULAR LENSES,5192319,"Ophtec USA, Inc., subsidiary of Ophtec B.V.",2545.0,2107,438.0,"September 5, 2006","September 24, 1997","September 10, 2004",PMA P030028,1484
Determination of Regulatory Review Period for Purposes of Patent Extension; GEM 21S GROWTH-FACTOR ENHANCED MATRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GEM 21S GROWTH-FACTOR ENHANCED MATRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 30598,E7-10633,https://www.federalregister.gov/documents/2007/06/01/E7-10633/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gem-21s-growth-factor,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10633.pdf,2007-06-01, GEM 21S GROWTH-FACTOR ENHANCED MATRIX,,John,GEM 21S GROWTH-FACTOR ENHANCED MATRIX,5124316,"Biomimetic Therapeutics, Inc. (previously Biomimetic Pharmaceuticals, Inc.)",1361.0,744,617.0,"January 8, 2007","February 28, 2002","November 18, 2005",PMA P040013,987
Determination of Regulatory Review Period for Purposes of Patent Extension; X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 30596,E7-10618,https://www.federalregister.gov/documents/2007/06/01/E7-10618/determination-of-regulatory-review-period-for-purposes-of-patent-extension-x-stop-interspinous,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10618.pdf,2007-06-01, X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM,,John,X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM,6235030,"St. Francis Medical Technologies, Inc.",2224.0,1538,686.0,"December 12, 2006","December 12, 2006","November 21, 2005",PMA P040001,1053
Determination of Regulatory Review Period for Purposes of Patent Extension; NAMENDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NAMENDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",72 FR 31075,E7-10730,https://www.federalregister.gov/documents/2007/06/05/E7-10730/determination-of-regulatory-review-period-for-purposes-of-patent-extension-namenda,https://www.govinfo.gov/content/pkg/FR-2007-06-05/pdf/E7-10730.pdf,2007-06-05, NAMENDA,,John,NAMENDA,5061703 and 5614560,"Forest Laboratories, Inc., acting as agent for Merz Pharma GmbH & Co. KGaA",5001.0,4699,302.0,"January 26, 2007","February 7, 1990","October 16, 2003",NDA 21-487,1250
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPLON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAPLON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 31331,E7-10853,https://www.federalregister.gov/documents/2007/06/06/E7-10853/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raplon,https://www.govinfo.gov/content/pkg/FR-2007-06-06/pdf/E7-10853.pdf,2007-06-06, RAPLON,,John,RAPLON,5418226,Akzo Nobel N.V.,1724.0,1304,420.0,"April 26, 2000","November 30, 1994","August 18, 1999",NDA 20-984,126
Determination of Regulatory Review Period for Purposes of Patent Extension; CHANTIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CHANTIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 31588,E7-10915,https://www.federalregister.gov/documents/2007/06/07/E7-10915/determination-of-regulatory-review-period-for-purposes-of-patent-extension-chantix,https://www.govinfo.gov/content/pkg/FR-2007-06-07/pdf/E7-10915.pdf,2007-06-07, CHANTIX,,John,CHANTIX,6410550,"Pfizer, Inc.",2401.0,2219,182.0,"January 26, 2007","October 15, 1999","May 10, 2006",NDA 21-928,545
Determination of Regulatory Review Period for Purposes of Patent Extension; ACRYSOF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACRYSOF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",73 FR 17985,E8-6851,https://www.federalregister.gov/documents/2008/04/02/E8-6851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-acrysof,https://www.govinfo.gov/content/pkg/FR-2008-04-02/pdf/E8-6851.pdf,2008-04-02, ACRYSOF,,John,ACRYSOF,5470932,"Alcon Manufacturing, Ltd.",1084.0,538,546.0,"July 7, 2000","July 7, 2000","June 24, 2003",PMA P930014,832
Determination of Regulatory Review Period for Purposes of Patent Extension; ARTEFILL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARTEFILL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",73 FR 24072,E8-9592,https://www.federalregister.gov/documents/2008/05/01/E8-9592/determination-of-regulatory-review-period-for-purposes-of-patent-extension-artefill,https://www.govinfo.gov/content/pkg/FR-2008-05-01/pdf/E8-9592.pdf,2008-05-01, ARTEFILL,,John,ARTEFILL,5344452,"Artes Medical USA, Inc.",3530.0,1859,1671.0,"February 28, 1997","February 28, 1997","October 27, 2006",PMA P020012,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; AZILECT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AZILECT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 24073,E8-9591,https://www.federalregister.gov/documents/2008/05/01/E8-9591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-azilect,https://www.govinfo.gov/content/pkg/FR-2008-05-01/pdf/E8-9591.pdf,2008-05-01, AZILECT,,John,AZILECT,5453446,"Teva Pharmaceutical Industries, Ltd.",4269.0,3284,985.0,"September 9, 1994","September 9, 1994","May 16, 2006",NDA 21-641,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; TEKTURNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEKTURNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 24295,E8-9699,https://www.federalregister.gov/documents/2008/05/02/E8-9699/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tekturna,https://www.govinfo.gov/content/pkg/FR-2008-05-02/pdf/E8-9699.pdf,2008-05-02, TEKTURNA,,John,TEKTURNA,5559111,Novartis Corporation,2023.0,1637,386.0,"August 22, 2001","August 22, 2001","March 5, 2007",NDA 21-985,2022
Determination of Regulatory Review Period for Purposes of Patent Extension; OMNARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OMNARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 26999,E8-10466,https://www.federalregister.gov/documents/2008/05/12/E8-10466/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omnaris,https://www.govinfo.gov/content/pkg/FR-2008-05-12/pdf/E8-10466.pdf,2008-05-12, OMNARIS,,John,OMNARIS,5482934,Altana Pharma AG,3196.0,2893,303.0,"January 21, 1998","January 21, 1998","October 20, 2006",NDA 22-004,1748
Determination of Regulatory Review Period for Purposes of Patent Extension; VECTIBIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VECTIBIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27000,E8-10512,https://www.federalregister.gov/documents/2008/05/12/E8-10512/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vectibix,https://www.govinfo.gov/content/pkg/FR-2008-05-12/pdf/E8-10512.pdf,2008-05-12, VECTIBIX,,John,VECTIBIX,6235883,Amgen Fremont Inc.,2662.0,2479,183.0,"June 16, 1999","June 16, 1999","September 27, 2006",BLA 125147,1122
Determination of Regulatory Review Period for Purposes of Patent Extension; INVEGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVEGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 27837,E8-10685,https://www.federalregister.gov/documents/2008/05/14/E8-10685/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invega,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10685.pdf,2008-05-14, INVEGA,,John,INVEGA,5158952,"Janssen, L.P.",1406.0,1021,385.0,"February 14, 2003","February 14, 2003","December 19, 2006",NDA 21-999,896
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOLINZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZOLINZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 27838,E8-10689,https://www.federalregister.gov/documents/2008/05/14/E8-10689/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zolinza,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10689.pdf,2008-05-14, ZOLINZA,,John,ZOLINZA,RE38506 E,Sloan-Kettering Institute for Cancer Research,2449.0,2266,183.0,"January 24, 2000","January 24, 2000","October 6, 2006",NDA 21-991,1433
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,2008-05-14, AVASTIN,,John,AVASTIN,6639055,"Genentech, Inc.",2551.0,2401,150.0,"March 5, 1997","March 5, 1997","February 26, 2004",BLA 125085,121
Determination of Regulatory Review Period for Purposes of Patent Extension; TYZEKA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYZEKA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submissions of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",73 FR 28119,E8-10857,https://www.federalregister.gov/documents/2008/05/15/E8-10857/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tyzeka,https://www.govinfo.gov/content/pkg/FR-2008-05-15/pdf/E8-10857.pdf,2008-05-15, TYZEKA,,John,TYZEKA,6395716 and 6569837,"Idenix Pharmaceuticals, Inc., Centre National de La Recherche Scientifique",2309.0,2009,300.0,"July 1, 2000","August 15, 2000","October 25, 2006",NDA 22-011,442
Determination of Regulatory Review Period for Purposes of Patent Extension; LUCENTIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUCENTIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",73 FR 30949,E8-12007,https://www.federalregister.gov/documents/2008/05/29/E8-12007/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lucentis,https://www.govinfo.gov/content/pkg/FR-2008-05-29/pdf/E8-12007.pdf,2008-05-29, LUCENTIS,,John,LUCENTIS,6407213; 6884879; and 7060269,"Genentech, Inc.",2430.0,2247,183.0,"November 6, 1999","November 6, 1999","June 30, 2006",BLA 125156,378
Determination of Regulatory Review Period for Purposes of Patent Extension; VEREGEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VEREGEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",73 FR 31697,E8-12296,https://www.federalregister.gov/documents/2008/06/03/E8-12296/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veregen,https://www.govinfo.gov/content/pkg/FR-2008-06-03/pdf/E8-12296.pdf,2008-06-03, VEREGEN,,John,VEREGEN,5795911 and 5968973,"Mitsui Norin Co., Ltd.",3002.0,2605,397.0,"August 14, 1998","August 14, 1998","October 31, 2006",NDA 21-902,1300
Determination of Regulatory Review Period for Purposes of Patent Extension; TYZEKA; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 15, 2008 (73 FR 28119), announcing FDA's determination of the regulatory review period for TYZEKA. The document published with an incorrect docket number. This document corrects that error.",73 FR 31697,E8-12300,https://www.federalregister.gov/documents/2008/06/03/E8-12300/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tyzeka-correction,https://www.govinfo.gov/content/pkg/FR-2008-06-03/pdf/E8-12300.pdf,2008-06-03, TYZEKA, Correction,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ROTATEQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ROTATEQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 33095,E8-13109,https://www.federalregister.gov/documents/2008/06/11/E8-13109/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rotateq,https://www.govinfo.gov/content/pkg/FR-2008-06-11/pdf/E8-13109.pdf,2008-06-11, ROTATEQ,,John,ROTATEQ,5626851,the Wistar Institute of Anatomy,4577.0,4272,305.0,"July 26, 1993","July 26, 1993","February 3, 2006",BLA 125122,1751
Determination of Regulatory Review Period for Purposes of Patent Extension; ERAXIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ERAXIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 35402,E8-14156,https://www.federalregister.gov/documents/2008/06/23/E8-14156/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eraxis,https://www.govinfo.gov/content/pkg/FR-2008-06-23/pdf/E8-14156.pdf,2008-06-23, ERAXIS,,John,ERAXIS,5965525,Eli Lilly,3476.0,2446,1030.0,"August 14, 1996","August 14, 1996","February 17, 2006",NDA 21-948,1224
Determination of Regulatory Review Period for Purposes of Patent Extension; TYKERB,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYKERB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 66647,E8-26679,https://www.federalregister.gov/documents/2008/11/10/E8-26679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tykerb,https://www.govinfo.gov/content/pkg/FR-2008-11-10/pdf/E8-26679.pdf,2008-11-10, TYKERB,,John,TYKERB,6713485,SmithKline Beecham Corp. (doing business as GlaxoSmithKline),2260.0,2078,182.0,"January 5, 2001","January 5, 2001","March 13, 2007",NDA 22-059,628
Determination of Regulatory Review Period for Purposes of Patent Extension; IXEMPRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IXEMPRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 66646,E8-26678,https://www.federalregister.gov/documents/2008/11/10/E8-26678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ixempra,https://www.govinfo.gov/content/pkg/FR-2008-11-10/pdf/E8-26678.pdf,2008-11-10, IXEMPRA,,John,IXEMPRA,6605599,Bristol Myers Squibb Co.,3002.0,2818,184.0,"July 30, 1999","July 30, 1999","October 16, 2007",NDA 22-065,854
Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOMATULINE DEPOT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 67874,E8-27179,https://www.federalregister.gov/documents/2008/11/17/E8-27179/determination-of-regulatory-review-period-for-purposes-of-patent-extension-somatuline-depot,https://www.govinfo.gov/content/pkg/FR-2008-11-17/pdf/E8-27179.pdf,2008-11-17, SOMATULINE DEPOT,,John,SOMATULINE DEPOT,5595760,Society De Conseils De Recherches Et D'Applications Scientifiques,3629.0,3324,305.0,"September 24, 1997","September 24, 1997","August 30, 2007",NDA 22-074,5
Determination of Regulatory Review Period for Purposes of Patent Extension; LETAIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LETAIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",74 FR 6635,E9-2683,https://www.federalregister.gov/documents/2009/02/10/E9-2683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-letairis,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2683.pdf,2009-02-10, LETAIRIS,,John,LETAIRIS,5703017; 5840722; 5932730; and 7109205,"Abbott Gmbh & Co., KG",1871.0,1691,180.0,"May 3, 2002","May 3, 2002","June 15, 2007",NDA 22-081,995
Determination of Regulatory Review Period for Purposes of Patent Extension; LUNESTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUNESTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 6636,E9-2681,https://www.federalregister.gov/documents/2009/02/10/E9-2681/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lunesta,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2681.pdf,2009-02-10, LUNESTA,,John,LUNESTA,6444673,"Sepracor, Inc.",1941.0,1256,685.0,"August 25, 1999","August 25, 1999","December 15, 2004",NDA 21-476,760
Determination of Regulatory Review Period for Purposes of Patent Extension; MIRCERA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MIRCERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 6637,E9-2812,https://www.federalregister.gov/documents/2009/02/10/E9-2812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mircera,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2812.pdf,2009-02-10, MIRCERA,,John,MIRCERA,6583272,Hoffmann-La Roche Inc.,2140.0,1565,575.0,"January 6, 2002","January 6, 2002","November 14, 2007",BLA B125164,5
Determination of Regulatory Review Period for Purposes of Patent Extension; SELZENTRY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SELZENTRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 6638,E9-2813,https://www.federalregister.gov/documents/2009/02/10/E9-2813/determination-of-regulatory-review-period-for-purposes-of-patent-extension-selzentry,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2813.pdf,2009-02-10, SELZENTRY,,John,SELZENTRY,6667314,Pfizer Inc.,1524.0,1294,230.0,"June 6, 2003","June 6, 2003","August 6, 2007",NDA 22-128,73
Determination of Regulatory Review Period for Purposes of Patent Extension; VETMEDIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VETMEDIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 6639,E9-2684,https://www.federalregister.gov/documents/2009/02/10/E9-2684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vetmedin,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2684.pdf,2009-02-10, VETMEDIN,,John,VETMEDIN,5364646,Dr. Karl Thomae GmbH,2751.0,2715,36.0,"October 20, 1999","March 26, 2007","April 30, 2007",NADA 141-273,1492
Determination of Regulatory Review Period for Purposes of Patent Extension; MACROPLASTIQUE IMPLANTS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MACROPLASTIQUE IMPLANTS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that medical device.",74 FR 6901,E9-2903,https://www.federalregister.gov/documents/2009/02/11/E9-2903/determination-of-regulatory-review-period-for-purposes-of-patent-extension-macroplastique-implants,https://www.govinfo.gov/content/pkg/FR-2009-02-11/pdf/E9-2903.pdf,2009-02-11, MACROPLASTIQUE IMPLANTS,,John,MACROPLASTIQUE IMPLANTS,5258028;. 5336263; and 5571182,"Uroplasty, Inc.",2651.0,1973,678.0,"July 30, 1999","July 30, 1999","October 30, 2006",PMA P040050,1640
Determination of Regulatory Review Period for Purposes of Patent Extension; ENDEAVOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENDEAVOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",74 FR 9249,E9-4374,https://www.federalregister.gov/documents/2009/03/03/E9-4374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-endeavor,https://www.govinfo.gov/content/pkg/FR-2009-03-03/pdf/E9-4374.pdf,2009-03-03, ENDEAVOR,,John,ENDEAVOR,5624411,"Medtronic, Inc.",1507.0,1068,439.0,"December 19, 2003","December 19, 2003","February 1, 2008",PMA P060033,954
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 9406,E9-4526,https://www.federalregister.gov/documents/2009/03/04/E9-4526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-soliris,https://www.govinfo.gov/content/pkg/FR-2009-03-04/pdf/E9-4526.pdf,2009-03-04, SOLIRIS,,John,SOLIRIS,6355245,"Alexion Pharmaceuticals, Inc.",1360.0,1177,183.0,"June 27, 2003","June 27, 2003","March 16, 2007",BLA 125166,735
Determination of Regulatory Review Period for Purposes of Patent Extension; ARRANON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARRANON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 9823,E9-4770,https://www.federalregister.gov/documents/2009/03/06/E9-4770/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arranon,https://www.govinfo.gov/content/pkg/FR-2009-03-06/pdf/E9-4770.pdf,2009-03-06, ARRANON,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ALTABAX OINTMENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALTABAX OINTMENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 10055,E9-4914,https://www.federalregister.gov/documents/2009/03/09/E9-4914/determination-of-regulatory-review-period-for-purposes-of-patent-extension-altabax-ointment,https://www.govinfo.gov/content/pkg/FR-2009-03-09/pdf/E9-4914.pdf,2009-03-09, ALTABAX OINTMENT,,John,ALTABAX OINTMENT,RE39128E,SmithKline Beecham P.L.C.,1602.0,1297,305.0,"November 24, 2002","November 24, 2002","April 12, 2007",NDA 22-055,833
Determination of Regulatory Review Period for Purposes of Patent Extension; CERENIA TABLETS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERENIA TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 10597,E9-5109,https://www.federalregister.gov/documents/2009/03/11/E9-5109/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerenia-tablets,https://www.govinfo.gov/content/pkg/FR-2009-03-11/pdf/E9-5109.pdf,2009-03-11, CERENIA TABLETS,,John,CERENIA TABLETS,6255320,Pfizer Inc.,1887.0,1841,46.0,"December 1, 2001","January 29, 2007","January 29, 2007",NADA 141-262,267
Determination of Regulatory Review Period for Purposes of Patent Extension; CERENIA INJECTABLE SOLUTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERENIA INJECTABLE SOLUTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 10596,E9-5112,https://www.federalregister.gov/documents/2009/03/11/E9-5112/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerenia-injectable,https://www.govinfo.gov/content/pkg/FR-2009-03-11/pdf/E9-5112.pdf,2009-03-11, CERENIA INJECTABLE SOLUTION,,John,CERENIA INJECTABLE SOLUTION,6222038,Pfizer Inc.,1887.0,1841,46.0,"December 1, 2001","January 29, 2007","January 29, 2007",NADA 141-263,1078
Determination of Regulatory Review Period for Purposes of Patent Extension; PROFENDER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROFENDER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 10744,E9-5374,https://www.federalregister.gov/documents/2009/03/12/E9-5374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-profender,https://www.govinfo.gov/content/pkg/FR-2009-03-12/pdf/E9-5374.pdf,2009-03-12, PROFENDER,,John,PROFENDER,5514773,Astellas Pharma Inc.,1585.0,1542,43.0,"February 27, 2003","June 29, 2007","June 29, 2007",NADA 141-275,1314
Determination of Regulatory Review Period for Purposes of Patent Extension; NEUPRO TRANSDERMAL SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEUPRO TRANSDERMAL SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 21696,E9-10818,https://www.federalregister.gov/documents/2009/05/08/E9-10818/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neupro-transdermal-system,https://www.govinfo.gov/content/pkg/FR-2009-05-08/pdf/E9-10818.pdf,2009-05-08, NEUPRO TRANSDERMAL SYSTEM,,John,NEUPRO TRANSDERMAL SYSTEM,6884434,Schwarz Pharma Limited,4367.0,3535,832.0,"May 27, 1995","May 27, 1995","May 9, 2007",NDA 21-829,744
Determination of Regulatory Review Period for Purposes of Patent Extension; SENSIPAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SENSIPAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 22750,E9-11219,https://www.federalregister.gov/documents/2009/05/14/E9-11219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sensipar,https://www.govinfo.gov/content/pkg/FR-2009-05-14/pdf/E9-11219.pdf,2009-05-14, SENSIPAR,,John,SENSIPAR,6011068; 6211244; and 6313146,"NPS Pharmaceuticals, Inc.",2089.0,1906,183.0,"June 21, 1998","June 21, 1998","March 8, 2004",NDA 21-688,449
Determination of Regulatory Review Period for Purposes of Patent Extension; INTELENCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INTELENCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 24014,E9-12050,https://www.federalregister.gov/documents/2009/05/22/E9-12050/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intelence,https://www.govinfo.gov/content/pkg/FR-2009-05-22/pdf/E9-12050.pdf,2009-05-22, INTELENCE,,John,INTELENCE,7037917,"Janssen Pharmaceutica, N.V.",2235.0,2050,185.0,"December 7, 2001","December 7, 2001","January 18, 2008",NDA 22-187,404
Determination of Regulatory Review Period for Purposes of Patent Extension; DUREZOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DUREZOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 37716,E9-18034,https://www.federalregister.gov/documents/2009/07/29/E9-18034/determination-of-regulatory-review-period-for-purposes-of-patent-extension-durezol,https://www.govinfo.gov/content/pkg/FR-2009-07-29/pdf/E9-18034.pdf,2009-07-29, DUREZOL,,John,DUREZOL,6114319,Senju Pharmaceutical Co. Ltd.,560.0,369,181.0,"December 13, 2006","December 13, 2006","June 23, 2008",NDA 22-212,369
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPAFLO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAPAFLO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 37715,E9-18032,https://www.federalregister.gov/documents/2009/07/29/E9-18032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapaflo,https://www.govinfo.gov/content/pkg/FR-2009-07-29/pdf/E9-18032.pdf,2009-07-29, RAPAFLO,,John,RAPAFLO,5387603,"Kissei Pharmaceutical Co., Ltd.",3681.0,3380,301.0,"September 12, 1998","September 12, 1998","October 8, 2008",NDA 22-206,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; EOVIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EOVIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 38660,E9-18527,https://www.federalregister.gov/documents/2009/08/04/E9-18527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eovist,https://www.govinfo.gov/content/pkg/FR-2009-08-04/pdf/E9-18527.pdf,2009-08-04, EOVIST,,John,EOVIST,6039931,Bayer Schering Pharma Aktiengesellschaft,3818.0,3450,368.0,"January 21, 1998","January 21, 1998","July 3, 2008",NDA 22-090,1699
Determination of Regulatory Review Period for Purposes of Patent Extension; RECOTHROM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RECOTHROM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",74 FR 38658,E9-18528,https://www.federalregister.gov/documents/2009/08/04/E9-18528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recothrom,https://www.govinfo.gov/content/pkg/FR-2009-08-04/pdf/E9-18528.pdf,2009-08-04, RECOTHROM,,John,RECOTHROM,5476777 5502034 and 5527692,"ZymoGenetics, Inc.",1511.0,1115,396.0,"November 30, 2003","November 30, 2003","January 17, 2008",BLA 125248,952
Determination of Regulatory Review Period for Purposes of Patent Extension; XIENCE V EECSS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIENCE V EECSS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",74 FR 38659,E9-18530,https://www.federalregister.gov/documents/2009/08/04/E9-18530/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xience-v-eecss,https://www.govinfo.gov/content/pkg/FR-2009-08-04/pdf/E9-18530.pdf,2009-08-04, XIENCE V EECSS,,John,XIENCE V EECSS,5451233,"Abbott Cardiovascular Systems, Inc.",1157.0,759,398.0,"May 4, 2005","May 4, 2005","July 2, 2008",PMA 70015,937
Determination of Regulatory Review Period for Purposes of Patent Extension; NPLATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NPLATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 40205,E9-19233,https://www.federalregister.gov/documents/2009/08/11/E9-19233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nplate,https://www.govinfo.gov/content/pkg/FR-2009-08-11/pdf/E9-19233.pdf,2009-08-11, NPLATE,,John,NPLATE,6835809,Amgen Inc.,2319.0,2014,305.0,"April 19, 2002","April 19, 2002","August 22, 2008",BLA 125268,818
Determination of Regulatory Review Period for Purposes of Patent Extension; LEXISCAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEXISCAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",74 FR 42678,E9-20307,https://www.federalregister.gov/documents/2009/08/24/E9-20307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lexiscan,https://www.govinfo.gov/content/pkg/FR-2009-08-24/pdf/E9-20307.pdf,2009-08-24, LEXISCAN,,John,LEXISCAN,6403567 and 6642210,"CV Therapeutics, Inc.",2446.0,2113,333.0,"August 1, 2001","August 1, 2001","April 10, 2008",NDA 22-161,977
Determination of Regulatory Review Period for Purposes of Patent Extension; TAPENTADOL HYDROCHLORIDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TAPENTADOL HYDROCHLORIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 45225,E9-21100,https://www.federalregister.gov/documents/2009/09/01/E9-21100/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tapentadol-hydrochloride,https://www.govinfo.gov/content/pkg/FR-2009-09-01/pdf/E9-21100.pdf,2009-09-01, TAPENTADOL HYDROCHLORIDE,,John,TAPENTADOL HYDROCHLORIDE,RE 39593,Grunenthal GmbH,2880.0,2577,303.0,"January 3, 2001","January 3, 2001","November 20, 2008",NDA 22-304,1492
Determination of Regulatory Review Period for Purposes of Patent Extension; BANZEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BANZEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 45864,E9-21428,https://www.federalregister.gov/documents/2009/09/04/E9-21428/determination-of-regulatory-review-period-for-purposes-of-patent-extension-banzel,https://www.govinfo.gov/content/pkg/FR-2009-09-04/pdf/E9-21428.pdf,2009-09-04, BANZEL,,John,BANZEL,6740669,Novartis AG,6595.0,5501,1094.0,"October 27, 1990","October 27, 1990","November 14, 2008",NDA 21-911,819
Determination of Regulatory Review Period for Purposes of Patent Extension; DORIBAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DORIBAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 45863,E9-21365,https://www.federalregister.gov/documents/2009/09/04/E9-21365/determination-of-regulatory-review-period-for-purposes-of-patent-extension-doribax,https://www.govinfo.gov/content/pkg/FR-2009-09-04/pdf/E9-21365.pdf,2009-09-04, DORIBAX,,John,DORIBAX,5317016,Shionogi Seiyaku Kabushiki Kaisha,1746.0,1442,304.0,"January 2, 2003","January 2, 2003","October 12, 2007",NDA 22-106,1025
Determination of Regulatory Review Period for Purposes of Patent Extension; TALENT ABDOMINAL STENT GRAFT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TALENT ABDOMINAL STENT GRAFT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",74 FR 45865,E9-21424,https://www.federalregister.gov/documents/2009/09/04/E9-21424/determination-of-regulatory-review-period-for-purposes-of-patent-extension-talent-abdominal-stent,https://www.govinfo.gov/content/pkg/FR-2009-09-04/pdf/E9-21424.pdf,2009-09-04, TALENT ABDOMINAL STENT GRAFT SYSTEM,,John,TALENT ABDOMINAL STENT GRAFT SYSTEM,6306141,"Medtronic, Inc.",4024.0,3843,181.0,"April 11, 1997","April 11, 1997","April 15, 2008",PMA P070027,1183
Determination of Regulatory Review Period for Purposes of Patent Extension; CLEVIPREX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLEVIPREX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 50801,E9-23650,https://www.federalregister.gov/documents/2009/10/01/E9-23650/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cleviprex,https://www.govinfo.gov/content/pkg/FR-2009-10-01/pdf/E9-23650.pdf,2009-10-01, CLEVIPREX,,John,CLEVIPREX,5739152 and 5856346,AstraZeneca AB,4475.0,4078,397.0,"May 3, 1996","May 3, 1996","August 1, 2008",NDA 22-156,1314
Determination of Regulatory Review Period for Purposes of Patent Extension; EMEND FOR INJECTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMEND FOR INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 51159,E9-23900,https://www.federalregister.gov/documents/2009/10/05/E9-23900/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emend-for-injection,https://www.govinfo.gov/content/pkg/FR-2009-10-05/pdf/E9-23900.pdf,2009-10-05, EMEND FOR INJECTION,,John,EMEND FOR INJECTION,5691336,"Merck & Co., Inc.",4473.0,3810,663.0,"October 29, 1995","October 29, 1995","January 25, 2008",NDA 22-023,1826
"Determination of Regulatory Review Period for Purposes of Patent Extension; ENTEREG; U.S. Patent Nos. 5,250,542 and 5,434,171",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENTEREG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",74 FR 52241,E9-24457,https://www.federalregister.gov/documents/2009/10/09/E9-24457/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entereg-us-patent-nos,https://www.govinfo.gov/content/pkg/FR-2009-10-09/pdf/E9-24457.pdf,2009-10-09, ENTEREG," U.S. Patent Nos. 5,250,542 and 5,434,171",John,ENTEREG,5250542 and 5434171,Eli Lilly,5305.0,3879,1426.0,"November 12, 1993","November 12, 1993","May 20, 2008",NDA 21-775,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; FIRMAGON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FIRMAGON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 9227,2010-4159,https://www.federalregister.gov/documents/2010/03/01/2010-4159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-firmagon,https://www.govinfo.gov/content/pkg/FR-2010-03-01/pdf/2010-4159.pdf,2010-03-01, FIRMAGON,,John,FIRMAGON,5925730,Ferring BV,2695.0,2394,301.0,"August 10, 2001","August 10, 2001","December 24, 2008",NDA 22-201,1498
Determination of Regulatory Review Period for Purposes of Patent Extension; LUSEDRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUSEDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 17142,2010-7516,https://www.federalregister.gov/documents/2010/04/05/2010-7516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lusedra,https://www.govinfo.gov/content/pkg/FR-2010-04-05/pdf/2010-7516.pdf,2010-04-05, LUSEDRA,,John,LUSEDRA,6204257 and 6872838,University of Kansas,2405.0,1962,443.0,"May 15, 2002","May 15, 2002","December 12, 2008",NDA 22-244,1424
Determination of Regulatory Review Period for Purposes of Patent Extension; FANAPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FANAPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 17415,2010-7678,https://www.federalregister.gov/documents/2010/04/06/2010-7678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fanapt,https://www.govinfo.gov/content/pkg/FR-2010-04-06/pdf/2010-7678.pdf,2010-04-06, FANAPT,,John,FANAPT,RE39198,Aventis Holdings Inc.,6552.0,5964,588.0,"May 31, 1991","May 31, 1991","May 6, 2009",NDA 22-192,5
Determination of Regulatory Review Period for Purposes of Patent Extension; TOVIAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TOVIAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 17414,2010-7679,https://www.federalregister.gov/documents/2010/04/06/2010-7679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-toviaz,https://www.govinfo.gov/content/pkg/FR-2010-04-06/pdf/2010-7679.pdf,2010-04-06, TOVIAZ,,John,TOVIAZ,6858650,Schwarz Pharma AG,2395.0,1445,950.0,"April 13, 2002","April 13, 2002","October 31, 2008",NDA 22-030,1155
Determination of Regulatory Review Period for Purposes of Patent Extension; MOZOBIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MOZOBIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 18213,2010-8172,https://www.federalregister.gov/documents/2010/04/09/2010-8172/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mozobil,https://www.govinfo.gov/content/pkg/FR-2010-04-09/pdf/2010-8172.pdf,2010-04-09, MOZOBIL,,John,MOZOBIL,5583131,Genzyme Corp.,3849.0,3666,183.0,"June 4, 1998","June 4, 1998","December 15, 2008",NDA 22-311,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 19406,2010-8443,https://www.federalregister.gov/documents/2010/04/14/2010-8443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afinitor,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8443.pdf,2010-04-14, AFINITOR,,John,AFINITOR,5665772,Novartis AG,4486.0,4212,274.0,"December 19, 1996","December 19, 1996","March 30, 2009",NDA 22-334,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; SAVELLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAVELLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 19407,2010-8518,https://www.federalregister.gov/documents/2010/04/14/2010-8518/determination-of-regulatory-review-period-for-purposes-of-patent-extension-savella,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8518.pdf,2010-04-14, SAVELLA,,John,SAVELLA,6602911 and 6992110,"Cypress Bioscience, Inc.",2571.0,2177,394.0,"January 2, 2002","January 2, 2002","January 14, 2009",NDA 22-256,435
Determination of Regulatory Review Period for Purposes of Patent Extension; VIMPAT-NDA 22-254,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIMPAT based on new drug application (NDA) 22-254 for VIMPAT injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim the human drug product, VIMPAT. The regulatory review period determination for VIMPAT Tablets is publishing in this issue of the Federal Register.",75 FR 21299,2010-9509,https://www.federalregister.gov/documents/2010/04/23/2010-9509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vimpat-nda-22-254,https://www.govinfo.gov/content/pkg/FR-2010-04-23/pdf/2010-9509.pdf,2010-04-23, VIMPAT-NDA 22-254,,John,VIMPAT,5654301 and RE38551,"Research Corporation Technologies, Inc.",3452.0,3055,397.0,"May 19, 1999","September 29, 2009","October 28, 2008",NDA 22-254,1104
Determination of Regulatory Review Period for Purposes of Patent Extension; VIMPAT -NDA 22-253,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIMPAT based on new drug application (NDA) 22-253 for VIMPAT TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extensions of patents which claim the human drug product, VIMPAT. The regulatory review period determination for VIMPAT Injection is publishing in this issue of the Federal Register.",75 FR 21298,2010-9512,https://www.federalregister.gov/documents/2010/04/23/2010-9512/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vimpat--nda-22-253,https://www.govinfo.gov/content/pkg/FR-2010-04-23/pdf/2010-9512.pdf,2010-04-23, VIMPAT -NDA 22-253,,John,VIMPAT,5654301 and RE38551,"Research Corporation Technologies, Inc.",3452.0,3055,397.0,"May 19, 1999","September 29, 2009","October 28, 2008",NDA 22-253,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; ABLAVAR,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA) has determined the,75 FR 32479,2010-13655,https://www.federalregister.gov/documents/2010/06/08/2010-13655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ablavar,https://www.govinfo.gov/content/pkg/FR-2010-06-08/pdf/2010-13655.pdf,2010-06-08, ABLAVAR,,John,ABLAVAR,6676929 and 7060250,"Epix Pharmaceuticals, Inc.",4508.0,2673,1835.0,"August 21, 1996","August 21, 1996","December 22, 2008",NDA 21-711,1806
Determination of Regulatory Review Period for Purposes of Patent Extension; PROMACTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROMACTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 32951,2010-13905,https://www.federalregister.gov/documents/2010/06/10/2010-13905/determination-of-regulatory-review-period-for-purposes-of-patent-extension-promacta,https://www.govinfo.gov/content/pkg/FR-2010-06-10/pdf/2010-13905.pdf,2010-06-10, PROMACTA,,John,PROMACTA,7160870,SmithKline Beecham Corp. (DBA GlaxoSmithKline),1485.0,1147,338.0,"October 29, 2004","October 29, 2004","November 20, 2008",NDA 22-291,347
"Determination of Regulatory Review Period for Purposes of Patent Extension; BYSTOLIC; U.S. Patent Nos. 5,759,580 and 6,545,040",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BYSTOLIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 34749,2010-14814,https://www.federalregister.gov/documents/2010/06/18/2010-14814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bystolic-us-patent-nos,https://www.govinfo.gov/content/pkg/FR-2010-06-18/pdf/2010-14814.pdf,2010-06-18, BYSTOLIC," U.S. Patent Nos. 5,759,580 and 6,545,040",John,BYSTOLIC,5759580 and 6545040,"Forest Laboratories, Inc.",6790.0,5463,1327.0,"May 17, 1989","May 17, 1989","December 17, 2007",NDA 21-742,1828
Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRISTIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 53314,2010-21586,https://www.federalregister.gov/documents/2010/08/31/2010-21586/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pristiq,https://www.govinfo.gov/content/pkg/FR-2010-08-31/pdf/2010-21586.pdf,2010-08-31, PRISTIQ,,John,PRISTIQ,6673838 and 7291347,Wyeth,2124.0,1324,800.0,"May 9, 2002","May 9, 2002","February 29, 2008",NDA 21-966,17
Determination of Regulatory Review Period for Purposes of Patent Extension; ONGLYZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ONGLYZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 53315,2010-21583,https://www.federalregister.gov/documents/2010/08/31/2010-21583/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onglyza,https://www.govinfo.gov/content/pkg/FR-2010-08-31/pdf/2010-21583.pdf,2010-08-31, ONGLYZA,,John,ONGLYZA,6395767,Bristol-Myers Squibb Co.,2794.0,2397,397.0,"December 8, 2001","December 8, 2001","July 31, 2009",NDA 22-350,896
Determination of Regulatory Review Period for Purposes of Patent Extension; ONGLYZA,Notice,Health and Human Services Department; Food and Drug Administration,,75 FR 53969,C1-2010-21583,https://www.federalregister.gov/documents/2010/09/02/C1-2010-21583/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onglyza,https://www.govinfo.gov/content/pkg/FR-2010-09-02/pdf/C1-2010-21583.pdf,2010-09-02, ONGLYZA,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ,Notice,Health and Human Services Department; Food and Drug Administration,,75 FR 53969,C1-2010-21586,https://www.federalregister.gov/documents/2010/09/02/C1-2010-21586/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pristiq,https://www.govinfo.gov/content/pkg/FR-2010-09-02/pdf/C1-2010-21586.pdf,2010-09-02, PRISTIQ,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NEURX DIAPHRAGM PACING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEURX DIAPHRAGM PACING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 54152,2010-22081,https://www.federalregister.gov/documents/2010/09/03/2010-22081/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neurx-diaphragm-pacing,https://www.govinfo.gov/content/pkg/FR-2010-09-03/pdf/2010-22081.pdf,2010-09-03, NEURX DIAPHRAGM PACING SYSTEM,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EFFIENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EFFIENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 54344,2010-22234,https://www.federalregister.gov/documents/2010/09/07/2010-22234/determination-of-regulatory-review-period-for-purposes-of-patent-extension-effient,https://www.govinfo.gov/content/pkg/FR-2010-09-07/pdf/2010-22234.pdf,2010-09-07, EFFIENT,,John,EFFIENT,5288726,Daiichi Sankyo Co. Ltd.,2795.0,2232,563.0,"November 16, 2001","November 16, 2001","July 10, 2009",NDA 22-307,1679
Determination of Regulatory Review Period for Purposes of Patent Extension; BRYAN CERVICAL DISC SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BRYAN CERVICAL DISC SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 54345,2010-22177,https://www.federalregister.gov/documents/2010/09/07/2010-22177/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bryan-cervical-disc,https://www.govinfo.gov/content/pkg/FR-2010-09-07/pdf/2010-22177.pdf,2010-09-07, BRYAN CERVICAL DISC SYSTEM,,John,BRYAN CERVICAL DISC SYSTEM,6156067,"Medtronic Sofamor Danek, Inc.",2702.0,1653,1049.0,"December 20, 2001","December 20, 2001","May 12, 2009",PMA P060023,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; IXIARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IXIARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 54888,2010-22394,https://www.federalregister.gov/documents/2010/09/09/2010-22394/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ixiaro,https://www.govinfo.gov/content/pkg/FR-2010-09-09/pdf/2010-22394.pdf,2010-09-09, IXIARO,,John,IXIARO,6309650,Chiel Jedang Corp.,3461.0,2994,467.0,"October 10, 1999","October 10, 1999","March 30, 2009",BLA B125280,1588
Determination of Regulatory Review Period for Purposes of Patent Extension; REPEL-CV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REPEL-CV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 54887,2010-22496,https://www.federalregister.gov/documents/2010/09/09/2010-22496/determination-of-regulatory-review-period-for-purposes-of-patent-extension-repel-cv,https://www.govinfo.gov/content/pkg/FR-2010-09-09/pdf/2010-22496.pdf,2010-09-09, REPEL-CV,,John,REPEL-CV,5711958,"SyntheMed, Inc.",4023.0,3256,767.0,"March 3, 1998","March 3, 1998","March 6, 2009",PMA P070005,1742
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPHRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAPHRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 55331,2010-22519,https://www.federalregister.gov/documents/2010/09/10/2010-22519/determination-of-regulatory-review-period-for-purposes-of-patent-extension-saphris,https://www.govinfo.gov/content/pkg/FR-2010-09-10/pdf/2010-22519.pdf,2010-09-10, SAPHRIS,,John,SAPHRIS,5763476,NV Organon,4547.0,3833,714.0,"March 4, 1997","March 4, 1997","August 13, 2009",NDA 22-117,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; ULORIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULORIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 55332,2010-22521,https://www.federalregister.gov/documents/2010/09/10/2010-22521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uloric,https://www.govinfo.gov/content/pkg/FR-2010-09-10/pdf/2010-22521.pdf,2010-09-10, ULORIC,,John,ULORIC,5614520,Teijin Pharma Ltd.,3395.0,1873,1522.0,"October 31, 1999","October 31, 1999","February 13, 2009",NDA 21-856,5
Determination of Regulatory Review Period for Purposes of Patent Extension; STELARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STELARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 75678,2010-30512,https://www.federalregister.gov/documents/2010/12/06/2010-30512/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stelara,https://www.govinfo.gov/content/pkg/FR-2010-12-06/pdf/2010-30512.pdf,2010-12-06, STELARA,,John,STELARA,6902734 and 7166285,Centocor Ortho Biotech Inc.,3165.0,2498,667.0,"January 27, 2001","January 27, 2001","September 25, 2009",BLA 125261,510
Determination of Regulatory Review Period for Purposes of Patent Extension; BESIVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BESIVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 75679,2010-30510,https://www.federalregister.gov/documents/2010/12/06/2010-30510/determination-of-regulatory-review-period-for-purposes-of-patent-extension-besivance,https://www.govinfo.gov/content/pkg/FR-2010-12-06/pdf/2010-30510.pdf,2010-12-06, BESIVANCE,,John,BESIVANCE,5447926,Bausch & Lomb Inc.,2271.0,1910,361.0,"March 12, 2003","March 12, 2003","May 28, 2009",NDA 22-308,1316
Determination of Regulatory Review Period for Purposes of Patent Extension; ILARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ILARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 76739,2010-30992,https://www.federalregister.gov/documents/2010/12/09/2010-30992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilaris,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30992.pdf,2010-12-09, ILARIS,,John,ILARIS,7446175,Novartis AG,1072.0,889,183.0,"July 13, 2006","July 13, 2006","June 17, 2009",BLA 125319,177
Determination of Regulatory Review Period for Purposes of Patent Extension; BEPREVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEPREVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 76740,2010-30991,https://www.federalregister.gov/documents/2010/12/09/2010-30991/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bepreve,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30991.pdf,2010-12-09, BEPREVE,,John,BEPREVE,6780877,"Ube Industries, Ltd.",964.0,663,301.0,"January 20, 2007","January 20, 2007","September 8, 2009",NDA 22-288,631
Determination of Regulatory Review Period for Purposes of Patent Extension; SABRIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SABRIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 76741,2010-30995,https://www.federalregister.gov/documents/2010/12/09/2010-30995/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sabril,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30995.pdf,2010-12-09, SABRIL,,John,SABRIL,5380936,"Lundbeck, Inc.",10205.0,4614,5591.0,"September 14, 1981","September 14, 1981","August 21, 2009",NDA 20-427,5
Determination of Regulatory Review Period for Purposes of Patent Extension; COARTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COARTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 76990,2010-31074,https://www.federalregister.gov/documents/2010/12/10/2010-31074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-coartem,https://www.govinfo.gov/content/pkg/FR-2010-12-10/pdf/2010-31074.pdf,2010-12-10, COARTEM,,John,COARTEM,5677331,Novartis AG,285.0,285,284.0,"June 27, 2008","June 27, 2008","April 7, 2009",NDA 22-268,284
Determination of Regulatory Review Period for Purposes of Patent Extension; MULTAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MULTAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 76991,2010-31064,https://www.federalregister.gov/documents/2010/12/10/2010-31064/determination-of-regulatory-review-period-for-purposes-of-patent-extension-multaq,https://www.govinfo.gov/content/pkg/FR-2010-12-10/pdf/2010-31064.pdf,2010-12-10, MULTAQ,,John,MULTAQ,5223510 and 7323493,Sanofi-Aventis,5076.0,3593,1483.0,"August 10, 1995","August 10, 1995","July 1, 2009",NDA 21-913,519
Determination of Regulatory Review Period for Purposes of Patent Extension; VIBATIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIBATIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 77877,2010-31250,https://www.federalregister.gov/documents/2010/12/14/2010-31250/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vibativ,https://www.govinfo.gov/content/pkg/FR-2010-12-14/pdf/2010-31250.pdf,2010-12-14, VIBATIV,,John,VIBATIV,6635618; 6872701; and 7208471,"Theravance, Inc.",2635.0,1637,998.0,"June 27, 2002","June 27, 2002","September 11, 2009",NDA 22-110,863
Determination of Regulatory Review Period for Purposes of Patent Extension; SAMSCA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAMSCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 77879,2010-31298,https://www.federalregister.gov/documents/2010/12/14/2010-31298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-samsca,https://www.govinfo.gov/content/pkg/FR-2010-12-14/pdf/2010-31298.pdf,2010-12-14, SAMSCA,,John,SAMSCA,5258510 and 5753677,"Otsuka Pharmaceutical Co., Ltd.",4722.0,4147,575.0,"June 16, 1996","June 16, 1996","May 19, 2009",NDA 22-275,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; FREESTYLE NAVIGATOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FREESTYLE NAVIGATOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 77878,2010-31240,https://www.federalregister.gov/documents/2010/12/14/2010-31240/determination-of-regulatory-review-period-for-purposes-of-patent-extension-freestyle-navigator,https://www.govinfo.gov/content/pkg/FR-2010-12-14/pdf/2010-31240.pdf,2010-12-14, FREESTYLE NAVIGATOR,,John,FREESTYLE NAVIGATOR,5262035,Abbott Diabetes Care Inc.,2320.0,750,1570.0,"November 6, 2001","November 6, 2001","March 12, 2008",PMA P030048,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANGIOMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 78714,2010-31583,https://www.federalregister.gov/documents/2010/12/16/2010-31583/determination-of-regulatory-review-period-for-purposes-of-patent-extension-angiomax,https://www.govinfo.gov/content/pkg/FR-2010-12-16/pdf/2010-31583.pdf,2010-12-16, ANGIOMAX,,John,ANGIOMAX,5196404,The Medicines Company,3665.0,2576,1089.0,"December 5, 1990","December 5, 1990","December 15, 2000",NDA 20-873,1773
Determination of Regulatory Review Period for Purposes of Patent Extension; FOLOTYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FOLOTYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 79381,2010-31846,https://www.federalregister.gov/documents/2010/12/20/2010-31846/determination-of-regulatory-review-period-for-purposes-of-patent-extension-folotyn,https://www.govinfo.gov/content/pkg/FR-2010-12-20/pdf/2010-31846.pdf,2010-12-20, FOLOTYN,,John,FOLOTYN,6028071,"Southern Research Institute, Sloan-Kettering Institute for Cancer Research",4591.0,4406,185.0,"March 2, 1997","March 2, 1997","September 24, 2009",NDA 22-468,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; LIVALO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LIVALO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 79382,2010-31847,https://www.federalregister.gov/documents/2010/12/20/2010-31847/determination-of-regulatory-review-period-for-purposes-of-patent-extension-livalo,https://www.govinfo.gov/content/pkg/FR-2010-12-20/pdf/2010-31847.pdf,2010-12-20, LIVALO,,John,LIVALO,5856336,"Nissan Chemical Industries, Ltd.",3341.0,3036,305.0,"June 12, 2000","June 12, 2000","August 3, 2009",NDA 22-363,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; AMPYRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMPYRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",76 FR 12974,2011-5312,https://www.federalregister.gov/documents/2011/03/09/2011-5312/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ampyra,https://www.govinfo.gov/content/pkg/FR-2011-03-09/pdf/2011-5312.pdf,2011-03-09, AMPYRA,,John,AMPYRA,5370879 and 5540938,Elan Pharma International Ltd.,9845.0,9569,276.0,"February 10, 1983","February 10, 1983","January 22, 2010",NDA 22-250,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; CERVARIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERVARIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",76 FR 12975,2011-5310,https://www.federalregister.gov/documents/2011/03/09/2011-5310/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cervarix,https://www.govinfo.gov/content/pkg/FR-2011-03-09/pdf/2011-5310.pdf,2011-03-09, CERVARIX,,John,CERVARIX,7351533,"MedImmune, LLC.",4027.0,3094,933.0,"October 26, 2010","October 9, 1998","October 16, 2009",BLA 125259,562
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTODAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ISTODAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 14671,2011-6162,https://www.federalregister.gov/documents/2011/03/17/2011-6162/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istodax,https://www.govinfo.gov/content/pkg/FR-2011-03-17/pdf/2011-6162.pdf,2011-03-17, ISTODAX,,John,ISTODAX,4977138,"Gloucester Pharmaceuticals, Inc.",2717.0,2419,298.0,"May 31, 2002","May 31, 2002","November 5, 2009",NDA 22-393,1523
Determination of Regulatory Review Period for Purposes of Patent Extension; VPRIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VPRIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 15322,2011-6514,https://www.federalregister.gov/documents/2011/03/21/2011-6514/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vpriv,https://www.govinfo.gov/content/pkg/FR-2011-03-21/pdf/2011-6514.pdf,2011-03-21, VPRIV,,John,VPRIV,7138262,"Shire Human Genetic Therapies, Inc.",2221.0,2041,180.0,"January 30, 2004","January 30, 2004","February 26, 2010",NDA 22-575,687
Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ATRYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",76 FR 15323,2011-6509,https://www.federalregister.gov/documents/2011/03/21/2011-6509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-atryn,https://www.govinfo.gov/content/pkg/FR-2011-03-21/pdf/2011-6509.pdf,2011-03-21, ATRYN,,John,ATRYN,6441145,"GTC Biotherapeutics, Inc.",4468.0,4285,183.0,"November 15, 1996","November 15, 1996","February 6, 2009",BLA 125284,1243
Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of March 21, 2011 (76 FR 15323). The document announced the determination of the regulatory review period for ATRYN. The document was published with an incorrect docket number. This document corrects that error.",76 FR 21381,2011-9153,https://www.federalregister.gov/documents/2011/04/15/2011-9153/determination-of-regulatory-review-period-for-purposes-of-patent-extension-atryn-correction,https://www.govinfo.gov/content/pkg/FR-2011-04-15/pdf/2011-9153.pdf,2011-04-15, ATRYN, Correction,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CONVENIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CONVENIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",76 FR 24034,2011-10379,https://www.federalregister.gov/documents/2011/04/29/2011-10379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-convenia,https://www.govinfo.gov/content/pkg/FR-2011-04-29/pdf/2011-10379.pdf,2011-04-29, CONVENIA,,John,CONVENIA,6020329,"Pfizer, Inc.",2841.0,2801,40.0,"July 17, 2000","April 25, 2008","April 25, 2008",NADA 141-285,1462
Determination of Regulatory Review Period for Purposes of Patent Extension; VOTRIENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VOTRIENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 25357,2011-10870,https://www.federalregister.gov/documents/2011/05/04/2011-10870/determination-of-regulatory-review-period-for-purposes-of-patent-extension-votrient,https://www.govinfo.gov/content/pkg/FR-2011-05-04/pdf/2011-10870.pdf,2011-05-04, VOTRIENT,,John,VOTRIENT,7105530,"GlaxoSmithKline, LLC.",2568.0,2263,305.0,"October 10, 2002","October 10, 2002","October 19, 2009",NDA 22-465,719
Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ; Correction and Reopening of the Comment Period,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting notices concerning FDA's determination of the regulatory review period for PRISTIQ that appeared in the Federal Registers of August 31, 2010 (75 FR 53314) and September 2, 2010 (75 FR 53969). The documents omitted docket number FDA-2009-E-0086. This document corrects those omissions. Because the comment period for the notices closed on February 28, 2011, FDA is reopening the comment period to allow interested parties to submit comments or petitions to docket number FDA-2009-E-0086.",76 FR 28235,2011-11903,https://www.federalregister.gov/documents/2011/05/16/2011-11903/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pristiq-correction-and,https://www.govinfo.gov/content/pkg/FR-2011-05-16/pdf/2011-11903.pdf,2011-05-16, PRISTIQ, Correction and Reopening of the Comment Period,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTEMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTEMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",76 FR 31349,2011-13388,https://www.federalregister.gov/documents/2011/05/31/2011-13388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actemra,https://www.govinfo.gov/content/pkg/FR-2011-05-31/pdf/2011-13388.pdf,2011-05-31, ACTEMRA,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MYFORTIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYFORTIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 35899,2011-15197,https://www.federalregister.gov/documents/2011/06/20/2011-15197/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myfortic,https://www.govinfo.gov/content/pkg/FR-2011-06-20/pdf/2011-15197.pdf,2011-06-20, MYFORTIC,,John,MYFORTIC,6306900,Novartis AG,1947.0,1643,304.0,"October 31, 1998","October 31, 1998","February 27, 2004",NDA 50-791,323
Determination of Regulatory Review Period for Purposes of Patent Extension; METVIXIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for METVIXIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36548,2011-15625,https://www.federalregister.gov/documents/2011/06/22/2011-15625/determination-of-regulatory-review-period-for-purposes-of-patent-extension-metvixia,https://www.govinfo.gov/content/pkg/FR-2011-06-22/pdf/2011-15625.pdf,2011-06-22, METVIXIA,,John,METVIXIA,6034267,PhotoCure ASA,1695.0,659,1036.0,"December 8, 1999","December 8, 1999","July 27, 2004",NDA 21-415,871
Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BROVANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36928,2011-15691,https://www.federalregister.gov/documents/2011/06/23/2011-15691/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brovana,https://www.govinfo.gov/content/pkg/FR-2011-06-23/pdf/2011-15691.pdf,2011-06-23, BROVANA,,John,BROVANA,6589508,"Sepracor Inc. (now Sunovion Pharmaceuticals, Inc.)",3118.0,2819,299.0,"March 26, 1998","March 26, 1998","October 6, 2006",NDA 21-912,745
Determination of Regulatory Review Period for Purposes of Patent Extension; DEXILANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DEXILANT (previously KAPIDEX) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36929,2011-15692,https://www.federalregister.gov/documents/2011/06/23/2011-15692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dexilant,https://www.govinfo.gov/content/pkg/FR-2011-06-23/pdf/2011-15692.pdf,2011-06-23, DEXILANT,,John,DEXILANT,6462058; 6664276 and 6939971,"Takeda Pharmaceutical Co., Ltd.",1675.0,1278,397.0,"July 2, 2004","July 2, 2004","January 30, 2009",NDA 22-287,959
"Determination of Regulatory Review Period for Purposes of Patent Extension; Fusilev, Levoleucovorin",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Fusilev (Levoleucovorin) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36927,2011-15689,https://www.federalregister.gov/documents/2011/06/23/2011-15689/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fusilev-levoleucovorin,https://www.govinfo.gov/content/pkg/FR-2011-06-23/pdf/2011-15689.pdf,2011-06-23," Fusilev, Levoleucovorin",,John,Fusilev,6500829,the University of Strathclyde,6993.0,703,6290.0,"January 15, 1989","January 15, 1989","March 7, 2008",NDA 20-140,797
Determination of Regulatory Review Period for Purposes of Patent Extension; XYZAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XYZAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 37127,2011-15910,https://www.federalregister.gov/documents/2011/06/24/2011-15910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xyzal,https://www.govinfo.gov/content/pkg/FR-2011-06-24/pdf/2011-15910.pdf,2011-06-24, XYZAL,,John,XYZAL,5698558,UCB Inc.,305.0,0,305.0,"July 25, 2006","July 25, 2006","May 25, 2007",NDA 22-064,245
Determination of Regulatory Review Period for Purposes of Patent Extension; INVEGA SUSTENNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVEGA SUSTENNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 37128,2011-15905,https://www.federalregister.gov/documents/2011/06/24/2011-15905/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invega-sustenna,https://www.govinfo.gov/content/pkg/FR-2011-06-24/pdf/2011-15905.pdf,2011-06-24, INVEGA SUSTENNA,,John,INVEGA SUSTENNA,5254556,"Janssen, L.P.",2253.0,1608,645.0,"June 2, 2003","June 2, 2003","July 31, 2009",NDA 22-264,1449
Determination of Regulatory Review Period for Purposes of Patent Extension; FLECTOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLECTOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 20644,2012-8235,https://www.federalregister.gov/documents/2012/04/05/2012-8235/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flector,https://www.govinfo.gov/content/pkg/FR-2012-04-05/pdf/2012-8235.pdf,2012-04-05, FLECTOR,,John,FLECTOR,5607690,Altergon S.A.,4031.0,1796,2235.0,"January 20, 1996","January 20, 1996","January 31, 2007",NDA 21-344,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; VIIBRYD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIIBRYD and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",77 FR 20830,2012-8341,https://www.federalregister.gov/documents/2012/04/06/2012-8341/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viibryd,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8341.pdf,2012-04-06, VIIBRYD,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TEFLARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEFLARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",77 FR 20827,2012-8339,https://www.federalregister.gov/documents/2012/04/06/2012-8339/determination-of-regulatory-review-period-for-purposes-of-patent-extension-teflaro,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8339.pdf,2012-04-06, TEFLARO,,John,TEFLARO,6417175 and 6906055,Takeda Pharmaceutical Company Limited,2118.0,1814,304.0,"January 12, 2005","January 12, 2005","October 29, 2010",NDA 200-327,1211
Determination of Regulatory Review Period for Purposes of Patent Extension; NATROBA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NATROBA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",77 FR 20829,2012-8337,https://www.federalregister.gov/documents/2012/04/06/2012-8337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natroba,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8337.pdf,2012-04-06, NATROBA,,John,NATROBA,6063771 and 6342482,Eli Lilly,2261.0,1534,727.0,"November 11, 2004","November 11, 2004","January 18, 2011",NDA 22-408,1493
Determination of Regulatory Review Period for Purposes of Patent Extension; DATSCAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DATSCAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 20829,2012-8340,https://www.federalregister.gov/documents/2012/04/06/2012-8340/determination-of-regulatory-review-period-for-purposes-of-patent-extension-datscan,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8340.pdf,2012-04-06, DATSCAN,,John,DATSCAN,5310912,GE Healthcare Limited,677.0,0,677.0,"June 19, 1997","March 9, 2009","January 14, 2011",NDA 22-454,5
Determination of Regulatory Review Period for Purposes of Patent Extension; LATUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LATUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 20828,2012-8354,https://www.federalregister.gov/documents/2012/04/06/2012-8354/determination-of-regulatory-review-period-for-purposes-of-patent-extension-latuda,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8354.pdf,2012-04-06, LATUDA,,John,LATUDA,5532372,"Dainippon Sumitomo Pharma Co., Ltd.",3602.0,3299,303.0,"December 19, 2000","December 19, 2000","October 28, 2010",NDA 200-603,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; KEPIVANCE; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 2, 2007 (72 FR 15699). The document concerned FDA's determination of the regulatory review period for KEPIVANCE. The document cited an incorrect statute under which the KEPIVANCE biologics license application was submitted. This document corrects the citation.",77 FR 23268,2012-9325,https://www.federalregister.gov/documents/2012/04/18/2012-9325/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kepivance-correction,https://www.govinfo.gov/content/pkg/FR-2012-04-18/pdf/2012-9325.pdf,2012-04-18, KEPIVANCE, Correction,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALBITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26017,2012-10518,https://www.federalregister.gov/documents/2012/05/02/2012-10518/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalbitor,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10518.pdf,2012-05-02, KALBITOR,,John,KALBITOR,5795685 and 7276480,Dyax Corp.,2855.0,2420,435.0,"February 8, 2002","February 8, 2002","December 1, 2009",BLA 125277,178
Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Victoza and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26018,2012-10517,https://www.federalregister.gov/documents/2012/05/02/2012-10517/determination-of-regulatory-review-period-for-purposes-of-patent-extension-victoza,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10517.pdf,2012-05-02, Victoza,,John,Victoza,6268343,Novo Nordisk A/S,3370.0,2757,613.0,"November 5, 2000","November 5, 2000","January 25, 2010",NDA 22-341,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; Alair Bronchial Thermoplasty System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Alair Bronchial Thermoplasty System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",77 FR 26016,2012-10516,https://www.federalregister.gov/documents/2012/05/02/2012-10516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alair-bronchial,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10516.pdf,2012-05-02, Alair Bronchial Thermoplasty System,,John,Alair Bronchial Thermoplasty System,6411852,"Asthmatx, Inc.",1743.0,1259,484.0,"July 21, 2005","July 21, 2005","April 27, 2010",PMA P080032,1114
Determination of Regulatory Review Period for Purposes of Patent Extension; HALAVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HALAVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26288,2012-10716,https://www.federalregister.gov/documents/2012/05/03/2012-10716/determination-of-regulatory-review-period-for-purposes-of-patent-extension-halaven,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10716.pdf,2012-05-03, HALAVEN,,John,HALAVEN,6214865,"Eisai R&D Management Co., Ltd.",2758.0,2527,231.0,"April 30, 2003","April 30, 2003","November 15, 2010",NDA 201-532,1495
Determination of Regulatory Review Period for Purposes of Patent Extension; KRYSTEXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KRYSTEXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26290,2012-10697,https://www.federalregister.gov/documents/2012/05/03/2012-10697/determination-of-regulatory-review-period-for-purposes-of-patent-extension-krystexxa,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10697.pdf,2012-05-03, KRYSTEXXA,,John,KRYSTEXXA,[[Page 26291]]6783965,"Mountain View Pharmaceuticals, Inc.",3193.0,2509,684.0,"December 19, 2001","December 19, 2001","September 14, 2010",BLA 125293,1445
Determination of Regulatory Review Period for Purposes of Patent Extension; LASTACAFT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LASTACAFT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26291,2012-10694,https://www.federalregister.gov/documents/2012/05/03/2012-10694/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lastacaft,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10694.pdf,2012-05-03, LASTACAFT,,John,LASTACAFT,5468743,Janssen Pharmaceutica N.V.,2189.0,1886,303.0,"August 1, 2004","August 1, 2004","July 28, 2010",NDA 22-134,1246
Determination of Regulatory Review Period for Purposes of Patent Extension; PRADAXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRADAXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26289,2012-10712,https://www.federalregister.gov/documents/2012/05/03/2012-10712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pradaxa,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10712.pdf,2012-05-03, PRADAXA,,John,PRADAXA,6087380,Boehringer Ingelheim Pharma GmbH & Co. KG,2633.0,2449,184.0,"August 6, 2003","August 6, 2003","October 19, 2010",NDA 22-512,1469
Determination of Regulatory Review Period for Purposes of Patent Extension; GILENYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GILENYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26554,2012-10819,https://www.federalregister.gov/documents/2012/05/04/2012-10819/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilenya,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10819.pdf,2012-05-04, GILENYA,,John,GILENYA,5604229,Novartis Pharmaceuticals Corp.,4296.0,4021,275.0,"December 19, 1998","December 19, 1998","September 21, 2010",NDA 22-527,5
Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EGRIFTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26555,2012-10808,https://www.federalregister.gov/documents/2012/05/04/2012-10808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-egrifta,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10808.pdf,2012-05-04, EGRIFTA,,John,EGRIFTA,5861379,"Theratechnologies, Inc.",3284.0,2753,531.0,"November 15, 2001","November 15, 2001","November 10, 2010",NDA 22-505,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; FERAHEME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FERAHEME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26557,2012-10849,https://www.federalregister.gov/documents/2012/05/04/2012-10849/determination-of-regulatory-review-period-for-purposes-of-patent-extension-feraheme,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10849.pdf,2012-05-04, FERAHEME,,John,FERAHEME,6599498,"AMAG Pharmaceuticals, Inc.",3680.0,3120,560.0,"June 5, 1999","June 5, 1999","June 30, 2009",NDA 22-180,1209
Determination of Regulatory Review Period for Purposes of Patent Extension; JEVTANA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JEVTANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26558,2012-10828,https://www.federalregister.gov/documents/2012/05/04/2012-10828/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jevtana,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10828.pdf,2012-05-04, JEVTANA,,John,JEVTANA,5847170 and 6331635,Aventis Pharma S.A.,4250.0,4171,79.0,"October 30, 1998","October 30, 1998","June 17, 2010",NDA 201023,1591
Determination of Regulatory Review Period for Purposes of Patent Extension; EQUIDONE GEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EQUIDONE GEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",77 FR 26556,2012-10853,https://www.federalregister.gov/documents/2012/05/04/2012-10853/determination-of-regulatory-review-period-for-purposes-of-patent-extension-equidone-gel,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10853.pdf,2012-05-04, EQUIDONE GEL,,John,EQUIDONE GEL,5372818,"Dechra, Ltd.",6378.0,6336,42.0,"March 26, 1993","September 9, 2010","September 9, 2010",NADA 141-314,5
Determination of Regulatory Review Period for Purposes of Patent Extension; PROLIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROLIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26768,2012-10959,https://www.federalregister.gov/documents/2012/05/07/2012-10959/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prolia,https://www.govinfo.gov/content/pkg/FR-2012-05-07/pdf/2012-10959.pdf,2012-05-07, PROLIA,,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 2, 2012 (77 FR 26017). The document concerned FDA's determination of the regulatory review period for KALBITOR. The document published with an incorrect patent number for KALBITOR. This document corrects that error.",77 FR 34051,2012-13902,https://www.federalregister.gov/documents/2012/06/08/2012-13902/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalbitor-correction,https://www.govinfo.gov/content/pkg/FR-2012-06-08/pdf/2012-13902.pdf,2012-06-08, KALBITOR, Correction,John,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CYSVIEW (Previously HEXVIX),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYSVIEW (previously HEXVIX) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 34388,2012-14003,https://www.federalregister.gov/documents/2012/06/11/2012-14003/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cysview-previously-hexvix,https://www.govinfo.gov/content/pkg/FR-2012-06-11/pdf/2012-14003.pdf,2012-06-11, CYSVIEW (Previously HEXVIX),,John,CYSVIEW,7247655 and 7348361,Photocure ASA,3103.0,2770,333.0,"November 30, 2001","November 30, 2001","May 28, 2010",NDA 22-555,686
Determination of Regulatory Review Period for Purposes of Patent Extension; Progel Pleural Air Leak Sealant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Progel Pleural Air Leak Sealant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",77 FR 34389,2012-14000,https://www.federalregister.gov/documents/2012/06/11/2012-14000/determination-of-regulatory-review-period-for-purposes-of-patent-extension-progel-pleural-air-leak,https://www.govinfo.gov/content/pkg/FR-2012-06-11/pdf/2012-14000.pdf,2012-06-11, Progel Pleural Air Leak Sealant,,John,Progel Pleural Air Leak Sealant,RE38158,"Neomend, Inc.",3854.0,787,3067.0,"June 29, 1999","June 29, 1999","January 14, 2010",PMA P010047,5
Determination of Regulatory Review Period for Purposes of Patent Extension; TORISEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TORISEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 52035,2012-21239,https://www.federalregister.gov/documents/2012/08/28/2012-21239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-torisel,https://www.govinfo.gov/content/pkg/FR-2012-08-28/pdf/2012-21239.pdf,2012-08-28, TORISEL,,John,TORISEL,5362718,Wyeth,3290.0,3052,238.0,"May 29, 1998","May 29, 1998","May 30, 2007",NDA 22-088,1764
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,2013-01-31, XALKORI,,John,XALKORI,7230098,Pfizer Inc.,2054.0,1904,150.0,"January 12, 2006","January 12, 2006","August 26, 2011",NDA 202-570,178
Determination of Regulatory Review Period for Purposes of Patent Extension; BEYAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEYAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02086,https://www.federalregister.gov/documents/2013/01/31/2013-02086/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beyaz,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02086.pdf,2013-01-31, BEYAZ,,John,BEYAZ,6441168,Eprova AG,1271.0,874,397.0,"April 4, 2007","April 4, 2007","September 24, 2010",NDA 22-532,834
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN TRANSCATHETER HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAPIEN TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",78 FR 12330,2013-04016,https://www.federalregister.gov/documents/2013/02/22/2013-04016/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-transcatheter,https://www.govinfo.gov/content/pkg/FR-2013-02-22/pdf/2013-04016.pdf,2013-02-22, SAPIEN TRANSCATHETER HEART VALVE,,John,SAPIEN TRANSCATHETER HEART VALVE,5411552,Edwards Lifesciences AG,2473.0,2106,367.0,"January 26, 2005","January 26, 2005","November 2, 2011",PMA P100041,1757
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYTIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZYTIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 13684,2013-04645,https://www.federalregister.gov/documents/2013/02/28/2013-04645/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zytiga,https://www.govinfo.gov/content/pkg/FR-2013-02-28/pdf/2013-04645.pdf,2013-02-28, ZYTIGA,,John,ZYTIGA,5604213,BTG International LTD,1927.0,1797,130.0,"January 19, 2006","January 19, 2006","April 28, 2011",NDA 202-379,1024
Determination of Regulatory Review Period for Purposes of Patent Extension; LAVIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LAVIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",78 FR 13685,2013-04646,https://www.federalregister.gov/documents/2013/02/28/2013-04646/determination-of-regulatory-review-period-for-purposes-of-patent-extension-laviv,https://www.govinfo.gov/content/pkg/FR-2013-02-28/pdf/2013-04646.pdf,2013-02-28, LAVIV,,John,LAVIV,5591444,"Fibrocell Technologies, Inc.",3338.0,2500,838.0,"May 3, 2002","May 3, 2002","June 21, 2011",BLA 125348,5
Determination of Regulatory Review Period for Purposes of Patent Extension; GADAVIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GADAVIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 3832,2014-01307,https://www.federalregister.gov/documents/2014/01/23/2014-01307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gadavist,https://www.govinfo.gov/content/pkg/FR-2014-01-23/pdf/2014-01307.pdf,2014-01-23, GADAVIST,,John,GADAVIST,5980864,Bayer Schering Pharma Aktiengesellschaft,4269.0,3964,305.0,"July 8, 1999","July 8, 1999","March 14, 2011",NDA 201-277,1470
Determination of Regulatory Review Period for Purposes of Patent Extension; DALIRESP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DALIRESP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 3831,2014-01306,https://www.federalregister.gov/documents/2014/01/23/2014-01306/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daliresp,https://www.govinfo.gov/content/pkg/FR-2014-01-23/pdf/2014-01306.pdf,2014-01-23, DALIRESP,,John,DALIRESP,5712298,Nycomed GmbH,4237.0,3645,592.0,"July 26, 1999","July 26, 1999","February 28, 2011",NDA 22-522,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; NULOJIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NULOJIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 18036,2014-07060,https://www.federalregister.gov/documents/2014/03/31/2014-07060/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nulojix,https://www.govinfo.gov/content/pkg/FR-2014-03-31/pdf/2014-07060.pdf,2014-03-31, NULOJIX,,John,NULOJIX,7094874,Bristol-Myers Squibb Company,4479.0,3764,715.0,"March 13, 1999","March 13, 1999","June 15, 2011",BLA 125288,789
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVNAR-13,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVNAR-13 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 18035,2014-07058,https://www.federalregister.gov/documents/2014/03/31/2014-07058/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevnar-13,https://www.govinfo.gov/content/pkg/FR-2014-03-31/pdf/2014-07058.pdf,2014-03-31, PREVNAR-13,,John,PREVNAR-13,5614382,Wyeth Holdings Corp.,2102.0,1771,331.0,"May 26, 2004","May 26, 2004","February 24, 2010",BLA 125324,1312
Determination of Regulatory Review Period for Purposes of Patent Extension; POTIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for POTIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 18564,2014-07334,https://www.federalregister.gov/documents/2014/04/02/2014-07334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-potiga,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07334.pdf,2014-04-02, POTIGA,,John,POTIGA,6538151,Valeant Pharmaceuticals North America,5021.0,4432,589.0,"September 12, 1997","September 12, 1997","June 10, 2011",NDA 22-345,1794
Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FIRAZYR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 18565,2014-07331,https://www.federalregister.gov/documents/2014/04/02/2014-07331/determination-of-regulatory-review-period-for-purposes-of-patent-extension-firazyr,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07331.pdf,2014-04-02, FIRAZYR,,John,FIRAZYR,5648333,Sanofi-Aventis Deutschland GmbH,2663.0,1263,1400.0,"May 12, 2004","May 12, 2004","August 25, 2011",NDA 22-150,5
Determination of Regulatory Review Period for Purposes of Patent Extension; EYLEA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EYLEA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 18566,2014-07333,https://www.federalregister.gov/documents/2014/04/02/2014-07333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eylea,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07333.pdf,2014-04-02, EYLEA,,John,EYLEA,7070959; 7374757; and 7374758,"Regeneron Pharmaceuticals, Inc.",2349.0,2075,274.0,"June 15, 2005","June 15, 2005","November 18, 2011",BLA 125387,1118
Determination of Regulatory Review Period for Purposes of Patent Extension; ONSIOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ONSIOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 18563,2014-07336,https://www.federalregister.gov/documents/2014/04/02/2014-07336/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onsior,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07336.pdf,2014-04-02, ONSIOR,,John,ONSIOR,6291523 and 7115662,"Novartis Animal Health US, Inc.",3.0,1704,1650.0,"July 10, 2006","March 8, 2011","March 8, 2011",NADA 141-320,1308
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOTFF-100A SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOTFF-100A SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 18567,2014-07329,https://www.federalregister.gov/documents/2014/04/02/2014-07329/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novotff-100a-system,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07329.pdf,2014-04-02, NOVOTFF-100A SYSTEM,,John,NOVOTFF-100A SYSTEM,7136699,Novocure Limited,1704.0,1468,236.0,"August 10, 2006","August 10, 2006","April 8, 2011",PMA P100034,807
Determination of Regulatory Review Period for Purposes of Patent Extension; MELAFIND SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MELAFIND SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 19101,2014-07657,https://www.federalregister.gov/documents/2014/04/07/2014-07657/determination-of-regulatory-review-period-for-purposes-of-patent-extension-melafind-system,https://www.govinfo.gov/content/pkg/FR-2014-04-07/pdf/2014-07657.pdf,2014-04-07, MELAFIND SYSTEM,,John,MELAFIND SYSTEM,6208749,MELA Sciences Inc.,3837.0,2961,876.0,"May 2, 2001","June 9, 2009","November 1, 2011",PMA P090012,2355
Determination of Regulatory Review Period for Purposes of Patent Extension; BRILINTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BRILINTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 24444,2014-09772,https://www.federalregister.gov/documents/2014/04/30/2014-09772/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brilinta,https://www.govinfo.gov/content/pkg/FR-2014-04-30/pdf/2014-09772.pdf,2014-04-30, BRILINTA,,John,BRILINTA,6525060; 6251910; 7250419; and 7265124,AstraZeneca UK Limited,2976.0,2364,612.0,"May 29, 2003","May 29, 2003","July 20, 2011",NDA 22-433,1794
Determination of Regulatory Review Period for Purposes of Patent Extension; YERVOY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for YERVOY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 24735,2014-09910,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09910.pdf,2014-05-01, YERVOY,,Jonathan,YERVOY (ipilimumab),"6,984,720; 7,605,238","Medarex, Inc.",3879.0,3605.0,274.0,2000-08-12 00:00:00,2010-06-25,2011-03-25,BLA 125377/0,966 or 398 days
Determination of Regulatory Review Period for Purposes of Patent Extension; EDURANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EDURANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 24736,2014-09911,https://www.federalregister.gov/documents/2014/05/01/2014-09911/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edurant,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09911.pdf,2014-05-01, EDURANT,,Jonathan,EDURANT (rilpivirine hydrochloride),7125879,Janssen Pharmaceutica N.V.,2396.0,2094.0,302.0,2004-10-29 00:00:00,2010-07-23,2011-05-20,NDA 202022,768
Determination of Regulatory Review Period for Purposes of Patent Extension; SURFAXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SURFAXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27314,2014-10904,https://www.federalregister.gov/documents/2014/05/13/2014-10904/determination-of-regulatory-review-period-for-purposes-of-patent-extension-surfaxin,https://www.govinfo.gov/content/pkg/FR-2014-05-13/pdf/2014-10904.pdf,2014-05-13, SURFAXIN,,Jonathan,"SURFAXIN (lucinactant, which is a combination of four active ingredients—sinapultide, colfosceril palmitate, POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol), and palmitic acid)",5407914,"Discovery Laboratories, Inc.",7124.0,4239.0,2885.0,1992-09-05 00:00:00,2004-04-13,2012-03-06,NDA 21-746,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; TRADJENTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRADJENTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27316,2014-10945,https://www.federalregister.gov/documents/2014/05/13/2014-10945/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tradjenta,https://www.govinfo.gov/content/pkg/FR-2014-05-13/pdf/2014-10945.pdf,2014-05-13, TRADJENTA,,Jonathan,TRADJENTA (linagliptin),7407955,Boehringer Ingelheim Pharma GmbH & Co. KGA,2051.0,1746.0,305.0,2005-09-21 00:00:00,2010-07-02,2011-05-02,NDA 201-280,629
Determination of Regulatory Review Period for Purposes of Patent Extension; IMPROVEST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMPROVEST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 27315,2014-10951,https://www.federalregister.gov/documents/2014/05/13/2014-10951/determination-of-regulatory-review-period-for-purposes-of-patent-extension-improvest,https://www.govinfo.gov/content/pkg/FR-2014-05-13/pdf/2014-10951.pdf,2014-05-13, IMPROVEST,,Jonathan,IMPROVEST (gonadotropin releasing factor analog-diptheria toxoid conjugate),7534441,Pfizer Inc.,2555.0,2498.0,57.0,2004-03-25 00:00:00,2011-01-25,2011-03-22,NADA 141-322,366
Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYPROLIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27877,2014-11175,https://www.federalregister.gov/documents/2014/05/15/2014-11175/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kyprolis,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf,2014-05-15, KYPROLIS,,Jonathan,KYPROLIS (carfilzomib),"7,232,818; 7,417,042; 7,491,704; 8,207,125; 8,207,126; 8,207,127; and 8,207,297","Onyx Therapeutics, Inc.",2565.0,2267.0,298.0,2005-07-14 00:00:00,2011-09-27,2012-07-20,NDA 202714,24 days; 43 days; or 462 days
Determination of Regulatory Review Period for Purposes of Patent Extension; BENLYSTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BENLYSTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 27878,2014-11176,https://www.federalregister.gov/documents/2014/05/15/2014-11176/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benlysta,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11176.pdf,2014-05-15, BENLYSTA,,Jonathan,BENLYSTA (belimumab),"6,403,770; 7,138,501; and 7,879,328",Human Genome Sciences Inc.,3426.0,3152.0,274.0,2001-10-23 00:00:00,2010-06-09,2011-03-09,BLA 125370/0,"1,733 days or 610 days or 37 days"
Determination of Regulatory Review Period for Purposes of Patent Extension; PALLADIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PALLADIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 27879,2014-11172,https://www.federalregister.gov/documents/2014/05/15/2014-11172/determination-of-regulatory-review-period-for-purposes-of-patent-extension-palladia,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11172.pdf,2014-05-15, PALLADIA,,Jonathan,PALLADIA (toceranib phosphate),6573293,"Sugen, Inc. and Pharmacia & Upjohn Company LLC",2711.0,2681.0,30.0,2001-12-21 00:00:00,2009-04-23,2009-05-22,NADA 141-295,827
Determination of Regulatory Review Period for Purposes of Patent Extension; ELELYSO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELELYSO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28733,2014-11516,https://www.federalregister.gov/documents/2014/05/19/2014-11516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elelyso,https://www.govinfo.gov/content/pkg/FR-2014-05-19/pdf/2014-11516.pdf,2014-05-19, ELELYSO,,Jonathan,ELELYSO (taliglucerase alfa),7951557,Protalix Ltd.,2483.0,1746.0,737.0,2005-07-16 00:00:00,2010-04-26,2012-05-01,NDA 22-458,336
Determination of Regulatory Review Period for Purposes of Patent Extension; ZIOPTAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZIOPTAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28735,2014-11517,https://www.federalregister.gov/documents/2014/05/19/2014-11517/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zioptan,https://www.govinfo.gov/content/pkg/FR-2014-05-19/pdf/2014-11517.pdf,2014-05-19, ZIOPTAN,,Jonathan,ZIOPTAN (tafluprost),5886035,Asahi Glass Company Ltd.,3881.0,3481.0,400.0,2001-06-28 00:00:00,2011-01-07,2012-02-10,NDA 202514,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; PERJETA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PERJETA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 28734,2014-11515,https://www.federalregister.gov/documents/2014/05/19/2014-11515/determination-of-regulatory-review-period-for-purposes-of-patent-extension-perjeta,https://www.govinfo.gov/content/pkg/FR-2014-05-19/pdf/2014-11515.pdf,2014-05-19, PERJETA,,Jonathan,PERJETA (pertuzumab),"6,949,245; 7,560,111; 7,862,817","Genentech, Inc.",3925.0,3741.0,184.0,2001-09-11 00:00:00,2011-12-08,2012-06-08,BLA 125409,"1,317 or 624 or 354 days"
Determination of Regulatory Review Period for Purposes of Patent Extension; PICATO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PICATO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28928,2014-11521,https://www.federalregister.gov/documents/2014/05/20/2014-11521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-picato,https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11521.pdf,2014-05-20, PICATO,,Jonathan,PICATO (ingenol mebutate),7410656,Leo Laboratories Ltd.,2737.0,2432.0,305.0,2004-07-28 00:00:00,2011-03-25,2012-01-23,NDA 202833,783
Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OMONTYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28930,2014-11523,https://www.federalregister.gov/documents/2014/05/20/2014-11523/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omontys,https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11523.pdf,2014-05-20, OMONTYS,,Jonathan,OMONTYS (Peginesatide acetate),7414105,"Affymax, Inc.",2528.0,2222.0,306.0,2005-04-27 00:00:00,2011-05-27,2012-03-27,NDA 202799,684
Determination of Regulatory Review Period for Purposes of Patent Extension; INCIVEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INCIVEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28929,2014-11525,https://www.federalregister.gov/documents/2014/05/20/2014-11525/determination-of-regulatory-review-period-for-purposes-of-patent-extension-incivek,https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11525.pdf,2014-05-20, INCIVEK,,Jonathan,INCIVEK (telaprevir),7820671,Vertex Pharmaceuticals Incorporated,2003.0,1821.0,182.0,2005-11-29 00:00:00,2010-11-23,2011-05-23,NDA 201-917,87
Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LINZESS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 29782,2014-11926,https://www.federalregister.gov/documents/2014/05/23/2014-11926/determination-of-regulatory-review-period-for-purposes-of-patent-extension-linzess,https://www.govinfo.gov/content/pkg/FR-2014-05-23/pdf/2014-11926.pdf,2014-05-23, LINZESS,,Jonathan,LINZESS (linaclotide),7304036,"Ironwood Pharmaceuticals, Inc.",2863.0,2475.0,388.0,2004-10-30 00:00:00,2011-08-09,2012-08-30,NDA 202811,945
Determination of Regulatory Review Period for Purposes of Patent Extension; INLYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 29783,2014-11925,https://www.federalregister.gov/documents/2014/05/23/2014-11925/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inlyta,https://www.govinfo.gov/content/pkg/FR-2014-05-23/pdf/2014-11925.pdf,2014-05-23, INLYTA,,Jonathan,INLYTA (axitinib),6534524,"Agouron Pharmaceuticals, Inc.",3699.0,3410.0,289.0,2001-12-13 00:00:00,2011-04-14,2012-01-27,NDA 202324,1763
Determination of Regulatory Review Period for Purposes of Patent Extension; MYRBETRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYRBETRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 30622,2014-12292,https://www.federalregister.gov/documents/2014/05/28/2014-12292/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myrbetriq,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12292.pdf,2014-05-28, MYRBETRIQ,,Jonathan,MYRBETRIQ (mirabegron),"6,346,532; 7,342,117; 7,750,029",Astellas Pharma Inc.,2213.0,1908.0,305.0,2006-06-09 00:00:00,2011-08-29,2012-06-28,NDA 202611,"515, 938, or 1,259 days"
Determination of Regulatory Review Period for Purposes of Patent Extension; MENHIBRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MENHIBRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 30621,2014-12294,https://www.federalregister.gov/documents/2014/05/28/2014-12294/determination-of-regulatory-review-period-for-purposes-of-patent-extension-menhibrix,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12294.pdf,2014-05-28, MENHIBRIX,,Jonathan,MENHIBRIX (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine),"5,693,326 and 5,955,079",Henry M. Jackson Foundation for the Advancement of Military Medicine,2924.0,1886.0,1038.0,2004-06-14 00:00:00,2009-08-12,2012-06-14,BLA 125363,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; ADCETRIS-Biologics License Application 125399,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADCETRIS based on biologics license application (BLA) 125399 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product, ADCETRIS.",79 FR 30624,2014-12279,https://www.federalregister.gov/documents/2014/05/28/2014-12279/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adcetris-biologics,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12279.pdf,2014-05-28, ADCETRIS-Biologics License Application 125399,,Jonathan,ADCETRIS (brentuximab vedotin),"7,829,531 and 7,090,843","Seattle Genetics, Inc.",1851.0,1678.0,173.0,2006-07-27 00:00:00,2011-02-28,2011-08-19,BLA 125399,229
Determination of Regulatory Review Period for Purposes of Patent Extension; ADCETRIS-Biologics License Application 125388,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADCETRIS based on biologics license application (BLA) 125388 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product, ADCETRIS.",79 FR 30625,2014-12277,https://www.federalregister.gov/documents/2014/05/28/2014-12277/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adcetris-biologics,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12277.pdf,2014-05-28, ADCETRIS-Biologics License Application 125388,,Jonathan,ADCETRIS (brentuximab vedotin),"7,090,843 and 7,829,531","Seattle Genetics, Inc.",1851.0,1678.0,173.0,2006-07-27 00:00:00,2011-02-28,2011-08-19,BLA 125388,1002
Determination of Regulatory Review Period for Purposes of Patent Extension; RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 30623,2014-12295,https://www.federalregister.gov/documents/2014/05/28/2014-12295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-resolute-integrity,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12295.pdf,2014-05-28, RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM,,Jonathan,RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM,7419696,"Medtronic, Inc.",1586.0,1263.0,323.0,2007-10-17 00:00:00,2011-04-01,2012-02-17,PMA P110013,794
Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XARELTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 30855,2014-12349,https://www.federalregister.gov/documents/2014/05/29/2014-12349/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xarelto,https://www.govinfo.gov/content/pkg/FR-2014-05-29/pdf/2014-12349.pdf,2014-05-29, XARELTO,,Jonathan,XARELTO (rivaroxaban),7157456,Bayer Pharma Aktiengesellschaft,3291.0,2222.0,1069.0,2002-06-29 00:00:00,2008-07-28,2011-07-01,NDA 22-406,1354
Determination of Regulatory Review Period for Purposes of Patent Extension; ZACTRAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZACTRAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 30854,2014-12350,https://www.federalregister.gov/documents/2014/05/29/2014-12350/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zactran,https://www.govinfo.gov/content/pkg/FR-2014-05-29/pdf/2014-12350.pdf,2014-05-29, ZACTRAN,,Jonathan,ZACTRAN (gamithromycin),5985844,Merck Sharp & Dohme Corp.,2990.0,2930.0,60.0,2003-04-11 00:00:00,2011-04-18,2011-06-16,NADA 141-328,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,2014-05-30, KALYDECO,,Jonathan,KALYDECO (ivacaftor),7495103,Vertex Pharmaceuticals Inc.,2121.0,2015.0,106.0,2006-04-13 00:00:00,2011-10-18,2012-01-31,NDA 203188,0
Determination of Regulatory Review Period for Purposes of Patent Extension; PROGENSA PCA3 ASSAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROGENSA PCA3 ASSAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 31119,2014-12562,https://www.federalregister.gov/documents/2014/05/30/2014-12562/determination-of-regulatory-review-period-for-purposes-of-patent-extension-progensa-pca3-assay,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12562.pdf,2014-05-30, PROGENSA PCA3 ASSAY,,Jonathan,PROGENSA PCA3 ASSAY,7008765,"The Johns Hopkins University & The Stichting Katholieke Universiteit, The University Medical Centre Nijmegen",936.0,383.0,553.0,2009-07-24 00:00:00,2010-08-10,2012-02-13,PMA P100033,745
Determination of Regulatory Review Period for Purposes of Patent Extension; XIAFLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIAFLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 31951,2014-12808,https://www.federalregister.gov/documents/2014/06/03/2014-12808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xiaflex,https://www.govinfo.gov/content/pkg/FR-2014-06-03/pdf/2014-12808.pdf,2014-06-03, XIAFLEX,,Jonathan,XIAFLEX,RE39941,"Auxilium Pharmaceuticals, Inc.",5278.0,4937,341.0,"August 24, 1995","August 24, 1995","February 2, 2010",BLA 125338,1806
Determination of Regulatory Review Period for Purposes of Patent Extension; STENDRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STENDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 33198,2014-13444,https://www.federalregister.gov/documents/2014/06/10/2014-13444/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stendra,https://www.govinfo.gov/content/pkg/FR-2014-06-10/pdf/2014-13444.pdf,2014-06-10, STENDRA,,Jonathan,STENDRA,6656935,Mitsubishi Tanabe Pharma Corp.,3770.0,3466,304.0,"January 2, 2002","January 2, 2002","April 27, 2012",NDA 202276,1686
Determination of Regulatory Review Period for Purposes of Patent Extension; Xience Prime Ll Everolimus Eluting Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xience Prime Ll Everolimus Eluting Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 33199,2014-13445,https://www.federalregister.gov/documents/2014/06/10/2014-13445/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xience-prime-ll,https://www.govinfo.gov/content/pkg/FR-2014-06-10/pdf/2014-13445.pdf,2014-06-10, Xience Prime Ll Everolimus Eluting Coronary Stent System,,Jonathan,Xience Prime Ll Everolimus Eluting Coronary Stent System,5514154,Abbott Cardiovascular Systems Inc.,890.0,694,196.0,"May 27, 2009","May 27, 2009","November 1, 2011",PMA P110019,630
Determination of Regulatory Review Period for Purposes of Patent Extension; Vandetanib,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Vandetanib and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 33563,2014-13566,https://www.federalregister.gov/documents/2014/06/11/2014-13566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vandetanib,https://www.govinfo.gov/content/pkg/FR-2014-06-11/pdf/2014-13566.pdf,2014-06-11, Vandetanib,,Jonathan,Vandetanib,7173038,AstraZeneca AB,4009.0,3735,274.0,"April 16, 2000","April 16, 2000","April 6, 2011",NDA 22-405,898
Determination of Regulatory Review Period for Purposes of Patent Extension; Vandetanib,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA) has determined the regulatory review period for VANDETANIB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO) for the extension of a patent which claims that human drug product.,79 FR 33562,2014-13567,https://www.federalregister.gov/documents/2014/06/11/2014-13567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vandetanib,https://www.govinfo.gov/content/pkg/FR-2014-06-11/pdf/2014-13567.pdf,2014-06-11, Vandetanib,,Jonathan,Vandetanib,RE42353,AstraZeneca UK Limited,4009.0,3735,274.0,"April 16, 2000","April 16, 2000","April 6, 2011",NDA 22-405,1738
Determination of Regulatory Review Period for Purposes of Patent Extension; Zuprevo,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZUPREVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 33763,2014-13637,https://www.federalregister.gov/documents/2014/06/12/2014-13637/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zuprevo,https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/2014-13637.pdf,2014-06-12, Zuprevo,,Jonathan,ZUPREVO,6514946,Koueki Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai,2903.0,2842,61.0,"June 4, 2004","May 14, 2012","May 14, 2012",NADA 141-334,1524
Determination of Regulatory Review Period for Purposes of Patent Extension; Arcapta Neohaler,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Arcapta Neohaler and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 33761,2014-13638,https://www.federalregister.gov/documents/2014/06/12/2014-13638/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arcapta-neohaler,https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/2014-13638.pdf,2014-06-12, Arcapta Neohaler,,Jonathan,Arcapta Neohaler,6878721,Novartis AG,3097.0,2171,926.0,"January 9, 2003","January 9, 2003","July 1, 2011",NDA 22-383,1597
Determination of Regulatory Review Period for Purposes of Patent Extension; Arctic Front Cryocatheter System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Arctic Front Cryocatheter System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that medical device.",79 FR 33762,2014-13640,https://www.federalregister.gov/documents/2014/06/12/2014-13640/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arctic-front-cryocatheter,https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/2014-13640.pdf,2014-06-12, Arctic Front Cryocatheter System,,Jonathan,Arctic Front Cryocatheter System,6575966; 7648497; and 7727228,Medtronic CryoCath LP,2670.0,2389,281.0,"August 28, 2003","August 28, 2003","December 17, 2010",PMA P100010,1476
Determination of Regulatory Review Period for Purposes of Patent Extension; VICTRELIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VICTRELIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 36535,2014-15021,https://www.federalregister.gov/documents/2014/06/27/2014-15021/determination-of-regulatory-review-period-for-purposes-of-patent-extension-victrelis,https://www.govinfo.gov/content/pkg/FR-2014-06-27/pdf/2014-15021.pdf,2014-06-27, VICTRELIS,,Jonathan,VICTRELIS,RE43298,Schering Corporation,2160.0,1980,180.0,"June 15, 2005","June 15, 2005","May 13, 2011",NDA 202-258,1032
Determination of Regulatory Review Period for Purposes of Patent Extension; HORIZANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HORIZANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 40108,2014-16237,https://www.federalregister.gov/documents/2014/07/11/2014-16237/determination-of-regulatory-review-period-for-purposes-of-patent-extension-horizant,https://www.govinfo.gov/content/pkg/FR-2014-07-11/pdf/2014-16237.pdf,2014-07-11, HORIZANT,,Jonathan,HORIZANT,6818787,"XenoPort, Inc.",2277.0,1459,818.0,"January 12, 2005","January 12, 2005","April 6, 2011",NDA 22-399,882
Determination of Regulatory Review Period for Purposes of Patent Extension; CARBON DIOXIDE LASER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CARBON DIOXIDE LASER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the United States Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that food additive.",79 FR 63132,2014-25032,https://www.federalregister.gov/documents/2014/10/22/2014-25032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-carbon-dioxide-laser,https://www.govinfo.gov/content/pkg/FR-2014-10-22/pdf/2014-25032.pdf,2014-10-22, CARBON DIOXIDE LASER,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; JUXTAPID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JUXTAPID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 18414,2015-07809,https://www.federalregister.gov/documents/2015/04/06/2015-07809/determination-of-regulatory-review-period-for-purposes-of-patent-extension-juxtapid,https://www.govinfo.gov/content/pkg/FR-2015-04-06/pdf/2015-07809.pdf,2015-04-06, JUXTAPID,,Jonathan,JUXTAPID,5712279,"Aegerion Pharmaceuticals, Inc.",6002.0,5705,297.0,"July 18, 1996","July 18, 1996","December 21, 2012",NDA 203-858,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ELVITEGRAVIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELVITEGRAVIR (as a component of STRIBILD) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 19671,2015-08362,https://www.federalregister.gov/documents/2015/04/13/2015-08362/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elvitegravir,https://www.govinfo.gov/content/pkg/FR-2015-04-13/pdf/2015-08362.pdf,2015-04-13, ELVITEGRAVIR,,Jonathan,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; AUBAGIO-Patent No. 5,679,709",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AUBAGIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 20227,2015-08615,https://www.federalregister.gov/documents/2015/04/15/2015-08615/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aubagio-patent-no-5679709,https://www.govinfo.gov/content/pkg/FR-2015-04-15/pdf/2015-08615.pdf,2015-04-15," AUBAGIO-Patent No. 5,679,709",,Jonathan,AUBAGIO,5679709,sanofi-aventis Deutschland GMBH,2940.0,2542,398.0,"August 27, 2004","August 27, 2004","September 12, 2012",NDA 202992,5
"Determination of Regulatory Review Period for Purposes of Patent Extension; AUBAGIO-Patent No. 6,794,410",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AUBAGIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 20228,2015-08616,https://www.federalregister.gov/documents/2015/04/15/2015-08616/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aubagio-patent-no-6794410,https://www.govinfo.gov/content/pkg/FR-2015-04-15/pdf/2015-08616.pdf,2015-04-15," AUBAGIO-Patent No. 6,794,410",,Jonathan,AUBAGIO,6794410,Aventis Pharmaceuticals Inc.,2940.0,2542,398.0,"August 27, 2004","August 27, 2004","September 12, 2012",NDA 202992,1625
Determination of Regulatory Review Period for Purposes of Patent Extension; RAVICTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAVICTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 21247,2015-08845,https://www.federalregister.gov/documents/2015/04/17/2015-08845/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ravicti,https://www.govinfo.gov/content/pkg/FR-2015-04-17/pdf/2015-08845.pdf,2015-04-17, RAVICTI,,Jonathan,RAVICTI,5968979,"Hyperion Therapeutics, Inc.",2126.0,1719,407.0,"April 10, 2007","April 10, 2007","February 1, 2013",NDA 203284,1450
Determination of Regulatory Review Period for Purposes of Patent Extension; COMETRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COMETRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 22528,2015-09302,https://www.federalregister.gov/documents/2015/04/22/2015-09302/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cometriq,https://www.govinfo.gov/content/pkg/FR-2015-04-22/pdf/2015-09302.pdf,2015-04-22, COMETRIQ,,Jonathan,COMETRIQ,7579473,"Exelixis, Incorporated",2698.0,2513,185.0,"July 13, 2005","July 13, 2005","November 29, 2012",NDA 203756,688
Determination of Regulatory Review Period for Purposes of Patent Extension; FLUBLOK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLUBLOK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 23034,2015-09521,https://www.federalregister.gov/documents/2015/04/24/2015-09521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flublok,https://www.govinfo.gov/content/pkg/FR-2015-04-24/pdf/2015-09521.pdf,2015-04-24, FLUBLOK,,Jonathan,FLUBLOK,5762939,Protein Sciences Corporation,3010.0,1275,1735.0,"October 22, 2004","October 22, 2004","January 16, 2013",BLA 125285,5
Determination of Regulatory Review Period for Purposes of Patent Extension; KYNAMRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYNAMRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 23035,2015-09522,https://www.federalregister.gov/documents/2015/04/24/2015-09522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kynamro,https://www.govinfo.gov/content/pkg/FR-2015-04-24/pdf/2015-09522.pdf,2015-04-24, KYNAMRO,,Jonathan,KYNAMRO,7511131,Genzyme Corporation,2601.0,2294,307.0,"December 18, 2005","December 18, 2005","January 29, 2013",NDA 203568,853
Determination of Regulatory Review Period for Purposes of Patent Extension; Xience Xpedition Everolimus Eluting Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xience Xpedition Everolimus Eluting Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 23801,2015-09902,https://www.federalregister.gov/documents/2015/04/29/2015-09902/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xience-xpedition,https://www.govinfo.gov/content/pkg/FR-2015-04-29/pdf/2015-09902.pdf,2015-04-29, Xience Xpedition Everolimus Eluting Coronary Stent System,,Jonathan,Xience Xpedition Everolimus Eluting Coronary Stent System,7828766,Abbott Cardiovascular Systems Inc.,178.0,178,178.0,"June 27, 2012","June 27, 2012","December 21, 2012",PMA P110019,178
Determination of Regulatory Review Period for Purposes of Patent Extension; NESINA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NESINA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25300,2015-10337,https://www.federalregister.gov/documents/2015/05/04/2015-10337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nesina,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10337.pdf,2015-05-04, NESINA,,Jonathan,NESINA,8173663,Takeda Pharmaceuticals U.S.A.,3021.0,1164,1857.0,"October 20, 2004","October 20, 2004","January 25, 2013",NDA 22-271,264
Determination of Regulatory Review Period for Purposes of Patent Extension; BOSULIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BOSULIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25301,2015-10333,https://www.federalregister.gov/documents/2015/05/04/2015-10333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bosulif,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10333.pdf,2015-05-04, BOSULIF,,Jonathan,BOSULIF,RE42376,Wyeth Holdings Corporation,3032.0,2739,293.0,"May 19, 2004","May 19, 2004","September 4, 2012",NDA 203-341,1664
Determination of Regulatory Review Period for Purposes of Patent Extension; KAZANO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KAZANO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25302,2015-10335,https://www.federalregister.gov/documents/2015/05/04/2015-10335/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kazano,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10335.pdf,2015-05-04, KAZANO,,Jonathan,KAZANO,8288539,Takeda Pharmaceutical Company Limited,1365.0,934,431.0,"May 3, 2009","May 3, 2009","January 25, 2013",NDA 203-414,102
Determination of Regulatory Review Period for Purposes of Patent Extension; TUDORZA PRESSAIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TUDORZA PRESSAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25303,2015-10336,https://www.federalregister.gov/documents/2015/05/04/2015-10336/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tudorza-pressair,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10336.pdf,2015-05-04, TUDORZA PRESSAIR,,Jonathan,TUDORZA PRESSAIR,6750226 and 7078412,"Almiral, S.A.",3136.0,2739,397.0,"December 24, 2003","December 24, 2003","July 23, 2012",NDA 202-450,1298
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMERON HEALTH S-ICD SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CAMERON HEALTH S-ICD SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 25299,2015-10334,https://www.federalregister.gov/documents/2015/05/04/2015-10334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cameron-health-s-icd,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10334.pdf,2015-05-04, CAMERON HEALTH S-ICD SYSTEM,,Jonathan,CAMERON HEALTH S-ICD SYSTEM,6856835 and 7149575,Cameron Health Inc.,1024.0,743,281.0,"December 11, 2009","December 11, 2009","September 28, 2012",PMA P110042,651
Determination of Regulatory Review Period for Purposes of Patent Extension; RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for the RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 25298,2015-10338,https://www.federalregister.gov/documents/2015/05/04/2015-10338/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relay-thoracic,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10338.pdf,2015-05-04, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM,,Jonathan,the RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM,8062345 B2,Bolton Medical Inc.,2852.0,2529,323.0,"December 2, 2004","December 2, 2004","September 21, 2012",PMA P110038,225
Determination of Regulatory Review Period for Purposes of Patent Extension; SYNRIBO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYNRIBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26271,2015-11004,https://www.federalregister.gov/documents/2015/05/07/2015-11004/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synribo,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11004.pdf,2015-05-07, SYNRIBO,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GATTEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26272,2015-11000,https://www.federalregister.gov/documents/2015/05/07/2015-11000/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gattex,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11000.pdf,2015-05-07, GATTEX,,Jonathan,GATTEX,5789379 and 7056886,"NPS Pharmaceuticals, Inc.",4959.0,4571,388.0,"May 27, 1999","May 27, 1999","December 21, 2012",NDA 203441,1388
Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIGNIFOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26276,2015-10994,https://www.federalregister.gov/documents/2015/05/07/2015-10994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-signifor,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10994.pdf,2015-05-07, SIGNIFOR,,Jonathan,SIGNIFOR,7473761,Novartis AG,3440.0,3138,302.0,"July 17, 2003","July 17, 2003","December 14, 2012",NDA 200677,503
Determination of Regulatory Review Period for Purposes of Patent Extension; OSENI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OSENI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26277,2015-11002,https://www.federalregister.gov/documents/2015/05/07/2015-11002/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oseni,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11002.pdf,2015-05-07, OSENI,,Jonathan,OSENI,6329404,Takeda Pharmaceutical Company Limited,2482.0,895,1587.0,"April 12, 2006","April 12, 2006","January 25, 2013",NDA 22-426,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OVUGEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of U.S. Patents and Trademarks Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",80 FR 26274,2015-11003,https://www.federalregister.gov/documents/2015/05/07/2015-11003/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ovugel,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11003.pdf,2015-05-07, OVUGEL,,Jonathan,OVUGEL,5985320 and RE 42072,Penn State Research Foundation,3692.0,3644,48.0,"August 12, 2002","September 18, 2012","September 18, 2012",NADA 141-,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; COFLEX INTERLAMINAR TECHNOLOGY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COFLEX INTERLAMINAR TECHNOLOGY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patents and Trademarks Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 26273,2015-10998,https://www.federalregister.gov/documents/2015/05/07/2015-10998/determination-of-regulatory-review-period-for-purposes-of-patent-extension-coflex-interlaminar,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10998.pdf,2015-05-07, COFLEX INTERLAMINAR TECHNOLOGY,,Jonathan,COFLEX INTERLAMINAR TECHNOLOGY,5645599,"Paradigm Spine, LLC",2382.0,1787,595.0,"April 12, 2006","April 12, 2006","October 17, 2012",PMA P110008,1503
Determination of Regulatory Review Period for Purposes of Patent Extension; HVAD ROTARY BLOOD PUMP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HVAD ROTARY BLOOD PUMP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 26275,2015-11001,https://www.federalregister.gov/documents/2015/05/07/2015-11001/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hvad-rotary-blood-pump,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11001.pdf,2015-05-07, HVAD ROTARY BLOOD PUMP,,Jonathan,HVAD ROTARY BLOOD PUMP,6234772,"HeartWare, Inc.",1667.0,973,694.0,"April 30, 2008","April 30, 2008","November 20, 2012",PMA P100047,818
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTENT TRABECULAR MICRO-BYPASS STENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for the ISTENT TRABECULAR MICRO-BYPASS STENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 26268,2015-10999,https://www.federalregister.gov/documents/2015/05/07/2015-10999/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istent-trabecular,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10999.pdf,2015-05-07, ISTENT TRABECULAR MICRO-BYPASS STENT,,Jonathan,the ISTENT TRABECULAR MICRO-BYPASS STENT,6626858,Glaukos Corporation,2820.0,1535,1285.0,"October 7, 2004","October 7, 2004","June 25, 2012",PMA P080030,5
Determination of Regulatory Review Period for Purposes of Patent Extension; STIVARGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STIVARGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 29723,2015-12577,https://www.federalregister.gov/documents/2015/05/22/2015-12577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stivarga,https://www.govinfo.gov/content/pkg/FR-2015-05-22/pdf/2015-12577.pdf,2015-05-22, STIVARGA,,Jonathan,STIVARGA,7351834,Bayer HealthCare LLC,2234.0,2080,154.0,"August 18, 2006","August 18, 2006","September 27, 2012",NDA 203085,898
Determination of Regulatory Review Period for Purposes of Patent Extension; FLUCELVAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLUCELVAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 29724,2015-12397,https://www.federalregister.gov/documents/2015/05/22/2015-12397/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flucelvax,https://www.govinfo.gov/content/pkg/FR-2015-05-22/pdf/2015-12397.pdf,2015-05-22, FLUCELVAX,,Jonathan,FLUCELVAX,6656720,Novartis AG,2589.0,2224,365.0,"October 21, 2005","October 21, 2005","November 20, 2012",BLA 125408,1773
Determination of Regulatory Review Period for Purposes of Patent Extension; XELJANZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XELJANZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 33527,2015-14433,https://www.federalregister.gov/documents/2015/06/12/2015-14433/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xeljanz,https://www.govinfo.gov/content/pkg/FR-2015-06-12/pdf/2015-14433.pdf,2015-06-12, XELJANZ,,Jonathan,XELJANZ,RE41783,Pfizer Inc.,3947.0,3564,383.0,"January 18, 2002","January 18, 2002","November 6, 2012",NDA 203214,5
Determination of Regulatory Review Period for Purposes of Patent Extension; SIRTURO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIRTURO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76694,2015-31098,https://www.federalregister.gov/documents/2015/12/10/2015-31098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sirturo,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31098.pdf,2015-12-10, SIRTURO,,Jonathan,SIRTURO,7498343,"Janssen Pharmaceutica, N.V.",2213.0,2030,183.0,"December 9, 2006","December 9, 2006","December 28, 2012",NDA 204384,741
Determination of Regulatory Review Period for Purposes of Patent Extension; ELIQUIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELIQUIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76696,2015-31096,https://www.federalregister.gov/documents/2015/12/10/2015-31096/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eliquis,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31096.pdf,2015-12-10, ELIQUIS,,Jonathan,ELIQUIS,6967208,Bristol-Myers Squibb Company,3685.0,3227,458.0,"November 28, 2002","November 28, 2002","December 28, 2012",NDA 202155,1424
Determination of Regulatory Review Period for Purposes of Patent Extension; VERAFLOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VERAFLOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",80 FR 76701,2015-31099,https://www.federalregister.gov/documents/2015/12/10/2015-31099/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veraflox,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31099.pdf,2015-12-10, VERAFLOX,,Jonathan,VERAFLOX,6323213,Bayer Animal Health GmbH,3285.0,3235,50.0,"November 12, 2003","September 19, 2012","November 7, 2012",NADA 141-344,1901
Determination of Regulatory Review Period for Purposes of Patent Extension; FULYZAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FULYZAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76693,2015-31097,https://www.federalregister.gov/documents/2015/12/10/2015-31097/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fulyzaq,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31097.pdf,2015-12-10, FULYZAQ,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ARGUS II VISUAL STIMULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARGUS II VISUAL STIMULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 76697,2015-31095,https://www.federalregister.gov/documents/2015/12/10/2015-31095/determination-of-regulatory-review-period-for-purposes-of-patent-extension-argus-ii-visual,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31095.pdf,2015-12-10, ARGUS II VISUAL STIMULATION SYSTEM,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VIZAMYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIZAMYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 77640,2015-31401,https://www.federalregister.gov/documents/2015/12/15/2015-31401/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vizamyl,https://www.govinfo.gov/content/pkg/FR-2015-12-15/pdf/2015-31401.pdf,2015-12-15, VIZAMYL,,Jonathan,VIZAMYL,7270800,GE Healthcare Limited,1541.0,1176,365.0,"August 8, 2009","August 8, 2009","October 25, 2013",NDA 203137,951
Determination of Regulatory Review Period for Purposes of Patent Extension; RAXIBACUMAB,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAXIBACUMAB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 77643,2015-31400,https://www.federalregister.gov/documents/2015/12/15/2015-31400/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raxibacumab,https://www.govinfo.gov/content/pkg/FR-2015-12-15/pdf/2015-31400.pdf,2015-12-15, RAXIBACUMAB,,Jonathan,RAXIBACUMAB,7906119,Human Genome Sciences,3465.0,2154,1311.0,"June 22, 2003","June 22, 2003","December 14, 2012",BLA 125349,412
Determination of Regulatory Review Period for Purposes of Patent Extension; Trivascular Ovation Abdominal Stent Graft System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRIVASCULAR OVATION ABDOMINAL STENT GRAFT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 77638,2015-31397,https://www.federalregister.gov/documents/2015/12/15/2015-31397/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trivascular-ovation,https://www.govinfo.gov/content/pkg/FR-2015-12-15/pdf/2015-31397.pdf,2015-12-15, Trivascular Ovation Abdominal Stent Graft System,,Jonathan,TRIVASCULAR OVATION ABDOMINAL STENT GRAFT SYSTEM,6395019,"TriVascular, Inc.",3607.0,3429,178.0,"November 22, 2002","November 22, 2002","October 5, 2012",PMA P120006,1802
Determination of Regulatory Review Period for Purposes of Patent Extension; XTANDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XTANDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 79047,2015-31824,https://www.federalregister.gov/documents/2015/12/18/2015-31824/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xtandi,https://www.govinfo.gov/content/pkg/FR-2015-12-18/pdf/2015-31824.pdf,2015-12-18, XTANDI,,Jonathan,XTANDI,8183274,The Regents of the University of California,1892.0,1790,102.0,"June 29, 2007","June 29, 2007","August 31, 2012",NDA 203-415,101
Determination of Regulatory Review Period for Purposes of Patent Extension; JETREA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JETREA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 79903,2015-32247,https://www.federalregister.gov/documents/2015/12/23/2015-32247/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jetrea,https://www.govinfo.gov/content/pkg/FR-2015-12-23/pdf/2015-32247.pdf,2015-12-23, JETREA,,Jonathan,JETREA,7445775; 7547435; and 7914783,ThromboGenics NV,2171.0,1987,184.0,"November 9, 2006","November 9, 2006","October 17, 2012",BLA 125422,435
Determination of Regulatory Review Period for Purposes of Patent Extension; KADCYLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KADCYLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 80774,2015-32475,https://www.federalregister.gov/documents/2015/12/28/2015-32475/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kadcyla,https://www.govinfo.gov/content/pkg/FR-2015-12-28/pdf/2015-32475.pdf,2015-12-28, KADCYLA,,Jonathan,KADCYLA,7097840 and 8337856,"Genentech, Inc.",2594.0,2414,180.0,"January 18, 2006","January 18, 2006","February 22, 2013",BLA 125427,60
Determination of Regulatory Review Period for Purposes of Patent Extension; BREO ELLIPTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BREO ELLIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 8724,2016-03551,https://www.federalregister.gov/documents/2016/02/22/2016-03551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-breo-ellipta,https://www.govinfo.gov/content/pkg/FR-2016-02-22/pdf/2016-03551.pdf,2016-02-22, BREO ELLIPTA,,Jonathan,BREO ELLIPTA,7439393,Glaxo Group Limited,1980.0,1677,303.0,"December 10, 2007","December 10, 2007","May 10, 2013",NDA 204275,981
Determination of Regulatory Review Period for Purposes of Patent Extension; SUPERA PERIPHERAL STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SUPERA PERIPHERAL STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 8721,2016-03542,https://www.federalregister.gov/documents/2016/02/22/2016-03542/determination-of-regulatory-review-period-for-purposes-of-patent-extension-supera-peripheral-stent,https://www.govinfo.gov/content/pkg/FR-2016-02-22/pdf/2016-03542.pdf,2016-02-22, SUPERA PERIPHERAL STENT SYSTEM,,Jonathan,SUPERA PERIPHERAL STENT SYSTEM,8419788,IDEV Technologies Inc.,1894.0,1396,498.0,"January 21, 2009","January 21, 2009","March 28, 2014",PMA P120020,158
Determination of Regulatory Review Period for Purposes of Patent Extension; INVOKANA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVOKANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 10629,2016-04369,https://www.federalregister.gov/documents/2016/03/01/2016-04369/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invokana,https://www.govinfo.gov/content/pkg/FR-2016-03-01/pdf/2016-04369.pdf,2016-03-01, INVOKANA,,Jonathan,INVOKANA,8222219,"Mitsubishi Tanabe Pharma Corporation of Osaka, Japan",2137.0,1834,303.0,"May 25, 2007","May 31, 2012","March 29, 2013",NDA 204042,256
Determination of Regulatory Review Period for Purposes of Patent Extension; ANORO ELLIPTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANORO ELLIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 10630,2016-04370,https://www.federalregister.gov/documents/2016/03/01/2016-04370/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anoro-ellipta,https://www.govinfo.gov/content/pkg/FR-2016-03-01/pdf/2016-04370.pdf,2016-03-01, ANORO ELLIPTA,,Jonathan,ANORO ELLIPTA,7488827,Glaxo Group Limited,1589.0,1223,366.0,"August 14, 2009","August 14, 2009","December 18, 2013",NDA 203975,966
Determination of Regulatory Review Period for Purposes of Patent Extension; OPSUMIT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPSUMIT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 12741,2016-05389,https://www.federalregister.gov/documents/2016/03/10/2016-05389/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opsumit,https://www.govinfo.gov/content/pkg/FR-2016-03-10/pdf/2016-05389.pdf,2016-03-10, OPSUMIT,,Jonathan,OPSUMIT,7094781,Actelion Pharmaceuticals Ltd.,1935.0,1570,365.0,"July 3, 2008","July 3, 2008","October 18, 2013",NDA 204410,1151
Determination of Regulatory Review Period for Purposes of Patent Extension; BRINTELLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BRINTELLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 19188,2016-07477,https://www.federalregister.gov/documents/2016/04/04/2016-07477/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brintellix,https://www.govinfo.gov/content/pkg/FR-2016-04-04/pdf/2016-07477.pdf,2016-04-04, BRINTELLIX,,Jonathan,BRINTELLIX,7144884,H. Lundbeck A/S,2343.0,1979,364.0,"May 4, 2007","October 2, 2012","September 30, 2013",NDA 204447,1353
Determination of Regulatory Review Period for Purposes of Patent Extension; GAZYVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GAZYVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 21579,2016-08338,https://www.federalregister.gov/documents/2016/04/12/2016-08338/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gazyva,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08338.pdf,2016-04-12, GAZYVA,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADEMPAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADEMPAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 21555,2016-08337,https://www.federalregister.gov/documents/2016/04/12/2016-08337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adempas,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08337.pdf,2016-04-12, ADEMPAS,,Jonathan,ADEMPAS,7173037,Bayer Intellectual Property GmbH,2394.0,2151,243.0,"March 22, 2007","February 8, 2013","October 8, 2013",NDA 204819,1317
Determination of Regulatory Review Period for Purposes of Patent Extension; APOQUEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for APOQUEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",81 FR 21573,2016-08333,https://www.federalregister.gov/documents/2016/04/12/2016-08333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-apoquel,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08333.pdf,2016-04-12, APOQUEL,,Jonathan,APOQUEL,6890929,Pfizer Inc.,2226.0,2172,54.0,"April 12, 2007","April 12, 2007","May 14, 2013",NADA 141-345,1139
Determination of Regulatory Review Period for Purposes of Patent Extension; APTIOM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for APTIOM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 21574,2016-08334,https://www.federalregister.gov/documents/2016/04/12/2016-08334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aptiom,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08334.pdf,2016-04-12, APTIOM,,Jonathan,APTIOM,5753646,"BIAL-PORTELA & CA, S.A.",2517.0,832,1685.0,"December 20, 2006","March 30, 2009","November 8, 2013",NDA 22-416,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; CYRAMZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYRAMZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 22276,2016-08692,https://www.federalregister.gov/documents/2016/04/15/2016-08692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cyramza,https://www.govinfo.gov/content/pkg/FR-2016-04-15/pdf/2016-08692.pdf,2016-04-15, CYRAMZA,,Jonathan,CYRAMZA,7498414,Eli Lilly,3521.0,3279,242.0,"September 1, 2004","September 1, 2004","April 21, 2014",BLA 125477,1059
Determination of Regulatory Review Period for Purposes of Patent Extension; LUZU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUZU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 23722,2016-09374,https://www.federalregister.gov/documents/2016/04/22/2016-09374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luzu,https://www.govinfo.gov/content/pkg/FR-2016-04-22/pdf/2016-09374.pdf,2016-04-22, LUZU,,Jonathan,LUZU,5900488,"Nihon Nohyaku Co., Ltd.",2242.0,1903,339.0,"September 27, 2007","December 11, 2012","November 14, 2013",NDA 204153,1289
Determination of Regulatory Review Period for Purposes of Patent Extension; OLYSIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OLYSIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 34352,2016-12708,https://www.federalregister.gov/documents/2016/05/31/2016-12708/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olysio,https://www.govinfo.gov/content/pkg/FR-2016-05-31/pdf/2016-12708.pdf,2016-05-31, OLYSIO,,Jonathan,OLYSIO,7671032 and 8349869,Medivir AB,2006.0,1766,240.0,"May 28, 2008","March 28, 2013","November 22, 2013",NDA 205123,280
Determination of Regulatory Review Period for Purposes of Patent Extension; OSPHENA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OSPHENA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35026,2016-12823,https://www.federalregister.gov/documents/2016/06/01/2016-12823/determination-of-regulatory-review-period-for-purposes-of-patent-extension-osphena,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12823.pdf,2016-06-01, OSPHENA,,Jonathan,OSPHENA,6245819,Hormos Medical Ltd.,3585.0,3278,307.0,"May 7, 2003","April 26, 2012","February 26, 2013",NDA 203505,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; OTEZLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OTEZLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35029,2016-12829,https://www.federalregister.gov/documents/2016/06/01/2016-12829/determination-of-regulatory-review-period-for-purposes-of-patent-extension-otezla,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12829.pdf,2016-06-01, OTEZLA,,Jonathan,OTEZLA,7427638,Celgene Corporation,3494.0,3128,366.0,"August 28, 2004","March 21, 2013","March 21, 2014",NDA 205437,1186
Determination of Regulatory Review Period for Purposes of Patent Extension; MEKINIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MEKINIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35028,2016-12859,https://www.federalregister.gov/documents/2016/06/01/2016-12859/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mekinist,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12859.pdf,2016-06-01, MEKINIST,,Jonathan,MEKINIST,7378423,"Japan Tobacco, Inc.",1842.0,1542,300.0,"May 15, 2008","August 3, 2012","May 29, 2013",NDA 204-114,623
Determination of Regulatory Review Period for Purposes of Patent Extension; ALPROLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALPROLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",81 FR 36928,2016-13526,https://www.federalregister.gov/documents/2016/06/08/2016-13526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alprolix,https://www.govinfo.gov/content/pkg/FR-2016-06-08/pdf/2016-13526.pdf,2016-06-08, ALPROLIX,,Jonathan,ALPROLIX,7348004 7862820 and 8329182,Biogen Idec Hemophilia Inc.,2223.0,1767,456.0,"February 27, 2008","February 27, 2008","March 28, 2014",BLA 125444,1326
Determination of Regulatory Review Period for Purposes of Patent Extension; ELOCTATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELOCTATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",81 FR 36929,2016-13521,https://www.federalregister.gov/documents/2016/06/08/2016-13521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eloctate,https://www.govinfo.gov/content/pkg/FR-2016-06-08/pdf/2016-13521.pdf,2016-06-08, ELOCTATE,,Jonathan,ELOCTATE,7348004; 7404956; 7862820; and 8329182,Biogen Idec Hemophilia Inc.,1695.0,1239,456.0,"October 17, 2009","October 17, 2009","June 6, 2014",BLA 125487,1049
Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TANZEUM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 37611,2016-13797,https://www.federalregister.gov/documents/2016/06/10/2016-13797/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tanzeum,https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13797.pdf,2016-06-10, TANZEUM,,Jonathan,TANZEUM,7141547,"Human Genome Sciences, Inc.",3014.0,2557,457.0,"January 15, 2006","January 15, 2006","April 15, 2014",BLA 125431,1577
Determination of Regulatory Review Period for Purposes of Patent Extension; POMALYST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for POMALYST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 37606,2016-13796,https://www.federalregister.gov/documents/2016/06/10/2016-13796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pomalyst,https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13796.pdf,2016-06-10, POMALYST,,Jonathan,POMALYST,6316471 and 8198262,Celgene Corporation,60.0,3716,3411.0,"December 9, 2002","December 9, 2002","February 8, 2013",NDA 204026,241
Determination of Regulatory Review Period for Purposes of Patent Extension; ORBACTIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ORBACTIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 39649,2016-14353,https://www.federalregister.gov/documents/2016/06/17/2016-14353/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orbactiv,https://www.govinfo.gov/content/pkg/FR-2016-06-17/pdf/2016-14353.pdf,2016-06-17, ORBACTIV,,Jonathan,ORBACTIV,5840684,Eli Lilly,6539.0,6295,244.0,"September 12, 1996","September 12, 1996","August 6, 2014",NDA 206334,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ZILVER PTX DRUG ELUTING PERIPHERAL STENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZILVER PTX DRUG ELUTING PERIPHERAL STENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications by Boston Scientific Scimed, Inc., to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",81 FR 39648,2016-14357,https://www.federalregister.gov/documents/2016/06/17/2016-14357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zilver-ptx-drug-eluting,https://www.govinfo.gov/content/pkg/FR-2016-06-17/pdf/2016-14357.pdf,2016-06-17, ZILVER PTX DRUG ELUTING PERIPHERAL STENT,,Jonathan,ZILVER PTX DRUG ELUTING PERIPHERAL STENT,6515009 and 7820193,"Boston Scientific Scimed, Inc.",3075.0,2180,895.0,"June 16, 2004","June 16, 2004","November 14, 2012",PMA P100022,751
Determination of Regulatory Review Period for Purposes of Patent Extension; ZILVER PTX DRUG ELUTING PERIPHERAL STENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZILVER PTX DRUG ELUTING PERIPHERAL STENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application by Cook Medical Technologies, LLC, to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 39652,2016-14356,https://www.federalregister.gov/documents/2016/06/17/2016-14356/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zilver-ptx-drug-eluting,https://www.govinfo.gov/content/pkg/FR-2016-06-17/pdf/2016-14356.pdf,2016-06-17, ZILVER PTX DRUG ELUTING PERIPHERAL STENT,,Jonathan,ZILVER PTX DRUG ELUTING PERIPHERAL STENT,6299604,"Cook Medical Technologies, LLC",3075.0,2180,895.0,"June 16, 2004","June 16, 2004","November 14, 2012",PMA P100022,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; XOFIGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XOFIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 40316,2016-14551,https://www.federalregister.gov/documents/2016/06/21/2016-14551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xofigo,https://www.govinfo.gov/content/pkg/FR-2016-06-21/pdf/2016-14551.pdf,2016-06-21, XOFIGO,,Jonathan,XOFIGO,6635234,Algeta ASA,1945.0,1792,153.0,"January 19, 2008","January 19, 2008","May 15, 2013",NDA 203971,1032
Determination of Regulatory Review Period for Purposes of Patent Extension; QUTENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for QUTENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 47399,2016-17187,https://www.federalregister.gov/documents/2016/07/21/2016-17187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qutenza,https://www.govinfo.gov/content/pkg/FR-2016-07-21/pdf/2016-17187.pdf,2016-07-21, QUTENZA,,Jonathan,QUTENZA,6239180,"NeurogesX, Inc.",2944.0,2547,397.0,"October 27, 2001","October 27, 2001","November 16, 2009",NDA 22-395,1687
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTYVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENTYVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patents and Trademarks Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 63773,2016-22344,https://www.federalregister.gov/documents/2016/09/16/2016-22344/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entyvio,https://www.govinfo.gov/content/pkg/FR-2016-09-16/pdf/2016-22344.pdf,2016-09-16, ENTYVIO,,Jonathan,ENTYVIO,7147851,"Millenium Pharmaceuticals, Inc.",5066.0,4731,335.0,"July 8, 2000","July 8, 2000","May 20, 2014",BLA 125476,1526
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMASON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUMASON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 63770,2016-22345,https://www.federalregister.gov/documents/2016/09/16/2016-22345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumason,https://www.govinfo.gov/content/pkg/FR-2016-09-16/pdf/2016-22345.pdf,2016-09-16, LUMASON,,Jonathan,LUMASON,5686060,Bracco Suisse SA,7199.0,6174,1025.0,"January 26, 1995","January 26, 1995","October 10, 2014",NDA 203684,5
Determination of Regulatory Review Period for Purposes of Patent Extension; RESQCPR SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RESQCPR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 63771,2016-22343,https://www.federalregister.gov/documents/2016/09/16/2016-22343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-resqcpr-system,https://www.govinfo.gov/content/pkg/FR-2016-09-16/pdf/2016-22343.pdf,2016-09-16, RESQCPR SYSTEM,,Jonathan,RESQCPR SYSTEM,5454779,University of California,3608.0,2247,1361.0,"April 21, 2005","April 21, 2005","March 6, 2015",PMA P110024,5
Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYALEPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 65656,2016-22935,https://www.federalregister.gov/documents/2016/09/23/2016-22935/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myalept,https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22935.pdf,2016-09-23, MYALEPT,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FYCOMPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FYCOMPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 65655,2016-22933,https://www.federalregister.gov/documents/2016/09/23/2016-22933/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fycompa,https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22933.pdf,2016-09-23, FYCOMPA,,Jonathan,FYCOMPA,6949571,"Eisai R&D Management Co., Ltd.",3274.0,2968,306.0,"November 7, 2003","December 22, 2011","October 22, 2012",NDA 202834,1549
Determination of Regulatory Review Period for Purposes of Patent Extension; BELVIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BELVIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 65658,2016-22937,https://www.federalregister.gov/documents/2016/09/23/2016-22937/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belviq,https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22937.pdf,2016-09-23, BELVIQ,,Jonathan,BELVIQ,6953787; 7514422; and 7977329,"Arena Pharmaceuticals, Inc.",2928.0,2009,919.0,"June 23, 2004","December 22, 2009","June 27, 2012",NDA 22-529,352
Determination of Regulatory Review Period for Purposes of Patent Extension; IONSYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IONSYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 66662,2016-23330,https://www.federalregister.gov/documents/2016/09/28/2016-23330/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ionsys,https://www.govinfo.gov/content/pkg/FR-2016-09-28/pdf/2016-23330.pdf,2016-09-28, IONSYS,,Jonathan,IONSYS,5697896,Alza Corp.,4835.0,3862,973.0,"February 26, 1993","February 26, 1993","May 22, 2006",NDA 21-338,5
Determination of Regulatory Review Period for Purposes of Patent Extension; REPATHA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REPATHA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 72059,2016-25221,https://www.federalregister.gov/documents/2016/10/19/2016-25221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-repatha,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25221.pdf,2016-10-19, REPATHA,,Jonathan,REPATHA,8030457; 8829165; and 8981064,Amgen Inc.,2267.0,1901,366.0,"June 14, 2009","June 14, 2009","August 27, 2015",BLA 125522,164
Determination of Regulatory Review Period for Purposes of Patent Extension; PLEGRIDY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PLEGRIDY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 72062,2016-25222,https://www.federalregister.gov/documents/2016/10/19/2016-25222/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plegridy,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25222.pdf,2016-10-19, PLEGRIDY,,Jonathan,PLEGRIDY,7446173; 8017733; and 8524660,Biogen Idec MA Inc.,2643.0,2186,457.0,"May 23, 2007","May 23, 2007","August 15, 2014",BLA 125499,346
Determination of Regulatory Review Period for Purposes of Patent Extension; PRILOSEC OTC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRILOSEC OTC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 72060,2016-25220,https://www.federalregister.gov/documents/2016/10/19/2016-25220/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prilosec-otc,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25220.pdf,2016-10-19, PRILOSEC OTC,,Jonathan,PRILOSEC OTC,5817338,AstraZeneca AB,2045.0,804,1241.0,"November 15, 1997","November 15, 1997","June 20, 2003",NDA 21-229,623
Determination of Regulatory Review Period for Purposes of Patent Extension; ANAVIP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANAVIP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 83845,2016-28049,https://www.federalregister.gov/documents/2016/11/22/2016-28049/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anavip,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28049.pdf,2016-11-22, ANAVIP,,Jonathan,ANAVIP,6709655,"Instituto Bioclon, SA de CV",4223.0,3443,780.0,"October 15, 2003","October 15, 2003","May 6, 2015",BLA 125488,5
Determination of Regulatory Review Period for Purposes of Patent Extension; RUCONEST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RUCONEST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 83850,2016-28046,https://www.federalregister.gov/documents/2016/11/22/2016-28046/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ruconest,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28046.pdf,2016-11-22, RUCONEST,,Jonathan,RUCONEST,7067713 and RE43691,Pharming Intellectual Property B.V.,3502.0,3045,457.0,"December 15, 2004","December 15, 2004","July 16, 2014",BLA 125495,557
Determination of Regulatory Review Period for Purposes of Patent Extension; CERDELGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERDELGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 83852,2016-28045,https://www.federalregister.gov/documents/2016/11/22/2016-28045/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerdelga,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28045.pdf,2016-11-22, CERDELGA,,Jonathan,CERDELGA,7196205,Genzyme Corporation,3854.0,3520,334.0,"February 1, 2004","February 1, 2004","August 19, 2014",NDA 205494,1518
Determination of Regulatory Review Period for Purposes of Patent Extension; CORE VALVE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CORE VALVE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 83849,2016-28047,https://www.federalregister.gov/documents/2016/11/22/2016-28047/determination-of-regulatory-review-period-for-purposes-of-patent-extension-core-valve-system,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28047.pdf,2016-11-22, CORE VALVE SYSTEM,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IXINITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IXINITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 85965,2016-28653,https://www.federalregister.gov/documents/2016/11/29/2016-28653/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ixinity,https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/2016-28653.pdf,2016-11-29, IXINITY,,Jonathan,IXINITY,7645602 and 8603823,the University of North Carolina at Chapel Hill,2437.0,1318,1119.0,"August 28, 2008","August 28, 2008","April 29, 2015",BLA 125426,505
Determination of Regulatory Review Period for Purposes of Patent Extension; NUWIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NUWIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 85974,2016-28654,https://www.federalregister.gov/documents/2016/11/29/2016-28654/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuwiq,https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/2016-28654.pdf,2016-11-29, NUWIQ,,Jonathan,NUWIQ,7572619,Octapharma AG,2622.0,2165,457.0,"July 2, 2008","July 2, 2008","September 4, 2015",BLA 125555,1336
Determination of Regulatory Review Period for Purposes of Patent Extension; TRUMENBA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRUMENBA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87041,2016-28916,https://www.federalregister.gov/documents/2016/12/02/2016-28916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trumenba,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28916.pdf,2016-12-02, TRUMENBA,,Jonathan,TRUMENBA,8101194 and 8563007,Wyeth Holdings LLC,2079.0,1943,136.0,"February 20, 2009","February 20, 2009","October 29, 2014",BLA 125549,573
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,2016-12-02, OPDIVO,,Jonathan,OPDIVO,8008449,"E.R. Squibb & Sons, LLC",3071.0,2925,146.0,"July 28, 2006","July 28, 2006","December 22, 2014",BLA 125554,552
Determination of Regulatory Review Period for Purposes of Patent Extension; TRESIBA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRESIBA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 87045,2016-28939,https://www.federalregister.gov/documents/2016/12/02/2016-28939/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tresiba,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28939.pdf,2016-12-02, TRESIBA,,Jonathan,TRESIBA,7615532,Novo Nordisk A/S,2914.0,1456,1458.0,"October 5, 2007","October 5, 2007","September 25, 2015",NDA 203-314,1803
Determination of Regulatory Review Period for Purposes of Patent Extension; BEXSERO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEXSERO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87568,2016-29025,https://www.federalregister.gov/documents/2016/12/05/2016-29025/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bexsero,https://www.govinfo.gov/content/pkg/FR-2016-12-05/pdf/2016-29025.pdf,2016-12-05, BEXSERO,,Jonathan,BEXSERO,8273360 and 8663656,GlaxoSmithKline Biologicals SA,3963.0,3779,184.0,"March 20, 2004","March 20, 2004","January 23, 2015",BLA 125546,255
Determination of Regulatory Review Period for Purposes of Patent Extension; GARDASIL 9,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GARDASIL 9 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 88245,2016-29303,https://www.federalregister.gov/documents/2016/12/07/2016-29303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gardasil-9,https://www.govinfo.gov/content/pkg/FR-2016-12-07/pdf/2016-29303.pdf,2016-12-07, GARDASIL 9,,Jonathan,GARDASIL 9,7476389 and 7482015,Merck Sharp & Dohme Corp. for CSL Limited,2662.0,2296,366.0,"types 6, 11","August 29, 2007","December 10, 2014",BLA 125508,1254
Determination of Regulatory Review Period for Purposes of Patent Extension; NUCALA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NUCALA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 89946,2016-29838,https://www.federalregister.gov/documents/2016/12/13/2016-29838/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nucala,https://www.govinfo.gov/content/pkg/FR-2016-12-13/pdf/2016-29838.pdf,2016-12-13, NUCALA,,Jonathan,NUCALA,5693323,GlaxoSmithKline LLC,6862.0,6496,366.0,"January 22, 1997","January 22, 1997","November 4, 2015",BLA 125526,5
Determination of Regulatory Review Period for Purposes of Patent Extension; TRULICITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRULICITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 91938,2016-30399,https://www.federalregister.gov/documents/2016/12/19/2016-30399/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulicity,https://www.govinfo.gov/content/pkg/FR-2016-12-19/pdf/2016-30399.pdf,2016-12-19, TRULICITY,,Jonathan,TRULICITY,7452966,Eli Lilly,3303.0,2937,366.0,"September 4, 2005","September 4, 2005","September 18, 2014",BLA 125469,1249
Determination of Regulatory Review Period for Purposes of Patent Extension; COSENTYX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COSENTYX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 92832,2016-30528,https://www.federalregister.gov/documents/2016/12/20/2016-30528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cosentyx,https://www.govinfo.gov/content/pkg/FR-2016-12-20/pdf/2016-30528.pdf,2016-12-20, COSENTYX,,Jonathan,COSENTYX,7807155,Novartis AG,3381.0,2926,455.0,"October 21, 2005","October 21, 2005","January 21, 2015",BLA 125504,629
Determination of Regulatory Review Period for Purposes of Patent Extension; IMLYGIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMLYGIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 95618,2016-31322,https://www.federalregister.gov/documents/2016/12/28/2016-31322/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imlygic,https://www.govinfo.gov/content/pkg/FR-2016-12-28/pdf/2016-31322.pdf,2016-12-28, IMLYGIC,,Jonathan,IMLYGIC,7063835; 7223593; and 7537924,BioVex Limited,3809.0,3352,457.0,"May 25, 2005","May 25, 2005","October 27, 2015",BLA 125518,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; EMPLICITI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMPLICITI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 2380,2017-00108,https://www.federalregister.gov/documents/2017/01/09/2017-00108/determination-of-regulatory-review-period-for-purposes-of-patent-extension-empliciti,https://www.govinfo.gov/content/pkg/FR-2017-01-09/pdf/2017-00108.pdf,2017-01-09, EMPLICITI,,Jonathan,EMPLICITI,7709610,"AbbVie Biotherapeutics, Inc.",3400.0,3245,155.0,"August 11, 2006","August 11, 2006","November 30, 2015",BLA 761035,1095
Determination of Regulatory Review Period for Purposes of Patent Extension; ADYNOVATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADYNOVATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 2378,2017-00095,https://www.federalregister.gov/documents/2017/01/09/2017-00095/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adynovate,https://www.govinfo.gov/content/pkg/FR-2017-01-09/pdf/2017-00095.pdf,2017-01-09, ADYNOVATE,,Jonathan,ADYNOVATE,7199223 and 8247536,Nektar Therapeutics,1061.0,707,354.0,"December 19, 2012","December 19, 2012","November 13, 2015",BLA 125566,708
Determination of Regulatory Review Period for Purposes of Patent Extension; HETLIOZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HETLIOZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 27261,2017-12323,https://www.federalregister.gov/documents/2017/06/14/2017-12323/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hetlioz,https://www.govinfo.gov/content/pkg/FR-2017-06-14/pdf/2017-12323.pdf,2017-06-14, HETLIOZ,,Jonathan,HETLIOZ,5856529,"Vanda Pharmaceuticals, Inc.",5802.0,5556,246.0,"March 16, 1998","May 31, 2013","January 31, 2014",NDA 205677,5
Determination of Regulatory Review Period for Purposes of Patent Extension; NEUROPACE RNS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEUROPACE RNS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 27266,2017-12322,https://www.federalregister.gov/documents/2017/06/14/2017-12322/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuropace-rns-system,https://www.govinfo.gov/content/pkg/FR-2017-06-14/pdf/2017-12322.pdf,2017-06-14, NEUROPACE RNS SYSTEM,,Jonathan,NEUROPACE RNS SYSTEM,6016449; 6360122; and 6810285,"NeuroPace, Inc.",3796.0,2694,1102.0,"June 26, 2003","June 26, 2003","November 14, 2013",PMA P100026,5
Determination of Regulatory Review Period for Purposes of Patent Extension; NATPARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NATPARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 27496,2017-12359,https://www.federalregister.gov/documents/2017/06/15/2017-12359/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natpara,https://www.govinfo.gov/content/pkg/FR-2017-06-15/pdf/2017-12359.pdf,2017-06-15, NATPARA,,Jonathan,NATPARA,5496801,NPS Pharmaceuticals Inc.,7268.0,6811,457.0,"March 3, 1995","March 3, 1995","January 23, 2015",BLA 125511,5
Determination of Regulatory Review Period for Purposes of Patent Extension; Intercept Blood System for Plasma,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INTERCEPT BLOOD SYSTEM FOR PLASMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 31974,2017-14454,https://www.federalregister.gov/documents/2017/07/11/2017-14454/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intercept-blood-system,https://www.govinfo.gov/content/pkg/FR-2017-07-11/pdf/2017-14454.pdf,2017-07-11, Intercept Blood System for Plasma,,Jonathan,INTERCEPT BLOOD SYSTEM FOR PLASMA,5593823 and 6951713,Cerus Corporation,6497.0,6114,383.0,"March 5, 1997","March 5, 1997","December 16, 2014",PMA BP130076,1860
Determination of Regulatory Review Period for Purposes of Patent Extension; Intercept Blood System for Platelets,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Intercept Blood System for Platelets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 32002,2017-14455,https://www.federalregister.gov/documents/2017/07/11/2017-14455/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intercept-blood-system,https://www.govinfo.gov/content/pkg/FR-2017-07-11/pdf/2017-14455.pdf,2017-07-11, Intercept Blood System for Platelets,,Jonathan,Intercept Blood System for Platelets,7037642 and 7611831,Cerus Corporation,7080.0,6909,171.0,"August 2, 1995","August 2, 1995","December 18, 2014",PMA BP140143,999
Determination of Regulatory Review Period for Purposes of Patent Extension; CINQAIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CINQAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 36790,2017-16516,https://www.federalregister.gov/documents/2017/08/07/2017-16516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cinqair,https://www.govinfo.gov/content/pkg/FR-2017-08-07/pdf/2017-16516.pdf,2017-08-07, CINQAIR,,Jonathan,CINQAIR,RE39548,UCB Celltech,5685.0,5325,360.0,"August 31, 2000","August 31, 2000","March 23, 2016",BLA 761033,1660
Determination of Regulatory Review Period for Purposes of Patent Extension; VONVENDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VONVENDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 36794,2017-16515,https://www.federalregister.gov/documents/2017/08/07/2017-16515/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vonvendi,https://www.govinfo.gov/content/pkg/FR-2017-08-07/pdf/2017-16515.pdf,2017-08-07, VONVENDI,,Jonathan,VONVENDI,6465624; 6531577; and 6579723,Baxalta GmbH,2690.0,2335,355.0,"July 29, 2008","July 29, 2008","December 8, 2015",BLA 125577,1521
Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECUVYRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",82 FR 39587,2017-17566,https://www.federalregister.gov/documents/2017/08/21/2017-17566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recuvyra,https://www.govinfo.gov/content/pkg/FR-2017-08-21/pdf/2017-17566.pdf,2017-08-21, RECUVYRA,,Jonathan,RECUVYRA,6299900; 6818226; and 6916486,Acrux DDS Pty. Ltd.,2092.0,2037,55.0,"October 3, 2006","June 23, 2012","June 23, 2012",NADA 141-337,1279
Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation,Notice,Health and Human Services Department; Food and Drug Administration,,82 FR 40008,2017-17961,https://www.federalregister.gov/documents/2017/08/23/2017-17961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recuvyra-affirmation,https://www.govinfo.gov/content/pkg/FR-2017-08-23/pdf/2017-17961.pdf,2017-08-23, RECUVYRA, Affirmation,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XTORO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XTORO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 41271,2017-18379,https://www.federalregister.gov/documents/2017/08/30/2017-18379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xtoro,https://www.govinfo.gov/content/pkg/FR-2017-08-30/pdf/2017-18379.pdf,2017-08-30, XTORO,,Jonathan,XTORO,6133260,Alcon Pharmaceutials Ltd. for Bayer Intellectual Property GmbH,1880.0,1643,237.0,"October 26, 2009","October 26, 2009","December 17, 2014",NDA 206307,1058
Determination of Regulatory Review Period for Purposes of Patent Extension; KENGREAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KENGREAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 41274,2017-18380,https://www.federalregister.gov/documents/2017/08/30/2017-18380/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kengreal,https://www.govinfo.gov/content/pkg/FR-2017-08-30/pdf/2017-18380.pdf,2017-08-30, KENGREAL,,Jonathan,KENGREAL,6114313 and 6130208,AstraZeneca UK Limited,6122.0,5338,784.0,"September 19, 1998","September 19, 1998","June 22, 2015",NDA 204958,5
Determination of Regulatory Review Period for Purposes of Patent Extension; KOVALTRY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KOVALTRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 46496,2017-21421,https://www.federalregister.gov/documents/2017/10/05/2017-21421/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kovaltry,https://www.govinfo.gov/content/pkg/FR-2017-10-05/pdf/2017-21421.pdf,2017-10-05, KOVALTRY,,Jonathan,KOVALTRY,5804420,Bayer HealthCare LLC,2478.0,2021,457.0,"June 5, 2009","June 5, 2009","March 16, 2016",BLA 125574,1466
Determination of Regulatory Review Period for Purposes of Patent Extension; TECFIDERA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECFIDERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 46502,2017-21435,https://www.federalregister.gov/documents/2017/10/05/2017-21435/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecfidera,https://www.govinfo.gov/content/pkg/FR-2017-10-05/pdf/2017-21435.pdf,2017-10-05, TECFIDERA,,Jonathan,TECFIDERA,6509376; 7320999; 7619001; and 7803840,Biogen Idec International GmbH,2480.0,2085,395.0,"June 14, 2006","June 14, 2006","March 27, 2013",NDA 204063,654
Determination of Regulatory Review Period for Purposes of Patent Extension; IMPELLA 2.5 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMPELLA 2.5 SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 46498,2017-21436,https://www.federalregister.gov/documents/2017/10/05/2017-21436/determination-of-regulatory-review-period-for-purposes-of-patent-extension-impella-25-system,https://www.govinfo.gov/content/pkg/FR-2017-10-05/pdf/2017-21436.pdf,2017-10-05, IMPELLA 2.5 SYSTEM,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OBIZUR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OBIZUR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 49031,2017-22898,https://www.federalregister.gov/documents/2017/10/23/2017-22898/determination-of-regulatory-review-period-for-purposes-of-patent-extension-obizur,https://www.govinfo.gov/content/pkg/FR-2017-10-23/pdf/2017-22898.pdf,2017-10-23, OBIZUR,,Jonathan,OBIZUR,6180371; 6458563; and 7560107,Emory University,4216.0,3883,333.0,"April 10, 2003","April 10, 2003","October 23, 2014",BLA 125512,5
Determination of Regulatory Review Period for Purposes of Patent Extension; MITRACLIP CDS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MITRACLIP CDS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 49027,2017-22895,https://www.federalregister.gov/documents/2017/10/23/2017-22895/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mitraclip-cds,https://www.govinfo.gov/content/pkg/FR-2017-10-23/pdf/2017-22895.pdf,2017-10-23, MITRACLIP CDS,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Inspire Upper Airway Stimulation System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Inspire Upper Airway Stimulation System (Inspire UAS System) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 49029,2017-22897,https://www.federalregister.gov/documents/2017/10/23/2017-22897/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inspire-upper-airway,https://www.govinfo.gov/content/pkg/FR-2017-10-23/pdf/2017-22897.pdf,2017-10-23, Inspire Upper Airway Stimulation System,,Jonathan,INSPIRE UAS SYSTEM,6021352,"Inspire Medical Systems, Inc.",2002.0,1653,349.0,"November 7, 2008","November 7, 2008","April 30, 2014",PMA P130008,1184
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPIVAB,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAPIVAB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56244,2017-25676,https://www.federalregister.gov/documents/2017/11/28/2017-25676/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapivab,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25676.pdf,2017-11-28, RAPIVAB,,Jonathan,RAPIVAB,6503745 and 6562861,"BioCryst Pharmaceuticals, Inc.",3287.0,2925,362.0,"December 21, 2005","December 23, 2013","December 19, 2014",NDA 206426,1824
Determination of Regulatory Review Period for Purposes of Patent Extension; YONDELIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YONDELIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56246,2017-25683,https://www.federalregister.gov/documents/2017/11/28/2017-25683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yondelis,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25683.pdf,2017-11-28, YONDELIS,,Jonathan,YONDELIS,7420051,"Pharma Mar, S.A.",7107.0,6773,334.0,"May 10, 1996","May 10, 1996","October 23, 2015",NDA 207953,1471
Determination of Regulatory Review Period for Purposes of Patent Extension; SAVAYSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAVAYSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56252,2017-25703,https://www.federalregister.gov/documents/2017/11/28/2017-25703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-savaysa,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25703.pdf,2017-11-28, SAVAYSA,,Jonathan,SAVAYSA,7365205,"Daiichi Sankyo Co., Ltd.",10.0,3845,3479.0,"July 1, 2004","January 8, 2014","January 8, 2015",NDA 206316,1406
Determination of Regulatory Review Period for Purposes of Patent Extension; ZERBAXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZERBAXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56253,2017-25682,https://www.federalregister.gov/documents/2017/11/28/2017-25682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zerbaxa,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25682.pdf,2017-11-28, ZERBAXA,,Jonathan,ZERBAXA,7129232,"Astellas Pharma, Inc.",2360.0,2117,243.0,"July 5, 2008","July 5, 2008","December 19, 2014",NDA 206829,1302
Determination of Regulatory Review Period for Purposes of Patent Extension; Senza Spinal Cord Stimulation System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Senza Spinal Cord Stimulation System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 56250,2017-25684,https://www.federalregister.gov/documents/2017/11/28/2017-25684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-senza-spinal-cord,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25684.pdf,2017-11-28, Senza Spinal Cord Stimulation System,,Jonathan,Senza Spinal Cord Stimulation System,8712533 and 8768472,Nevro Corporation,1136.0,820,316.0,"March 30, 2012","March 30, 2012","May 8, 2015",PMA P130022,312
Determination of Regulatory Review Period for Purposes of Patent Extension; XURIDEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XURIDEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56605,2017-25770,https://www.federalregister.gov/documents/2017/11/29/2017-25770/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xuriden,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25770.pdf,2017-11-29, XURIDEN,,Jonathan,XURIDEN,6258795,Wellstat Therapeutics Corp.,8494.0,8254,240.0,"June 4, 1992","June 4, 1992","September 4, 2015",NDA 208169,5
Determination of Regulatory Review Period for Purposes of Patent Extension; VELTASSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VELTASSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56609,2017-25761,https://www.federalregister.gov/documents/2017/11/29/2017-25761/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veltassa,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25761.pdf,2017-11-29, VELTASSA,,Jonathan,VELTASSA,8147873,"Relypsa, Inc.",2844.0,2478,366.0,"January 9, 2008","October 21, 2014","October 21, 2015",NDA 205739,832
Determination of Regulatory Review Period for Purposes of Patent Extension; REXULTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REXULTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56612,2017-25772,https://www.federalregister.gov/documents/2017/11/29/2017-25772/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rexulti,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25772.pdf,2017-11-29, REXULTI,,Jonathan,REXULTI,7888362,"Otsuka Pharmaceutical Co., Ltd.",2636.0,2271,365.0,"April 23, 2008","April 23, 2008","July 10, 2015",NDA 205422,868
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLX SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOLX SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56613,2017-25773,https://www.federalregister.gov/documents/2017/11/29/2017-25773/determination-of-regulatory-review-period-for-purposes-of-patent-extension-solx-system,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25773.pdf,2017-11-29, SOLX SYSTEM,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADVANTAME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADVANTAME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that food additive.",82 FR 56828,2017-25780,https://www.federalregister.gov/documents/2017/11/30/2017-25780/determination-of-regulatory-review-period-for-purposes-of-patent-extension-advantame,https://www.govinfo.gov/content/pkg/FR-2017-11-30/pdf/2017-25780.pdf,2017-11-30, ADVANTAME,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SIVEXTRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SIVEXTRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61008,2017-27684,https://www.federalregister.gov/documents/2017/12/26/2017-27684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sivextro,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27684.pdf,2017-12-26, SIVEXTRO,,Jonathan,SIVEXTRO,7816379,"Trius Therapeutics, Inc.",2366.0,2123,243.0,"December 30, 2007","December 30, 2007","June 20, 2014",NDA 205435,118
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYKADIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYKADIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61010,2017-27745,https://www.federalregister.gov/documents/2017/12/26/2017-27745/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zykadia,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27745.pdf,2017-12-26, ZYKADIA,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; STRIVERDI RESPIMAT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STRIVERDI RESPIMAT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61006,2017-27710,https://www.federalregister.gov/documents/2017/12/26/2017-27710/determination-of-regulatory-review-period-for-purposes-of-patent-extension-striverdi-respimat,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27710.pdf,2017-12-26, STRIVERDI RESPIMAT,,Jonathan,STRIVERDI RESPIMAT,7727984,Boehringer Ingelheim Pharma GmbH & Co. KG,2712.0,1903,809.0,"February 28, 2007","May 14, 2012","July 31, 2014",NDA 203108,1166
Determination of Regulatory Review Period for Purposes of Patent Extension; EPANOVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EPANOVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 1366,2018-00353,https://www.federalregister.gov/documents/2018/01/11/2018-00353/determination-of-regulatory-review-period-for-purposes-of-patent-extension-epanova,https://www.govinfo.gov/content/pkg/FR-2018-01-11/pdf/2018-00353.pdf,2018-01-11, EPANOVA,,Jonathan,EPANOVA,5948818; 7960370; 7792795; and 8383678,AstraZeneca Pharmaceuticals LP,4269.0,3964,305.0,"August 29, 2002","August 29, 2002","May 5, 2014",NDA 205060,682
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTYCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENTYCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 1365,2018-00358,https://www.federalregister.gov/documents/2018/01/11/2018-00358/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entyce,https://www.govinfo.gov/content/pkg/FR-2018-01-11/pdf/2018-00358.pdf,2018-01-11, ENTYCE,,Jonathan,ENTYCE,6107306 and 6673929,RaQualia Pharma Inc.,1645.0,1589,56.0,"November 16, 2011","May 16, 2016","May 16, 2016",NADA 141-457,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; MICRA TRANSCATHETER PACING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MICRA TRANSCATHETER PACING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 1370,2018-00355,https://www.federalregister.gov/documents/2018/01/11/2018-00355/determination-of-regulatory-review-period-for-purposes-of-patent-extension-micra-transcatheter,https://www.govinfo.gov/content/pkg/FR-2018-01-11/pdf/2018-00355.pdf,2018-01-11, MICRA TRANSCATHETER PACING SYSTEM,,Jonathan,MICRA TRANSCATHETER PACING SYSTEM,7824805 and 8129622,"Medtronic, Inc.",788.0,585,203.0,"February 10, 2014","February 10, 2014","April 6, 2016",PMA P150033,494
Determination of Regulatory Review Period for Purposes of Patent Extension; PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 1620,2018-00404,https://www.federalregister.gov/documents/2018/01/12/2018-00404/determination-of-regulatory-review-period-for-purposes-of-patent-extension-proact-adjustable,https://www.govinfo.gov/content/pkg/FR-2018-01-12/pdf/2018-00404.pdf,2018-01-12, PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN,,Jonathan,PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN,7014606 and 7828716,"Uromedica, Inc.",3892.0,3179,713.0,"March 31, 2005","March 31, 2005","November 24, 2015",PMA 130018,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; DAKLINZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAKLINZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2454,2018-00675,https://www.federalregister.gov/documents/2018/01/17/2018-00675/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daklinza,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00675.pdf,2018-01-17, DAKLINZA,,Jonathan,DAKLINZA,8329159,Bristol-Myers Squibb Company,2808.0,2327,481.0,"November 17, 2007","November 17, 2007","July 24, 2015",NDA 206843,467
Determination of Regulatory Review Period for Purposes of Patent Extension; AVYCAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVYCAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2449,2018-00678,https://www.federalregister.gov/documents/2018/01/17/2018-00678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avycaz,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00678.pdf,2018-01-17, AVYCAZ,,Jonathan,AVYCAZ,7112592,Forest Laboratories Holdings Ltd.,2579.0,2333,246.0,"February 5, 2008","June 25, 2014","February 25, 2015",NDA 206494,1411
Determination of Regulatory Review Period for Purposes of Patent Extension; AXUMIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AXUMIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2459,2018-00684,https://www.federalregister.gov/documents/2018/01/17/2018-00684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axumin,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00684.pdf,2018-01-17, AXUMIN,,Jonathan,AXUMIN,5808146,Emory University,4006.0,3763,243.0,"June 10, 2005","June 10, 2005","May 27, 2016",NDA 208054,5
Determination of Regulatory Review Period for Purposes of Patent Extension; SYNERGY EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYNERGY EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 2452,2018-00679,https://www.federalregister.gov/documents/2018/01/17/2018-00679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synergy,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00679.pdf,2018-01-17, SYNERGY EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM,,Jonathan,SYNERGY,8348992,"Boston Scientific Scimed, Inc.",1206.0,950,256.0,"June 15, 2012","June 15, 2012","October 2, 2015",PMA P150003,629
Determination of Regulatory Review Period for Purposes of Patent Extension; NINLARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NINLARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 3000,2018-00994,https://www.federalregister.gov/documents/2018/01/22/2018-00994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ninlaro,https://www.govinfo.gov/content/pkg/FR-2018-01-22/pdf/2018-00994.pdf,2018-01-22, NINLARO,,Jonathan,NINLARO,7442830; 7687662; 8003819; and 8859504,"Millennium Pharmaceuticals, Inc.",2538.0,2404,134.0,"December 10, 2008","December 10, 2008","November 20, 2015",NDA 208462,157
Determination of Regulatory Review Period for Purposes of Patent Extension; ZURAMPIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZURAMPIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2999,2018-00992,https://www.federalregister.gov/documents/2018/01/22/2018-00992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zurampic,https://www.govinfo.gov/content/pkg/FR-2018-01-22/pdf/2018-00992.pdf,2018-01-22, ZURAMPIC,,Jonathan,ZURAMPIC,8003681; 8084483; 8283369; 8357713; and 8546437,"Ardea Biosciences, Inc.",2245.0,1886,359.0,"October 31, 2009","October 31, 2009","December 22, 2015",NDA 207988,237
Determination of Regulatory Review Period for Purposes of Patent Extension; PERCEVAL SUTURELESS HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PERCEVAL SUTURELESS HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 2997,2018-00995,https://www.federalregister.gov/documents/2018/01/22/2018-00995/determination-of-regulatory-review-period-for-purposes-of-patent-extension-perceval-sutureless-heart,https://www.govinfo.gov/content/pkg/FR-2018-01-22/pdf/2018-00995.pdf,2018-01-22, PERCEVAL SUTURELESS HEART VALVE,,Jonathan,PERCEVAL SUTURELESS HEART VALVE,8540768,Sorin Group Italia S.r.l.,1003.0,694,309.0,"April 12, 2013","April 12, 2013","January 8, 2016",PMA P150011,576
Determination of Regulatory Review Period for Purposes of Patent Extension; VARUBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VARUBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 3732,2018-01373,https://www.federalregister.gov/documents/2018/01/26/2018-01373/determination-of-regulatory-review-period-for-purposes-of-patent-extension-varubi,https://www.govinfo.gov/content/pkg/FR-2018-01-26/pdf/2018-01373.pdf,2018-01-26, VARUBI,,Jonathan,VARUBI,7049320,"OPKO Health, Inc.",3070.0,2708,362.0,"April 8, 2007","April 8, 2007","September 1, 2015",NDA 206500,1716
Determination of Regulatory Review Period for Purposes of Patent Extension; VRAYLAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VRAYLAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 3737,2018-01368,https://www.federalregister.gov/documents/2018/01/26/2018-01368/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vraylar,https://www.govinfo.gov/content/pkg/FR-2018-01-26/pdf/2018-01368.pdf,2018-01-26, VRAYLAR,,Jonathan,VRAYLAR,7737142 and 7943621,"Forest Laboratories, LLC",3742.0,2709,1033.0,"June 21, 2005","June 21, 2005","September 17, 2015",NDA 204370,275
Determination of Regulatory Review Period for Purposes of Patent Extension; UPTRAVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UPTRAVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4219,2018-01637,https://www.federalregister.gov/documents/2018/01/30/2018-01637/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uptravi,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01637.pdf,2018-01-30, UPTRAVI,,Jonathan,UPTRAVI,7205302,"Actelion Pharmaceuticals, Ltd.",2246.0,1881,365.0,"October 29, 2009","October 29, 2009","December 21, 2015",NDA 207947,1305
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEPATIER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEPATIER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4213,2018-01642,https://www.federalregister.gov/documents/2018/01/30/2018-01642/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zepatier,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01642.pdf,2018-01-30, ZEPATIER,,Jonathan,ZEPATIER,7973040,Merck Sharp & Dohme Corp.,1865.0,1619,246.0,"December 22, 2010","December 22, 2010","January 28, 2016",NDA 208-261,188
Determination of Regulatory Review Period for Purposes of Patent Extension; GALLIPRANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GALLIPRANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 4214,2018-01640,https://www.federalregister.gov/documents/2018/01/30/2018-01640/determination-of-regulatory-review-period-for-purposes-of-patent-extension-galliprant,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01640.pdf,2018-01-30, GALLIPRANT,,Jonathan,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LONSURF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LONSURF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4223,2018-01641,https://www.federalregister.gov/documents/2018/01/30/2018-01641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lonsurf,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01641.pdf,2018-01-30, LONSURF,,Jonathan,LONSURF,6479500 and 7799783,"Taiho Pharmaceutical Co., Ltd.",6083.0,5805,278.0,"January 28, 1999","December 19, 2014","September 22, 2015",NDA 207981,1013
Determination of Regulatory Review Period for Purposes of Patent Extension; VIEKIRA PAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIEKIRA PAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4218,2018-01651,https://www.federalregister.gov/documents/2018/01/30/2018-01651/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viekira-pak,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01651.pdf,2018-01-30, VIEKIRA PAK,,Jonathan,VIEKIRA PAK,8501238,AbbVie Inc.,2391.0,2148,243.0,"June 4, 2008","April 21, 2014","December 19, 2014",NDA 206619,93
Determination of Regulatory Review Period for Purposes of Patent Extension; Cardiomems HF Monitoring System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CARDIOMEMS HF MONITORING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4211,2018-01644,https://www.federalregister.gov/documents/2018/01/30/2018-01644/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cardiomems-hf-monitoring,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01644.pdf,2018-01-30, Cardiomems HF Monitoring System,,Jonathan,CARDIOMEMS HF MONITORING SYSTEM,7839153,"CardioMEMS, Inc.",2786.0,1525,1261.0,"October 13, 2006","October 13, 2006","May 28, 2014",PMA P100045,1026
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN 3 TRANSCATHETER HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPIEN 3 TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4224,2018-01655,https://www.federalregister.gov/documents/2018/01/30/2018-01655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-3-transcatheter,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01655.pdf,2018-01-30, SAPIEN 3 TRANSCATHETER HEART VALVE,,Jonathan,SAPIEN 3 TRANSCATHETER HEART VALVE,7585321 and 8591575,"Edwards Lifesciences PVT, Inc.",30.0,1736,1558.0,"September 17, 2010","September 17, 2010","June 17, 2015",PMA P140031,250
Determination of Regulatory Review Period for Purposes of Patent Extension; CRESEMBA-New Drug Aapplication 207500,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRESEMBA as approved under new drug application (NDA) 207500 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product as approved under NDA 207500.",83 FR 4221,2018-01645,https://www.federalregister.gov/documents/2018/01/30/2018-01645/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cresemba-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01645.pdf,2018-01-30, CRESEMBA-New Drug Aapplication 207500,,Jonathan,CRESEMBA as approved under NDA 207500,6812238 and 7459561,Basilea Pharmaceutica International Ltd.,3528.0,3286,242.0,"July 10, 2005","April 2, 2018","March 6, 2015",NDA 207500,1264
Determination of Regulatory Review Period for Purposes of Patent Extension; LENVIMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LENVIMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4489,2018-01920,https://www.federalregister.gov/documents/2018/01/31/2018-01920/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lenvima,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01920.pdf,2018-01-31, LENVIMA,,Jonathan,LENVIMA,7253286,"EISAI R&D Management Co., Ltd.",3580.0,3396,184.0,"April 28, 2005","August 14, 2014","February 13, 2015",NDA 206947,1465
Determination of Regulatory Review Period for Purposes of Patent Extension; DUAVEE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DUAVEE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4487,2018-01894,https://www.federalregister.gov/documents/2018/01/31/2018-01894/determination-of-regulatory-review-period-for-purposes-of-patent-extension-duavee,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01894.pdf,2018-01-31, DUAVEE,,Jonathan,DUAVEE,5998402 and 6479535,Wyeth LLC,5683.0,5317,366.0,"March 15, 1998","October 3, 2012","October 3, 2013",NDA 022247,5
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,2018-01-31, KEYTRUDA,,Jonathan,KEYTRUDA,8354509,Merck Sharp & Dohme B.V.,1338.0,1148,190.0,"January 7, 2011","January 7, 2011","September 4, 2014",BLA 125514,83
Determination of Regulatory Review Period for Purposes of Patent Extension; MOBI-C CERVICAL DISC PROSTHESIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOBI-C CERVICAL DISC PROSTHESIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4490,2018-01889,https://www.federalregister.gov/documents/2018/01/31/2018-01889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mobi-c-cervical-disc,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01889.pdf,2018-01-31, MOBI-C CERVICAL DISC PROSTHESIS,,Jonathan,MOBI-C CERVICAL DISC PROSTHESIS,8627999,Beaurain et al.,2758.0,1821,937.0,"January 20, 2006","January 20, 2006","August 7, 2013",PMA P110002,323
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN XT TRANSCATHETER HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPIEN XT TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4486,2018-01891,https://www.federalregister.gov/documents/2018/01/31/2018-01891/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-xt-transcatheter,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01891.pdf,2018-01-31, SAPIEN XT TRANSCATHETER HEART VALVE,,Jonathan,SAPIEN XT TRANSCATHETER HEART VALVE,7510575 and 7585321,"Edwards Lifesciences PVT, Inc.",30.0,1370,959.0,"the 23, 26","September 17, 2010","June 16, 2014",PMA P130009,889
Determination of Regulatory Review Period for Purposes of Patent Extension; CRESEMBA-New Drug Application 207501,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRESEMBA as approved under new drug application (NDA) 207501 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product as approved under NDA 207501.",83 FR 4494,2018-01892,https://www.federalregister.gov/documents/2018/01/31/2018-01892/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cresemba-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01892.pdf,2018-01-31, CRESEMBA-New Drug Application 207501,,Jonathan,CRESEMBA as approved under NDA 207501,6812238 and 7459561,Basilea Pharmaceutica International Ltd.,3528.0,3286,242.0,"April 2, 2018","April 2, 2018","March 6, 2015",NDA 207501,1264
Determination of Regulatory Review Period for Purposes of Patent Extension; CORLANOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CORLANOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4661,2018-01979,https://www.federalregister.gov/documents/2018/02/01/2018-01979/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corlanor,https://www.govinfo.gov/content/pkg/FR-2018-02-01/pdf/2018-01979.pdf,2018-02-01, CORLANOR,,Jonathan,CORLANOR,7879842 and 7867996,Les Laboratoires Servier,293.0,0,293.0,"June 27, 2014","June 27, 2014","April 15, 2015",NDA 206143,292
Determination of Regulatory Review Period for Purposes of Patent Extension; VIBERZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIBERZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5105,2018-02187,https://www.federalregister.gov/documents/2018/02/05/2018-02187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viberzi,https://www.govinfo.gov/content/pkg/FR-2018-02-05/pdf/2018-02187.pdf,2018-02-05, VIBERZI,,Nicolas,VIBERZI,7741356; 8344011; and 8609709,"Janssen Pharmaceutica, N.V.",2716.0,2381,335.0,"December 21, 2007","June 27, 2014","May 27, 2015",NDA 206940,431
Determination of Regulatory Review Period for Purposes of Patent Extension; FARXIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FARXIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5436,2018-02418,https://www.federalregister.gov/documents/2018/02/07/2018-02418/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farxiga,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02418.pdf,2018-02-07, FARXIGA,,Nicolas,FARXIGA,6414126 and 6515117,AstraZeneca AB,3673.0,2565,1108.0,"December 21, 2003","December 21, 2003","January 8, 2014",NDA 202293,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2018-02-07, BLINCYTO,,Nicolas,BLINCYTO,7112324 and 8007796,Amgen Research (Munich) GMBH,2850.0,2774,76.0,"February 15, 2007","February 15, 2007","December 3, 2014",BLA 125557,432
Determination of Regulatory Review Period for Purposes of Patent Extension; GENVOYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GENVOYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5431,2018-02403,https://www.federalregister.gov/documents/2018/02/07/2018-02403/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genvoya,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02403.pdf,2018-02-07, GENVOYA,,Nicolas,GENVOYA,7390791 and 7803788,"Gilead Sciences, Inc.",5031.0,4665,366.0,"January 28, 2002","January 28, 2002","November 5, 2015",NDA 207561,1116
Determination of Regulatory Review Period for Purposes of Patent Extension; SEDASYS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for SEDASYS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 5429,2018-02432,https://www.federalregister.gov/documents/2018/02/07/2018-02432/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sedasys-system,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02432.pdf,2018-02-07, SEDASYS SYSTEM,,Nicolas,SEDASYS SYSTEM,6807965,"Scott Laboratories, Inc.",2816.0,950,1866.0,"August 19, 2005","August 19, 2005","May 3, 2013",PMA P080009,2283
Determination of Regulatory Review Period for Purposes of Patent Extension; JUBLIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JUBLIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5633,2018-02522,https://www.federalregister.gov/documents/2018/02/08/2018-02522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jublia,https://www.govinfo.gov/content/pkg/FR-2018-02-08/pdf/2018-02522.pdf,2018-02-08, JUBLIA,,Nicolas,JUBLIA,7214506,"Kaken Pharmaceutical Co., Ltd.",2521.0,1840,681.0,"July 14, 2007","July 14, 2007","June 6, 2014",NDA 203567,1601
Determination of Regulatory Review Period for Purposes of Patent Extension; STRENSIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STRENSIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5776,2018-02588,https://www.federalregister.gov/documents/2018/02/09/2018-02588/determination-of-regulatory-review-period-for-purposes-of-patent-extension-strensiq,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02588.pdf,2018-02-09, STRENSIQ,,Nicolas,STRENSIQ,7763712,"Alexion Pharmaceuticals, Inc.",2670.0,2365,305.0,"July 3, 2008","July 3, 2008","October 23, 2015",BLA 125513,1109
Determination of Regulatory Review Period for Purposes of Patent Extension; ODOMZO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ODOMZO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5780,2018-02658,https://www.federalregister.gov/documents/2018/02/09/2018-02658/determination-of-regulatory-review-period-for-purposes-of-patent-extension-odomzo,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02658.pdf,2018-02-09, ODOMZO,,Nicolas,ODOMZO,8178563,Novartis AG,2414.0,2112,302.0,"December 15, 2008","September 26, 2014","July 24, 2015",NDA 205266,169
Determination of Regulatory Review Period for Purposes of Patent Extension; IDELVION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IDELVION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5787,2018-02666,https://www.federalregister.gov/documents/2018/02/09/2018-02666/determination-of-regulatory-review-period-for-purposes-of-patent-extension-idelvion,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02666.pdf,2018-02-09, IDELVION,,Nicolas,IDELVION,7939632,CSL Behring GmbH,1479.0,1023,456.0,"February 17, 2012","February 17, 2012","March 4, 2016",BLA 125582,531
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2018-02-09, LYNPARZA,,Nicolas,LYNPARZA,7449464,Kudos Pharmaceuticals Limited,3012.0,2692,320.0,"September 22, 2006","February 3, 2014","December 19, 2014",NDA 206162,1275
Determination of Regulatory Review Period for Purposes of Patent Extension; ONIVYDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ONIVYDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5790,2018-02590,https://www.federalregister.gov/documents/2018/02/09/2018-02590/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onivyde,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02590.pdf,2018-02-09, ONIVYDE,,Nicolas,ONIVYDE,8147867 and 8329213,"Merrimack Pharmaceuticals, Inc.",2536.0,2354,182.0,"November 13, 2008","April 24, 2015","October 22, 2015",NDA 207793,1215
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTRESTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENTRESTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5781,2018-02592,https://www.federalregister.gov/documents/2018/02/09/2018-02592/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entresto,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02592.pdf,2018-02-09, ENTRESTO,,Nicolas,ENTRESTO,7468390; 8101659; 8404744; 8796331; and 8877938,Novartis Pharmaceuticals Corporation,3148.0,2945,203.0,"November 25, 2006","December 17, 2014","July 7, 2015",NDA 207620,225
Determination of Regulatory Review Period for Purposes of Patent Extension; KAMRA INLAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KAMRA INLAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 5778,2018-02582,https://www.federalregister.gov/documents/2018/02/09/2018-02582/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kamra-inlay,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02582.pdf,2018-02-09, KAMRA INLAY,,Nicolas,KAMRA INLAY,8460374,"AcuFocus, Inc.",2347.0,1541,806.0,"July 12, 2016","November 14, 2008","April 17, 2015",PMA P120023,676
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2018-02-12, IMBRUVICA,,Nicolas,IMBRUVICA,8008309,"Pharmacyclics, Inc.",1865.0,1726,139.0,"October 7, 2008","October 7, 2008","November 13, 2013",NDA 205552,320
Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DALVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6031,2018-02768,https://www.federalregister.gov/documents/2018/02/12/2018-02768/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dalvance,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02768.pdf,2018-02-12, DALVANCE,,Nicolas,DALVANCE,6900175,"Vicuron Pharmaceuticals, Inc.",5033.0,1592,3441.0,"August 13, 2000","August 13, 2000","May 23, 2014",NDA 21883,1612
Determination of Regulatory Review Period for Purposes of Patent Extension; BELSOMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BELSOMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6034,2018-02763,https://www.federalregister.gov/documents/2018/02/12/2018-02763/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belsomra,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02763.pdf,2018-02-12, BELSOMRA,,Nicolas,BELSOMRA,7951797,Merck Sharp & Dohme Corp.,2291.0,1577,714.0,"May 7, 2008","May 7, 2008","August 13, 2014",NDA 204569,0
Determination of Regulatory Review Period for Purposes of Patent Extension; AKYNZEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AKYNZEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6038,2018-02756,https://www.federalregister.gov/documents/2018/02/12/2018-02756/determination-of-regulatory-review-period-for-purposes-of-patent-extension-akynzeo,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02756.pdf,2018-02-12, AKYNZEO,,Nicolas,AKYNZEO,6297375,Hoffmann-La Roche Inc.,1858.0,1479,379.0,"September 10, 2009","September 27, 2013","October 10, 2014",NDA 205718,1118
Determination of Regulatory Review Period for Purposes of Patent Extension; GILOTRIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GILOTRIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6026,2018-02767,https://www.federalregister.gov/documents/2018/02/12/2018-02767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilotrif,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02767.pdf,2018-02-12, GILOTRIF,,Nicolas,GILOTRIF,RE43431,"Boehringer Ingelheim Pharma Gmbh & Co., KG",3453.0,3213,240.0,"January 30, 2004","November 15, 2012","July 12, 2013",NDA 201292,1057
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRAVECTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 6033,2018-02761,https://www.federalregister.gov/documents/2018/02/12/2018-02761/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02761.pdf,2018-02-12, BRAVECTO,,Nicolas,BRAVECTO,7662972,"Nissan Chemical Industries, Ltd.",1017.0,979,38.0,"August 4, 2011","April 8, 2014","May 15, 2014",NADA 141-426,792
Determination of Regulatory Review Period for Purposes of Patent Extension; VASCEPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VASCEPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6192,2018-02851,https://www.federalregister.gov/documents/2018/02/13/2018-02851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vascepa,https://www.govinfo.gov/content/pkg/FR-2018-02-13/pdf/2018-02851.pdf,2018-02-13, VASCEPA,,Nicolas,VASCEPA,8188146,Amarin Pharmaceuticals Ireland Limited,1133.0,828,305.0,"June 21, 2009","June 21, 2009","July 26, 2012",NDA 202057,58
Determination of Regulatory Review Period for Purposes of Patent Extension; FARYDAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FARYDAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6198,2018-02868,https://www.federalregister.gov/documents/2018/02/13/2018-02868/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farydak,https://www.govinfo.gov/content/pkg/FR-2018-02-13/pdf/2018-02868.pdf,2018-02-13, FARYDAK,,Nicolas,FARYDAK,6552065; 6833384; and 7067551,Novartis AG,4334.0,3997,337.0,"April 15, 2003","April 15, 2003","February 23, 2015",NDA 205353,1751
Determination of Regulatory Review Period for Purposes of Patent Extension; BELEODAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BELEODAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6576,2018-03041,https://www.federalregister.gov/documents/2018/02/14/2018-03041/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beleodaq,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03041.pdf,2018-02-14, BELEODAQ,,Nicolas,BELEODAQ,6888027,"Spectrum Pharmaceuticals, Inc.",3488.0,3281,207.0,"December 16, 2004","December 9, 2013","July 3, 2014",NDA 206256,1779
Determination of Regulatory Review Period for Purposes of Patent Extension; IBRANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IBRANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6581,2018-03029,https://www.federalregister.gov/documents/2018/02/14/2018-03029/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibrance,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03029.pdf,2018-02-14, IBRANCE,,Nicolas,IBRANCE,6936612 and 7208489,"Warner-Lambert Company, LLC",3954.0,3779,175.0,"April 9, 2004","August 13, 2014","February 3, 2015",NDA 207103,1509
Determination of Regulatory Review Period for Purposes of Patent Extension; JARDIANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for JARDIANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6583,2018-02992,https://www.federalregister.gov/documents/2018/02/14/2018-02992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jardiance,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02992.pdf,2018-02-14, JARDIANCE,,Nicolas,JARDIANCE,7579449,Boehringer Ingelheim International GmbH,2275.0,1760,515.0,"May 11, 2008","May 11, 2008","August 1, 2014",NDA 204629,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; KERYDIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KERYDIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6579,2018-02993,https://www.federalregister.gov/documents/2018/02/14/2018-02993/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kerydin,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02993.pdf,2018-02-14, KERYDIN,,Nicolas,KERYDIN,7582621,"Anacor Pharmaceuticals, Inc.",3112.0,2768,344.0,"December 31, 2005","July 29, 2013","July 7, 2014",NDA 204427,408
Determination of Regulatory Review Period for Purposes of Patent Extension; OSURNIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OSURNIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 6577,2018-02991,https://www.federalregister.gov/documents/2018/02/14/2018-02991/determination-of-regulatory-review-period-for-purposes-of-patent-extension-osurnia,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02991.pdf,2018-02-14, OSURNIA,,Nicolas,OSURNIA,7854943,IDEXX,4034.0,3980,54.0,"October 21, 2003","November 4, 2014","November 4, 2014",NADA 141-,235
Determination of Regulatory Review Period for Purposes of Patent Extension; JUVEDERM VOLUMA XC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JUVEDERM VOLUMA XC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 6574,2018-03017,https://www.federalregister.gov/documents/2018/02/14/2018-03017/determination-of-regulatory-review-period-for-purposes-of-patent-extension-juvederm-voluma-xc,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03017.pdf,2018-02-14, JUVEDERM VOLUMA XC,,Nicolas,JUVEDERM VOLUMA XC,7741476,Pierre Lebreton,1896.0,1110,786.0,"October 30, 2015","October 30, 2015","October 22, 2013",PMA P110033,567
Determination of Regulatory Review Period for Purposes of Patent Extension; SYLVANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYLVANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 6866,2018-03126,https://www.federalregister.gov/documents/2018/02/15/2018-03126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sylvant,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03126.pdf,2018-02-15, SYLVANT,,Nicolas,SYLVANT,7612182 and 7291721,"Janssen Biotech, Inc.",3747.0,3510,237.0,"January 21, 2004","January 21, 2004","April 23, 2014",BLA 125496,1300
Determination of Regulatory Review Period for Purposes of Patent Extension; AVEED,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVEED and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6858,2018-03136,https://www.federalregister.gov/documents/2018/02/15/2018-03136/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aveed,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03136.pdf,2018-02-15, AVEED,,Nicolas,AVEED,8338395,Bayer Intellectual Property GmbH,2923.0,541,2382.0,"March 6, 2006","March 6, 2006","March 5, 2014",NDA 022219,435
Determination of Regulatory Review Period for Purposes of Patent Extension; FETZIMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FETZIMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6859,2018-03129,https://www.federalregister.gov/documents/2018/02/15/2018-03129/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fetzima,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03129.pdf,2018-02-15, FETZIMA,,Nicolas,FETZIMA,RE43879,Pierre Fabre Medicament,1602.0,1298,304.0,"March 8, 2009","September 25, 2012","July 25, 2013",NDA 204168,954
Determination of Regulatory Review Period for Purposes of Patent Extension; ZONTIVITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZONTIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6864,2018-03170,https://www.federalregister.gov/documents/2018/02/15/2018-03170/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zontivity,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03170.pdf,2018-02-15, ZONTIVITY,,Nicolas,ZONTIVITY,7304078,Merck Sharp & Dohme Corp.,3401.0,3037,364.0,"January 16, 2005","May 10, 2013","May 8, 2014",NDA 204886,1357
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIDION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIDION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6856,2018-03137,https://www.federalregister.gov/documents/2018/02/15/2018-03137/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bridion,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03137.pdf,2018-02-15, BRIDION,,Nicolas,BRIDION,RE44733,"Merck Sharp & Dohme, B.V.",4265.0,1297,2968.0,"April 13, 2004","April 13, 2004","December 15, 2015",NDA 022225,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ORKAMBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORKAMBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6868,2018-03127,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03127.pdf,2018-02-15, ORKAMBI,,Nicolas,ORKAMBI,8653103; 8741933; and 8846718,Vertex Pharmaceuticals Inc.,2785.0,2545,240.0,"November 18, 2007","November 5, 2014","July 2, 2015",NDA 206038,317
Determination of Regulatory Review Period for Purposes of Patent Extension; ADDYI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADDYI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6855,2018-03130,https://www.federalregister.gov/documents/2018/02/15/2018-03130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-addyi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03130.pdf,2018-02-15, ADDYI,,Nicolas,ADDYI,7151103 and 7420057,"Sprout Pharmaceuticals, Inc.",6852.0,4730,2122.0,"November 15, 1996","October 27, 2009","August 18, 2015",NDA 22-526,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYDELIG-New Drug Application 205858,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYDELIG based on new drug application (NDA) 205858 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product and that NDA.",83 FR 6861,2018-03134,https://www.federalregister.gov/documents/2018/02/15/2018-03134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03134.pdf,2018-02-15, ZYDELIG-New Drug Application 205858,,Nicolas,ZYDELIG,RE44599 and RE44638,ICOS Corporation,2247.0,1931,316.0,"May 30, 2008","April 16, 2018","July 23, 2014",NDA 205858,751
Determination of Regulatory Review Period for Purposes of Patent Extension; HYMOVIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYMOVIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 7059,2018-03229,https://www.federalregister.gov/documents/2018/02/16/2018-03229/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hymovis,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03229.pdf,2018-02-16, HYMOVIS,,Nicolas,HYMOVIS,7863256,Fidia Farmaceutici S.p.A.,1845.0,1665,180.0,"August 11, 2010","August 11, 2010","August 28, 2015",PMA P150010,938
Determination of Regulatory Review Period for Purposes of Patent Extension; COTELLIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for COTELLIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7054,2018-03218,https://www.federalregister.gov/documents/2018/02/16/2018-03218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cotellic,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03218.pdf,2018-02-16, COTELLIC,,Nicolas,COTELLIC,7803839 and 8362002,"Exelixis, Inc.",3219.0,2884,335.0,"January 19, 2007","December 11, 2014","November 10, 2015",NDA 206192,676
Determination of Regulatory Review Period for Purposes of Patent Extension; MOVANTIK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOVANTIK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7042,2018-03245,https://www.federalregister.gov/documents/2018/02/16/2018-03245/determination-of-regulatory-review-period-for-purposes-of-patent-extension-movantik,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03245.pdf,2018-02-16, MOVANTIK,,Nicolas,MOVANTIK,7662365 and 7786133,Nektar Therapeutics,2493.0,2127,366.0,"November 21, 2007","November 21, 2007","September 16, 2014",NDA 204760,272
Determination of Regulatory Review Period for Purposes of Patent Extension; PORTRAZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PORTRAZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7191,2018-03345,https://www.federalregister.gov/documents/2018/02/20/2018-03345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-portrazza,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03345.pdf,2018-02-20, PORTRAZZA,,Nicolas,PORTRAZZA,7598350,Eli Lilly,2533.0,2175,358.0,"December 19, 2008","December 19, 2008","November 24, 2015",BLA 125547,1321
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2018-02-20, DARZALEX,,Nicolas,DARZALEX,7829673,Genmab A/S,1939.0,1808,131.0,"July 28, 2010","July 28, 2010","November 16, 2015",BLA 761,1000
Determination of Regulatory Review Period for Purposes of Patent Extension; MAESTRO RECHARGEABLE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAESTRO RECHARGEABLE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 7196,2018-03343,https://www.federalregister.gov/documents/2018/02/20/2018-03343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maestro-rechargeable,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03343.pdf,2018-02-20, MAESTRO RECHARGEABLE SYSTEM,,Nicolas,MAESTRO RECHARGEABLE SYSTEM,7672727,EnteroMedics Inc.,2866.0,2296,570.0,"March 13, 2007","March 13, 2007","January 14, 2015",PMA P130019,385
Determination of Regulatory Review Period for Purposes of Patent Extension; LYMPHOSEEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYMPHOSEEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7734,2018-03610,https://www.federalregister.gov/documents/2018/02/22/2018-03610/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lymphoseek,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03610.pdf,2018-02-22, LYMPHOSEEK,,Nicolas,LYMPHOSEEK,6409990,"Navidea Biopharmaceuticals, Inc.",4398.0,3816,582.0,"February 28, 2001","February 28, 2001","March 13, 2013",NDA 202207,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; OFEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OFEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7747,2018-03606,https://www.federalregister.gov/documents/2018/02/22/2018-03606/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ofev,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03606.pdf,2018-02-22, OFEV,,Nicolas,OFEV,6762180,Boehringer Ingelheim Pharma Gmbh & Co. KG,3480.0,3313,167.0,"April 7, 2005","April 7, 2005","October 15, 2014",NDA 205832,1822
Determination of Regulatory Review Period for Purposes of Patent Extension; ESBRIET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ESBRIET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7732,2018-03612,https://www.federalregister.gov/documents/2018/02/22/2018-03612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-esbriet,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03612.pdf,2018-02-22, ESBRIET,,Nicolas,ESBRIET,7767225; 7767700; 7988994; 8383150; and 8420674,InterMune Inc.,14993.0,13186,1807.0,"September 29, 1973","September 29, 1973","October 15, 2014",NDA 22-535,754
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYDELIG-New Drug Application 206545,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYDELIG based on new drug application (NDA) 206545 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 8088,2018-03701,https://www.federalregister.gov/documents/2018/02/23/2018-03701/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-02-23/pdf/2018-03701.pdf,2018-02-23, ZYDELIG-New Drug Application 206545,,Nicolas,ZYDELIG,RE44599 and RE44638,ICOS Corporation,2247.0,2017,230.0,"May 30, 2008","April 24, 2018","July 23, 2014",NDA 206545,708
Determination of Regulatory Review Period for Purposes of Patent Extension; TREMFYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TREMFYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52471,2018-22571,https://www.federalregister.gov/documents/2018/10/17/2018-22571/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tremfya,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22571.pdf,2018-10-17, TREMFYA,,Nicolas,TREMFYA,and 7993645,"Janssen Biotech, Inc.",2968.0,2728,240.0,"May 30, 2009","May 30, 2009","July 13, 2017",BLA 761061,1203
Determination of Regulatory Review Period for Purposes of Patent Extension; DUPIXENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DUPIXENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52481,2018-22566,https://www.federalregister.gov/documents/2018/10/17/2018-22566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dupixent,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22566.pdf,2018-10-17, DUPIXENT,,Nicolas,DUPIXENT,7608693,"Regeneron Pharmaceuticals, Inc.",2728.0,2485,243.0,"October 10, 2009","October 10, 2009","March 28, 2017",BLA 761055,1273
Determination of Regulatory Review Period for Purposes of Patent Extension; BRINEURA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINEURA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52483,2018-22559,https://www.federalregister.gov/documents/2018/10/17/2018-22559/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brineura,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22559.pdf,2018-10-17, BRINEURA,,Nicolas,BRINEURA,8029781,"Rutgers, the State University of New Jersey",995.0,659,336.0,"August 8, 2014","August 8, 2014","April 27, 2017",BLA 761052,666
Determination of Regulatory Review Period for Purposes of Patent Extension; OCREVUS,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA or the Agency) has,83 FR 52837,2018-22699,https://www.federalregister.gov/documents/2018/10/18/2018-22699/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocrevus,https://www.govinfo.gov/content/pkg/FR-2018-10-18/pdf/2018-22699.pdf,2018-10-18, OCREVUS,,Nicolas,OCREVUS,7799900 and 8562992,"Genentech, Inc.",4844.0,4509,335.0,"December 25, 2003","December 25, 2003","March 28, 2017",BLA 761053,795
Determination of Regulatory Review Period for Purposes of Patent Extension; AFSTYLA,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA or the Agency) has,83 FR 52839,2018-22696,https://www.federalregister.gov/documents/2018/10/18/2018-22696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afstyla,https://www.govinfo.gov/content/pkg/FR-2018-10-18/pdf/2018-22696.pdf,2018-10-18, AFSTYLA,,Nicolas,AFSTYLA,7041635,"SK Chemicals Co, LTD.",1734.0,1371,363.0,"August 28, 2011","August 28, 2011","May 25, 2016",BLA 125591,1047
Determination of Regulatory Review Period for Purposes of Patent Extension; IMFINZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMFINZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53067,2018-22806,https://www.federalregister.gov/documents/2018/10/19/2018-22806/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imfinzi,https://www.govinfo.gov/content/pkg/FR-2018-10-19/pdf/2018-22806.pdf,2018-10-19, IMFINZI,,Nicolas,IMFINZI,8779108 and 9493565,MedImmune Limited,1755.0,1554,201.0,"July 13, 2012","July 13, 2012","May 1, 2017",BLA 761069,159
Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TYMLOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 53260,2018-22956,https://www.federalregister.gov/documents/2018/10/22/2018-22956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tymlos,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22956.pdf,2018-10-22, TYMLOS,,Nicolas,TYMLOS,7803770; 8148333; and 8748382,"Radius Health, Inc.",4130.0,3735,395.0,"January 8, 2006","January 8, 2006","April 28, 2017",NDA 208743,1128
Determination of Regulatory Review Period for Purposes of Patent Extension; BESPONSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BESPONSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53273,2018-22958,https://www.federalregister.gov/documents/2018/10/22/2018-22958/determination-of-regulatory-review-period-for-purposes-of-patent-extension-besponsa,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22958.pdf,2018-10-22, BESPONSA,,Nicolas,BESPONSA,8153768; 8835611; and 8747857,Wyeth Holdings LLC,5298.0,5057,241.0,"February 16, 2003","February 16, 2003","August 17, 2017",BLA 761040,1099
Determination of Regulatory Review Period for Purposes of Patent Extension; TECENTRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECENTRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53259,2018-22957,https://www.federalregister.gov/documents/2018/10/22/2018-22957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecentriq,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22957.pdf,2018-10-22, TECENTRIQ,,Nicolas,TECENTRIQ,8217149,"Genentech, Inc.",1836.0,1708,128.0,"May 11, 2011","May 11, 2011","May 18, 2016",BLA 761034,769
Determination of Regulatory Review Period for Purposes of Patent Extension; NUPLAZID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NUPLAZID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 53481,2018-23057,https://www.federalregister.gov/documents/2018/10/23/2018-23057/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuplazid,https://www.govinfo.gov/content/pkg/FR-2018-10-23/pdf/2018-23057.pdf,2018-10-23, NUPLAZID,,Nicolas,NUPLAZID,7601740; 7659285; and 7732615,ACADIA Pharmaceuticals Inc.,4557.0,4315,242.0,"November 9, 2003","November 9, 2003","April 29, 2016",NDA 207-318,1316
Determination of Regulatory Review Period for Purposes of Patent Extension; SILIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SILIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53476,2018-23058,https://www.federalregister.gov/documents/2018/10/23/2018-23058/determination-of-regulatory-review-period-for-purposes-of-patent-extension-siliq,https://www.govinfo.gov/content/pkg/FR-2018-10-23/pdf/2018-23058.pdf,2018-10-23, SILIQ,,Nicolas,SILIQ,7767206; 7939070; 8435518; and 8545842,"Kirin-Amgen, Inc.",3101.0,2643,458.0,"August 22, 2008","August 22, 2008","February 15, 2017",BLA 761032,847
Determination of Regulatory Review Period for Purposes of Patent Extension; LARTRUVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LARTRUVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53640,2018-23219,https://www.federalregister.gov/documents/2018/10/24/2018-23219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lartruvo,https://www.govinfo.gov/content/pkg/FR-2018-10-24/pdf/2018-23219.pdf,2018-10-24, LARTRUVO,,Nicolas,LARTRUVO,8128929,Imclone LLC,3766.0,3527,239.0,"June 30, 2006","June 30, 2006","October 19, 2016",BLA 761038,1003
Determination of Regulatory Review Period for Purposes of Patent Extension; TALTZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALTZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 54108,2018-23438,https://www.federalregister.gov/documents/2018/10/26/2018-23438/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taltz,https://www.govinfo.gov/content/pkg/FR-2018-10-26/pdf/2018-23438.pdf,2018-10-26, TALTZ,,Nicolas,TALTZ,7838638 and 8110191,Eli Lilly,3036.0,2670,366.0,"December 1, 2007","December 1, 2007","March 22, 2016",BLA 125521,935
Determination of Regulatory Review Period for Purposes of Patent Extension; REBINYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBINYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 54112,2018-23437,https://www.federalregister.gov/documents/2018/10/26/2018-23437/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rebinyn,https://www.govinfo.gov/content/pkg/FR-2018-10-26/pdf/2018-23437.pdf,2018-10-26, REBINYN,,Nicolas,REBINYN,7138371 and 7179617,Novo Nordisk A/S,2793.0,2412,381.0,"October 9, 2009","October 9, 2009","May 31, 2017",BLA 125611,1660
Determination of Regulatory Review Period for Purposes of Patent Extension; RAINDROP NEAR VISION INLAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAINDROP NEAR VISION INLAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 54360,2018-23527,https://www.federalregister.gov/documents/2018/10/29/2018-23527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raindrop-near-vision,https://www.govinfo.gov/content/pkg/FR-2018-10-29/pdf/2018-23527.pdf,2018-10-29, RAINDROP NEAR VISION INLAY,,Nicolas,RAINDROP NEAR VISION INLAY,8057541,"ReVision Optics, Inc.",2354.0,2074,280.0,"September 20, 2017","January 20, 2010","June 29, 2016",PMA P150034,828
Determination of Regulatory Review Period for Purposes of Patent Extension; KEVZARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEVZARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 61643,2018-26033,https://www.federalregister.gov/documents/2018/11/30/2018-26033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kevzara,https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26033.pdf,2018-11-30, KEVZARA,,Nicolas,KEVZARA,7582298 and 8568721,"Regeneron Pharmaceuticals, Inc.",3478.0,2907,571.0,"November 15, 2007","November 15, 2007","May 22, 2017",BLA 761037,937
Determination of Regulatory Review Period for Purposes of Patent Extension; PROVAYBLUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PROVAYBLUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 61645,2018-26035,https://www.federalregister.gov/documents/2018/11/30/2018-26035/determination-of-regulatory-review-period-for-purposes-of-patent-extension-provayblue,https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26035.pdf,2018-11-30, PROVAYBLUE,,Nicolas,PROVAYBLUE,8765942,Provepharm S.A.S.,415.0,232,183.0,"February 20, 2015","February 20, 2015","April 8, 2016",NDA 204630,298
Determination of Regulatory Review Period for Purposes of Patent Extension; TRULANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRULANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 62590,2018-26289,https://www.federalregister.gov/documents/2018/12/04/2018-26289/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulance,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26289.pdf,2018-12-04, TRULANCE,,Nicolas,TRULANCE,7041786,"Synergy Pharmaceuticals, Inc.",3186.0,2829,357.0,"May 2, 2008","May 2, 2008","January 19, 2017",NDA 208745,1771
Determination of Regulatory Review Period for Purposes of Patent Extension; OCALIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OCALIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 62591,2018-26288,https://www.federalregister.gov/documents/2018/12/04/2018-26288/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocaliva,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26288.pdf,2018-12-04, OCALIVA,,Nicolas,OCALIVA,7138390,"Intercept Pharmaceuticals, Inc.",3742.0,3408,334.0,"March 1, 2006","March 1, 2006","May 27, 2016",NDA 207999,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ASPIRE ASSIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ASPIRE ASSIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 62580,2018-26290,https://www.federalregister.gov/documents/2018/12/04/2018-26290/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aspire-assist,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26290.pdf,2018-12-04, ASPIRE ASSIST,,Nicolas,ASPIRE ASSIST,9039677,"Aspire Bariatrics, Inc.",2785.0,2444,341.0,"October 31, 2008","October 31, 2008","June 14, 2016",PMA P150024,385
Determination of Regulatory Review Period for Purposes of Patent Extension; EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM (EXABLATE) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 62593,2018-26282,https://www.federalregister.gov/documents/2018/12/04/2018-26282/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exablate-neuro-model-4000,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26282.pdf,2018-12-04, EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM,,Nicolas,EXABLATE,6612988,Brigham,2050.0,1785,265.0,"February 4, 2019","December 2, 2010","July 11, 2016",PMA P150038,1158
Determination of Regulatory Review Period for Purposes of Patent Extension; ABSORB GT1 BIORESORBABLE SCAFFOLD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ABSORB GT1 Bioresorbable Scaffold and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 65680,2018-27678,https://www.federalregister.gov/documents/2018/12/21/2018-27678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-absorb-gt1-bioresorbable,https://www.govinfo.gov/content/pkg/FR-2018-12-21/pdf/2018-27678.pdf,2018-12-21, ABSORB GT1 BIORESORBABLE SCAFFOLD,,Nicolas,ABSORB GT1 BIORESORBABLE SCAFFOLD,7971333 and 8323329,Abbott Cardiovascular Systems Inc.,1303.0,932,371.0,"December 12, 2012","December 12, 2012","July 5, 2016",PMA P150023,841
Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for ADLYXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 66279,2018-27805,https://www.federalregister.gov/documents/2018/12/26/2018-27805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adlyxin,https://www.govinfo.gov/content/pkg/FR-2018-12-26/pdf/2018-27805.pdf,2018-12-26, ADLYXIN,,Nicolas,ADLYXIN,RE45313,ZP Holding SPV K/S,5500.0,5133,367.0,"July 8, 2001","July 8, 2001","July 27, 2016",NDA 208471,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PARSABIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67293,2018-28221,https://www.federalregister.gov/documents/2018/12/28/2018-28221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-parsabiv,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28221.pdf,2018-12-28, PARSABIV,,Nicolas,PARSABIV,8377880; 8999932; and 9278995,"KAI Pharmaceuticals, Inc.",2335.0,1801,534.0,"September 19, 2010","September 19, 2010","February 7, 2017",NDA 208325,193
Determination of Regulatory Review Period for Purposes of Patent Extension; XERMELO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XERMELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67296,2018-28218,https://www.federalregister.gov/documents/2018/12/28/2018-28218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xermelo,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28218.pdf,2018-12-28, XERMELO,,Nicolas,XERMELO,7709493,"Lexicon Pharmaceuticals, Inc.",3329.0,2993,336.0,"January 20, 2008","January 20, 2008","February 28, 2017",NDA 208794,1175
Determination of Regulatory Review Period for Purposes of Patent Extension; RUBRACA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUBRACA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67290,2018-28217,https://www.federalregister.gov/documents/2018/12/28/2018-28217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rubraca,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28217.pdf,2018-12-28, RUBRACA,,Nicolas,RUBRACA,6495541,"Agouron Pharmaceuticals, LLC",2644.0,2464,180.0,"September 25, 2009","September 25, 2009","December 19, 2016",NDA 209115,1412
Determination of Regulatory Review Period for Purposes of Patent Extension; RYDAPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYDAPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67295,2018-28216,https://www.federalregister.gov/documents/2018/12/28/2018-28216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rydapt,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28216.pdf,2018-12-28, RYDAPT,,Nicolas,RYDAPT,7973031; 8222244; and 8575146,Novartis AG,6737.0,6494,243.0,"November 19, 1998","November 19, 1998","April 28, 2017",NDA 207997,1183
Determination of Regulatory Review Period for Purposes of Patent Extension; EXONDYS 51,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXONDYS 51 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3186,2019-01851,https://www.federalregister.gov/documents/2019/02/11/2019-01851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exondys-51,https://www.govinfo.gov/content/pkg/FR-2019-02-11/pdf/2019-01851.pdf,2019-02-11, EXONDYS 51,,Nicolas,EXONDYS 51,7807816 and 9018368,the University of Western Australia,2280.0,1828,452.0,"September 18, 2015","June 25, 2010","September 19, 2016",NDA 206488,481
Determination of Regulatory Review Period for Purposes of Patent Extension; EUCRISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EUCRISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",84 FR 3458,2019-01956,https://www.federalregister.gov/documents/2019/02/12/2019-01956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eucrisa,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-01956.pdf,2019-02-12, EUCRISA,,Nicolas,EUCRISA,8039451 and 8168614,"Anacor Pharmaceuticals, Inc.",3121.0,2778,343.0,"May 31, 2008","May 31, 2008","December 14, 2016",NDA 207695,1114
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEJULA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEJULA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3470,2019-02036,https://www.federalregister.gov/documents/2019/02/12/2019-02036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zejula,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02036.pdf,2019-02-12, ZEJULA,,Nicolas,ZEJULA,8071623,MSD Italia S.R.l.,3234.0,3086,148.0,"May 21, 2008","May 21, 2008","March 27, 2017",NDA 208447,370
Determination of Regulatory Review Period for Purposes of Patent Extension; XADAGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XADAGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3456,2019-02044,https://www.federalregister.gov/documents/2019/02/12/2019-02044/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xadago,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02044.pdf,2019-02-12, XADAGO,,Nicolas,XADAGO,8076515 and 8283380,Newron Pharmaceuticals S.p.A.,5019.0,4205,814.0,"June 26, 2003","June 26, 2003","March 21, 2017",NDA 207145,831
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMPROIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMPROIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 15226,2019-07459,https://www.federalregister.gov/documents/2019/04/15/2019-07459/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symproic,https://www.govinfo.gov/content/pkg/FR-2019-04-15/pdf/2019-07459.pdf,2019-04-15, SYMPROIC,,Nicolas,SYMPROIC,RE46365,"Shionogi & Co., Ltd.",2523.0,2157,366.0,"April 28, 2010","April 28, 2010","March 23, 2017",NDA 208854,1140
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,2019-04-29, YESCARTA,,Nicolas,YESCARTA,7741465,Cabaret Biotech Ltd.,3243.0,3041,202.0,"December 3, 2008","December 3, 2008","October 18, 2017",BLA 125643,1498
Determination of Regulatory Review Period for Purposes of Patent Extension; AUSTEDO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AUSTEDO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 20896,2019-09805,https://www.federalregister.gov/documents/2019/05/13/2019-09805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-austedo,https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09805.pdf,2019-05-13, AUSTEDO,,Nicolas,AUSTEDO,8524733,"Auspex Pharmaceuticals, Inc.",1736.0,1060,676.0,"July 3, 2012","July 3, 2012","April 3, 2017",NDA 208082,8
Determination of Regulatory Review Period for Purposes of Patent Extension; GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 20894,2019-09817,https://www.federalregister.gov/documents/2019/05/13/2019-09817/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gore-viabahn-vbx-balloon,https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09817.pdf,2019-05-13, GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,,Nicolas,the GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,6461665,"W.L. Gore & Associates, Inc.",1136.0,931,205.0,"December 20, 2013","December 20, 2013","January 27, 2017",PMA P160021,669
Determination of Regulatory Review Period for Purposes of Patent Extension; EDWARDS INTUITY ELITE AORTIC VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EDWARDS INTUITY ELITE AORTIC VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 24158,2019-10889,https://www.federalregister.gov/documents/2019/05/24/2019-10889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edwards-intuity-elite,https://www.govinfo.gov/content/pkg/FR-2019-05-24/pdf/2019-10889.pdf,2019-05-24, EDWARDS INTUITY ELITE AORTIC VALVE,,Nicolas,EDWARDS INTUITY ELITE AORTIC VALVE,8911493,Edwards Lifesciences Corp.,1508.0,1203,305.0,"June 28, 2012","June 28, 2012","August 12, 2016",PMA P150036,605
Determination of Regulatory Review Period for Purposes of Patent Extension; ALUNBRIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALUNBRIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27137,2019-12320,https://www.federalregister.gov/documents/2019/06/11/2019-12320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alunbrig,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12320.pdf,2019-06-11, ALUNBRIG,,Nicolas,ALUNBRIG,9012462,"ARIAD Pharmaceutials, Inc.",2105.0,1862,243.0,"July 26, 2011","July 26, 2011","April 28, 2017",NDA 208772,81
Determination of Regulatory Review Period for Purposes of Patent Extension; KISQALI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KISQALI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",84 FR 27128,2019-12305,https://www.federalregister.gov/documents/2019/06/11/2019-12305/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kisqali,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12305.pdf,2019-06-11, KISQALI,,Nicolas,KISQALI,8324225; 8415355; 8685980; 8962630; and 9416136,Novartis AG,2393.0,2196,197.0,"August 26, 2010","August 26, 2010","March 13, 2017",NDA 209092,204
Determination of Regulatory Review Period for Purposes of Patent Extension; BAXDELA TABLETS-NDA 208610,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAXDELA TABLETS under NDA 208610 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27133,2019-12299,https://www.federalregister.gov/documents/2019/06/11/2019-12299/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-tablets-nda,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12299.pdf,2019-06-11, BAXDELA TABLETS-NDA 208610,,Nicolas,BAXDELA,7728143 and 8252813,"Melinta Therapeutics, Inc.",5813.0,5569,244.0,"July 22, 2001","July 22, 2001","June 19, 2017",NDA 208610,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; BAXDELA IV INJECTION-NDA 208611,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAXDELA IV INJECTION under new drug application (NDA) 208611 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27126,2019-12298,https://www.federalregister.gov/documents/2019/06/11/2019-12298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-iv-injection-nda,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12298.pdf,2019-06-11, BAXDELA IV INJECTION-NDA 208611,,Nicolas,BAXDELA,7728143 and 8252813,"Melinta Therapeutics, Inc.",5813.0,5569,244.0,"July 22, 2001","August 12, 2019","June 19, 2017",NDA 208611,1001
Determination of Regulatory Review Period for Purposes of Patent Extension; NERLYNX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NERLYNX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 45769,2019-18816,https://www.federalregister.gov/documents/2019/08/30/2019-18816/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nerlynx,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18816.pdf,2019-08-30, NERLYNX,,Nicolas,NERLYNX,7399865 and 9211291,"Puma Biotechnology, Inc.",5102.0,4738,364.0,"July 31, 2003","July 31, 2003","July 17, 2017",NDA 208051,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; MACI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MACI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 45776,2019-18805,https://www.federalregister.gov/documents/2019/08/30/2019-18805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maci,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18805.pdf,2019-08-30, MACI,,Nicolas,MACI,8029992,Vericel Corporation,345.0,0,345.0,"January 4, 2016","January 4, 2016","December 13, 2016",BLA 125603,345
Determination of Regulatory Review Period for Purposes of Patent Extension; BEVYXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEVYXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 45778,2019-18788,https://www.federalregister.gov/documents/2019/08/30/2019-18788/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bevyxxa,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18788.pdf,2019-08-30, BEVYXXA,,Nicolas,BEVYXXA,6376515; 6835739; 7598276; and 8518977,"Millennium Pharmaceuticals, Inc.",4244.0,4001,243.0,"November 11, 2005","November 11, 2005","June 23, 2017",NDA 208383,821
Determination of Regulatory Review Period for Purposes of Patent Extension; GIAPREZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GIAPREZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 46740,2019-19110,https://www.federalregister.gov/documents/2019/09/05/2019-19110/determination-of-regulatory-review-period-for-purposes-of-patent-extension-giapreza,https://www.govinfo.gov/content/pkg/FR-2019-09-05/pdf/2019-19110.pdf,2019-09-05, GIAPREZA,,Nicolas,GIAPREZA,9572856,George Washington University,1639.0,1463,176.0,"June 28, 2013","June 28, 2013","December 21, 2017",NDA 209360,241
Determination of Regulatory Review Period for Purposes of Patent Extension; SHINGRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SHINGRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 46953,2019-19205,https://www.federalregister.gov/documents/2019/09/06/2019-19205/determination-of-regulatory-review-period-for-purposes-of-patent-extension-shingrix,https://www.govinfo.gov/content/pkg/FR-2019-09-06/pdf/2019-19205.pdf,2019-09-06, SHINGRIX,,Nicolas,SHINGRIX,7939084,GlaxoSmithKline Biologicals SA,3257.0,2892,365.0,"November 21, 2008","November 21, 2008","October 20, 2017",BLA 125614,1361
Determination of Regulatory Review Period for Purposes of Patent Extension; AEGEA VAPOR SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AEGEA VAPOR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 47520,2019-19496,https://www.federalregister.gov/documents/2019/09/10/2019-19496/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aegea-vapor-system,https://www.govinfo.gov/content/pkg/FR-2019-09-10/pdf/2019-19496.pdf,2019-09-10, AEGEA VAPOR SYSTEM,,Nicolas,AEGEA VAPOR SYSTEM,8574226,"Tsunami MedTech, LLC",1381.0,1148,233.0,"September 4, 2013","September 4, 2013","June 14, 2017",PMA P160047,931
Determination of Regulatory Review Period for Purposes of Patent Extension; Edwards Pericardial Aortic Bioprosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS (Models 11000A and 11500A) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 47960,2019-19600,https://www.federalregister.gov/documents/2019/09/11/2019-19600/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edwards-pericardial,https://www.govinfo.gov/content/pkg/FR-2019-09-11/pdf/2019-19600.pdf,2019-09-11, Edwards Pericardial Aortic Bioprosthesis,,Nicolas,EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS MODEL 11000A and MODEL 11500A,7972376; 8007992; 8357387; and 9029418,Edwards Lifesciences Corporation,1858.0,1491,367.0,"May 30, 2012","May 30, 2012","June 29, 2017",PMA P150048,1111
Determination of Regulatory Review Period for Purposes of Patent Extension; Med-El Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MED-EL Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System (MED-EL EAS) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 50042,2019-20657,https://www.federalregister.gov/documents/2019/09/24/2019-20657/determination-of-regulatory-review-period-for-purposes-of-patent-extension-med-el-electric-and,https://www.govinfo.gov/content/pkg/FR-2019-09-24/pdf/2019-20657.pdf,2019-09-24, Med-El Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System,,Nicolas,MED-EL EAS,7917224,Med-El Electromedizinische Gerate GmbH,4537.0,4269,268.0,"April 16, 2004","April 16, 2004","September 15, 2016",PMA P000025,998
Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRYSVITA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",84 FR 65823,2019-25821,https://www.federalregister.gov/documents/2019/11/29/2019-25821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crysvita,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25821.pdf,2019-11-29, CRYSVITA,,Nicolas,CRYSVITA,7314618; 7883705; and 9290569,Indiana University Research,3485.0,3241,244.0,"October 3, 2008","October 3, 2008","April 17, 2018",BLA 761068,"5 days, 1,168 days, or 501 days"
Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OZEMPIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 65826,2019-25850,https://www.federalregister.gov/documents/2019/11/29/2019-25850/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ozempic,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25850.pdf,2019-11-29, OZEMPIC,,Nicolas,OZEMPIC,8129343,Novo Nordisk A/S,3336.0,2970,366.0,"October 19, 2008","October 19, 2008","December 5, 2017",NDA 209637,1040
Determination of Regulatory Review Period for Purposes of Patent Extension; AIMOVIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AIMOVIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66201,2019-26081,https://www.federalregister.gov/documents/2019/12/03/2019-26081/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aimovig,https://www.govinfo.gov/content/pkg/FR-2019-12-03/pdf/2019-26081.pdf,2019-12-03, AIMOVIG,,Nicolas,AIMOVIG,9102731,"Amgen, Inc.",2042.0,1675,367.0,"October 16, 2012","October 16, 2012","May 17, 2018",BLA 761077,689
Determination of Regulatory Review Period for Purposes of Patent Extension; LUXTURNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUXTURNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66682,2019-26252,https://www.federalregister.gov/documents/2019/12/05/2019-26252/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luxturna,https://www.govinfo.gov/content/pkg/FR-2019-12-05/pdf/2019-26252.pdf,2019-12-05, LUXTURNA,,Nicolas,LUXTURNA,9433688,"Trustees of the University of Pennsylvania, the University of Florida Research Foundation, Inc.",3809.0,3591,218.0,"July 18, 2007","July 18, 2007","December 19, 2017",BLA 125610,344
Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANDEXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",84 FR 66671,2019-26251,https://www.federalregister.gov/documents/2019/12/05/2019-26251/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andexxa,https://www.govinfo.gov/content/pkg/FR-2019-12-05/pdf/2019-26251.pdf,2019-12-05, ANDEXXA,,Nicolas,ANDEXXA,8153590; 8889129; and 9388401,"Portola Pharmaceuticals, Inc.",2171.0,1302,869.0,"May 25, 2012","May 25, 2012","May 3, 2018",BLA 125586,1066
Determination of Regulatory Review Period for Purposes of Patent Extension; PALYNZIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PALYNZIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66916,2019-26327,https://www.federalregister.gov/documents/2019/12/06/2019-26327/determination-of-regulatory-review-period-for-purposes-of-patent-extension-palynziq,https://www.govinfo.gov/content/pkg/FR-2019-12-06/pdf/2019-26327.pdf,2019-12-06, PALYNZIQ,,Nicolas,PALYNZIQ,7534595 and 7537923,Biomarin Pharmaceutical Inc.,3803.0,3474,329.0,"December 27, 2007","December 27, 2007","May 24, 2018",BLA B761079,1743
Determination of Regulatory Review Period for Purposes of Patent Extension; VABOMERE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VABOMERE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67746,2019-26655,https://www.federalregister.gov/documents/2019/12/11/2019-26655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vabomere,https://www.govinfo.gov/content/pkg/FR-2019-12-11/pdf/2019-26655.pdf,2019-12-11, VABOMERE,,Nicolas,VABOMERE,8680136,"Rempex Pharmaceuticals, Inc.",1316.0,1072,244.0,"January 23, 2014","January 23, 2014","August 29, 2017",NDA 209776,12
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT INJECTION New Drug Application 205837,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67945,2019-26812,https://www.federalregister.gov/documents/2019/12/12/2019-26812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-injection-new,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26812.pdf,2019-12-12, BRIVIACT INJECTION New Drug Application 205837,,Nicolas,BRIVIACT INJECTION,6784197,UCB Biopharma SPRL,4293.0,3753,540.0,"August 12, 2004","January 18, 2017","February 18, 2016",NDA 205837,1547
"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL TABLETS, New Drug Application 205836",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT ORAL TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67947,2019-26813,https://www.federalregister.gov/documents/2019/12/12/2019-26813/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-oral-tablets-new,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26813.pdf,2019-12-12," BRIVIACT ORAL TABLETS, New Drug Application 205836",,Nicolas,BRIVIACT ORAL TABLETS,6911461,UCB Biopharma SPRL,4293.0,3753,540.0,"August 12, 2004","January 18, 2017","February 18, 2016",NDA 205836,5
"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL SOLUTION, New Drug Application 205838",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT ORAL SOLUTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67942,2019-26814,https://www.federalregister.gov/documents/2019/12/12/2019-26814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-oral-solution,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26814.pdf,2019-12-12," BRIVIACT ORAL SOLUTION, New Drug Application 205838",,Nicolas,BRIVIACT ORAL SOLUTION,8492416,UCB Biopharma SPRL,4293.0,3753,540.0,"August 12, 2004","January 18, 2017","February 18, 2016",NDA 205836,698
Determination of Regulatory Review Period for Purposes of Patent Extension; MAVYRET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAVYRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",85 FR 3694,2020-00936,https://www.federalregister.gov/documents/2020/01/22/2020-00936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mavyret,https://www.govinfo.gov/content/pkg/FR-2020-01-22/pdf/2020-00936.pdf,2020-01-22, MAVYRET,,Nicolas,MAVYRET,8937150 and 9586978,"AbbVie, Inc.",1725.0,1492,233.0,"November 14, 2012","November 12, 2012","August 3, 2017",NDA 209394,150
Determination of Regulatory Review Period for Purposes of Patent Extension; INTRAROSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INTRAROSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 8879,2020-03115,https://www.federalregister.gov/documents/2020/02/18/2020-03115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intrarosa,https://www.govinfo.gov/content/pkg/FR-2020-02-18/pdf/2020-03115.pdf,2020-02-18, INTRAROSA,,Nicolas,INTRAROSA,8629129 and 8957054,"Endorecherche, Inc.",3381.0,2983,398.0,"August 17, 2007","August 17, 2007","November 16, 2016",NDA 208470,518
Determination of Regulatory Review Period for Purposes of Patent Extension; ILUMYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ILUMYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 12565,2020-04362,https://www.federalregister.gov/documents/2020/03/03/2020-04362/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilumya,https://www.govinfo.gov/content/pkg/FR-2020-03-03/pdf/2020-04362.pdf,2020-03-03, ILUMYA,,Nicolas,ILUMYA,8293883 and 8404813,Merck Sharp & Dohme Corp.,3452.0,3089,363.0,"October 8, 2008","October 8, 2008","March 20, 2018",BLA 761067,1092
Determination of Regulatory Review Period for Purposes of Patent Extension; FASENRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FASENRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 12793,2020-04363,https://www.federalregister.gov/documents/2020/03/04/2020-04363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fasenra,https://www.govinfo.gov/content/pkg/FR-2020-03-04/pdf/2020-04363.pdf,2020-03-04, FASENRA,,Nicolas,FASENRA,7179464; 7718175; and 8101185,"Kyowa Hakko Kirin Co., Ltd.",4127.0,3763,364.0,"July 30, 2006","July 30, 2006","November 14, 2017",BLA 761070,1244
Determination of Regulatory Review Period for Purposes of Patent Extension; INGREZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INGREZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 12928,2020-04545,https://www.federalregister.gov/documents/2020/03/05/2020-04545/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ingrezza,https://www.govinfo.gov/content/pkg/FR-2020-03-05/pdf/2020-04545.pdf,2020-03-05, INGREZZA,,Nicolas,INGREZZA,8039627,"Neurocrine Biosciences, Inc.",2071.0,1827,244.0,"August 12, 2011","August 12, 2011","April 11, 2017",NDA 209241,552
Determination of Regulatory Review Period for Purposes of Patent Extension; CARTIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CARTIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",85 FR 41999,2020-15011,https://www.federalregister.gov/documents/2020/07/13/2020-15011/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cartiva,https://www.govinfo.gov/content/pkg/FR-2020-07-13/pdf/2020-15011.pdf,2020-07-13, CARTIVA,,Nicolas,CARTIVA,5981826,"Cartiva, Inc.",2407.0,1979,428.0,"September 11, 2020","July 1, 2016","July 1, 2016",PMA 150017,1429
Determination of Regulatory Review Period for Purposes of Patent Extension; XEPI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XEPI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 41996,2020-15013,https://www.federalregister.gov/documents/2020/07/13/2020-15013/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xepi,https://www.govinfo.gov/content/pkg/FR-2020-07-13/pdf/2020-15013.pdf,2020-07-13, XEPI,,Nicolas,XEPI,6335447,"Toyama Chemical Co., Ltd.",2819.0,2282,537.0,"September 11, 2020","March 26, 2010","December 11, 2017",NDA 208945,1678
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",85 FR 42863,2020-15295,https://www.federalregister.gov/documents/2020/07/15/2020-15295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istent-inject-trabecular,https://www.govinfo.gov/content/pkg/FR-2020-07-15/pdf/2020-15295.pdf,2020-07-15, ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,,Nicolas,ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,7867186; 9301875; and 9597230,Glaukos Corporation,2508.0,2330,178.0,"September 14, 2020","August 11, 2011","June 21, 2018",PMA 170043,1783
Determination of Regulatory Review Period for Purposes of Patent Extension; OXERVATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXERVATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 51446,2020-18239,https://www.federalregister.gov/documents/2020/08/20/2020-18239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxervate,https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18239.pdf,2020-08-20, OXERVATE,,Nicolas,OXERVATE,8501439,Dompe Farmaceutici S.p.A.,1484.0,1240,244.0,"October 19, 2020","August 1, 2014","August 22, 2018",BLA 761094,863
Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYLEESI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 51448,2020-18240,https://www.federalregister.gov/documents/2020/08/20/2020-18240/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyleesi,https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18240.pdf,2020-08-20, VYLEESI,,Nicolas,VYLEESI,6579968 and 6794489,"Palatin Technologies, Inc.",6721.0,6265,456.0,"October 19, 2020","January 27, 2001","June 21, 2019",NDA 210557,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; POTELIGEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POTELIGEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 53823,2020-19036,https://www.federalregister.gov/documents/2020/08/31/2020-19036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-poteligeo,https://www.govinfo.gov/content/pkg/FR-2020-08-31/pdf/2020-19036.pdf,2020-08-31, POTELIGEO,,Nicolas,POTELIGEO,6989145 and 7504104,Kyowa Hakko Kirin,3536.0,3227,309.0,"October 30, 2020","December 4, 2008","August 8, 2018",BLA 761051,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ELZONRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELZONRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 53824,2020-19085,https://www.federalregister.gov/documents/2020/08/31/2020-19085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elzonris,https://www.govinfo.gov/content/pkg/FR-2020-08-31/pdf/2020-19085.pdf,2020-08-31, ELZONRIS,,Nicolas,ELZONRIS,9181317 and 9631006,Scott & White Memorial Hospital,5541.0,5357,184.0,"October 30, 2020","October 22, 2003","December 21, 2018",BLA 761116,394
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMOXITI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMOXITI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",85 FR 54388,2020-19214,https://www.federalregister.gov/documents/2020/09/01/2020-19214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumoxiti,https://www.govinfo.gov/content/pkg/FR-2020-09-01/pdf/2020-19214.pdf,2020-09-01, LUMOXITI,,Nicolas,LUMOXITI,8809502; 9580461; and 10072083,the U.S. Department of Health,4320.0,4092,228.0,"November 2, 2020","November 17, 2006","September 13, 2018",BLA 761104,2
Determination of Regulatory Review Period for Purposes of Patent Extension; EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM (EVERSENSE CGM SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",85 FR 56229,2020-20040,https://www.federalregister.gov/documents/2020/09/11/2020-20040/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eversense-continuous,https://www.govinfo.gov/content/pkg/FR-2020-09-11/pdf/2020-20040.pdf,2020-09-11, EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM,,Nicolas,EVERSENSE CGM SYSTEM,6400974,"Senseonics, Inc.",90.0,3727,3123.0,"November 10, 2020","November 10, 2020","June 21, 2018",PMA P160048,5
Determination of Regulatory Review Period for Purposes of Patent Extension; TAKHZYRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAKHZYRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 56622,2020-20104,https://www.federalregister.gov/documents/2020/09/14/2020-20104/determination-of-regulatory-review-period-for-purposes-of-patent-extension-takhzyro,https://www.govinfo.gov/content/pkg/FR-2020-09-14/pdf/2020-20104.pdf,2020-09-14, TAKHZYRO,,Nicolas,TAKHZYRO,8816055,Dyax Corp.,1857.0,1616,241.0,"November 13, 2020","July 25, 2013","August 23, 2018",BLA 761090,849
Determination of Regulatory Review Period for Purposes of Patent Extension; OCS LUNG SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for OCS LUNG SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 14455,2021-05372,https://www.federalregister.gov/documents/2021/03/16/2021-05372/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocs-lung-system,https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05372.pdf,2021-03-16, OCS LUNG SYSTEM,,Nicolas,OCS LUNG SYSTEM,6100082,"TransMedics, Inc.",2341.0,1672,669.0,"September 13, 2021","September 13, 2021","March 22, 2018",PMA P160013,1687
Determination of Regulatory Review Period for Purposes of Patent Extension; HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 14445,2021-05371,https://www.federalregister.gov/documents/2021/03/16/2021-05371/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hintermann-series-h3,https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05371.pdf,2021-03-16, HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,,Nicolas,HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,6409767,European Foot Platform,4676.0,3661,1015.0,"September 13, 2021","August 17, 2006","June 4, 2019",PMA 160036,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; BAROSTIM NEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAROSTIM NEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 15950,2021-06210,https://www.federalregister.gov/documents/2021/03/25/2021-06210/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barostim-neo,https://www.govinfo.gov/content/pkg/FR-2021-03-25/pdf/2021-06210.pdf,2021-03-25, BAROSTIM NEO,,Nicolas,BAROSTIM NEO,8606359; 9044609; and 9427583,"CVRx, Inc.",2550.0,2310,240.0,"September 21, 2021","September 21, 2021","August 16, 2019",PMA 180050,1038
Determination of Regulatory Review Period for Purposes of Patent Extension; IBSRELA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IBSRELA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17157,2021-06693,https://www.federalregister.gov/documents/2021/04/01/2021-06693/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibsrela,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06693.pdf,2021-04-01, IBSRELA,,Nicolas,IBSRELA,8541448,"Ardelyx, Inc.",3219.0,2853,366.0,"September 28, 2021","November 21, 2010","September 12, 2019",NDA 211801,1272
Determination of Regulatory Review Period for Purposes of Patent Extension; TPOXX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for TPOXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17160,2021-06696,https://www.federalregister.gov/documents/2021/04/01/2021-06696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tpoxx,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06696.pdf,2021-04-01, TPOXX,,Nicolas,TPOXX,7737168 and 8124643,"SIGA Technologies, Inc.",4601.0,4383,218.0,"September 28, 2021","December 9, 2005","July 13, 2018",NDA 208627,1585
Determination of Regulatory Review Period for Purposes of Patent Extension; BIOMIMICS 3D VASCULAR STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BIOMIMICS 3D VASCULAR STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 17167,2021-06709,https://www.federalregister.gov/documents/2021/04/01/2021-06709/determination-of-regulatory-review-period-for-purposes-of-patent-extension-biomimics-3d-vascular,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06709.pdf,2021-04-01, BIOMIMICS 3D VASCULAR STENT SYSTEM,,Nicolas,BIOMIMICS 3D VASCULAR STENT SYSTEM,9314353,Veryan Medical Limited,1234.0,973,261.0,"September 28, 2021","September 28, 2021","October 4, 2018",PMA 180003,580
Determination of Regulatory Review Period for Purposes of Patent Extension; OPTIMIZER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OPTIMIZER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 30957,2021-12192,https://www.federalregister.gov/documents/2021/06/10/2021-12192/determination-of-regulatory-review-period-for-purposes-of-patent-extension-optimizer,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12192.pdf,2021-06-10, OPTIMIZER,,Nicolas,OPTIMIZER,8260416 and 8311629,Impulse Dynamics N.V.,5434.0,5236,198.0,"December 7, 2021","May 6, 2004","March 21, 2019",PMA 180036,1293
Determination of Regulatory Review Period for Purposes of Patent Extension; WAKIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for WAKIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30947,2021-12148,https://www.federalregister.gov/documents/2021/06/10/2021-12148/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wakix,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12148.pdf,2021-06-10, WAKIX,,Nicolas,WAKIX,8207197 and 8486947,Bioprojet,505.0,261,244.0,"December 7, 2021","March 29, 2018","August 14, 2019",NDA 211150,389
Determination of Regulatory Review Period for Purposes of Patent Extension; SARCLISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SARCLISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30950,2021-12189,https://www.federalregister.gov/documents/2021/06/10/2021-12189/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sarclisa,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12189.pdf,2021-06-10, SARCLISA,,Nicolas,SARCLISA,8153765 and 10342869,SANOFI,3718.0,3410,308.0,"December 7, 2021","December 29, 2009","March 2, 2020",BLA 761113,1596
Determination of Regulatory Review Period for Purposes of Patent Extension; SPRAVATO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPRAVATO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30955,2021-12193,https://www.federalregister.gov/documents/2021/06/10/2021-12193/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spravato,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12193.pdf,2021-06-10, SPRAVATO,,Nicolas,SPRAVATO,8785500 and 9592207,"Icahn School of Medicine at Mt. Sinai, Yale University",2456.0,2273,183.0,"December 7, 2021","June 15, 2012","March 5, 2019",NDA 211243,596
Determination of Regulatory Review Period for Purposes of Patent Extension; EVENITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVENITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30942,2021-12199,https://www.federalregister.gov/documents/2021/06/10/2021-12199/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evenity,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12199.pdf,2021-06-10, EVENITY,,Nicolas,EVENITY,7592429; 8017120; and 8440193,Amgen Inc.,4519.0,3524,995.0,"December 7, 2021","November 26, 2006","April 9, 2019",BLA 761062,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; XPOVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XPOVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30945,2021-12167,https://www.federalregister.gov/documents/2021/06/10/2021-12167/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xpovio,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12167.pdf,2021-06-10, XPOVIO,,Nicolas,XPOVIO,8999996,Karyopharm Therapeutics Inc.,2585.0,2253,332.0,"December 7, 2021","June 6, 2012","July 3, 2019",NDA 212306,291
Determination of Regulatory Review Period for Purposes of Patent Extension; MAYZENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAYZENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30949,2021-12171,https://www.federalregister.gov/documents/2021/06/10/2021-12171/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mayzent,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12171.pdf,2021-06-10, MAYZENT,,Nicolas,MAYZENT,7939519 and 8492441,Novartis AG,4544.0,4299,245.0,"December 7, 2021","October 19, 2006","March 26, 2019",NDA 209884,848
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) published a notice in the Federal Register of February 12, 2018. After review of a timely request for reconsideration by the applicant of the determination of the regulatory review period of the animal drug, BRAVECTO, in that notice, FDA has determined that a revision of the SUPPLEMENTARY INFORMATION section is warranted. This document presents the revised regulatory review period.",86 FR 31318,2021-12284,https://www.federalregister.gov/documents/2021/06/11/2021-12284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto-correction,https://www.govinfo.gov/content/pkg/FR-2021-06-11/pdf/2021-12284.pdf,2021-06-11, BRAVECTO, Correction,Nicolas,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GIVLAARI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GIVLAARI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 32936,2021-13176,https://www.federalregister.gov/documents/2021/06/23/2021-13176/determination-of-regulatory-review-period-for-purposes-of-patent-extension-givlaari,https://www.govinfo.gov/content/pkg/FR-2021-06-23/pdf/2021-13176.pdf,2021-06-23, GIVLAARI,,Nicolas,GIVLAARI,9133461,"Alnylam Pharmaceuticals, Inc.",1533.0,1363,170.0,"December 20, 2021","September 11, 2015","November 20, 2019",NDA 212194,190
Determination of Regulatory Review Period for Purposes of Patent Extension; TURALIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TURALIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 32950,2021-13186,https://www.federalregister.gov/documents/2021/06/23/2021-13186/determination-of-regulatory-review-period-for-purposes-of-patent-extension-turalio,https://www.govinfo.gov/content/pkg/FR-2021-06-23/pdf/2021-13186.pdf,2021-06-23, TURALIO,,Nicolas,TURALIO,7893075; 8461169; and 9169250,Plexxikon Inc.,3637.0,3394,243.0,"December 20, 2021","August 19, 2009","August 2, 2019",NDA 211810,810
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOLGENSMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZOLGENSMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 33307,2021-13411,https://www.federalregister.gov/documents/2021/06/24/2021-13411/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zolgensma,https://www.govinfo.gov/content/pkg/FR-2021-06-24/pdf/2021-13411.pdf,2021-06-24, ZOLGENSMA,,Nicolas,ZOLGENSMA,7906111,"REGENXBIO, Inc.",2088.0,1852,236.0,"December 21, 2021","September 6, 2013","May 24, 2019",BLA 125694,1162
Determination of Regulatory Review Period for Purposes of Patent Extension; TAZVERIK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAZVERIK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34022,2021-13743,https://www.federalregister.gov/documents/2021/06/28/2021-13743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tazverik,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13743.pdf,2021-06-28, TAZVERIK,,Nicolas,TAZVERIK,8410088,"Epizyme, Inc.",1618.0,1372,246.0,"December 27, 2021","August 21, 2015","January 23, 2020",NDA 211723,650
Determination of Regulatory Review Period for Purposes of Patent Extension; GORE CARDIOFORM ASD OCCLUDER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for GORE CARDIOFORM ASD OCCLUDER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 34023,2021-13687,https://www.federalregister.gov/documents/2021/06/28/2021-13687/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gore-cardioform-asd,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13687.pdf,2021-06-28, GORE CARDIOFORM ASD OCCLUDER,,Nicolas,GORE CARDIOFORM ASD OCCLUDER,9474517,"W.L. Gore & Associates, Inc.",931.0,751,556.0,"December 27, 2021","November 10, 2016","May 28, 2019",PMA 050006,556
"Determination of Regulatory Review Period for Purposes of Patent Extension; Smallpox and Monkeypox Vaccine, Live",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Smallpox and Monkeypox Vaccine, Live and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 34018,2021-13686,https://www.federalregister.gov/documents/2021/06/28/2021-13686/determination-of-regulatory-review-period-for-purposes-of-patent-extension-smallpox-and-monkeypox,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13686.pdf,2021-06-28," Smallpox and Monkeypox Vaccine, Live",,Nicolas,"Smallpox and Monkeypox Vaccine, Live",7335364,Bavarian Nordic A/S,5650.0,5315,335.0,"December 27, 2021","April 7, 2004","September 24, 2019",BLA 125678,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; OXBRYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXBRYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34767,2021-13976,https://www.federalregister.gov/documents/2021/06/30/2021-13976/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxbryta,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13976.pdf,2021-06-30, OXBRYTA,,Nicolas,OXBRYTA,9018210 10017491 and 10034879,"Global Blood Therapeutics, Inc.",1847.0,1694,153.0,"December 27, 2021","November 6, 2014","November 25, 2019",NDA 213137,332
Determination of Regulatory Review Period for Purposes of Patent Extension; FETROJA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FETROJA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34762,2021-13971,https://www.federalregister.gov/documents/2021/06/30/2021-13971/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fetroja,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13971.pdf,2021-06-30, FETROJA,,Nicolas,FETROJA,9238657,"Shionogi & Co., Ltd.",2400.0,2064,336.0,"December 27, 2021","April 21, 2013","November 14, 2019",NDA 209445,726
Determination of Regulatory Review Period for Purposes of Patent Extension; BALVERSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BALVERSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34764,2021-13973,https://www.federalregister.gov/documents/2021/06/30/2021-13973/determination-of-regulatory-review-period-for-purposes-of-patent-extension-balversa,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13973.pdf,2021-06-30, BALVERSA,,Nicolas,BALVERSA,8895601,Astex Therapeutics Ltd.,2179.0,1972,207.0,"December 27, 2021","April 26, 2013","April 12, 2019",NDA 212018,691
Determination of Regulatory Review Period for Purposes of Patent Extension; POLIVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POLIVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",86 FR 34768,2021-13949,https://www.federalregister.gov/documents/2021/06/30/2021-13949/determination-of-regulatory-review-period-for-purposes-of-patent-extension-polivy,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13949.pdf,2021-06-30, POLIVY,,Nicolas,POLIVY,8088378; 8545850; and 8691531,"Genentech, Inc.",3050.0,2876,174.0,"December 27, 2021","February 4, 2011","June 10, 2019",BLA 761121,1445
Determination of Regulatory Review Period for Purposes of Patent Extension; AXONICS SACRAL NEUROMODULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AXONICS SACRAL NEUROMODULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 34757,2021-13972,https://www.federalregister.gov/documents/2021/06/30/2021-13972/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axonics-sacral,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13972.pdf,2021-06-30, AXONICS SACRAL NEUROMODULATION SYSTEM,,Nicolas,AXONICS SACRAL NEUROMODULATION SYSTEM,7331499,Alfred E. Mann Foundation for Scientific[[Page 34759]]Research,681.0,494,187.0,"December 27, 2021","October 27, 2017","September 6, 2019",PMA 190006,434
Determination of Regulatory Review Period for Purposes of Patent Extension; BARHEMSYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BARHEMSYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 35803,2021-14461,https://www.federalregister.gov/documents/2021/07/07/2021-14461/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barhemsys,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14461.pdf,2021-07-07, BARHEMSYS,,Nicolas,BARHEMSYS,9084765,Acacia Pharma Limited,2960.0,2085,875.0,"January 3, 2022","January 21, 2012","February 26, 2020",NDA 209510,1085
Determination of Regulatory Review Period for Purposes of Patent Extension; BEOVU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEOVU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 35805,2021-14473,https://www.federalregister.gov/documents/2021/07/07/2021-14473/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beovu,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14473.pdf,2021-07-07, BEOVU,,Nicolas,BEOVU,8349322 and 9090684,Novartis AG,3064.0,2821,243.0,"January 3, 2022","May 20, 2011","October 7, 2019",BLA 761125,1354
Determination of Regulatory Review Period for Purposes of Patent Extension; Zephyr Endobronchial Valve Implant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zephyr Endobronchial Valve Implant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 35807,2021-14482,https://www.federalregister.gov/documents/2021/07/07/2021-14482/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zephyr-endobronchial,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14482.pdf,2021-07-07, Zephyr Endobronchial Valve Implant,,Nicolas,ZEPHYR ENDOBRONCHIAL VALVE IMPLANT,6527761 and 7798147,Pulmonx Corp.,5744.0,5565,179.0,"January 3, 2022","January 3, 2022","June 29, 2018",PMA 180002,1510
Determination of Regulatory Review Period for Purposes of Patent Extension; PIQRAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIQRAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 36142,2021-14490,https://www.federalregister.gov/documents/2021/07/08/2021-14490/determination-of-regulatory-review-period-for-purposes-of-patent-extension-piqray,https://www.govinfo.gov/content/pkg/FR-2021-07-08/pdf/2021-14490.pdf,2021-07-08, PIQRAY,,Nicolas,PIQRAY,8277462 and 8476268,Novartis AG,3264.0,3106,158.0,"January 4, 2022","June 18, 2010","May 24, 2019",NDA 212526,1156
Determination of Regulatory Review Period for Purposes of Patent Extension; AJOVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AJOVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 36285,2021-14652,https://www.federalregister.gov/documents/2021/07/09/2021-14652/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ajovy,https://www.govinfo.gov/content/pkg/FR-2021-07-09/pdf/2021-14652.pdf,2021-07-09, AJOVY,,Nicolas,AJOVY,8007794,Teva Pharmaceuticals International GmbH,3216.0,2882,334.0,"January 5, 2022","November 26, 2009","September 14, 2018",BLA 761089,1454
Determination of Regulatory Review Period for Purposes of Patent Extension; NUBEQA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NUBEQA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 58670,2021-23074,https://www.federalregister.gov/documents/2021/10/22/2021-23074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nubeqa,https://www.govinfo.gov/content/pkg/FR-2021-10-22/pdf/2021-23074.pdf,2021-10-22, NUBEQA,,Nicolas,NUBEQA,8975254,Orion Corporation,2576.0,2420,156.0,"April 20, 2022","July 13, 2012","July 30, 2019",NDA 212099,879
Determination of Regulatory Review Period for Purposes of Patent Extension; INREBIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INREBIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59397,2021-23388,https://www.federalregister.gov/documents/2021/10/27/2021-23388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inrebic,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23388.pdf,2021-10-27, INREBIC,,Nicolas,INREBIC,7528143; 7825246; and 8138199,"Impact Biomedicines, Inc.",4285.0,4059,226.0,"April 25, 2022","November 24, 2007","August 16, 2019",NDA 212327,1796
Determination of Regulatory Review Period for Purposes of Patent Extension; XENLETA Tablets New Drug Application 211672,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENLETA tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59392,2021-23387,https://www.federalregister.gov/documents/2021/10/27/2021-23387/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenleta-tablets-new-drug,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23387.pdf,2021-10-27, XENLETA Tablets New Drug Application 211672,,Nicolas,XENLETA tablets,8071643; 8153689; and 9120727,Nabriva Therapeutics GMBH,3595.0,3351,244.0,"April 25, 2022","October 13, 2020","August 19, 2019",NDA 211672,1528
Determination of Regulatory Review Period for Purposes of Patent Extension; XENLETA Injection New Drug Application 211673,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENLETA injection new drug application (NDA) 211673 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59394,2021-23386,https://www.federalregister.gov/documents/2021/10/27/2021-23386/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenleta-injection-new,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23386.pdf,2021-10-27, XENLETA Injection New Drug Application 211673,,Nicolas,XENLETA injection,8071643 and 8153689,Nabriva Therapeutics GMBH,3595.0,3351,244.0,"April 25, 2022","December 27, 2021","August 19, 2019",NDA 211673,1528
Determination of Regulatory Review Period for Purposes of Patent Extension; SPINRAZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPINRAZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",86 FR 60248,2021-23719,https://www.federalregister.gov/documents/2021/11/01/2021-23719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spinraza,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23719.pdf,2021-11-01, SPINRAZA,,Nicolas,SPINRAZA,"U.S. Patent Nos. 7,838,657 and 8,110,560 from University of Massachusetts, and U.S. Patent Nos. 8,361,977 and 8,980,853 from Biogen MA Inc., and Cold Spring Harbor Laboratory","University of Massachusetts and Biogen MA Inc., and Cold Spring Harbor Laboratory",1891.0,1799,92.0,"October 22, 2011","October 22, 2011","December 23, 2016",NDA 209531,992
Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENHERTU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60252,2021-23725,https://www.federalregister.gov/documents/2021/11/01/2021-23725/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23725.pdf,2021-11-01, ENHERTU,,Nicolas,ENHERTU,9808537; 10155821; and 10195288,"Daiichi Sankyo Company, Limited",1395.0,186,1209.0,"February 26, 2016","February 26, 2016","December 20, 2019",BLA 761139,71
Determination of Regulatory Review Period for Purposes of Patent Extension; VYONDYS 53,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYONDYS 53 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60256,2021-23724,https://www.federalregister.gov/documents/2021/11/01/2021-23724/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyondys-53,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23724.pdf,2021-11-01, VYONDYS 53,,Nicolas,VYONDYS 53,9024007; 9994851; 10227590; 10266827; 10421966; and RE47691,The University of Western Australia,1833.0,1474,359.0,"December 7, 2014","December 7, 2014","December 12, 2019",NDA 211970,888
Determination of Regulatory Review Period for Purposes of Patent Extension; ADAKVEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADAKVEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60829,2021-24070,https://www.federalregister.gov/documents/2021/11/04/2021-24070/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adakveo,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24070.pdf,2021-11-04, ADAKVEO,,Nicolas,ADAKVEO,8377440 and 9556266,Novartis AG,3152.0,2968,184.0,"April 1, 2011","April 1, 2011","November 15, 2019",BLA 761128,601
Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCENESSE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60832,2021-24074,https://www.federalregister.gov/documents/2021/11/04/2021-24074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-scenesse,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24074.pdf,2021-11-04, SCENESSE,,Nicolas,SCENESSE,8334265,Clinuvel Pharmaceuticals Limited,3914.0,3579,335.0,"January 21, 2009","January 21, 2009","October 8, 2019",NDA 210797,1481
Determination of Regulatory Review Period for Purposes of Patent Extension; SEVENFACT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEVENFACT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60827,2021-24065,https://www.federalregister.gov/documents/2021/11/04/2021-24065/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sevenfact,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24065.pdf,2021-11-04, SEVENFACT,,Nicolas,SEVENFACT,9029316,Laboratoire Francais du Fractionnement et des Biotechnologies S.A. (LFB S.A.),2785.0,1518,1267.0,"August 18, 2012","August 18, 2012","April 1, 2020",BLA 125641,482
Determination of Regulatory Review Period for Purposes of Patent Extension; AKLIEF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AKLIEF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60831,2021-24077,https://www.federalregister.gov/documents/2021/11/04/2021-24077/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aklief,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24077.pdf,2021-11-04, AKLIEF,,Nicolas,AKLIEF,7807708; 8227507; and 8470871,Galderma Research & Development,3137.0,2771,366.0,"March 5, 2011","March 5, 2011","October 4, 2019",NDA 211527,1329
Determination of Regulatory Review Period for Purposes of Patent Extension; DENGVAXIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DENGVAXIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60835,2021-24067,https://www.federalregister.gov/documents/2021/11/04/2021-24067/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dengvaxia,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24067.pdf,2021-11-04, DENGVAXIA,,Nicolas,DENGVAXIA,8142795,Sanofi Pasteur,5710.0,5466,244.0,"September 14, 2003","September 14, 2003","May 1, 2019",BLA 125682,1248
Determination of Regulatory Review Period for Purposes of Patent Extension; RECARBRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECARBRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60837,2021-24068,https://www.federalregister.gov/documents/2021/11/04/2021-24068/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recarbrio,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24068.pdf,2021-11-04, RECARBRIO,,Nicolas,RECARBRIO,8487093,Merck Sharp & Dohme Corp.,3200.0,2957,243.0,"October 13, 2010","October 13, 2010","July 16, 2019",NDA 212819,1218
Determination of Regulatory Review Period for Purposes of Patent Extension; DOJOLVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DOJOLVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",86 FR 62181,2021-24435,https://www.federalregister.gov/documents/2021/11/09/2021-24435/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dojolvi,https://www.govinfo.gov/content/pkg/FR-2021-11-09/pdf/2021-24435.pdf,2021-11-09, DOJOLVI,,Nicolas,DOJOLVI,8697748 and 9186344,Ultragenyx Pharmaceutical Inc.,2511.0,2175,336.0,"August 17, 2013","August 17, 2013","June 30, 2020",NDA 213687,1303
Determination of Regulatory Review Period for Purposes of Patent Extension; QINLOCK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QINLOCK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 63402,2021-24978,https://www.federalregister.gov/documents/2021/11/16/2021-24978/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qinlock,https://www.govinfo.gov/content/pkg/FR-2021-11-16/pdf/2021-24978.pdf,2021-11-16, QINLOCK,,Nicolas,QINLOCK,8188113 and 8461179,Deciphera Pharmaceuticals LLC,1741.0,1586,155.0,"August 11, 2015","August 11, 2015","May 15, 2020",NDA 213973,947
Determination of Regulatory Review Period for Purposes of Patent Extension; SUNOSI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SUNOSI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 64947,2021-25297,https://www.federalregister.gov/documents/2021/11/19/2021-25297/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sunosi,https://www.govinfo.gov/content/pkg/FR-2021-11-19/pdf/2021-25297.pdf,2021-11-19, SUNOSI,,Nicolas,SUNOSI,8440715,"JAZZ Pharmaceutials, Inc.",8209.0,7664,545.0,"December 27, 1996","December 27, 1996","June 17, 2019",IND 52082,1386
Determination of Regulatory Review Period for Purposes of Patent Extension; TRODELVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRODELVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 67065,2021-25612,https://www.federalregister.gov/documents/2021/11/24/2021-25612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trodelvy,https://www.govinfo.gov/content/pkg/FR-2021-11-24/pdf/2021-25612.pdf,2021-11-24, TRODELVY,,Nicolas,TRODELVY,7999083,"Immunomedics, Inc.",2856.0,2150,706.0,"June 29, 2012","June 29, 2012","April 22, 2020",BLA 761115,1780
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEPZELCA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEPZELCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 67960,2021-26009,https://www.federalregister.gov/documents/2021/11/30/2021-26009/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zepzelca,https://www.govinfo.gov/content/pkg/FR-2021-11-30/pdf/2021-26009.pdf,2021-11-30, ZEPZELCA,,Nicolas,ZEPZELCA,7763615,"Pharma Mar, S.A.",4170.0,3987,183.0,"January 16, 2009","January 16, 2009","June 15, 2020",NDA 213702,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of November 1, 2021, for the determination of a regulatory review period for purposes of patent extension for the human biological product, ENHERTU. This document corrects that notice by adjusting the applicable regulatory review period for the testing phase and approval phase of the product, ENHERTU.",87 FR 1762,2022-00404,https://www.federalregister.gov/documents/2022/01/12/2022-00404/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu-correction,https://www.govinfo.gov/content/pkg/FR-2022-01-12/pdf/2022-00404.pdf,2022-01-12, ENHERTU, Correction,Nicolas,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DANYELZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DANYELZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 38761,2022-13860,https://www.federalregister.gov/documents/2022/06/29/2022-13860/determination-of-regulatory-review-period-for-purposes-of-patent-extension-danyelza,https://www.govinfo.gov/content/pkg/FR-2022-06-29/pdf/2022-13860.pdf,2022-06-29, DANYELZA,,Nicolas,DANYELZA,9315585,Memorial Sloan Kettering Cancer Center,3423.0,3183,240.0,"July 15, 2011","July 15, 2011","November 25, 2020",BLA 761171,3421
Determination of Regulatory Review Period for Purposes of Patent Extension; RUKOBIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUKOBIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 38763,2022-13856,https://www.federalregister.gov/documents/2022/06/29/2022-13856/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rukobia,https://www.govinfo.gov/content/pkg/FR-2022-06-29/pdf/2022-13856.pdf,2022-06-29, RUKOBIA,,Nicolas,RUKOBIA,8168615,ViiV Healthcare UK,5322.0,5110,212.0,"December 8, 2005","December 8, 2005","July 2, 2020",NDA 212950,1597
Determination of Regulatory Review Period for Purposes of Patent Extension; TEPEZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEPEZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 39099,2022-13956,https://www.federalregister.gov/documents/2022/06/30/2022-13956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tepezza,https://www.govinfo.gov/content/pkg/FR-2022-06-30/pdf/2022-13956.pdf,2022-06-30, TEPEZZA,,Nicolas,TEPEZZA,7572897,Hoffman-La Roche Inc.,2958.0,2760,198.0,"December 18, 2011","December 18, 2011","January 21, 2020",BLA 761143,1578
Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMCIVREE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 39531,2022-14134,https://www.federalregister.gov/documents/2022/07/01/2022-14134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imcivree,https://www.govinfo.gov/content/pkg/FR-2022-07-01/pdf/2022-14134.pdf,2022-07-01, IMCIVREE,,Nicolas,IMCIVREE,8039435; 9458195,"RHYTHM PHARMACEUTICALS, INC.",3304.0,3060,244.0,"November 11, 2011","November 11, 2011","November 25, 2020",NDA 213793,1774
Determination of Regulatory Review Period for Purposes of Patent Extension; VYEPTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYEPTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40248,2022-14350,https://www.federalregister.gov/documents/2022/07/06/2022-14350/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyepti,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14350.pdf,2022-07-06, VYEPTI,,Nicolas,VYEPTI,9745373,AlderBio Holdings LLC,2599.0,2233,366.0,"January 11, 2013","January 11, 2013","February 21, 2020",BLA 761119,637
Determination of Regulatory Review Period for Purposes of Patent Extension; MONJUVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONJUVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40251,2022-14357,https://www.federalregister.gov/documents/2022/07/06/2022-14357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monjuvi,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14357.pdf,2022-07-06, MONJUVI,,Nicolas,MONJUVI,8524867; 9803020,"Xenocor, Inc.",3806.0,3590,216.0,"March 3, 2010","March 3, 2010","July 31, 2020",BLA 761163,1370
Determination of Regulatory Review Period for Purposes of Patent Extension; MARGENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MARGENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40256,2022-14360,https://www.federalregister.gov/documents/2022/07/06/2022-14360/determination-of-regulatory-review-period-for-purposes-of-patent-extension-margenza,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14360.pdf,2022-07-06, MARGENZA,,Nicolas,MARGENZA,8802093,"MacroGenics, Inc.",3950.0,3585,365.0,"February 24, 2010","February 24, 2010","December 16, 2020",BLA 761150,1342
Determination of Regulatory Review Period for Purposes of Patent Extension; XEGLYZE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XEGLYZE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 40534,2022-14430,https://www.federalregister.gov/documents/2022/07/07/2022-14430/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xeglyze,https://www.govinfo.gov/content/pkg/FR-2022-07-07/pdf/2022-14430.pdf,2022-07-07, XEGLYZE,,Nicolas,XEGLYZE,7812163; 8212038,"Dr. Reddy's Laboratories, S.A.",4573.0,2797,1776.0,"January 18, 2008","January 18, 2008","July 24, 2020",NDA 206966,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; RINVOQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RINVOQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",87 FR 40536,2022-14431,https://www.federalregister.gov/documents/2022/07/07/2022-14431/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rinvoq,https://www.govinfo.gov/content/pkg/FR-2022-07-07/pdf/2022-14431.pdf,2022-07-07, RINVOQ,,Nicolas,RINVOQ,8962629; RE47221,AbbVie,2604.0,2365,239.0,"July 1, 2012","July 1, 2012","August 16, 2019",NDA 211675,989
Determination of Regulatory Review Period for Purposes of Patent Extension; UPLIZNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UPLIZNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40851,2022-14539,https://www.federalregister.gov/documents/2022/07/08/2022-14539/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uplizna,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14539.pdf,2022-07-08, UPLIZNA,,Nicolas,UPLIZNA,8323653,"Viela Bio, Inc.",4033.0,3666,367.0,"May 29, 2009","May 29, 2009","June 11, 2020",BLA 761142,1557
Determination of Regulatory Review Period for Purposes of Patent Extension; PADCEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PADCEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40847,2022-14548,https://www.federalregister.gov/documents/2022/07/08/2022-14548/determination-of-regulatory-review-period-for-purposes-of-patent-extension-padcev,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14548.pdf,2022-07-08, PADCEV,,Nicolas,PADCEV,9078931; 9314538; 9962454; RE48389 (previously U.S. Patent No. 8637642),"AGENSYS, Inc.",2546.0,2389,157.0,"December 30, 2012","December 30, 2012","December 18, 2019",BLA 761137,811
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROZLYTREK INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 40849,2022-14546,https://www.federalregister.gov/documents/2022/07/08/2022-14546/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-injection,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14546.pdf,2022-07-08, ROZLYTREK INJECTION,,Nicolas,ROZLYTREK INJECTION,8299057; 8673893; 9029356; and 9085565,"Genentech, Inc.",1968.0,1727,241.0,"March 28, 2014","March 28, 2014","August 15, 2019",NDA 212726,1104
Determination of Regulatory Review Period for Purposes of Patent Extension; TABRECTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TABRECTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 41133,2022-14674,https://www.federalregister.gov/documents/2022/07/11/2022-14674/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tabrecta,https://www.govinfo.gov/content/pkg/FR-2022-07-11/pdf/2022-14674.pdf,2022-07-11, TABRECTA,,Nicolas,TABRECTA,7767675; 8420645,Incyte Corp.,4164.0,4015,149.0,"December 13, 2008","December 13, 2008","May 6, 2020",NDA 213591,5
Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENSPRYNG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",87 FR 41724,2022-14930,https://www.federalregister.gov/documents/2022/07/13/2022-14930/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enspryng,https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14930.pdf,2022-07-13, ENSPRYNG,,Nicolas,ENSPRYNG,8562991; 10022319; 10662245,"Genentech, Inc.",2495.0,2128,367.0,"October 18, 2013","October 18, 2013","August 14, 2020",BLA 761149,1428
Determination of Regulatory Review Period for Purposes of Patent Extension; BLENREP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLENREP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 41727,2022-14916,https://www.federalregister.gov/documents/2022/07/13/2022-14916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blenrep,https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14916.pdf,2022-07-13, BLENREP,,Nicolas,BLENREP,9273141,Glaxo Group Ltd,2352.0,2107,245.0,"February 28, 2014","February 28, 2014","August 5, 2020",BLA 761158,803
Determination of Regulatory Review Period for Purposes of Patent Extension; TAUVID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAUVID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 43874,2022-15679,https://www.federalregister.gov/documents/2022/07/22/2022-15679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tauvid,https://www.govinfo.gov/content/pkg/FR-2022-07-22/pdf/2022-15679.pdf,2022-07-22, TAUVID,,Nicolas,TAUVID,8932557,Eli Lilly,3067.0,2825,242.0,"January 6, 2012","January 6, 2012","May 28, 2020",NDA 212123,1102
Determination of Regulatory Review Period for Purposes of Patent Extension; VUMERITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VUMERITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 44126,2022-15823,https://www.federalregister.gov/documents/2022/07/25/2022-15823/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vumerity,https://www.govinfo.gov/content/pkg/FR-2022-07-25/pdf/2022-15823.pdf,2022-07-25, VUMERITY,,Tianlun,VUMERITY (diroximel fumarate),"8,669,281; 9,090,558; 10,080,733",Alkermes Pharma Ireland Limited,1944.0,1623.0,321.0,2014-07-05 00:00:00,2018-12-13,2019-10-29,NDA 211855,40
Determination of Regulatory Review Period for Purposes of Patent Extension; REBLOZYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBLOZYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 46963,2022-16385,https://www.federalregister.gov/documents/2022/08/01/2022-16385/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reblozyl,https://www.govinfo.gov/content/pkg/FR-2022-08-01/pdf/2022-16385.pdf,2022-08-01, REBLOZYL,,Tianlun,REBLOZYL (luspatercept-aamt),"8,058,229; 8,343,933; 8,361,957",Acceleron Pharma Inc.,3041.0,2822.0,219.0,2011-07-14 00:00:00,2019-04-04,2019-11-08,BLA 761136,"1,347, 1,361, or 1,548"
"Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK TABLETS, New Drug Application 212725",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROZLYTREK TABLETS new drug application (NDA) 212725 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",87 FR 47217,2022-16504,https://www.federalregister.gov/documents/2022/08/02/2022-16504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-tablets-new,https://www.govinfo.gov/content/pkg/FR-2022-08-02/pdf/2022-16504.pdf,2022-08-02," ROZLYTREK TABLETS, New Drug Application 212725",,Tianlun,ROZLYTREK TABLETS (entrectinib),"8,299,057; 8,673,893; 9,029,356; and 9,085,565","Genentech, Inc.",1968.0,1727.0,241.0,2014-03-28 00:00:00,2018-12-18,2019-08-15,NDA 212725,"864, 899, or 1,104"
Determination of Regulatory Review Period for Purposes of Patent Extension; UBRELVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UBRELVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 53475,2022-18753,https://www.federalregister.gov/documents/2022/08/31/2022-18753/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ubrelvy,https://www.govinfo.gov/content/pkg/FR-2022-08-31/pdf/2022-18753.pdf,2022-08-31, UBRELVY,,Tianlun,UBRELVY (ubrogepant),"8,912,210 and 9,833,448",Allergan Sales LLC,2883.0,2520.0,363.0,2012-02-02 00:00:00,2018-12-26,2019-12-23,NDA 211765,555 or 774
Determination of Regulatory Review Period for Purposes of Patent Extension; THEROX DOWNSTREAM SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for THEROX DOWNSTREAM SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",87 FR 53474,2022-18754,https://www.federalregister.gov/documents/2022/08/31/2022-18754/determination-of-regulatory-review-period-for-purposes-of-patent-extension-therox-downstream-system,https://www.govinfo.gov/content/pkg/FR-2022-08-31/pdf/2022-18754.pdf,2022-08-31, THEROX DOWNSTREAM SYSTEM,,Tianlun,THEROX DOWNSTREAM SYSTEM,"6,582,387; 7,820,102; and 8,264,564",TherOx Inc.,7386.0,6824.0,562.0,1999-01-13 00:00:00,2017-09-18,2019-04-02,PMA P170027,"991, 1,591, or 1,826"
Determination of Regulatory Review Period for Purposes of Patent Extension; ORILISSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORILISSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",87 FR 55434,2022-19506,https://www.federalregister.gov/documents/2022/09/09/2022-19506/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orilissa,https://www.govinfo.gov/content/pkg/FR-2022-09-09/pdf/2022-19506.pdf,2022-09-09, ORILISSA,,Tianlun,ORILISSA (elagolix sodium),"7,056,927 and 7,419,983","Neurocrine Biosciences, Inc.",5452.0,5117.0,335.0,2003-08-21 00:00:00,2017-08-23,2018-07-23,NDA 210450,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; REYVOW,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REYVOW and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 56072,2022-19714,https://www.federalregister.gov/documents/2022/09/13/2022-19714/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reyvow,https://www.govinfo.gov/content/pkg/FR-2022-09-13/pdf/2022-19714.pdf,2022-09-13, REYVOW,,Tianlun,REYVOW (lasmiditan),7423050,Eli Lilly and Company,3097.0,2619.0,478.0,2011-08-11 00:00:00,2018-10-11,2019-10-11,NDA 211280,1786
Determination of Regulatory Review Period for Purposes of Patent Extension; BULKAMID URETHRAL BULKING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BULKAMID URETHRAL BULKING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",87 FR 56062,2022-19723,https://www.federalregister.gov/documents/2022/09/13/2022-19723/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bulkamid-urethral-bulking,https://www.govinfo.gov/content/pkg/FR-2022-09-13/pdf/2022-19723.pdf,2022-09-13, BULKAMID URETHRAL BULKING SYSTEM,,Tianlun,BULKAMID URETHRAL BULKING SYSTEM,"7,678,146; 7,758,497; and 7,780,958",Contura A/S,4529.0,3617.0,912.0,2007-09-06 00:00:00,2017-07-31,2020-01-28,PMA P170023,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; CAPLYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAPLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 56686,2022-19898,https://www.federalregister.gov/documents/2022/09/15/2022-19898/determination-of-regulatory-review-period-for-purposes-of-patent-extension-caplyta,https://www.govinfo.gov/content/pkg/FR-2022-09-15/pdf/2022-19898.pdf,2022-09-15, CAPLYTA,,Tianlun,CAPLYTA (lumateperone tosylate),"8,598,119 and 8,648,077","Intra-Cellular Therapies, Inc.",4421.0,3970.0,451.0,2007-11-15 00:00:00,2018-09-27,2019-12-20,NDA 209500,"1,294 or 1,329"
Determination of Regulatory Review Period for Purposes of Patent Extension; TAVALISSE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAVALISSE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 56687,2022-19993,https://www.federalregister.gov/documents/2022/09/15/2022-19993/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tavalisse,https://www.govinfo.gov/content/pkg/FR-2022-09-15/pdf/2022-19993.pdf,2022-09-15, TAVALISSE,,Tianlun,TAVALISSE (fostamatinib disodium hexahydrate),7449458,"Rigel Pharmaceuticals, Inc.",4564.0,4198.0,366.0,2005-10-20 00:00:00,2017-04-17,2018-04-17,NDA 209299,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; NURTEC ODT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NURTEC ODT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 58116,2022-20634,https://www.federalregister.gov/documents/2022/09/23/2022-20634/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nurtec-odt,https://www.govinfo.gov/content/pkg/FR-2022-09-23/pdf/2022-20634.pdf,2022-09-23, NURTEC ODT,,Tianlun,NURTEC ODT (rimegepant sulfate),"8,314,117 and 8,759,372",Biohaven Pharmaceutical Holding Company Ltd.,3390.0,3144.0,246.0,2010-11-18 00:00:00,2019-06-27,2020-02-27,NDA 212728,"368 or 1,102"
Determination of Regulatory Review Period for Purposes of Patent Extension; NOURIANZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NOURIANZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67039,2022-24217,https://www.federalregister.gov/documents/2022/11/07/2022-24217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nourianz,https://www.govinfo.gov/content/pkg/FR-2022-11-07/pdf/2022-24217.pdf,2022-11-07, NOURIANZ,,Tianlun,NOURIANZ (istradefylline),"7,727,993 and 7,727,994","Kyowa Kirin Co., Ltd.",7300.0,2792.0,4508.0,1999-09-03 00:00:00,2007-04-25,2019-08-27,NDA 22075,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; ANGELMED GUARDIAN SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANGELMED GUARDIAN SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",87 FR 67042,2022-24216,https://www.federalregister.gov/documents/2022/11/07/2022-24216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-angelmed-guardian-system,https://www.govinfo.gov/content/pkg/FR-2022-11-07/pdf/2022-24216.pdf,2022-11-07, ANGELMED GUARDIAN SYSTEM,,Tianlun,ANGELMED GUARDIAN SYSTEM,6609023,"Angel Medical Systems, Inc.",4037.0,2916.0,1121.0,2007-03-23 00:00:00,2015-03-16,2018-04-09,PMA P150009,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; XCOPRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XCOPRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67696,2022-24457,https://www.federalregister.gov/documents/2022/11/09/2022-24457/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xcopri,https://www.govinfo.gov/content/pkg/FR-2022-11-09/pdf/2022-24457.pdf,2022-11-09, XCOPRI,,Tianlun,XCOPRI (cenobamate),7598279,"SK Biopharmaceuticals Co., Ltd.",5326.0,4850.0,476.0,2005-08-12 00:00:00,2018-11-21,2020-03-10,NDA 212839,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; TISSUEBLUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TISSUEBLUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67698,2022-24434,https://www.federalregister.gov/documents/2022/11/09/2022-24434/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tissueblue,https://www.govinfo.gov/content/pkg/FR-2022-11-09/pdf/2022-24434.pdf,2022-11-09, TISSUEBLUE,,Tianlun,TISSUEBLUE (Brilliant blue G Ophthalmic Solution),7731941,"Kyushu University, National University Corporation",4631.0,4395.0,236.0,2007-04-18 00:00:00,2019-04-29,2019-12-20,NDA 209569,1375
Determination of Regulatory Review Period for Purposes of Patent Extension; NEXLETOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NEXLETOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67699,2022-24431,https://www.federalregister.gov/documents/2022/11/09/2022-24431/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nexletol,https://www.govinfo.gov/content/pkg/FR-2022-11-09/pdf/2022-24431.pdf,2022-11-09, NEXLETOL,,Tianlun,NEXLETOL (bempedoic acid),7335799,"Esperion Therapeutics, Inc.",3774.0,3408.0,366.0,2009-10-24 00:00:00,2019-02-21,2020-02-21,NDA 211616,1826
"Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS, New Drug Application 209939",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA, Agency, or we) has determined the regulatory review period for PREVYMIS, new drug application (NDA) 209939, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 68177,2022-24718,https://www.federalregister.gov/documents/2022/11/14/2022-24718/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevymis-new-drug,https://www.govinfo.gov/content/pkg/FR-2022-11-14/pdf/2022-24718.pdf,2022-11-14," PREVYMIS, New Drug Application 209939",,Tianlun,PREVYMIS (letermovir),RE46791,AiCuris Anti-infective Cures GmbH,3157.0,2911.0,246.0,2009-03-20 00:00:00,2017-03-08,2017-11-08,NDA 209939,1701
"Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS IV Solution, New Drug Application 209940",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PREVYMIS IV Solution, new drug application (NDA) 209940, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 68174,2022-24719,https://www.federalregister.gov/documents/2022/11/14/2022-24719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevymis-iv-solution-new,https://www.govinfo.gov/content/pkg/FR-2022-11-14/pdf/2022-24719.pdf,2022-11-14," PREVYMIS IV Solution, New Drug Application 209940",,Tianlun,PREVYMIS (letermovir),8513255,AiCuris Anti-infective Cures GmbH,3157.0,2911.0,246.0,2009-03-20 00:00:00,2017-03-08,2017-11-08,NDA 209940,894
Determination of Regulatory Review Period for Purposes of Patent Extension; BYFAVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BYFAVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 4185,2023-01220,https://www.federalregister.gov/documents/2023/01/24/2023-01220/determination-of-regulatory-review-period-for-purposes-of-patent-extension-byfavo,https://www.govinfo.gov/content/pkg/FR-2023-01-24/pdf/2023-01220.pdf,2023-01-24, BYFAVO,,Tianlun,BYFAVO (remimazolam),9827251,Acacia Pharma Limited,4482.0,3931.0,551.0,2008-07-01 00:00:00,2019-04-05,2020-10-06,NDA 212295,796
Determination of Regulatory Review Period for Purposes of Patent Extension; OLUMIANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OLUMIANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7731,2023-02441,https://www.federalregister.gov/documents/2023/02/06/2023-02441/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olumiant,https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02441.pdf,2023-02-06, OLUMIANT,,Tianlun,OLUMIANT (baricitinib),8158616,Eli Lilly and Co.,3649.0,2781.0,868.0,2008-06-05 00:00:00,2016-01-15,2018-05-31,NDA 207924,723
Determination of Regulatory Review Period for Purposes of Patent Extension; XIIDRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XIIDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7733,2023-02452,https://www.federalregister.gov/documents/2023/02/06/2023-02452/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xiidra,https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02452.pdf,2023-02-06, XIIDRA,,Tianlun,XIIDRA (lifitegrast),"7,314,938; 7,790,743; 8,084,047; 8,168,655; 8,592,450",SARcode Bioscience Inc.,2883.0,2380.0,503.0,2008-08-21 00:00:00,2015-02-25,2016-07-11,NDA 208073,"1,693, 1,319, 1,081, 1,018 or 731 "
Determination of Regulatory Review Period for Purposes of Patent Extension; DOPTELET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DOPTELET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7739,2023-02482,https://www.federalregister.gov/documents/2023/02/06/2023-02482/determination-of-regulatory-review-period-for-purposes-of-patent-extension-doptelet,https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02482.pdf,2023-02-06, DOPTELET,,Tianlun,DOPTELET (avatrombopag maleate),7638536,Astellas Pharma Inc.,4632.0,4389.0,243.0,2005-09-16 00:00:00,2017-09-21,2018-05-21,NDA 210238,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; YUPELRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YUPELRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7979,2023-02498,https://www.federalregister.gov/documents/2023/02/07/2023-02498/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yupelri,https://www.govinfo.gov/content/pkg/FR-2023-02-07/pdf/2023-02498.pdf,2023-02-07, YUPELRI,,Tianlun,YUPELRI (revefenacin),"7,288,657 and 7,585,879","Theravance Biopharma R&D IP, LLC",1724.0,1362.0,362.0,2014-02-21 00:00:00,2017-11-13,2018-11-09,NDA 210598,1042
Determination of Regulatory Review Period for Purposes of Patent Extension; SKYRIZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKYRIZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 8289,2023-02680,https://www.federalregister.gov/documents/2023/02/08/2023-02680/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skyrizi,https://www.govinfo.gov/content/pkg/FR-2023-02-08/pdf/2023-02680.pdf,2023-02-08, SKYRIZI,,Tianlun,SKYRIZI (risankizumab-rzaa),"8,778,346 and 10,202,448",Boehringer Ingelheim International GmbH,2582.0,2216.0,366.0,2012-03-30 00:00:00,2018-04-23,2019-04-23,BLA 761105,70 or 538
Determination of Regulatory Review Period for Purposes of Patent Extension; LOKELMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LOKELMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 8291,2023-02667,https://www.federalregister.gov/documents/2023/02/08/2023-02667/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lokelma,https://www.govinfo.gov/content/pkg/FR-2023-02-08/pdf/2023-02667.pdf,2023-02-08, LOKELMA,,Tianlun,LOKELMA (sodium zirconium cyclosilicate),"8,802,152 and 8,808,750",ZS Pharma Inc.,2384.0,1295.0,1089.0,2011-11-09 00:00:00,2015-05-26,2018-05-18,NDA 207078,29 or 98
Determination of Regulatory Review Period for Purposes of Patent Extension; REMEDE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REMEDE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 8287,2023-02669,https://www.federalregister.gov/documents/2023/02/08/2023-02669/determination-of-regulatory-review-period-for-purposes-of-patent-extension-remede-system,https://www.govinfo.gov/content/pkg/FR-2023-02-08/pdf/2023-02669.pdf,2023-02-08, REMEDE SYSTEM,,Tianlun,REMEDE SYSTEM,8233987,"Respicardia, Inc.",3685.0,3289.0,396.0,2007-09-06 00:00:00,2016-09-06,2017-10-06,PMA 160039,301
Determination of Regulatory Review Period for Purposes of Patent Extension; XOSPATA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XOSPATA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 8431,2023-02745,https://www.federalregister.gov/documents/2023/02/09/2023-02745/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xospata,https://www.govinfo.gov/content/pkg/FR-2023-02-09/pdf/2023-02745.pdf,2023-02-09, XOSPATA,,Tianlun,XOSPATA (gilteritinib),"8,969,336 and 9,487,491",Astellas Pharma Inc.,2002.0,1757.0,245.0,2013-06-07 00:00:00,2018-03-29,2018-11-28,NDA 211349,671 or 498
Determination of Regulatory Review Period for Purposes of Patent Extension; ERLEADA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ERLEADA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 8434,2023-02743,https://www.federalregister.gov/documents/2023/02/09/2023-02743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-erleada,https://www.govinfo.gov/content/pkg/FR-2023-02-09/pdf/2023-02743.pdf,2023-02-09, ERLEADA,,Tianlun,ERLEADA (apalutamide),"8,445,507; 8,802,689; 9,388,159",The Regents of the University of California,2795.0,2667.0,128.0,2010-06-23 00:00:00,2017-10-10,2018-02-14,NDA 210951,"518, 706, or 356"
Determination of Regulatory Review Period for Purposes of Patent Extension; ALIQOPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALIQOPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 9522,2023-03070,https://www.federalregister.gov/documents/2023/02/14/2023-03070/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aliqopa,https://www.govinfo.gov/content/pkg/FR-2023-02-14/pdf/2023-03070.pdf,2023-02-14, ALIQOPA,,Tianlun,ALIQOPA (copanlisib dihydrochloride),"7,511,041 and RE46856",ayer Intellectual Property GmbH,3004.0,2821.0,183.0,2009-06-26 00:00:00,2017-03-16,2017-09-14,NDA 209936,"1,594 or 692"
Determination of Regulatory Review Period for Purposes of Patent Extension; VERZENIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VERZENIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 12938,2023-04177,https://www.federalregister.gov/documents/2023/03/01/2023-04177/determination-of-regulatory-review-period-for-purposes-of-patent-extension-verzenio,https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04177.pdf,2023-03-01, VERZENIO,,Tianlun,VERZENIO (abemaciclib),7855211,Eli Lilly and Company,2907.0,2760.0,147.0,2009-10-15 00:00:00,2017-05-05,2017-09-28,NDA 208716,652
Determination of Regulatory Review Period for Purposes of Patent Extension; VYZULTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYZULTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 12950,2023-04178,https://www.federalregister.gov/documents/2023/03/01/2023-04178/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyzulta,https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04178.pdf,2023-03-01, VYZULTA,,Tianlun,VYZULTA (latanoprostene bunod),"7,273,946; 7,629,345; and 8,058,467",Nicox S.A.,3879.0,3043.0,836.0,2007-03-23 00:00:00,2015-07-21,2017-11-02,NDA 207795,"1,826 or 1,507"
Determination of Regulatory Review Period for Purposes of Patent Extension; JIVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JIVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 16639,2023-05570,https://www.federalregister.gov/documents/2023/03/20/2023-05570/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jivi,https://www.govinfo.gov/content/pkg/FR-2023-03-20/pdf/2023-05570.pdf,2023-03-20, JIVI,,Tianlun,"JIVI (antihemophilic factor (recombinant), PEGylated-aucl)",7632921,Bayer HealthCare LLC,2991.0,2626.0,365.0,2010-06-23 00:00:00,2017-08-30,2018-08-29,BLA 125661,1677
Determination of Regulatory Review Period for Purposes of Patent Extension; IC-8 APTHERA INTRAOCULAR LENS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IC-8 APTHERA INTRAOCULAR LENS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 16642,2023-05641,https://www.federalregister.gov/documents/2023/03/20/2023-05641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ic-8-apthera-intraocular,https://www.govinfo.gov/content/pkg/FR-2023-03-20/pdf/2023-05641.pdf,2023-03-20, IC-8 APTHERA INTRAOCULAR LENS,,Tianlun,IC-8 APTHERA INTRAOCULAR LENS,9005281,"AcuFocus, Inc.",1341.0,827.0,514.0,2018-11-21 00:00:00,2021-02-24,2022-07-22,PMA 210005,928
Determination of Regulatory Review Period for Purposes of Patent Extension; ESPEROCT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ESPEROCT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 16992,2023-05658,https://www.federalregister.gov/documents/2023/03/21/2023-05658/determination-of-regulatory-review-period-for-purposes-of-patent-extension-esperoct,https://www.govinfo.gov/content/pkg/FR-2023-03-21/pdf/2023-05658.pdf,2023-03-21, ESPEROCT,,Tianlun,"ESPEROCT (antihemophilic factor (recombinant), glycopegylated-exei)",8536126,Novo Nordisk A/S,3129.0,2771.0,358.0,2010-07-29 00:00:00,2018-02-27,2019-02-19,BLA 125671,1170
Determination of Regulatory Review Period for Purposes of Patent Extension; MULPLETA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MULPLETA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 17233,2023-05799,https://www.federalregister.gov/documents/2023/03/22/2023-05799/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mulpleta,https://www.govinfo.gov/content/pkg/FR-2023-03-22/pdf/2023-05799.pdf,2023-03-22, MULPLETA,,Tianlun,MULPLETA (lusutrombopag),"7,601,746 and 8,889,722","Shionogi & Co., Ltd",3464.0,3246.0,218.0,2009-02-06 00:00:00,2017-12-26,2018-07-31,NDA 210923,"784 or 1,715"
Determination of Regulatory Review Period for Purposes of Patent Extension; GALAFOLD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GALAFOLD and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 17235,2023-05897,https://www.federalregister.gov/documents/2023/03/22/2023-05897/determination-of-regulatory-review-period-for-purposes-of-patent-extension-galafold,https://www.govinfo.gov/content/pkg/FR-2023-03-22/pdf/2023-05897.pdf,2023-03-22, GALAFOLD,,Tianlun,GALAFOLD (migalastat),"8,592,362 and 9,000,011","Amicus Therapeutics, Inc.",5132.0,4891.0,241.0,2004-07-24 00:00:00,2017-12-13,2018-08-10,NDA 208623,732 or 980
Determination of Regulatory Review Period for Purposes of Patent Extension; TEGSEDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEGSEDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 17583,2023-05906,https://www.federalregister.gov/documents/2023/03/23/2023-05906/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tegsedi,https://www.govinfo.gov/content/pkg/FR-2023-03-23/pdf/2023-05906.pdf,2023-03-23, TEGSEDI,,Tianlun,TEGSEDI (inotersen sodium),"8,101,743; 9,061,044; 9,399,774","Ionis Pharmaceuticals, Inc. ",2158.0,1824.0,334.0,2012-11-09 00:00:00,2017-11-06,2018-10-05,NDA 211172,"526 or 1,246"
Determination of Regulatory Review Period for Purposes of Patent Extension; CINTEC PLUS CYTOLOGY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CINTEC PLUS CYTOLOGY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 17579,2023-05908,https://www.federalregister.gov/documents/2023/03/23/2023-05908/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cintec-plus-cytology,https://www.govinfo.gov/content/pkg/FR-2023-03-23/pdf/2023-05908.pdf,2023-03-23, CINTEC PLUS CYTOLOGY,,Tianlun,CINTEC PLUS CYTOLOGY,8367353,"Ventana Medical Systems, Inc.",181.0,0.0,181.0,not applicable,2019-09-12,2020-03-10,PMA P190024,547
Determination of Regulatory Review Period for Purposes of Patent Extension; RECELL AUTOLOGOUS CELL HARVESTING DEVICE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECELL AUTOLOGOUS CELL HARVESTING DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological device.",88 FR 17581,2023-05948,https://www.federalregister.gov/documents/2023/03/23/2023-05948/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recell-autologous-cell,https://www.govinfo.gov/content/pkg/FR-2023-03-23/pdf/2023-05948.pdf,2023-03-23, RECELL AUTOLOGOUS CELL HARVESTING DEVICE,,Tianlun,RECELL AUTOLOGOUS CELL HARVESTING DEVICE,9029140,Avita Medical Ltd.,4455.0,4097.0,358.0,2006-07-12 00:00:00,2017-09-28,2018-09-20,BP170122,793
Determination of Regulatory Review Period for Purposes of Patent Extension; M6-C Artificial Cervical Disc,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for M6-C ARTIFICIAL CERVICAL DISC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 19155,2023-06580,https://www.federalregister.gov/documents/2023/03/30/2023-06580/determination-of-regulatory-review-period-for-purposes-of-patent-extension-m6-c-artificial-cervical,https://www.govinfo.gov/content/pkg/FR-2023-03-30/pdf/2023-06580.pdf,2023-03-30, M6-C Artificial Cervical Disc,,Tianlun,M6-C ARTIFICIAL CERVICAL DISC,8377138,"Spinal Kinetics, Inc.",4081.0,3617.0,464.0,2007-12-07 00:00:00,2017-10-31,2019-02-06,PMA 170036,"715 or 1,321"
Determination of Regulatory Review Period for Purposes of Patent Extension; Detectnet,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Detectnet and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 30133,2023-09891,https://www.federalregister.gov/documents/2023/05/10/2023-09891/determination-of-regulatory-review-period-for-purposes-of-patent-extension-detectnet,https://www.govinfo.gov/content/pkg/FR-2023-05-10/pdf/2023-09891.pdf,2023-05-10, Detectnet,,Tianlun,Detectnet (copper Cu-64 dotatate),10383961,Somscan APS,989.0,744.0,245.0,2017-12-21 00:00:00,2020-01-03,2020-09-03,NDA 213227,312
Determination of Regulatory Review Period for Purposes of Patent Extension; Zemdri,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zemdri and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 30982,2023-10316,https://www.federalregister.gov/documents/2023/05/15/2023-10316/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemdri,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10316.pdf,2023-05-15, Zemdri,,Tianlun,Zemdri (plazomicin),8383596,"Achaogen, Inc. ",3447.0,3203.0,244.0,2009-01-18 00:00:00,2017-10-25,2018-06-25,NDA 210303,389 or 819
Determination of Regulatory Review Period for Purposes of Patent Extension; Cablivi,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Cablivi and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 30983,2023-10295,https://www.federalregister.gov/documents/2023/05/15/2023-10295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cablivi,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10295.pdf,2023-05-15, Cablivi,,Tianlun,Cablivi (caplacizumab-yhdp),"7,807,162 and 8,372,398",Ablynx N.V.,2998.0,2752.0,246.0,2010-11-24 00:00:00,2018-06-06,2019-02-06,BLA 761112,"1,216 or 1,621"
Determination of Regulatory Review Period for Purposes of Patent Extension; Onpattro,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Onpattro and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 30985,2023-10317,https://www.federalregister.gov/documents/2023/05/15/2023-10317/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onpattro,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10317.pdf,2023-05-15, Onpattro,,Tianlun,Onpattro (patisiran),"8,168,775; 8,741,866; 9,234,196","Alnylam Pharmaceuticals, Inc.",1901.0,1658.0,243.0,2013-05-29 00:00:00,2017-12-11,2018-08-10,NDA 210922,"593, 887 or 1,025"
Determination of Regulatory Review Period for Purposes of Patent Extension; Tack Endovascular System (6F),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tack Endovascular System (6F) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",88 FR 30987,2023-10297,https://www.federalregister.gov/documents/2023/05/15/2023-10297/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tack-endovascular-system,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10297.pdf,2023-05-15, Tack Endovascular System (6F),,Tianlun,Tack Endovascular System (6F),"9,375,327 and 9,603,730","INTACT VASCULAR, INC.",1338.0,1114.0,224.0,2015-08-14 00:00:00,2018-08-31,2019-04-11,PMA P180034,485 or 621
Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 13, 2022. The document determined the regulatory review period for ENSPRYNG. After review of a timely request for reconsideration by the applicant of the calculation of the applicable regulatory review period of the biologic product ENSPRYNG in that notice, FDA has determined that a revision of the supplementary information section is warranted. This notice corrects the applicable regulatory review period language.",88 FR 33614,2023-10979,https://www.federalregister.gov/documents/2023/05/24/2023-10979/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enspryng-correction,https://www.govinfo.gov/content/pkg/FR-2023-05-24/pdf/2023-10979.pdf,2023-05-24, ENSPRYNG, Correction,Tianlun,ENSPRYNG (satralizumab-mwge),"8,562,991; 10,022,319; 10,662,245","Genentech, Inc.",2494.0,2128.0,366.0,2013-10-18 00:00:00,2019-08-15,2020-08-14,BLA 761149,"81, 563, or 1,428"
Determination of Regulatory Review Period for Purposes of Patent Extension; BARRICAID ANULAR CLOSURE DEVICE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BARRICAID ANULAR CLOSURE DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 51839,2023-16614,https://www.federalregister.gov/documents/2023/08/04/2023-16614/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barricaid-anular-closure,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16614.pdf,2023-08-04, BARRICAID ANULAR CLOSURE DEVICE,,Tianlun,BARRICAID ANULAR CLOSURE DEVICE,"6,425,919; 7,524,333; 9,610,106","Intrinsic Therapeutics, Inc.",2980.0,2163.0,817.0,2010-12-14 00:00:00,2016-11-14,2019-02-08,PMA P160050,676 days or 5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; PIFELTRO-New Drug Application 210806,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIFELTRO, new drug application (NDA) 210806, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 51837,2023-16607,https://www.federalregister.gov/documents/2023/08/04/2023-16607/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pifeltro-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16607.pdf,2023-08-04, PIFELTRO-New Drug Application 210806,,Tianlun,PIFELTRO—NDA 210806 (doravirine),8486975,Merck Canada Inc.,2549.0,2237.0,312.0,2011-09-09 00:00:00,2017-10-23,2018-08-30,NDA 210806,328
Determination of Regulatory Review Period for Purposes of Patent Extension; DELSTRIGO-New Drug Application 210807,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DELSTRIGO, new drug application (NDA) 210807, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 51836,2023-16606,https://www.federalregister.gov/documents/2023/08/04/2023-16606/determination-of-regulatory-review-period-for-purposes-of-patent-extension-delstrigo-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16606.pdf,2023-08-04, DELSTRIGO-New Drug Application 210807,,Tianlun,"DELSTRIGO—NDA 210807 (doravirine, lamivudine, and tenofovir disoproxil fumarate)",8486975,Merck Canada Inc.,2549.0,2237.0,312.0,2011-09-09 00:00:00,2017-10-23,2018-08-30,NDA 210807,328
Determination of Regulatory Review Period for Purposes of Patent Extension; VERCISE DEEP BRAIN STIMULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VERCISE DEEP BRAIN STIMULATION SYSTEM (VERCISE DBS SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 51840,2023-16610,https://www.federalregister.gov/documents/2023/08/04/2023-16610/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vercise-deep-brain,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16610.pdf,2023-08-04, VERCISE DEEP BRAIN STIMULATION SYSTEM,,Tianlun,VERCISE DEEP BRAIN STIMULATION SYSTEM,8321025,Boston Scientific Neuromodulation Corp.,393.0,0.0,393.0,Not Applicable,2017-12-22,2019-01-18,PMA P150031 S002,392
Determination of Regulatory Review Period for Purposes of Patent Extension; Vercise Genus Deep Brain Stimulation System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VERCISE GENUS DEEP BRAIN STIMULATION SYSTEM (VERCISE GENUS DBS SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 54615,2023-17259,https://www.federalregister.gov/documents/2023/08/11/2023-17259/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vercise-genus-deep-brain,https://www.govinfo.gov/content/pkg/FR-2023-08-11/pdf/2023-17259.pdf,2023-08-11, Vercise Genus Deep Brain Stimulation System,,Tianlun,VERCISE GENUS DBS SYSTEM,8606362,Boston Scientific Neuromodulation Corporation,274.0,0.0,274.0,Not Applicable,2020-04-23,2021-01-21,PMA P150031 S034,273
Determination of Regulatory Review Period for Purposes of Patent Extension; Omegaven,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Omegaven and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 75003,2023-24124,https://www.federalregister.gov/documents/2023/11/01/2023-24124/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omegaven,https://www.govinfo.gov/content/pkg/FR-2023-11-01/pdf/2023-24124.pdf,2023-11-01, Omegaven,,Tianlun,Omegaven (fish oil triglycerides),9566260,Children's Medical Center Corporation,4246.0,4007.0,239.0,2006-12-13 00:00:00,2017-12-01,2018-07-27,NDA 210589,383
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of July 8, 2022. The document announced the determination of the regulatory review period for ROZLYTREK INJECTION (entrectinib) for purposes of patent extension. The document was published with an incorrect dosage form. This notice corrects the dosage form of the drug product.",88 FR 80317,2023-25489,https://www.federalregister.gov/documents/2023/11/17/2023-25489/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-injection,https://www.govinfo.gov/content/pkg/FR-2023-11-17/pdf/2023-25489.pdf,2023-11-17, ROZLYTREK INJECTION, Correction,Tianlun,ROZLYTREK CAPSULES (entrectinib),"8,299,057; 8,673,893; 9,029,356; and 9,085,565","Genentech, Inc.",1968.0,1727.0,241.0,2014-03-28 00:00:00,2018-12-18,2018-12-18,NDA 212726,"864, 899, or 1,104 "
Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Korsuva and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83136,2023-26106,https://www.federalregister.gov/documents/2023/11/28/2023-26106/determination-of-regulatory-review-period-for-purposes-of-patent-extension-korsuva,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26106.pdf,2023-11-28, Korsuva,,Tianlun,Korsuva (difelikefalin acetate),7402564,"Cara Therapeutics, Inc.",4625.0,4381.0,244.0,2008-12-26 00:00:00,2020-12-23,2021-08-23,NDA 214916,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; Tavneos,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tavneos and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",88 FR 83138,2023-26099,https://www.federalregister.gov/documents/2023/11/28/2023-26099/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tavneos,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26099.pdf,2023-11-28, Tavneos,,Tianlun,Tavneos (avacopan),"8,445,515 and 8,906,938","ChemoCentryx, Inc.",2642.0,2184.0,458.0,2014-07-16 00:00:00,2020-07-07,2021-10-07,NDA 214487,"1,476 or 1,549"
Determination of Regulatory Review Period for Purposes of Patent Extension; Cosela,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Cosela and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83140,2023-26098,https://www.federalregister.gov/documents/2023/11/28/2023-26098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cosela,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26098.pdf,2023-11-28, Cosela,,Tianlun,Cosela (trilaciclib),"8,598,186 and 9,487,530","GI Therapeutics, Inc.",2081.0,1838.0,243.0,2015-06-05 00:00:00,2020-06-15,2021-02-12,NDA 214200,"335 or 1,162"
Determination of Regulatory Review Period for Purposes of Patent Extension; Zeposia,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zeposia and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83141,2023-26097,https://www.federalregister.gov/documents/2023/11/28/2023-26097/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zeposia,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26097.pdf,2023-11-28, Zeposia,,Tianlun,Zeposia (ozanimod hydrochloride),8481573,Scripps Research Institute,3383.0,3016.0,367.0,2010-12-22 00:00:00,2019-03-25,2020-03-25,NDA 209899,1410
Determination of Regulatory Review Period for Purposes of Patent Extension; Lupkynis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Lupkynis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83411,2023-26247,https://www.federalregister.gov/documents/2023/11/29/2023-26247/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lupkynis,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26247.pdf,2023-11-29, Lupkynis,,Tianlun,Lupkynis (voclosporin),7332472,Aurinia Pharmaceuticals Inc.,7584.0,7338.0,246.0,2000-04-20 00:00:00,2020-05-22,2021-01-22,NDA 213716,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; ORGOVYX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Orgovyx and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 83412,2023-26258,https://www.federalregister.gov/documents/2023/11/29/2023-26258/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orgovyx,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26258.pdf,2023-11-29, ORGOVYX,,Tianlun,Orgovyx (relugolix),"7,300,935 and 8,058,280",Myovant Sciences on behalf of Takeda Pharmaceutical Company Limited,4875.0,4632.0,243.0,2007-08-16 00:00:00,2020-04-20,2020-12-18,NDA 214621,"1,783 or 1,827"
Determination of Regulatory Review Period for Purposes of Patent Extension; Kerendia,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Kerendia and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83415,2023-26251,https://www.federalregister.gov/documents/2023/11/29/2023-26251/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kerendia,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26251.pdf,2023-11-29, Kerendia,,Tianlun,Kerendia (finerenone),8436180,Bayer Intellectual Property GmbH,2950.0,2707.0,243.0,2013-06-13 00:00:00,2020-11-09,2021-07-09,NDA 215341,1597
Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Empaveli and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83418,2023-26255,https://www.federalregister.gov/documents/2023/11/29/2023-26255/determination-of-regulatory-review-period-for-purposes-of-patent-extension-empaveli,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26255.pdf,2023-11-29, Empaveli,,Tianlun,Empaveli (pegcetacoplan),"10,035,822; 10,125,171; and 10,875,893","Apellis Pharmaceuticals, Inc.",2501.0,2258.0,243.0,2014-07-11 00:00:00,2020-09-14,2021-05-14,NDA 215014,"137, 545, or 579"
Determination of Regulatory Review Period for Purposes of Patent Extension; Olinvyk,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Olinvyk and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83406,2023-26253,https://www.federalregister.gov/documents/2023/11/29/2023-26253/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olinvyk,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26253.pdf,2023-11-29, Olinvyk,,Tianlun,Olinvyk (oliceridine fumarate),"8,835,488; 9,309,234; 9,642,842","Trevena, Inc.",3206.0,2112.0,1094.0,2012-01-22 00:00:00,2017-11-02,2020-10-30,NDA 210730,951
Determination of Regulatory Review Period for Purposes of Patent Extension; PYLARIFY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PYLARIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",88 FR 83407,2023-26261,https://www.federalregister.gov/documents/2023/11/29/2023-26261/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pylarify,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26261.pdf,2023-11-29, PYLARIFY,,Tianlun,PYLARIFY (piflufolastat F18),"8,487,129; 8,778,305; and 9,861,713","Progenics Pharmaceuticals, Inc.",2681.0,2441.0,240.0,2014-01-24 00:00:00,2020-09-29,2021-05-26,NDA 214793,"736, 1,373 or 1,463"
Determination of Regulatory Review Period for Purposes of Patent Extension; Azstarys,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Azstarys and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83409,2023-26246,https://www.federalregister.gov/documents/2023/11/29/2023-26246/determination-of-regulatory-review-period-for-purposes-of-patent-extension-azstarys,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26246.pdf,2023-11-29, Azstarys,,Tianlun,Azstarys (serdexmethylphenidate and dexmethylphenidate),9079928,"KemPharm, Inc.",1676.0,1244.0,432.0,2016-10-06 00:00:00,2020-03-02,2021-05-07,NDA 212994,948
Determination of Regulatory Review Period for Purposes of Patent Extension; Tukysa,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tukysa and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83414,2023-26256,https://www.federalregister.gov/documents/2023/11/29/2023-26256/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tukysa,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26256.pdf,2023-11-29, Tukysa,,Tianlun,Tukysa (tucatinib),"7,452,895; 8,648,087; 9,457,093; and 9,693,989","Array BioPharma Inc. and Seattle Genetics, Inc. (Agent of Array BioPharma Inc.)",4653.0,4533.0,120.0,2007-07-24 00:00:00,2019-12-20,2020-04-17,NDA 213411,"552, 570, 1,101 or 1,826"
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEGALOGUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83547,2023-26260,https://www.federalregister.gov/documents/2023/11/30/2023-26260/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zegalogue,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26260.pdf,2023-11-30, ZEGALOGUE,,Tianlun,ZEGALOGUE (dasiglucagon),10442847,Zealand Pharma A/S,1734.0,1373.0,361.0,2016-06-24 00:00:00,2020-03-27,2021-03-22,NDA 214231,47
Determination of Regulatory Review Period for Purposes of Patent Extension; Qelbree,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Qelbree and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83548,2023-26301,https://www.federalregister.gov/documents/2023/11/30/2023-26301/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qelbree,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26301.pdf,2023-11-30, Qelbree,,Tianlun,Qelbree (viloxazine),"9,358,204; 9,603,853; 9,662,338","Supernus Pharmaceuticals, Inc. ",4328.0,3816.0,512.0,2009-05-29 00:00:00,2019-11-08,2021-04-02,NDA 211964,785
Determination of Regulatory Review Period for Purposes of Patent Extension; Koselugo,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Koselugo and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83556,2023-26324,https://www.federalregister.gov/documents/2023/11/30/2023-26324/determination-of-regulatory-review-period-for-purposes-of-patent-extension-koselugo,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26324.pdf,2023-11-30, Koselugo,,Tianlun,Koselugo (selumetinib),"7,425,637; 8,178,693; 9,156,795",AstraZeneca AB and Array BioPharma Inc.,5100.0,4889.0,211.0,2006-04-26 00:00:00,2019-09-13,2020-04-10,NDA 213756,"927 days, 1,550 days, or 5 years"
Determination of Regulatory Review Period for Purposes of Patent Extension; Rezurock,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Rezurock and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83558,2023-26358,https://www.federalregister.gov/documents/2023/11/30/2023-26358/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rezurock,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26358.pdf,2023-11-30, Rezurock,,Tianlun,Rezurock (belumosudil mesylate),8357693,"Kadmon Pharmaceuticals, LLC (agent for Surface Logix, LLC)",4327.0,4037.0,290.0,2009-09-12 00:00:00,2020-09-30,2021-07-16,NDA 214783,1154
Determination of Regulatory Review Period for Purposes of Patent Extension; Ukoniq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Ukoniq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83555,2023-26303,https://www.federalregister.gov/documents/2023/11/30/2023-26303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ukoniq,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26303.pdf,2023-11-30, Ukoniq,,Tianlun,Ukoniq (umbralisib tosylate),"9,150,579; 9,669,033; 10,072,013; and 10,570,142",Rhizen Pharmaceuticals SA,2963.0,2727.0,236.0,2012-12-28 00:00:00,2020-06-15,2021-02-05,NDA 213176,"291, 577, or 583"
Determination of Regulatory Review Period for Purposes of Patent Extension; Amondys 45,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Amondys 45 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83545,2023-26299,https://www.federalregister.gov/documents/2023/11/30/2023-26299/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amondys-45,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26299.pdf,2023-11-30, Amondys 45,,Tianlun,Amondys 45 (casimersen),"8,524,880; 9,228,187; 9,447,415; 9,758,783; 10,287,586; and 10,781,450",The University of Western Australia,2412.0,2166.0,246.0,2014-07-22 00:00:00,2020-06-25,2021-02-25,NDA 213026,"157, 450, 755, 933, 1,063, or 1,329"
Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Injection (New Drug Application 209817),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Injection (new drug application (NDA) 209817) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83550,2023-26363,https://www.federalregister.gov/documents/2023/11/30/2023-26363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuzyra-injection-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26363.pdf,2023-11-30, Nuzyra Injection (New Drug Application 209817),,Tianlun,Nuzyra Injection (NDA 209817) (omadacycline),7553828,"Paratek Pharmaceuticals, Inc.",4361.0,4118.0,243.0,2006-10-26 00:00:00,2018-02-02,2018-10-02,NDA 209817,1812
Determination of Regulatory Review Period for Purposes of Patent Extension; Truseltiq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Truseltiq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85291,2023-26885,https://www.federalregister.gov/documents/2023/12/07/2023-26885/determination-of-regulatory-review-period-for-purposes-of-patent-extension-truseltiq,https://www.govinfo.gov/content/pkg/FR-2023-12-07/pdf/2023-26885.pdf,2023-12-07, Truseltiq,,Tianlun,Truseltiq (infigratinib),8552002,"QED Therapeutics, Inc. (agent of Novartis AG)",4258.0,4016.0,242.0,2009-10-02 00:00:00,2020-09-29,2021-05-28,NDA 214622,1516
Determination of Regulatory Review Period for Purposes of Patent Extension; Tivdak,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tivdak and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",88 FR 85625,2023-26992,https://www.federalregister.gov/documents/2023/12/08/2023-26992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tivdak,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26992.pdf,2023-12-08, Tivdak,,Tianlun,Tivdak (tisotumab vedotin),"9,150,658; 9,168,314; and 9,492,565",Genmab A/S,2959.0,2736.0,223.0,2013-08-16 00:00:00,2021-02-10,2021-09-20,BLA B761208,"997, 1,077, or 1,190"
Determination of Regulatory Review Period for Purposes of Patent Extension; Pemazyre,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Pemazyre and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85627,2023-26996,https://www.federalregister.gov/documents/2023/12/08/2023-26996/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pemazyre,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26996.pdf,2023-12-08, Pemazyre,,Tianlun,Pemazyre (pemigatinib),"9,611,267; 10,131,667",Incyte Corp. and Incyte Holdings Corp.,1971.0,1770.0,201.0,2014-11-26 00:00:00,2019-09-30,2020-04-17,NDA 213736,309
Determination of Regulatory Review Period for Purposes of Patent Extension; EXKIVITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXKIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 85629,2023-27004,https://www.federalregister.gov/documents/2023/12/08/2023-27004/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exkivity,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27004.pdf,2023-12-08, EXKIVITY,,Tianlun,EXKIVITY (mobocertinib),"9,796,712; 10,227,342",Takeda Pharmaceutical Company Limited,2059.0,1857.0,202.0,2016-01-28 00:00:00,2021-02-26,2021-09-15,NDA 215310,126
Determination of Regulatory Review Period for Purposes of Patent Extension; Fotivda,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Fotivda and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85630,2023-26997,https://www.federalregister.gov/documents/2023/12/08/2023-26997/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fotivda,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26997.pdf,2023-12-08, Fotivda,,Tianlun,Fotivda (tivozanib hydrochloride),"6,821,987; 7,166,722","AVEO Pharmaceuticals, Inc. (agent of Kyowa Kirin Co., Ltd.)",5035.0,4690.0,345.0,2007-05-30 00:00:00,2020-03-31,2021-03-10,NDA 212904 ,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; Nextstellis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Nextstellis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85632,2023-26988,https://www.federalregister.gov/documents/2023/12/08/2023-26988/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nextstellis,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26988.pdf,2023-12-08, Nextstellis,,Tianlun,Nextstellis (drospirenone and estetrol),7732430,Mayne Pharma LLC,1732.0,1366.0,366.0,2016-07-20 00:00:00,2020-04-15,2021-04-15,NDA 214154,1048
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYNLONTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYNLONTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 85633,2023-26982,https://www.federalregister.gov/documents/2023/12/08/2023-26982/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zynlonta,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26982.pdf,2023-12-08, ZYNLONTA,,Tianlun,ZYNLONTA (loncastuximab tesirine-lpyl),9931414,ADC Therapeutics S.A.,1969.0,1754.0,215.0,2015-12-04 00:00:00,2020-09-21,2021-04-23,BLA 761196,559
Determination of Regulatory Review Period for Purposes of Patent Extension; SEYSARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEYSARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85635,2023-27003,https://www.federalregister.gov/documents/2023/12/08/2023-27003/determination-of-regulatory-review-period-for-purposes-of-patent-extension-seysara,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27003.pdf,2023-12-08, SEYSARA,,Tianlun,SEYSARA (sarecycline hydrochloride),8318706,"Paratek Pharmaceuticals, Inc.",2946.0,2599.0,347.0,2010-09-09 00:00:00,2017-10-20,2018-10-01,NDA 209521,1227
Determination of Regulatory Review Period for Purposes of Patent Extension; VIZIMPRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIZIMPRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85645,2023-27012,https://www.federalregister.gov/documents/2023/12/08/2023-27012/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vizimpro,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27012.pdf,2023-12-08, VIZIMPRO,,Tianlun,VIZIMPRO (dacomitinib),7772243,Warner-Lambert Co. LLC ,4794.0,4554.0,240.0,2005-08-14 00:00:00,2018-01-31,2018-09-27,NDA 211288,1493
Determination of Regulatory Review Period for Purposes of Patent Extension; VILTEPSO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VILTEPSO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85638,2023-27013,https://www.federalregister.gov/documents/2023/12/08/2023-27013/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viltepso,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27013.pdf,2023-12-08, VILTEPSO,,Tianlun,VILTEPSO (viltolarsen),9079934,"Nippon Shinyaku Co., LTD. ",1573.0,1255.0,318.0,2016-04-24 00:00:00,2019-09-30,2020-08-12,NDA 212154,1077
Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Tablets (New Drug Application 209816),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Tablets (new drug application (NDA) 209816) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85643,2023-26989,https://www.federalregister.gov/documents/2023/12/08/2023-26989/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuzyra-tablets-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26989.pdf,2023-12-08, Nuzyra Tablets (New Drug Application 209816),,Tianlun,Nuzyra Tablets (NDA 209816) (omadacycline),9265740,"Paratek Pharmaceuticals, Inc.",4361.0,4118.0,243.0,2006-10-26 00:00:00,2018-02-02,2018-10-02,NDA 209816,597
Determination of Regulatory Review Period for Purposes of Patent Extension; WELIREG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WELIREG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 85892,2023-27044,https://www.federalregister.gov/documents/2023/12/11/2023-27044/determination-of-regulatory-review-period-for-purposes-of-patent-extension-welireg,https://www.govinfo.gov/content/pkg/FR-2023-12-11/pdf/2023-27044.pdf,2023-12-11, WELIREG,,Tianlun,WELIREG (belzutifan),"9,908,845; 9,969,689","Peloton Therapeutics, Inc",1752.0,1541.0,211.0,2016-10-28 00:00:00,2021-01-15,2021-08-13,NDA 215383,342
Determination of Regulatory Review Period for Purposes of Patent Extension; LYBALVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYBALVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 88397,2023-28094,https://www.federalregister.gov/documents/2023/12/21/2023-28094/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lybalvi,https://www.govinfo.gov/content/pkg/FR-2023-12-21/pdf/2023-28094.pdf,2023-12-21, LYBALVI,,Tianlun,LYBALVI (olanzapine and samidorphan),"7,262,298; 9,119,848; 9,126,977; 10,300,054; and 10,716,785",Alkermes Inc. ,4564.0,4003.0,561.0,2008-11-30 00:00:00,2019-11-15,2021-05-28,NDA 213378,"311 days, 646 days, 1,325 days, 1,328 days, or 5 years"
Determination of Regulatory Review Period for Purposes of Patent Extension; Emgality,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Emgality and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 88625,2023-28233,https://www.federalregister.gov/documents/2023/12/22/2023-28233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emgality,https://www.govinfo.gov/content/pkg/FR-2023-12-22/pdf/2023-28233.pdf,2023-12-22, Emgality,,Tianlun,Emgality (galcanezumab-gnlm),9505838,Eli Lilly and Company,2738.0,2372.0,366.0,2011-04-01 00:00:00,2017-09-27,2018-09-27,BLA B761063,403
Determination of Regulatory Review Period for Purposes of Patent Extension; Copiktra,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Copiktra and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 88627,2023-28244,https://www.federalregister.gov/documents/2023/12/22/2023-28244/determination-of-regulatory-review-period-for-purposes-of-patent-extension-copiktra,https://www.govinfo.gov/content/pkg/FR-2023-12-22/pdf/2023-28244.pdf,2023-12-22, Copiktra,,Tianlun,Copiktra (duvelisib),8193182,"Verastem, Inc.",2596.0,2364.0,232.0,2011-08-18 00:00:00,2018-02-05,2018-09-24,NDA 211155,954
Determination of Regulatory Review Period for Purposes of Patent Extension; PONVORY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PONVORY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89455,2023-28509,https://www.federalregister.gov/documents/2023/12/27/2023-28509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ponvory,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28509.pdf,2023-12-27, PONVORY,,Tianlun,PONVORY (ponesimod),RE43728,Actelion Pharmaceuticals Ltd. ,4459.0,4092.0,367.0,2009-01-04 00:00:00,2020-03-18,2021-03-18,NDA 213498,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; CYTALUX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CYTALUX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89458,2023-28507,https://www.federalregister.gov/documents/2023/12/27/2023-28507/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cytalux,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28507.pdf,2023-12-27, CYTALUX,,Tianlun,CYTALUX (pafolacianine),9061057,Purdue Research Foundation,2610.0,2274.0,336.0,2014-10-09 00:00:00,2020-12-29,2021-11-29,NDA 214907,825
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOKINVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZOKINVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 89453,2023-28511,https://www.federalregister.gov/documents/2023/12/27/2023-28511/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zokinvy,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28511.pdf,2023-12-27, ZOKINVY,,Tianlun,ZOKINVY (lonafarnib),"7,838,531 and 8,828,356","the Government of the United States of America as represented by the Department of Health and Human Services; the Regents of the University of Michigan; Progeria Research Foundation, Inc.; and the University of North Carolina at Chapel Hill",5023.0,4777.0,246.0,2007-02-21 00:00:00,2020-03-20,2020-11-20,NDA 213969,"1,255 or 1,948"
Determination of Regulatory Review Period for Purposes of Patent Extension; SCEMBLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCEMBLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89456,2023-28519,https://www.federalregister.gov/documents/2023/12/27/2023-28519/determination-of-regulatory-review-period-for-purposes-of-patent-extension-scemblix,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28519.pdf,2023-12-27, SCEMBLIX,,Tianlun,SCEMBLIX (asciminib hydrochloride),8829195,Novartis AG,2845.0,2717.0,128.0,2014-01-16 00:00:00,2021-06-24,2021-10-29,NDA 215358,899
Determination of Regulatory Review Period for Purposes of Patent Extension; CABENUVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CABENUVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 4954,2024-01439,https://www.federalregister.gov/documents/2024/01/25/2024-01439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cabenuva,https://www.govinfo.gov/content/pkg/FR-2024-01-25/pdf/2024-01439.pdf,2024-01-25, CABENUVA,,Tianlun,CABENUVA (cabotegravir and rilpivirine),8410103,"ViiV Healthcare Company and Shionogi & Co., Ltd.",4719.0,4085.0,634.0,2008-02-22 00:00:00,2019-04-29,2021-01-21,NDA 212888,1742
Determination of Regulatory Review Period for Purposes of Patent Extension; VOCABRIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOCABRIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 4959,2024-01438,https://www.federalregister.gov/documents/2024/01/25/2024-01438/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vocabria,https://www.govinfo.gov/content/pkg/FR-2024-01-25/pdf/2024-01438.pdf,2024-01-25, VOCABRIA,,Tianlun,VOCABRIA (cabotegravir sodium),8410103,ViiV Healthcare Company,4719.0,4085.0,634.0,2008-02-22 00:00:00,2019-04-29,2021-01-21,NDA 212887 ,1742
Determination of Regulatory Review Period for Purposes of Patent Extension; SKYTROFA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKYTROFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 11304,2024-03031,https://www.federalregister.gov/documents/2024/02/14/2024-03031/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skytrofa,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03031.pdf,2024-02-14, SKYTROFA,,Tianlun,SKYTROFA (lonapegsomatropin-tcgd),"9,272,048; 9,511,122; and 10,682,395",Ascendis Pharma Endocrinology Division A/S,2133.0,1706.0,427.0,2015-10-25 00:00:00,2020-06-25,2021-08-25,BLA 761177,"431, 1,075 or 1,215"
Determination of Regulatory Review Period for Purposes of Patent Extension; QULIPTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QULIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 11306,2024-03019,https://www.federalregister.gov/documents/2024/02/14/2024-03019/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qulipta,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03019.pdf,2024-02-14, QULIPTA,,Tianlun,QULIPTA (atogepant),"8,754,096 and 9,499,545",Merck Sharp & Dohme Corp.,3374.0,3130.0,244.0,2012-07-05 00:00:00,2021-01-28,2021-09-28,NDA 215206,"1,008 or 1,166"
Determination of Regulatory Review Period for Purposes of Patent Extension; ERVEBO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ERVEBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 11288,2024-03030,https://www.federalregister.gov/documents/2024/02/14/2024-03030/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ervebo,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03030.pdf,2024-02-14, ERVEBO,,Tianlun,"ERVEBO (Ebola Zaire Vaccine, Live)",8012489,Merck Sharp & Dohme Corp.,1941.0,1783.0,158.0,2014-08-28 00:00:00,2019-07-15,2019-12-19,BLA 125690/0,1038
Determination of Regulatory Review Period for Purposes of Patent Extension; WINLEVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WINLEVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",89 FR 11299,2024-03022,https://www.federalregister.gov/documents/2024/02/14/2024-03022/determination-of-regulatory-review-period-for-purposes-of-patent-extension-winlevi,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03022.pdf,2024-02-14, WINLEVI,,Tianlun,WINLEVI (clascoterone),"8,143,240; 8,785,427; 8,865,690; 9,211,295; 9,433,628; 9,486,458; and 10,159,682",Cassiopea S.p.A.,3102.0,2736.0,366.0,2012-03-01 00:00:00,2019-08-27,2020-08-26,NDA 213433,"489, 877, 909, 1,042, 1,252, 1,297, or 1,721"
Determination of Regulatory Review Period for Purposes of Patent Extension; VIVISTIM SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIVISTIM SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11294,2024-03025,https://www.federalregister.gov/documents/2024/02/14/2024-03025/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vivistim-system,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03025.pdf,2024-02-14, VIVISTIM SYSTEM,,Tianlun,VIVISTIM SYSTEM,9522274,"MicroTransponder, Inc. (Agent of Board of Regents, The University of Texas System)",2719.0,2540.0,179.0,2014-03-20 00:00:00,2021-03-02,2021-08-27,PMA P210007,1359
Determination of Regulatory Review Period for Purposes of Patent Extension; REACTIV8 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REACTIV8 SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11289,2024-03026,https://www.federalregister.gov/documents/2024/02/14/2024-03026/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reactiv8-system,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03026.pdf,2024-02-14, REACTIV8 SYSTEM,,Tianlun,REACTIV8 SYSTEM,"8,606,358; 9,474,906; and 9,861,811",Mainstay Medical Limited,1729.0,1436.0,293.0,2015-09-24 00:00:00,2019-08-29,2020-06-16,PMA P190021,"591, 812, or 1,011"
Determination of Regulatory Review Period for Purposes of Patent Extension; SIMPLIFY CERVICAL ARTIFICIAL DISC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SIMPLIFY CERVICAL ARTIFICIAL DISC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",89 FR 11286,2024-03024,https://www.federalregister.gov/documents/2024/02/14/2024-03024/determination-of-regulatory-review-period-for-purposes-of-patent-extension-simplify-cervical,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03024.pdf,2024-02-14, SIMPLIFY CERVICAL ARTIFICIAL DISC,,Tianlun,SIMPLIFY CERVICAL ARTIFICIAL DISC,"7,753,956 and 9,107,762",Simplify Medical Pty Ltd.,2020.0,1842.0,178.0,2015-03-11 00:00:00,2020-03-25,2020-09-18,PMA P200022,1098
Determination of Regulatory Review Period for Purposes of Patent Extension; ORGAN CARE SYSTEM HEART,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORGAN CARE SYSTEM HEART (OCS HEART SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11301,2024-03028,https://www.federalregister.gov/documents/2024/02/14/2024-03028/determination-of-regulatory-review-period-for-purposes-of-patent-extension-organ-care-system-heart,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03028.pdf,2024-02-14, ORGAN CARE SYSTEM HEART,,Tianlun,OCS HEART SYSTEM,7651835,"TransMedics, Inc.",5518.0,4535.0,983.0,2006-07-28 00:00:00,2018-12-26,2021-09-03,PMA P180051,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ORGAN CARE SYSTEM LIVER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORGAN CARE SYSTEM LIVER (OCS LIVER) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11303,2024-03034,https://www.federalregister.gov/documents/2024/02/14/2024-03034/determination-of-regulatory-review-period-for-purposes-of-patent-extension-organ-care-system-liver,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03034.pdf,2024-02-14, ORGAN CARE SYSTEM LIVER,,Tianlun,OCS LIVER,10076112,"TransMedics, Inc.",2275.0,1819.0,456.0,2015-07-09 00:00:00,2020-06-30,2021-09-28,PMA P20031,72
Determination of Regulatory Review Period for Purposes of Patent Extension; PORTICO TRANSCATHETER AORTIC VALVE IMPLANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the PORTICO TRANSCATHETER AORTIC VALVE IMPLANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11293,2024-03029,https://www.federalregister.gov/documents/2024/02/14/2024-03029/determination-of-regulatory-review-period-for-purposes-of-patent-extension-portico-transcatheter,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03029.pdf,2024-02-14, PORTICO TRANSCATHETER AORTIC VALVE IMPLANT,,Tianlun,PORTICO TRANSCATHETER AORTIC VALVE IMPLANT,"9,011,527; 9,039,759; 9,241,791; 9,289,292; and 9,775,707","St. Jude Medical, Cardiology Division, Inc.",3028.0,2288.0,740.0,2013-06-05 00:00:00,2019-09-09,2021-09-17,PMA P190023,"660; 932; 1,093; 1,459; and 1,486"
"Determination of Regulatory Review Period for Purposes of Patent Extension; TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS (MM)) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11291,2024-03032,https://www.federalregister.gov/documents/2024/02/14/2024-03032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tack-endovascular-system,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03032.pdf,2024-02-14," TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS)",,Tianlun,"TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MM)","9,974,670; 10,137,013; and 10,271,973","Intact Vascular, Inc.",1203.0,1010.0,193.0,2016-12-26 00:00:00,2019-10-01,2020-04-10,PMA P190027,"271, 348, or 442"
Determination of Regulatory Review Period for Purposes of Patent Extension; Rybrevant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Rybrevant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14505,2024-03961,https://www.federalregister.gov/documents/2024/02/27/2024-03961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rybrevant,https://www.govinfo.gov/content/pkg/FR-2024-02-27/pdf/2024-03961.pdf,2024-02-27, Rybrevant,,Tianlun,Rybrevant (amivantamab-vmjw),9593164,"Janssen Biotech, Inc.",1284.0,1105.0,179.0,2017-11-16 00:00:00,2020-11-24,2021-05-21,BLA B761210,546
Determination of Regulatory Review Period for Purposes of Patent Extension; NULIBRY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NULIBRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14851,2024-04226,https://www.federalregister.gov/documents/2024/02/29/2024-04226/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nulibry,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04226.pdf,2024-02-29, NULIBRY,,Tianlun,NULIBRY (fosdenopterin),7504095,"Origin Biosciences, Inc.",2815.0,2572.0,243.0,2013-06-15 00:00:00,2020-06-29,2021-02-26,NDA 214018,1529
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTURISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ISTURISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",89 FR 14853,2024-04231,https://www.federalregister.gov/documents/2024/02/29/2024-04231/determination-of-regulatory-review-period-for-purposes-of-patent-extension-isturisa,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04231.pdf,2024-02-29, ISTURISA,,Tianlun,ISTURISA (osilodrostat phosphate),"8,314,097; 8,609,862",Recordati AG,4393.0,4026.0,367.0,2008-02-28 00:00:00,2019-03-07,2020-03-06,NDA 212801,1148
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDUALAG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OPDUALAG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14854,2024-04219,https://www.federalregister.gov/documents/2024/02/29/2024-04219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdualag,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04219.pdf,2024-02-29, OPDUALAG,,Tianlun,OPDUALAG (nivolumab and relatlimab-rmbw),"9,505,839 and 10,377,824",Bristol-Myers Squibb Company,3110.0,2867.0,243.0,2013-09-13 00:00:00,2021-07-19,2022-03-18,BLA 761234,552 or 596
Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOUNJARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14856,2024-04157,https://www.federalregister.gov/documents/2024/02/29/2024-04157/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mounjaro,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04157.pdf,2024-02-29, MOUNJARO,,Tianlun,MOUNJARO (tirzepatide),9474780,Eli Lilly and Company,2208.0,1967.0,241.0,2016-04-28 00:00:00,2021-09-15,2022-05-13,NDA 215866,129
Determination of Regulatory Review Period for Purposes of Patent Extension; SOGROYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOGROYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14857,2024-04208,https://www.federalregister.gov/documents/2024/02/29/2024-04208/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sogroya,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04208.pdf,2024-02-29, SOGROYA,,Tianlun,SOGROYA (somapacitan-beco),8779109,Novo Nordisk Health Care AG,2200.0,1833.0,367.0,2014-08-22 00:00:00,2019-08-28,2020-08-28,BLA 761156,1284
Determination of Regulatory Review Period for Purposes of Patent Extension; KLISYRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KLISYRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14859,2024-04232,https://www.federalregister.gov/documents/2024/02/29/2024-04232/determination-of-regulatory-review-period-for-purposes-of-patent-extension-klisyri,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04232.pdf,2024-02-29, KLISYRI,,Tianlun,KLISYRI (tirbanibulin),"7,300,931; 7,851,470",Athenex Inc.,4899.0,4548.0,351.0,2007-07-19 00:00:00,2019-12-30,2020-12-14,NDA 213189,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; TEMBEXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEMBEXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14861,2024-04205,https://www.federalregister.gov/documents/2024/02/29/2024-04205/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tembexa,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04205.pdf,2024-02-29, TEMBEXA,,Tianlun,TEMBEXA (brincidofovir),9303051,"Chimerix, Inc.",5463.0,5222.0,241.0,2006-06-22 00:00:00,2020-10-07,2021-06-04,NDA 214460,1064
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPHNELO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPHNELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14862,2024-04203,https://www.federalregister.gov/documents/2024/02/29/2024-04203/determination-of-regulatory-review-period-for-purposes-of-patent-extension-saphnelo,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04203.pdf,2024-02-29, SAPHNELO,,Tianlun,SAPHNELO (anifrolumab-fnia),"7,662,381; 8,460,668; 9,493,570; and 9,988,459","AstraZeneca AB (agent of E.R. Squibb & Sons, L.L.C.)",4578.0,4213.0,365.0,2009-01-18 00:00:00,2020-07-31,2021-07-30,BLA B761123,"5, 763, 778, and 1,673"
Determination of Regulatory Review Period for Purposes of Patent Extension; EVKEEZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVKEEZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14864,2024-04207,https://www.federalregister.gov/documents/2024/02/29/2024-04207/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evkeeza,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04207.pdf,2024-02-29, EVKEEZA,,Tianlun,EVKEEZA (evinacumab-dgnb),9018356,Regeneron,3002.0,2756.0,246.0,2012-11-25 00:00:00,2020-06-11,2021-02-11,BLA 761181,972
Determination of Regulatory Review Period for Purposes of Patent Extension; VONJO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VONJO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14866,2024-04162,https://www.federalregister.gov/documents/2024/02/29/2024-04162/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vonjo,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04162.pdf,2024-02-29, VONJO,,Tianlun,VONJO (pacritinib citrate),"8,153,632 and 9,573,964",CTI BioPharma Corp.,5138.0,4802.0,336.0,2008-02-06 00:00:00,2021-03-30,2022-02-28,NDA 208712,"1,085 days or 5 years"
Determination of Regulatory Review Period for Purposes of Patent Extension; ADUHELM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADUHELM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14869,2024-04214,https://www.federalregister.gov/documents/2024/02/29/2024-04214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aduhelm,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04214.pdf,2024-02-29, ADUHELM,,Tianlun,ADUHELM (aducanumab-avwa),"8,906,367 and 10,131,708",University of Zurich,3689.0,3353.0,336.0,2011-05-04 00:00:00,2020-07-07,2021-06-07,BLA 761178,"634 and 1,197"
Determination of Regulatory Review Period for Purposes of Patent Extension; RECORLEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECORLEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14870,2024-04156,https://www.federalregister.gov/documents/2024/02/29/2024-04156/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recorlev,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04156.pdf,2024-02-29, RECORLEV,,Tianlun,RECORLEV (levoketoconazole),9918984,"Xeris Pharmaceuticals, Inc.",5812.0,5507.0,305.0,2006-02-02 00:00:00,2021-03-01,2021-12-30,NDA 214133,844
Determination of Regulatory Review Period for Purposes of Patent Extension; VEKLURY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VEKLURY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14874,2024-04224,https://www.federalregister.gov/documents/2024/02/29/2024-04224/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veklury,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04224.pdf,2024-02-29, VEKLURY,,Tianlun,VEKLURY (remdesivir),"8,008,264; 8,318,682; 9,724,360; 9,949,994; 10,065,958; and RE46762","Gilead Sciences, Inc.",1904.0,1827.0,77.0,2015-08-08 00:00:00,2020-08-07,2020-10-22,NDA 214787,"429, 625, or 991"
Determination of Regulatory Review Period for Purposes of Patent Extension; EVRYSDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVRYSDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14875,2024-04217,https://www.federalregister.gov/documents/2024/02/29/2024-04217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evrysdi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04217.pdf,2024-02-29, EVRYSDI,,Tianlun,EVRYSDI (risdiplam),9586955,"Genentech, Inc. (agent for PtC Therapeutics Inc. and Hoffmann-La Roche Inc.)",1368.0,1049.0,319.0,2016-11-10 00:00:00,2019-09-24,2020-08-07,NDA 213535,545
Determination of Regulatory Review Period for Purposes of Patent Extension; BREXAFEMME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BREXAFEMME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14877,2024-04150,https://www.federalregister.gov/documents/2024/02/29/2024-04150/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brexafemme,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04150.pdf,2024-02-29, BREXAFEMME,,Tianlun,BREXAFEMME (ibrexafungerp tablets),8188085,"Scynexis, Inc.",4130.0,3886.0,244.0,2010-02-11 00:00:00,2020-10-01,2021-06-01,NDA 214900,1768
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMZYOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAMZYOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14880,2024-04165,https://www.federalregister.gov/documents/2024/02/29/2024-04165/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camzyos,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04165.pdf,2024-02-29, CAMZYOS,,Tianlun,CAMZYOS (mavacamten),"9,181,200; 9,585,883","Myokardia, Inc. ",2723.0,2266.0,457.0,2014-11-16 00:00:00,2021-01-28,2022-04-28,NDA 214998,679
Determination of Regulatory Review Period for Purposes of Patent Extension; GEMTESA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GEMTESA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14883,2024-04221,https://www.federalregister.gov/documents/2024/02/29/2024-04221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gemtesa,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04221.pdf,2024-02-29, GEMTESA,,Tianlun,GEMTESA (vibegron),"8,247,415 and 8,653,260",Urovant Sciences GmbH,3953.0,3589.0,364.0,2010-02-28 00:00:00,2019-12-26,2020-12-23,NDA 213006,"1,483 and 1,433"
Determination of Regulatory Review Period for Purposes of Patent Extension; XERAVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XERAVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14886,2024-04227,https://www.federalregister.gov/documents/2024/02/29/2024-04227/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xerava,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04227.pdf,2024-02-29, XERAVA,,Tianlun,XERAVA (eravacycline dihydrochloride),8906887,"Tetraphase Pharmaceutical, Inc.",3265.0,3022.0,243.0,2009-09-20 00:00:00,2017-09-28,2018-08-27,NDA 211109,608
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAMCEVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14892,2024-04218,https://www.federalregister.gov/documents/2024/02/29/2024-04218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camcevi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04218.pdf,2024-02-29, CAMCEVI,,Tianlun,CAMCEVI (leuprolide mesylate),"9,572,857; 9,744,207; 10,646,572","Foresee Pharmaceutials Co., Ltd.",2569.0,2266.0,303.0,2014-05-15 00:00:00,2020-07-27,2021-05-25,NDA 211488,"340, 834, or 928"
Determination of Regulatory Review Period for Purposes of Patent Extension; LEQVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LEQVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14867,2024-04230,https://www.federalregister.gov/documents/2024/02/29/2024-04230/determination-of-regulatory-review-period-for-purposes-of-patent-extension-leqvio,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04230.pdf,2024-02-29, LEQVIO,,Tianlun,LEQVIO (inclisiran sodium),"8,222,222; 8,809,292; 8,828,956; 9,370,582; 10,125,369",Novartis Pharmaceuticals Corporation,2134.0,1403.0,731.0,2016-02-20 00:00:00,2019-12-23,2021-12-22,NDA 214012,"492, 1,371, or 1,432"
Determination of Regulatory Review Period for Purposes of Patent Extension; ONGENTYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ONGENTYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14872,2024-04233,https://www.federalregister.gov/documents/2024/02/29/2024-04233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ongentys,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04233.pdf,2024-02-29, ONGENTYS,,Tianlun,ONGENTYS (opicapone),"8,168,793; 8,524,746; 9,550,759; 9,630,955; and 10,071,085","Bial-Portela & CA., S.A.",3306.0,2940.0,366.0,2011-04-09 00:00:00,2019-04-26,2020-04-24,NDA 212489,"478, 498, 1,323, 1,395, or 1,640"
Determination of Regulatory Review Period for Purposes of Patent Extension; INQOVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INQOVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14888,2024-04234,https://www.federalregister.gov/documents/2024/02/29/2024-04234/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inqovi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04234.pdf,2024-02-29, INQOVI,,Tianlun,INQOVI (decitabine and cedazuridine),"8,268,800; 8,618,075; and 9,567,363","Otsuka Pharmaceutical Co., Ltd.",2330.0,2120.0,210.0,2014-02-21 00:00:00,2019-12-11,2020-07-07,NDA 212576,"726, 1,270, or 2,330"
Determination of Regulatory Review Period for Purposes of Patent Extension; AMPLATZER AMULET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AMPLATZER AMULET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that medical device.",89 FR 14885,2024-04206,https://www.federalregister.gov/documents/2024/02/29/2024-04206/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amplatzer-amulet,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04206.pdf,2024-02-29, AMPLATZER AMULET,,Tianlun,AMPLATZER AMULET,"8,034,061; 8,758,389; 8,961,556; and 10,201,337","St. Jude Medical, Cardiology Division, Inc.",1846.0,1619.0,227.0,2016-07-27 00:00:00,2020-12-31,2021-08-14,PMA P200049,"571, 1,085, 1,296, and 1,616"
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVNAR-20,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PREVNAR-20 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14849,2024-04229,https://www.federalregister.gov/documents/2024/02/29/2024-04229/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevnar-20,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04229.pdf,2024-02-29, PREVNAR-20,,Tianlun,PREVNAR-20,7935787,Wyeth LLC,1678.0,1434.0,244.0,2016-11-05 00:00:00,2020-10-08,2021-06-08,BLA 125731,665 or 961
Determination of Regulatory Review Period for Purposes of Patent Extension; EPI-SENSE GUIDED COAGULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EPI-SENSE GUIDED COAGULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",89 FR 14878,2024-04204,https://www.federalregister.gov/documents/2024/02/29/2024-04204/determination-of-regulatory-review-period-for-purposes-of-patent-extension-epi-sense-guided,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04204.pdf,2024-02-29, EPI-SENSE GUIDED COAGULATION SYSTEM,,Tianlun,EPI-SENSE GUIDED COAGULATION SYSTEM,"7,399,300 and 7,572,257","AtriCure, Inc.",2919.0,2436.0,483.0,2013-05-03 00:00:00,2020-01-02,2021-04-28,PMA P200002,"1,826 or 1,827"
Determination of Regulatory Review Period for Purposes of Patent Extension; RELYVRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RELYVRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15588,2024-04480,https://www.federalregister.gov/documents/2024/03/04/2024-04480/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relyvrio,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04480.pdf,2024-03-04, RELYVRIO,,Tianlun,RELYVRIO (sodium phenylbutyrate and taurursodiol),"9,872,865; 10,251,896; 10,857,162; 11,071,742; 10,857,162; and 11,071,742",Amylyx Pharmaceuticals Inc.,3359.0,3023.0,336.0,2013-07-21 00:00:00,2021-10-29,2022-09-29,NDA 216660,"383, 499, 803, or 1,010"
Determination of Regulatory Review Period for Purposes of Patent Extension; FYARRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FYARRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15591,2024-04481,https://www.federalregister.gov/documents/2024/03/04/2024-04481/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fyarro,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04481.pdf,2024-03-04, FYARRO,,Tianlun,FYARRO (sirolimus protein-bound injectable suspension/albumin-bound),8911786,"Aadi Bioscience, Inc.",5416.0,5237.0,179.0,2007-01-26 00:00:00,2021-05-28,2021-11-22,NDA 213312 ,1357
Determination of Regulatory Review Period for Purposes of Patent Extension; SOTYKTU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOTYKTU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15585,2024-04483,https://www.federalregister.gov/documents/2024/03/04/2024-04483/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sotyktu,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04483.pdf,2024-03-04, SOTYKTU,,Tianlun,SOTYKTU (deucravacitinib),"RE47,929",Bristol-Myers Squibb Company,2136.0,1770.0,366.0,2016-11-06 00:00:00,2021-09-10,2022-09-09,NDA 214958,1037
Determination of Regulatory Review Period for Purposes of Patent Extension; VOXZOGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOXZOGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15593,2024-04479,https://www.federalregister.gov/documents/2024/03/04/2024-04479/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voxzogo,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04479.pdf,2024-03-04, VOXZOGO,,Tianlun,VOXZOGO (vosoritide),8198242,BioMarin Pharmaceutical Inc.,3614.0,3157.0,457.0,2011-12-30 00:00:00,2020-08-20,2021-11-19,NDA 214938,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 15586,2024-04478,https://www.federalregister.gov/documents/2024/03/04/2024-04478/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-3-ultra,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04478.pdf,2024-03-04, SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM,,Tianlun,SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM,7780723,Edwards Lifesciences Corporation,101.0,0.0,101.0,not available,2018-09-18,2018-12-27,PMA P140031S074,184
Determination of Regulatory Review Period for Purposes of Patent Extension; Light Adjustable Lens,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LIGHT ADJUSTABLE LENS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 17852,2024-05213,https://www.federalregister.gov/documents/2024/03/12/2024-05213/determination-of-regulatory-review-period-for-purposes-of-patent-extension-light-adjustable-lens,https://www.govinfo.gov/content/pkg/FR-2024-03-12/pdf/2024-05213.pdf,2024-03-12, Light Adjustable Lens,,Tianlun,LIGHT ADJUSTABLE LENS,"6,851,804 and 6,905,641","RxSight, Inc.",3346.0,3031.0,315.0,2008-09-26 00:00:00,2017-01-12,2017-11-22,PMA P160055,1825
Determination of Regulatory Review Period for Purposes of Patent Extension; DAURISMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAURISMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",89 FR 18423,2024-05305,https://www.federalregister.gov/documents/2024/03/13/2024-05305/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daurismo,https://www.govinfo.gov/content/pkg/FR-2024-03-13/pdf/2024-05305.pdf,2024-03-13, DAURISMO,,Tianlun,DAURISMO (glasdegib),"8,148,401; 8,431,597","Pfizer, Inc. ",3388.0,3179.0,209.0,2009-08-14 00:00:00,2018-04-27,2018-11-21,NDA 210656,"661 or 1,121"
Determination of Regulatory Review Period for Purposes of Patent Extension; PYRUKYND,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PYRUKYND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",89 FR 18641,2024-05407,https://www.federalregister.gov/documents/2024/03/14/2024-05407/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pyrukynd,https://www.govinfo.gov/content/pkg/FR-2024-03-14/pdf/2024-05407.pdf,2024-03-14, PYRUKYND,,Tianlun,PYRUKYND (mitapivat hemisulfate sesquihydrate),"9,193,701 and RE49,582","Agios Pharmaceuticals, Inc.",2885.0,2639.0,246.0,2014-03-28 00:00:00,2021-06-17,2022-02-17,NDA 216196,"1,209 or 1,507"
Determination of Regulatory Review Period for Purposes of Patent Extension; VTAMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VTAMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 18646,2024-05408,https://www.federalregister.gov/documents/2024/03/14/2024-05408/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vtama,https://www.govinfo.gov/content/pkg/FR-2024-03-14/pdf/2024-05408.pdf,2024-03-14, VTAMA,,Tianlun,VTAMA (tapinarof),10195160,"Dermavant Sciences, GmbH",3134.0,2771.0,363.0,2013-10-25 00:00:00,2021-05-26,2022-05-23,NDA 215272,4 days
Determination of Regulatory Review Period for Purposes of Patent Extension; CIBINQO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CIBINQO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 18643,2024-05421,https://www.federalregister.gov/documents/2024/03/14/2024-05421/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cibinqo,https://www.govinfo.gov/content/pkg/FR-2024-03-14/pdf/2024-05421.pdf,2024-03-14, CIBINQO,,Tianlun,CIBINQO (abrocitinib),"9,035,074; 9,545,405",PFIZER Inc.,3173.0,2665.0,508.0,2013-05-10 00:00:00,2020-08-25,2022-01-14,NDA 213871,695
Determination of Regulatory Review Period for Purposes of Patent Extension; JEMPERLI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JEMPERLI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 41443,2024-10361,https://www.federalregister.gov/documents/2024/05/13/2024-10361/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jemperli,https://www.govinfo.gov/content/pkg/FR-2024-05-13/pdf/2024-10361.pdf,2024-05-13, JEMPERLI,,Tianlun,JEMPERLI (dostarlimab-gxly),"9,815,897 and 10,738,117","GlaxoSmithKline (agent for AnaptysBio, Inc.)",1919.0,1428.0,491.0,2016-01-22 00:00:00,2019-12-19,2021-04-22,BLA 761174,355
Determination of Regulatory Review Period for Purposes of Patent Extension; ELFABRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELFABRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54839,2024-14536,https://www.federalregister.gov/documents/2024/07/02/2024-14536/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elfabrio,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14536.pdf,2024-07-02, ELFABRIO,,Tianlun,ELFABRIO (pegunigalsidase alfa-iwxj),"9,194,011 and 10,280,414",Protalix Ltd.,3927.0,2849.0,1078.0,2012-08-09 00:00:00,2020-05-27,2023-05-09,BLA 761161,"1,271 or 1,826"
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENPOZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54829,2024-14538,https://www.federalregister.gov/documents/2024/07/02/2024-14538/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenpozyme,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14538.pdf,2024-07-02, XENPOZYME,,Tianlun,XENPOZYME (olipudase alfa-rcpc),"8,314,319 and 8,658,162",Genzyme Corporation and Icahn School of Medicine at Mount Sinai,5971.0,5669.0,302.0,2006-04-28 00:00:00,2021-11-03,2022-08-31,BLA 761261,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; TEZSPIRE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEZSPIRE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54831,2024-14577,https://www.federalregister.gov/documents/2024/07/02/2024-14577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tezspire,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14577.pdf,2024-07-02, TEZSPIRE,,Tianlun,TEZSPIRE (tezepelumab-ekko),"7,982,016 and 8,163,284",Amgen Inc.,4848.0,4623.0,225.0,2008-09-10 00:00:00,2021-05-07,2021-12-17,BLA 761224,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; VYVGART,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYVGART and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54832,2024-14532,https://www.federalregister.gov/documents/2024/07/02/2024-14532/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyvgart,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14532.pdf,2024-07-02, VYVGART,,Tianlun,VYVGART (efgartigimod),"8,163,881 and 8,834,871",The Board of Regents of the University of Texas System,1710.0,1344.0,366.0,2017-04-14 00:00:00,2020-12-17,2021-12-17,BLA 761195,1038
Determination of Regulatory Review Period for Purposes of Patent Extension; KIMMTRAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KIMMTRAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54834,2024-14540,https://www.federalregister.gov/documents/2024/07/02/2024-14540/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kimmtrak,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14540.pdf,2024-07-02, KIMMTRAK,,Tianlun,KIMMTRAK (tebentafusp-tebn),8519100,Immunocore Ltd.,3641.0,3424.0,217.0,2012-02-08 00:00:00,2021-06-23,2022-01-25,BLA 761228,1739
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYNYZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYNYZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54836,2024-14541,https://www.federalregister.gov/documents/2024/07/02/2024-14541/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zynyz,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14541.pdf,2024-07-02, ZYNYZ,,Tianlun,ZYNYZ (retifanlimab-dlwr),10577422,"Incyte Corporation (Agent of MacroGenics, Inc.)",2372.0,2145.0,227.0,2016-09-24 00:00:00,2022-08-08,2023-03-22,BLA 761334,138
Determination of Regulatory Review Period for Purposes of Patent Extension; TECVAYLI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECVAYLI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54837,2024-14535,https://www.federalregister.gov/documents/2024/07/02/2024-14535/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecvayli,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14535.pdf,2024-07-02, TECVAYLI,,Tianlun,TECVAYLI (teclistamab-cqyv),10072088,"Janssen Biotech, Inc.",2050.0,1748.0,302.0,2017-03-17 00:00:00,2021-12-28,2022-10-25,BLA 761291,70
Determination of Regulatory Review Period for Purposes of Patent Extension; RYSTIGGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYSTIGGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55598,2024-14723,https://www.federalregister.gov/documents/2024/07/05/2024-14723/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rystiggo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14723.pdf,2024-07-05, RYSTIGGO,,Tianlun,RYSTIGGO (rozanolixizumab-noli),10233243,UCB Biopharma SRL,2283.0,2036.0,247.0,2017-03-29 00:00:00,2022-10-24,2023-06-26,BLA 761286,902
Determination of Regulatory Review Period for Purposes of Patent Extension; VABYSMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VABYSMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55600,2024-14720,https://www.federalregister.gov/documents/2024/07/05/2024-14720/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vabysmo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14720.pdf,2024-07-05, VABYSMO,,Tianlun,VABYSMO (faricimab-svoa),"8,268,314 and 9,695,233","Genentech, Inc.(Agent of Hoffmann-La Roche Inc.)",3046.0,2800.0,246.0,2013-09-28 00:00:00,2021-05-28,2022-01-28,BLA 761235,"931 and 1,646"
Determination of Regulatory Review Period for Purposes of Patent Extension; ENJAYMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENJAYMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55611,2024-14729,https://www.federalregister.gov/documents/2024/07/05/2024-14729/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enjaymo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14729.pdf,2024-07-05, ENJAYMO,,Tianlun,ENJAYMO (sutimlimab-jome),"8,877,197 and 10,450,382",Bioverativ USA Inc.,1845.0,1151.0,694.0,2017-01-18 00:00:00,2020-03-13,2022-02-04,BLA 761164,766 or 825
Determination of Regulatory Review Period for Purposes of Patent Extension; LUNSUMIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUNSUMIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55628,2024-14728,https://www.federalregister.gov/documents/2024/07/05/2024-14728/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lunsumio,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14728.pdf,2024-07-05, LUNSUMIO,,Tianlun,LUNSUMIO (mosunetuzumab-axgb),"10,174,124 and 11,186,650","Genentech, Inc.",2809.0,2571.0,238.0,2015-04-16 00:00:00,2022-04-29,2022-12-22,BLA 761263,313 or 842
Determination of Regulatory Review Period for Purposes of Patent Extension; DAXXIFY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAXXIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55597,2024-14732,https://www.federalregister.gov/documents/2024/07/05/2024-14732/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daxxify,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14732.pdf,2024-07-05, DAXXIFY,,Tianlun,DAXXIFY (daxibotulinumtoxinA-lanm),"9,340,587; 9,956,435; and 10,111,939","Revance Therapeutics, Inc.",2339.0,1321.0,1018.0,2016-04-14 00:00:00,2019-11-25,2022-09-07,BLA 761127,"1,214, 1,305, or 1,587"
Determination of Regulatory Review Period for Purposes of Patent Extension; Imjudo,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMJUDO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55626,2024-14716,https://www.federalregister.gov/documents/2024/07/05/2024-14716/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imjudo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14716.pdf,2024-07-05, Imjudo,,Tianlun,IMJUDO (tremelimumab-actl),"9,487,581; 10,232,040; and 11,446,377",AstraZeneca AB,7634.0,7393.0,241.0,2001-11-28 00:00:00,2022-02-23,2022-10-21,BLA 761289,"32, 529, or 1,208"
Determination of Regulatory Review Period for Purposes of Patent Extension; SPEVIGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPEVIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 56883,2024-15239,https://www.federalregister.gov/documents/2024/07/11/2024-15239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spevigo,https://www.govinfo.gov/content/pkg/FR-2024-07-11/pdf/2024-15239.pdf,2024-07-11, SPEVIGO,,Tianlun,SPEVIGO (spesolimab-sbzo),9023995,Boehringer Ingelheim International GmbH,1729.0,1393.0,336.0,2017-12-09 00:00:00,2021-10-01,2022-09-01,BLA 761244,1033
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.",89 FR 59121,2024-15998,https://www.federalregister.gov/documents/2024/07/22/2024-15998/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenpozyme-correction,https://www.govinfo.gov/content/pkg/FR-2024-07-22/pdf/2024-15998.pdf,2024-07-22, XENPOZYME, Correction,Tianlun,XENPOZYME (olipudase alfa-rcpc),"8,349,319 and 8,658,162",Genzyme Corporation and Icahn School of Medicine at Mount Sinai,5971.0,5669.0,302.0,2006-04-28 00:00:00,2021-11-03,2022-08-31,BLA 761261,1827
Determination of Regulatory Review Period for Purposes of Patent Extension; REZLIDHIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZLIDHIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64918,2024-17511,https://www.federalregister.gov/documents/2024/08/08/2024-17511/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rezlidhia,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17511.pdf,2024-08-08, REZLIDHIA,,Tianlun,REZLIDHIA (olutasidenib),9834539,"Forma Therapeutics, Inc.",2563.0,2273.0,290.0,2015-11-27 00:00:00,2022-02-15,2022-12-01,NDA 215814,440
Determination of Regulatory Review Period for Purposes of Patent Extension; XOFLUZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XOFLUZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64920,2024-17648,https://www.federalregister.gov/documents/2024/08/08/2024-17648/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xofluza,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17648.pdf,2024-08-08, XOFLUZA,,Tianlun,XOFLUZA (baloxavir marboxil),8987441,"Shionogi & Co., Ltd.",985.0,801.0,184.0,2016-02-14 00:00:00,2018-04-24,2018-10-24,NDA 210854 ,399
Determination of Regulatory Review Period for Purposes of Patent Extension; TALZENNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALZENNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64933,2024-17643,https://www.federalregister.gov/documents/2024/08/08/2024-17643/determination-of-regulatory-review-period-for-purposes-of-patent-extension-talzenna,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17643.pdf,2024-08-08, TALZENNA,,Tianlun,TALZENNA (talazoparib tosylate),8012976,Medivation Technologies LLC,2869.0,2675.0,194.0,2010-12-10 00:00:00,2018-04-06,2018-10-16,NDA 211651,1093
Determination of Regulatory Review Period for Purposes of Patent Extension; INPEFA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INPEFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64934,2024-17639,https://www.federalregister.gov/documents/2024/08/08/2024-17639/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inpefa,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17639.pdf,2024-08-08, INPEFA,,Tianlun,INPEFA (sotagliflozin),"7,781,577 and 8,217,156","Lexicon Pharmaceuticals, Inc.",5268.0,4903.0,365.0,2008-12-24 00:00:00,2022-05-27,2023-05-26,NDA 216203,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; VANFLYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VANFLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64931,2024-17510,https://www.federalregister.gov/documents/2024/08/08/2024-17510/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vanflyta,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17510.pdf,2024-08-08, VANFLYTA,,Tianlun,VANFLYTA (quizartinib),"7,820,657; 8,129,374; 8,357,690; 8,557,810; and 8,836,218",Ambit Biosciences Corporation,6110.0,5779.0,331.0,2006-10-29 00:00:00,2022-08-24,2023-07-20,NDA 216993,"1,781 or 1,826"
Determination of Regulatory Review Period for Purposes of Patent Extension; MIEBO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MIEBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 66415,2024-18265,https://www.federalregister.gov/documents/2024/08/15/2024-18265/determination-of-regulatory-review-period-for-purposes-of-patent-extension-miebo,https://www.govinfo.gov/content/pkg/FR-2024-08-15/pdf/2024-18265.pdf,2024-08-15, MIEBO,,Tianlun,MIEBO (perfluorohexyloctane),"10,058,615; 10,369,117; 10,449,164; 10,576,154; 11,357,738",Novaliq GmbH,2018.0,1693.0,325.0,2017-11-09 00:00:00,2022-06-28,2023-05-18,NDA 216675,"231, 748, 814, 853, or 1,024"
Determination of Regulatory Review Period for Purposes of Patent Extension; STEGLATRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STEGLATRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72851,2024-20149,https://www.federalregister.gov/documents/2024/09/06/2024-20149/determination-of-regulatory-review-period-for-purposes-of-patent-extension-steglatro,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20149.pdf,2024-09-06, STEGLATRO,,Tianlun,STEGLATRO (ertugliflozin),8080580,Pfizer Inc.,2976.0,2610.0,366.0,2009-10-28 00:00:00,2016-12-19,2017-12-19,NDA 209803,524
Determination of Regulatory Review Period for Purposes of Patent Extension; STEGLUJAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STEGLUJAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72844,2024-20150,https://www.federalregister.gov/documents/2024/09/06/2024-20150/determination-of-regulatory-review-period-for-purposes-of-patent-extension-steglujan,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20150.pdf,2024-09-06, STEGLUJAN,,Tianlun,STEGLUJAN (ertugliflozin and sitagliptin),"9,308,204 and 9,439,901",Pfizer Inc.,2976.0,2610.0,366.0,2009-10-28 00:00:00,2016-12-19,2017-12-19,NDA 209805,415 or 424
Determination of Regulatory Review Period for Purposes of Patent Extension; YCANTH,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YCANTH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72853,2024-20115,https://www.federalregister.gov/documents/2024/09/06/2024-20115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ycanth,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20115.pdf,2024-09-06, YCANTH,,Tianlun,YCANTH (cantharidin),11052064,Verrica Pharmaceuticals,2285.0,877.0,1408.0,2017-04-20 00:00:00,2019-09-13,2023-07-21,NDA 212905,745
Determination of Regulatory Review Period for Purposes of Patent Extension; SEGLUROMET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEGLUROMET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72855,2024-20148,https://www.federalregister.gov/documents/2024/09/06/2024-20148/determination-of-regulatory-review-period-for-purposes-of-patent-extension-segluromet,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20148.pdf,2024-09-06, SEGLUROMET,,Tianlun,SEGLUROMET (ertugliflozin and metformin hydrochloride),"9,308,204 and 9,439,902",Pfizer Inc.,2976.0,2610.0,366.0,2009-10-28 00:00:00,2016-12-19,2017-12-19,NDA 209806,415 or 424
Determination of Regulatory Review Period for Purposes of Patent Extension; PLUVICTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PLUVICTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73098,2024-20246,https://www.federalregister.gov/documents/2024/09/09/2024-20246/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pluvicto,https://www.govinfo.gov/content/pkg/FR-2024-09-09/pdf/2024-20246.pdf,2024-09-09, PLUVICTO,,Tianlun,PLUVICTO (lutetium Lu 177 vipivotide tetraxetan),10398791,"Advanced Accelerator Applications USA, Inc. (Agent of Deutsches Krebsforschungszentrum & Ruprecht-Karls-Universitat Heidelberg)",1881.0,1643.0,238.0,2017-01-29 00:00:00,2021-07-29,2022-03-23,NDA 215833,523
Determination of Regulatory Review Period for Purposes of Patent Extension; TECHNEGAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECHNEGAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73660,2024-20555,https://www.federalregister.gov/documents/2024/09/11/2024-20555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-technegas,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20555.pdf,2024-09-11, TECHNEGAS,,Tianlun,TECHNEGAS (technetium Tc 99m-labeled carbon),7722856,Cyclomedica Australia Pty Limited,4322.0,3039.0,1283.0,2011-12-01 00:00:00,2020-03-26,2023-09-29,NDA 22335,1826
Determination of Regulatory Review Period for Purposes of Patent Extension; ZTALMY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZTALMY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73662,2024-20549,https://www.federalregister.gov/documents/2024/09/11/2024-20549/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ztalmy,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20549.pdf,2024-09-11, ZTALMY,,Tianlun,ZTALMY (ganaxolone),8318714,"Marinus Pharmaceuticals, Inc.",10382.0,10065.0,317.0,1993-12-30 00:00:00,2021-07-20,2022-06-01,NDA 215904,5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; VOQUEZNA TRIPLE PAK-New Drug Application 215152,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOQUEZNA TRIPLE PAK--new drug application (NDA) 215152 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73656,2024-20552,https://www.federalregister.gov/documents/2024/09/11/2024-20552/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voquezna-triple-pak-new,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20552.pdf,2024-09-11, VOQUEZNA TRIPLE PAK-New Drug Application 215152,,Tianlun,VOQUEZNA TRIPLE PAK—NDA 215152 (vonoprazan tablets/amoxicillin capsules/clarithromycin tablets),7977488,"Phathom Pharmaceuticals, Inc. ",971.0,727.0,244.0,2019-09-08 00:00:00,2021-09-03,2022-05-03,NDA 215152,599
Determination of Regulatory Review Period for Purposes of Patent Extension; VOQUEZNA DUAL PAK-New Drug Application 215153,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOQUEZNA DUAL PAK--new drug application (NDA) 215153 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73658,2024-20551,https://www.federalregister.gov/documents/2024/09/11/2024-20551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voquezna-dual-pak-new,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20551.pdf,2024-09-11, VOQUEZNA DUAL PAK-New Drug Application 215153,,Tianlun,VOQUEZNA DUAL PAK (vonoprazan fumarate tablets/amoxicillin capsules),7977488,"Phathom Pharmaceuticals, Inc.",971.0,727.0,244.0,2019-09-08 00:00:00,2021-09-03,2022-05-03,NDA 215153,599
Determination of Regulatory Review Period for Purposes of Patent Extension; REZZAYO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZZAYO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 75546,2024-20894,https://www.federalregister.gov/documents/2024/09/16/2024-20894/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rezzayo,https://www.govinfo.gov/content/pkg/FR-2024-09-16/pdf/2024-20894.pdf,2024-09-16, REZZAYO,,Tianlun,REZZAYO (rezafungin acetate),"8,722,619; 9,526,835; and 10,702,573","Cidara Therapeutics, Inc.",2814.0,2570.0,244.0,2015-07-10 00:00:00,2022-07-22,2023-03-22,NDA 217417,"607, 1,261, or 1,529"
Determination of Regulatory Review Period for Purposes of Patent Extension; ORSERDU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORSERDU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 75543,2024-20893,https://www.federalregister.gov/documents/2024/09/16/2024-20893/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orserdu,https://www.govinfo.gov/content/pkg/FR-2024-09-16/pdf/2024-20893.pdf,2024-09-16, ORSERDU,,Tianlun,ORSERDU (elacestrant dihydrochloride),"7,612,114 and 8,399,520","Eisai R&D Management Co., Ltd.",2965.0,2740.0,225.0,2014-12-17 00:00:00,2022-06-17,2023-01-27,NDA 217639,"724, 841, or 1,595"
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMDEKO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMDEKO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77520,2024-21677,https://www.federalregister.gov/documents/2024/09/23/2024-21677/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symdeko,https://www.govinfo.gov/content/pkg/FR-2024-09-23/pdf/2024-21677.pdf,2024-09-23, SYMDEKO,,Tianlun,SYMDEKO (tezacaftor/co-packaged with ivacaftor),"7,645,789; 7,776,905; 8,415,387; 8,598,181; 8,623,905; and 9,035,072",Vertex Pharmaceuticals Inc.,2832.0,2602.0,230.0,2010-05-15 00:00:00,2017-06-28,2018-02-12,NDA 210491,"616, 864, 882, 1,001, 1,484, or 1,532"
Determination of Regulatory Review Period for Purposes of Patent Extension; QUVIVIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QUVIVIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77868,2024-21836,https://www.federalregister.gov/documents/2024/09/24/2024-21836/determination-of-regulatory-review-period-for-purposes-of-patent-extension-quviviq,https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21836.pdf,2024-09-24, QUVIVIQ,,Tianlun,QUVIVIQ (daridorexant hydrochloride),9732075,Idorsia Pharmaceuticals Ltd. ,2115.0,1660.0,455.0,2016-06-24 00:00:00,2021-01-08,2022-04-07,NDA 214985,1030
Determination of Regulatory Review Period for Purposes of Patent Extension; OJJAARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OJJAARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77867,2024-21844,https://www.federalregister.gov/documents/2024/09/24/2024-21844/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ojjaara,https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21844.pdf,2024-09-24, OJJAARA,,Tianlun,OJJAARA (momelotinib),"8,486,941 and RE48,285",GlaxoSmithKline LLC,5127.0,4670.0,457.0,2009-09-03 00:00:00,2022-06-16,2023-09-15,NDA 216873,828 days or 5 years
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 12, 2018, for the determination of the regulatory review period for the animal drug BRAVECTO. In accordance with the Court's order in Nissan Chemical Corp., et al. v. FDA, et al., No. 22-01598 (D.D.C), this document revises the SUPPLEMENTARY INFORMATION section of that notice by adjusting the start date of the testing phase for BRAVECTO. This notice supersedes the June 11, 2021, Federal Register document revising the February 12, 2018, notice.",89 FR 77866,2024-21841,https://www.federalregister.gov/documents/2024/09/24/2024-21841/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto-correction,https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21841.pdf,2024-09-24, BRAVECTO, Correction,Tianlun,BRAVECTO (fluralaner),7662972,"Nissan Chemical Industries, Ltd.",1548.0,1510.0,38.0,2011-08-04 00:00:00,2014-04-08,2014-05-15,NADA 141-426,792
Determination of Regulatory Review Period for Purposes of Patent Extension; OMLONTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMLONTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78306,2024-21847,https://www.federalregister.gov/documents/2024/09/25/2024-21847/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omlonti,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21847.pdf,2024-09-25, OMLONTI,,Tianlun,OMLONTI (omidenepag isopropyl ophthalmic solution),"8,648,097; 8,685,986; 10,702,511","Santen Pharmaceutical Co., Ltd.",3723.0,3050.0,673.0,2012-07-15 00:00:00,2020-11-19,2022-09-22,NDA 215092,"623 or 1,826"
Determination of Regulatory Review Period for Purposes of Patent Extension; ZAVZPRET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZAVZPRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78309,2024-21963,https://www.federalregister.gov/documents/2024/09/25/2024-21963/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zavzpret,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21963.pdf,2024-09-25, ZAVZPRET,,Tianlun,ZAVZPRET (zavegepant hydrochloride),8481546,Pfizer Inc. ,1619.0,1253.0,366.0,2018-10-04 00:00:00,2022-03-09,2023-03-09,NDA 216386,993
Determination of Regulatory Review Period for Purposes of Patent Extension; JESDUVROQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JESDUVROQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78310,2024-21848,https://www.federalregister.gov/documents/2024/09/25/2024-21848/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jesduvroq,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21848.pdf,2024-09-25, JESDUVROQ,,Tianlun,JESDUVROQ (daprodustat),8324208,GlaxoSmithKline LLC,5328.0,4962.0,366.0,2008-07-03 00:00:00,2022-02-01,2023-02-01,NDA 216951,2038
Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAYBUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78312,2024-21941,https://www.federalregister.gov/documents/2024/09/25/2024-21941/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daybue,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21941.pdf,2024-09-25, DAYBUE,,Tianlun,DAYBUE (trofinetide),9212204,Acadia Pharmaceuticals Inc.,5106.0,4864.0,242.0,2009-03-19 00:00:00,2022-07-12,2023-03-10,NDA 217026,1443
Determination of Regulatory Review Period for Purposes of Patent Extension; ELUCIREM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELUCIREM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78315,2024-21929,https://www.federalregister.gov/documents/2024/09/25/2024-21929/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elucirem,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21929.pdf,2024-09-25, ELUCIREM,,Tianlun,ELUCIREM (gadopiclenol),8114863,Guerbet LLC,2443.0,2199.0,244.0,2016-01-15 00:00:00,2022-01-21,2022-09-21,NDA 216986,1344
Determination of Regulatory Review Period for Purposes of Patent Extension; FRUZAQLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FRUZAQLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",89 FR 78307,2024-21930,https://www.federalregister.gov/documents/2024/09/25/2024-21930/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fruzaqla,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21930.pdf,2024-09-25, FRUZAQLA,,Tianlun,FRUZAQLA (fruquintinib),"7,829,574; 8,212,033; 10,519,142; and 11,046,674",HUTCHMED LTD.,2604.0,2380.0,224.0,2016-09-23 00:00:00,2023-03-30,2023-11-08,NDA 217564,"544, 793, or 1,414"
Determination of Regulatory Review Period for Purposes of Patent Extension; OGSIVEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OGSIVEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78880,2024-22105,https://www.federalregister.gov/documents/2024/09/26/2024-22105/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ogsiveo,https://www.govinfo.gov/content/pkg/FR-2024-09-26/pdf/2024-22105.pdf,2024-09-26, OGSIVEO,,Tianlun,OGSIVEO (nirogacestat hydrobromide),"7,342,118; 7,795,447; and 7,951,958",SpringWorks Therapeutics Inc.,5425.0,5089.0,336.0,2009-01-21 00:00:00,2022-12-27,2023-11-27,NDA 217677,1826
